WO2014053533A1

WO2014053533A1 - Use of substituted 3-heteroaroylamino-propionic acid derivatives as pharmaceuticals for prevention/treatment of atrial fibrillation

Info

Publication number: WO2014053533A1
Application number: PCT/EP2013/070524
Authority: WO
Inventors: Sven Ruf; Thorsten Sadowski; Klaus Wirth; Herman Schreuder; Christian Buning
Original assignee: Sanofi
Priority date: 2012-10-05
Filing date: 2013-10-02
Publication date: 2014-04-10

Abstract

The present invention relates to the use of compounds of the formula (I) for the treatment/prevention of atrial fibrillation, wherein A, D, E, G, R¹⁰, R³⁰, R⁴⁰, R⁵⁰ and R⁶⁰ have the meanings indicated in the claims. They are inhibitors of the protease cathepsin A.

Description

Use of Substituted 3-heteroaroylamino-propionic acid derivatives as pharmaceuticals for prevention/treatment of atrial fibrillation

Atrial fibrillation (AF) is the most common type of sustained tachyarrhythmia and is associated with significant morbidity and mortality.¹ Diabetes is a strong independent risk factor for atrial fibrillation (AF) and stroke ^2,3,4 and has been shown to produce an arrhythmogenic substrate in the atrium with an increase in AF susceptibility due to increased atrial fibrosis amount in a diabetic rat model.^5,6 Additionally, an abnormal response to exercise is frequently observed in asymptomatic diabetic patients who do not have clinical evidence of cardiovascular disease.^7,8,9 Atrial and/or ventricular dysfunction limit exercise capacity and increase risk for stroke in diabetic patients.¹⁰

Cathepsin A (CathA) is an extracellular enzyme which has been suggested to play an important role in degradation of extracellular peptides.^{11 ,12} Several peptide hormones have been described as substrates for CathA in vitro like angiotensin I and bradykinin. Evidence of upregulation of alternative angiotensin-generating enzymes like chymase or cathepsins has been described in many pathologies e.g. in myocardial infarction, CHF or diabetes.^13,14,15 Pharmacological inhibition of CathA by the natural product ebelactone B increased renal bradykinin levels and prevented the development of salt- induced hypertension.¹⁶ Similar effects were observed by antisense oligonucleotides suppressing the expression of CathA.¹⁷ CathA also has been suggested to play a role in inflammation.¹¹

Compounds with CathA inhibitory activity are described in WO201 1092187,

WO2012101 197, WO2012101 199, WO2013/014204, WO2013/014205.

A CathA inhibitory activity was also found for Telaprevir and Boceprevir

(WO2013/072327 and WO2013/072328). The invention was based on the object of providing compounds for the

treatment/prevention of atrial fibrillation.

A subject of the present invention is the use compound of the formula I, in any of its stereoisomeric forms or a mixture of stereoisomeric forms in any ratio, or a

physiologically acceptable salt thereof, or a physiologically acceptable solvate of any of them,

wherein

A is chosen from the series consisting of C(R¹) and N; D is chosen from the series consisting of N(R²), O and S;

E is chosen from the series consisting of C(R³) and N;

G is chosen from the series consisting of R⁷¹-O-C(O)-, R⁷²-N(R⁷³)-C(O)-, NC- and tetrazol-5-yl;

R¹ is chosen from the series consisting of hydrogen, halogen, (Ci-C6)-alkyl, Ar, HO-, (Ci-C₆)-alkyl-O-, (Ci-C₆)-alkyl-S(O)_m- and NC-;

R² is chosen from the series consisting of (Ci-C₇)-alkyl, (C3-C₇)-cycloalkyl-C₃H_2s- and Ar-C₃H_2s-, wherein s is an integer chosen from the series consisting of 0, 1 , 2 and 3;

R³ is chosen from the series consisting of hydrogen, halogen, (Ci-C6)-alkyl, (d-Ce)- alkyl-O-, (Ci-C₆)-alkyl-S(O)_m- and NC-; R¹⁰ is chosen from the series consisting of R^{1 1}-O-, R¹²-N(R¹³)-C(O)-O- and Het²-C(O)- O-;

R^{1 1} is chosen from the series consisting of hydrogen, R¹⁴, (C3-C₇)-cycloalkyl, Ar and Het³;

R¹² and R¹³ are independently of each other chosen from the series consisting of hydrogen, R¹⁵ and Ar; R¹⁴ is (Ci-Cio)-alkyl which is optionally substituted by one or more identical or different substituents chosen from the series consisting of halogen, HO-, R¹⁶-O-, oxo, (C3-C7)- cycloalkyl, Ar, Het¹ , Het³, NC-, H₂N-C(O)-, (Ci-C₄)-alkyl-NH-C(O)-, di((Ci-C₄)-alkyl)N- C(O)-, Het¹-C(O)-, (Ci-C₄)-alkyl-C(O)-NH- and (Ci-C₄)-alkyl-S(0)_m-; R¹⁵ is (Ci-C6)-alkyl which is optionally substituted by one or more identical or different substituents chosen from the series consisting halogen, HO- and (Ci-C6)-alkyl-O-;

R¹⁶ is (Ci-C6)-alkyl which is optionally substituted by one or more identical or different substituents chosen from the series consisting of HO-, (Ci-C₄)-alkyl-O- and NC-;

R³⁰ is chosen from the series consisting of R³¹ , (C3-C₇)-cycloalkyl, R³²-C_uH_2u- and Het³-C_uH_2u-, wherein u is an integer chosen from the series consisting of 0, 1 , 2 and 3;

R³¹ is (Ci-Cio)-alkyl which is optionally substituted by one or more identical or different substituents chosen from the series consisting of halogen, (C3-C₇)-cycloalkyl, HO-, (Ci- C₆)-alkyl-O-, (Ci-C₆)-alkyl-S(0)_m- and NC-;

R³² is chosen from the series consisting of phenyl and an aromatic 5-membered or 6- membered monocyclic heterocycle which comprises one, two or three identical or different ring heteroatoms chosen from the series consisting of nitrogen, oxygen and sulfur and is bonded via a ring carbon atom, wherein the phenyl and the heterocycle all are optionally substituted by one or more identical or different substituents chosen from the series consisting of halogen, (Ci-C6)-alkyl, (C3-C₇)-cycloalkyl, R³³, HO-, (C1-C-6)- alkyl-O-, R³³-O-, R³³-(Ci-C₄)-alkyl-O-, -O-CH2-O-, -O-CF2-O-, (Ci-C₆)-alkyl-S(O)_m-, H₂N-S(O)₂-, (Ci-C₄)-alkyl-NH-S(O)₂-, di((Ci-C₄)-alkyl)N-S(O)₂-, H₂N-, (Ci-C₆)-alkyl-NH- , di((Ci-C₆)-alkyl)N-, Het¹, (Ci-C₄)-alkyl-C(O)-NH-, Ar-C(O)-NH-, (Ci-C₄)-alkyl-S(O)₂- NH- and NC-;

R³³ is chosen from the series consisting of phenyl and an aromatic 5-membered or 6- membered monocyclic heterocycle which comprises one, two or three identical or different ring heteroatoms chosen from the series consisting of nitrogen, oxygen and sulfur and is bonded via a ring carbon atom, wherein the phenyl and the heterocycle all are optionally substituted by one or more identical or different substituents chosen from the series consisting of halogen, (Ci-C6)-alkyl, (C3-C₇)-cycloalkyl, HO-, (Ci-C-6)-alkyl-0- , (Ci-C₆)-alkyl-S(O)_m-, H₂N-S(O)₂-, (Ci-C₄)-alkyl-NH-S(O)₂-, di((Ci-C₄)-alkyl)N-S(O)₂- and NC-;

R⁴⁰ is chosen from the series consisting of hydrogen and (Ci-C₄)-alkyl; or R³⁰ and R⁴⁰ together are (CH₂)_X which is optionally substituted by one or more identical or different (Ci-C₄)-alkyl substituents, wherein x is an integer chosen from the series consisting of 2, 3, 4 and 5;

R⁵⁰ is chosen from the series consisting of hydrogen, (Ci-C6)-alkyl, HO- and (C1-C6)- alkyl-O-; R⁶⁰ is chosen from the series consisting of hydrogen and (Ci-C6)-alkyl; or R and R together are (CH₂)_y which is optionally substituted by one or more identical or different (Ci-C₄)-alkyl substituents, wherein y is an integer chosen from the series consisting of 2, 3, 4 and 5; R is chosen from the series consisting of hydrogen and (Ci-CsJ-alkyl which is optionally substituted by one or more identical or different substituents chosen from the series consisting (Ci-C6)-alkyl-O- and (Ci-C6)-alkyl-C(O)-O-; R⁷² is chosen from the series consisting of hydrogen, (Ci-C6)-alkyl, (C3-C6)-cycloalkyl, -CH₂-(CH₂)_b-(C3-C6)-cycloalkyl, Het⁴ and -(CH₂)_b-Het⁴, where alkyl or cycloalkyl is optionally substituted by one or more identical or different substituents chosen from the series consisting of halogen, HO-, HOOC-, (Ci-C₆)-alkyl-O- and (Ci-C₆)-alkyl-C(O)-O-, NC-, N((Ci-C₄)-alkyl)₂ and b is 0, 1 or 2;

R⁷³ is chosen from the series consisting of hydrogen, (Ci-C6)-alkyl;

or

R⁷² and R⁷³ together with the nitrogen atom to which they are bonded form a saturated 4-membered to 7-membered monocyclic heterocycle, which contain optionally one further ring heteroatom chosen from the series consisting of nitrogen, oxygen and sulfur, which is optionally substituted by one or more identical or different substituents chosen from the series consisting of halogen, (Ci-C₄)-alkyl, HO- and (Ci-C₄)-alkyl-O-;

Ar, independently of each other group Ar, is chosen from the series consisting of phenyl and an aromatic 5-membered or 6-membered monocyclic heterocycle which comprises one, two or three identical or different ring heteroatoms chosen from the series consisting of nitrogen, oxygen and sulfur and is bonded via a ring carbon atom, wherein the phenyl and the heterocycle all are optionally substituted by one or more identical or different substituents chosen from the series consisting of halogen, (Ci-Ce)- alkyl, (Ci-C₆)-alkyl-O-, -O-CH₂-O-, -O-CF₂-O-, (Ci-C₆)-alkyl-S(O)_m-, H₂N-S(O)₂- and NC-;

Het¹, independently of each other group Het¹, is a saturated or unsaturated 4- membered to 8-membered monocyclic heterocycle which comprises a ring nitrogen atom via which Het¹ is bonded and optionally one or two identical or different further ring heteroatoms chosen from the series consisting of nitrogen, oxygen and sulfur, which is optionally substituted by one or more identical or different substituents chosen from the series consisting of halogen, (Ci-C₄)-alkyl, HO-, (Ci-C₄)-alkyl-O-, oxo and NC-;

Het² is a saturated 4-mennbered to 7-mennbered monocyclic heterocycle which comprises a ring nitrogen atom via which Het² is bonded and optionally one further ring heteroatom chosen from the series consisting of nitrogen, oxygen and sulfur, which is optionally substituted by one or more identical or different substituents chosen from the series consisting of halogen, (Ci-C₄)-alkyl, HO- and (Ci-C₄)-alkyl-O-;

Het³, independently of each other group Het³, is a saturated 4-mennbered to 7- membered monocyclic heterocycle which comprises one or two identical or different ring heteroatoms chosen from the series consisting of nitrogen, oxygen and sulfur and is bonded via a ring carbon atom, which is optionally substituted by one or more identical or different substituents chosen from the series consisting of fluorine, (Ci-C₄)- alkyl and oxo;

Het⁴, independently of each other group Het⁴, is a saturated or unsaturated 4- membered to 8-membered monocyclic heterocycle which comprises one to four ring heteroatoms chosen from the series consisting of nitrogen, oxygen and sulfur which is optionally substituted by one or more identical or different substituents chosen from the series consisting of halogen, (Ci-C₄)-alkyl, HO-, (Ci-C₄)-alkyl-O-, oxo and NC-; m, independently of each other number m, is an integer chosen from the series consisting of 0, 1 and 2; wherein all cycloalkyl groups, independently of each other, are optionally substituted by one or more identical or different substituents chosen from the series consisting of fluorine and (Ci-C₄)-alkyl; wherein all alkyl, C_sH_2s, C_uH_2u, (CH₂)_X and (CH₂)_y groups, independently of each other, and independently of any other substituents, are optionally substituted by one or more fluorine substituents;

for the prevention and/or treatment of atrial fibrillation. Another embodiment is the use of a compound of the formula I, in any of its

stereoisomeric forms or a mixture of stereoisomeric forms in any ratio, or a

physiologically acceptable salt thereof, or a physiologically acceptable solvate of any of them, as claimed in claim 1 , wherein E is N.

Another embodiment is the use of a compound of the formula I, in any of its

stereoisomeric forms or a mixture of stereoisomeric forms in any ratio, or a

physiologically acceptable salt thereof, or a physiologically acceptable solvate of any of them, wherein D is N(R²).

Another embodiment is the use of a compound of the formula I, in any of its

stereoisomeric forms or a mixture of stereoisomeric forms in any ratio, or a

physiologically acceptable salt thereof, or a physiologically acceptable solvate of any of them, wherein

A is chosen from the series consisting of C(R¹) and N;

D is N(R²);

E is N;

R¹ is chosen from the series consisting of hydrogen, halogen and (Ci-C₄)-alkyl;

R² is Ar-C₃H_2s-, wherein s is an integer chosen from the series consisting of 0, 1 and 2.

Another embodiment is the use of a compound of the formula I, in any of its

stereoisomeric forms or a mixture of stereoisomeric forms in any ratio, or a

physiologically acceptable salt thereof, or a physiologically acceptable solvate of any of them, wherein R¹⁰ is R¹¹-O-.

Another embodiment is the use of a compound of the formula I, in any of its

stereoisomeric forms or a mixture of stereoisomeric forms in any ratio, or a

physiologically acceptable salt thereof, or a physiologically acceptable solvate of any of them, as claimed in any one or more of claims 1 to 5, wherein R³⁰ is R³²-C_uH_2u- wherein u is an integer chosen from the series consisting of 0 and 1 . A further embodiment is the use of a compound of the formula I, in any of its

stereoisomeric forms or a mixture of stereoisomeric forms in any ratio, or a

G is chosen from the series consisting of R⁷¹-O-C(O)- and R⁷²-N(R⁷³)-C(O)-;

R³⁰ is R³²-C_uH_2u-, wherein u is an integer chosen from the series consisting of 0 and 1 ; R³² is chosen from the series consisting of phenyl and an aromatic 6-membered monocyclic heterocycle which comprises one or two nitrogen atoms as ring

heteroatoms, wherein the phenyl and the heterocycle all are optionally substituted by one, two or three identical or different substituents chosen from the series consisting of halogen, (Ci-C₆)-alkyl, (C₃-C₇)-cycloalkyl, R³³, (Ci-C₆)-alkyl-O-, R³³-O-, R³³-(d-C₄)- alkyl-O-, -O-CH₂-O-, -O-CF₂-O-, (Ci-C₆)-alkyl-S(O)_m-, (Ci-C₆)-alkyl-NH-, di((Ci-C₆)- alkyl)N-, Het¹ and NC-;

R³³ is chosen from the series consisting of phenyl and pyridinyl which all are optionally substituted by one, two or three identical or different substituents chosen from the series consisting of halogen, (Ci-C₄)-alkyl, (Ci-C₄)-alkyl-O-, (Ci-C₄)-alkyl-S(O)_m- and NC-;

R⁴⁰ is hydrogen;

R⁵⁰ is hydrogen;

R⁶⁰ is hydrogen.

A further embodiment is the use of a compound of the formula I, in any of its

stereoisomeric forms or a mixture of stereoisomeric forms in any ratio, or a

A is chosen from the series consisting of C(R¹) and N;

D is N(R²);

E is chosen from the series consisting of C(R³) and N; G is chosen from the series consisting of R -O-C(O)- and R -N(R )-C(O)-;

R¹ is chosen from the series consisting of hydrogen, halogen, (Ci-C6)-alkyl, HO- and (Ci-C₆)-alkyl-O-;

R³ is chosen from the series consisting of hydrogen, halogen, (Ci-Ce)-alkyl and (Ci- C₆)-alkyl-O-;

R¹⁰ is chosen from the series consisting of R¹¹-O-, R¹²-N(R¹³)-C(O)-O- and Het²-C(O)- O-; R¹¹ is chosen from the series consisting of hydrogen, R¹⁴, (C3-C₇)-cycloalkyl and Het³;

R¹² and R¹³ are independently of each other chosen from the series consisting of hydrogen, R¹⁵ and Ar; R¹⁴ is (Ci-Cio)-alkyl which is optionally substituted by one or more identical or different substituents chosen from the series consisting of halogen, HO-, R¹⁶-O-, oxo, (C3-C₇)- cycloalkyl, Ar, Het¹, Het³, NC-, H₂N-C(O)-, (Ci-C₄)-alkyl-NH-C(O)-, di((Ci-C₄)-alkyl)N- C(O)- and Het¹-C(O)-; R¹⁵ is (Ci-C₆)-alkyl;

R¹⁶ is (Ci-C6)-alkyl which is optionally substituted by one or more identical or different substituents chosen from the series consisting of HO- and (Ci-C₄)-alkyl-O-; R³⁰ is chosen from the series consisting of (C3-C₇)-cycloalkyl, R³²-C_uH_2u- and Het³- C_uH_2u-, wherein u is an integer chosen from the series consisting of 0, 1 , 2 and 3; R is chosen from the series consisting of phenyl and an aromatic 6-membered monocyclic heterocycle which comprises one or two nitrogen atoms as ring

heteroatoms, wherein the phenyl and the heterocycle all are optionally substituted by one or more identical or different substituents chosen from the series consisting of halogen, (Ci-C₆)-alkyl, (C₃-C₇)-cycloalkyl, R³³, HO-, (Ci-C₆)-alkyl-O-, R³³-O-, R³³-(d- C₄)-alkyl-O-, -O-CH₂-O-, -O-CF₂-O-, (Ci-C₆)-alkyl-S(O)_m-, di((Ci-C₄)-alkyl)N-S(O)₂-, H₂N-, di((Ci-C₆)-alkyl)N-, Het¹, (Ci-C₄)-alkyl-C(O)-NH-, Ar-C(O)-NH- and NC-;

R³³ is chosen from the series consisting of phenyl and an aromatic 6-membered monocyclic heterocycle which comprises one or two nitrogen atoms as ring

heteroatoms, wherein the phenyl and the heterocycle all are optionally substituted by one or more identical or different substituents chosen from the series consisting of halogen, (Ci-C₆)-alkyl, (C₃-C₇)-cycloalkyl, HO-, (Ci-C₆)-alkyl-O-, (Ci-C₆)-alkyl-S(O)_m-, H₂N-S(O)₂-, di((Ci-C₄)-alkyl)N-S(O)₂- and NC-;

R⁴⁰ is hydrogen;

R is chosen from the series consisting of hydrogen and HO-; R^bU is hydrogen;

R is chosen from the series consisting of hydrogen and (Ci-Cs)-alkyl which is optionally substituted by one or more identical or different substituents chosen from the series consisting (Ci-C6)-alkyl-O- and (Ci-C6)-alkyl-C(O)-O-;

R⁷² and R⁷³ are independently of each other chosen from the series consisting of hydrogen and (Ci-C₄)-alkyl;

Ar, independently of each other group Ar, is chosen from the series consisting of phenyl and an aromatic 5-membered or 6-membered monocyclic heterocycle which comprises one, two or three identical or different ring heteroatoms chosen from the series consisting of nitrogen, oxygen and sulfur and is bonded via a ring carbon atom, wherein the phenyl and the heterocycle all are optionally substituted by one or more identical or different substituents chosen from the series consisting of halogen, (C1-C-6)- alkyl, (Ci-C₆)-alkyl-0-, -O-CH₂-O-, -O-CF₂-O-, (Ci-C₆)-alkyl-S(0)_m- and NC-; Het¹, independently of each other group Het¹, is a saturated or unsaturated 4- membered to 8-membered monocyclic heterocycle which comprises a ring nitrogen atom via which Het¹ is bonded and optionally one or two identical or different further ring heteroatoms chosen from the series consisting of nitrogen, oxygen and sulfur, which is optionally substituted by one or more identical or different substituents chosen from the series consisting of halogen, (Ci-C₄)-alkyl, HO-, (Ci-C₄)-alkyl-O-, oxo and NC-

Het² is a saturated 4-membered to 7-membered monocyclic heterocycle which comprises a ring nitrogen atom via which Het² is bonded and optionally one further ring heteroatom chosen from the series consisting of nitrogen, oxygen and sulfur, which is optionally substituted by one or more identical or different substituents chosen from the series consisting of halogen, (Ci-C₄)-alkyl, HO- and (Ci-C₄)-alkyl-O-;

Het³, independently of each other group Het³, is a saturated 4-membered to 7- membered monocyclic heterocycle which comprises one or two identical or different ring heteroatoms chosen from the series consisting of nitrogen, oxygen and sulfur and is bonded via a ring carbon atom, which is optionally substituted by one or more identical or different substituents chosen from the series consisting of fluorine, (Ci-C₄)- alkyl and oxo; m, independently of each other number m, is an integer chosen from the series consisting of 0, 1 and 2; wherein all cycloalkyl groups, independently of each other, are optionally substituted by one or more identical or different substituents chosen from the series consisting of fluorine and (Ci-C₄)-alkyl; wherein all alkyl, C_sH_2s, C_uH_2u, (CH₂)_X and (CH₂)_y groups, independently of each other, and independently of any other substituents, are optionally substituted by one or more fluorine substituents.

A further embodiment is the use of a compound of the formula I, in any of its

stereoisomeric forms or a mixture of stereoisomeric forms in any ratio, or a

A is C(R¹); D is N(R²); E is N;

G is chosen from the series consisting of R⁷¹-O-C(O)- and R⁷²-N(R⁷³)-C(O)-; R¹ is chosen from the series consisting of hydrogen, halogen and (Ci-C₄)-alkyl;

R² is Ar-C₃H_2s-, wherein s is 0; R¹⁰ is R¹¹-O-; R¹¹ is chosen from the series consisting of hydrogen and R¹⁴;

R¹⁴ is (Ci-Cio)-alkyl which is optionally substituted by one, two or three identical or different substituents chosen from the series consisting of HO-, R¹⁶-O-, oxo, (C3-C7)- cycloalkyl, Ar, Het¹, di((Ci-C₄)-alkyl)N- and Het¹-C(O)-;

R¹⁶ is (Ci-C6)-alkyl which is optionally substituted by one or two identical or different substituents chosen from the series consisting of HO- and (Ci-C₄)-alkyl-O-; R is R -C_uH_2u-, wherein u is an integer chosen from the series consisting of 0 and 1 ;

R³² is chosen from the series consisting of phenyl and an aromatic 6-membered monocyclic heterocycle which comprises one or two nitrogen atoms as ring

heteroatoms, wherein the phenyl and the heterocycle all are optionally substituted by one, two or three identical or different substituents chosen from the series consisting of halogen, (Ci-C₆)-alkyl, (C₃-C₇)-cycloalkyl, R³³, (Ci-C₆)-alkyl-O-, R³³-O-, R³³-(d-C₄)- alkyl-O-, -O-CH₂-O-, -O-CF₂-O-, (Ci-C₆)-alkyl-S(O)_m-, di((Ci-C₆)-alkyl)N-, Het¹ and NC- ;

R⁴⁰ is hydrogen;

R⁵⁰ is hydrogen;

R⁶⁰ is hydrogen;

R⁷¹ is chosen from the series consisting of hydrogen and (Ci-Cs)-alkyl which is optionally substituted by one substituent chosen from the series consisting (Ci-Ce)- alkyl-O- and (Ci-C₆)-alkyl-C(O)-O-;

R⁷² and R⁷³ are independently of each other chosen from the series consisting of hydrogen and (Ci-C2)-alkyl; Ar is chosen from the series consisting of phenyl and an aromatic 6-membered heterocycle which comprises one or two nitrogen atoms as ring heteroatoms, wherein the phenyl and the heterocycle are all optionally substituted by one, two or three identical or different substituents chosen from the series consisting of halogen, (C1-C-6)- alkyl, (Ci-C₆)-alkyl-O-, (Ci-C₆)-alkyl-S(0)_m- and NC-;

Het¹, independently of each other group Het¹, is a saturated or unsaturated 4- membered to 6-membered monocyclic heterocycle which comprises a ring nitrogen atom via which Het¹ is bonded and optionally one further ring heteroatom chosen from the series consisting of nitrogen, oxygen and sulfur, which is optionally substituted by one, two or three identical or different substituents chosen from the series consisting of fluorine, (Ci-C₄)-alkyl, HO- and oxo; m, independently of each other number m, is an integer chosen from the series consisting of 0, 1 and 2; wherein all cycloalkyl groups, independently of each other, are optionally substituted by one or more identical or different substituents chosen from the series consisting of fluorine and (Ci-C₄)-alkyl; wherein all alkyl, C_sH_2s and C_uH_2u groups, independently of each other, and

independently of any other substituents, are optionally substituted by one or more fluorine substituents.

Another embodiment is the use of a compound of the formula I, or a physiologically acceptable salt thereof, or a physiologically acceptable solvate of any of them, chosen from

3-[(5-Hydroxy-1 -phenyl-1 H-pyrazole-3-carbonyl)-amino]-3-(4-methoxy-phenyl)- propionic acid,

3-(3-tert-Butoxy-phenyl)-3-{[1 -(2,5-dimethyl-phenyl)-5-hydroxy-1 H-pyrazole-3- carbonyl]-amino}-propionic acid,

(S)-3-{[1 -(2-Fluoro-phenyl)-5-methoxy-1 H-pyrazole-3-carbonyl]-amino}-3-o-tolyl- propionic acid, 3-(3-Fluoro-2-methyl-phenyl)-3-{[1 -(4-fluoro-phenyl)-5-hydroxy-1 H-pyrazole-3- carbonyl]-amino}-propionic acid,

3-(2-Chloro-5-fluoro-phenyl)-3-{[1 -(4-fluoro-phenyl)-5-hydroxy-1 H-pyrazole-3- carbonyl]-amino}-propionic acid,

(S)-3-[(5-Methoxy-1 -phenyl-1 H-pyrazole-3-carbonyl)-amino]-3-o-tolyl-propionic acid, 3-[(5-Hydroxy-1 -phenyl-1 H-pyrazole-3-carbonyl)-amino]-3-(2-methoxy-5- trifluoronnethyl-phenyl)-propionic acid,

3-(2-Fluoro-4-methyl-phenyl)-3-[(5-hydroxy-1 -phenyl-1 H-pyrazole-3-carbonyl)-amino]- propionic acid,

3-{[1 -(2-Chloro-phenyl)-5-hydroxy-1 H-pyrazole-3-carbonyl]-amino}-3-(2'-fluoro- biphenyl-4-yl)-propionic acid,

3-[(5-Methoxy-1 -phenyl-1 H-pyrazole-3-carbonyl)-amino]-3-(4-pyridin-2-yl-phenyl)- propionic acid,

3-{[1 -(2-Fluoro-phenyl)-5-hydroxy-1 H-pyrazole-3-carbonyl]-amino}-3-(4- methanesulfonyl-phenyl)-propionic acid,

(S)-3-{[5-Hydroxy-1 -(2-methanesulfonyl-phenyl)-1 H)-pyrazole-3-carbonyl]-amino}-3-o- tolyl-propionic acid,

3-{[1 -(2-Fluoro-phenyl)-5-methoxy-1 H-pyrazole-3-carbonyl]-amino}-3-(4-methoxy-2- methyl-phenyl)-propionic acid,

(S)-3-{[1 -(2-Fluoro-phenyl)-5-methoxy-1 H-pyrazole-3-carbonyl]-amino}-3-(2- trifluoronnethyl-phenyl)-propionic acid,

3-(2,3-Dimethyl-phenyl)-3-{[1 -(2-fluoro-phenyl)-5-nnethoxy-1 H-pyrazole-3-carbonyl]- amino}-propionic acid,

3-{[5-Cyclopropylmethoxy-1 -(2-fluoro-phenyl)-1 H-pyrazole-3-carbonyl]-annino}-3-(3- fluoro-2-methyl-phenyl)-propionic acid,

(S)-3-{[5-Cyclopropylmethoxy-1 -(2-fluoro-phenyl)-1 H-pyrazole-3-carbonyl]-annino}-3- m-tolyl-propionic acid,

(S)-3-{[1 -(2-Fluoro-phenyl)-5-((R)-2-hydroxy-3,3-dimethyl-butoxy)-1 H-pyrazole-3- carbonyl]-amino}-3-o-tolyl-propionic acid,

(S)-3-{[1 -(2-fluoro-phenyl)-5-((S)-2-hydroxy-3,3-dimethyl-butoxy)-1 H-pyrazole-3- carbonyl]-amino}-3-o-tolyl-propionic acid, (S)-3-{[5-(3,3-Dimethyl-2-oxo-butoxy)-1 -(2-fluoro-phenyl)-1 H-pyrazole-3-carbonyl]- amino}-3-o-tolyl-propionic acid,

(S)-3-(2,4-Dichloro-phenyl)-3-{[1 -(2-fluoro-phenyl)-5-(2-hydroxy-2-methyl-propoxy)- 1 H-pyrazole-3-carbonyl]-amino}-propionic acid,

(S)-3-{[5-(2-Cyclopropyl-2-hydroxy-propoxy)-1 -(2-fluoro-phenyl)-1 H-pyrazole-3- carbonyl]-amino}-3-o-tolyl-propionic acid,

(S)-3-{[1 -(2-Fluoro-phenyl)-5-((R)-2-hydroxy-2,3,3-trimethyl-butoxy)-1 H-pyrazole-3- carbonyl]-amino}-3-o-tolyl-propionic acid,

(S)-3-{[1 -(2-Fluoro-phenyl)-5-((S)-2-hydroxy-2,3,3-trimethyl-butoxy)-1 H-pyrazole-3- carbonyl]-amino}-3-o-tolyl-propionic acid,

(S)-3-(2-Chloro-phenyl)-3-{[1 -(2-fluoro-phenyl)-5-((R)-2-hydroxy-2,3,3-trimethyl- butoxy)-1 H-pyrazole-3-carbonyl]-amino}-propionic acid,

(S)-3-(2-Chloro-phenyl)-3-{[1 -(2-fluoro-phenyl)-5-((S)-2-hydroxy-2,3,3-trimethyl- butoxy)-1 H-pyrazole-3-carbonyl]-amino}-propionic acid,

(S)-3-(2,4-Dichloro-phenyl)-3-{[5-(2-ethyl-2-hydroxy-butoxy)-1 -(2-fluoro-phenyl)-1 H- pyrazole-3-carbonyl]-amino}-propionic acid,

(S)-3-{[1 -(2-Fluoro-phenyl)-5-((R)-2-hydroxy-2,3-dimethyl-butoxy)-1 H-pyrazole-3- carbonyl]-amino}-3-o-tolyl-propionic acid,

(S)-3-{[1 -(2-Fluoro-phenyl)-5-((S)-2-hydroxy-2,3-dimethyl-butoxy)-1 H-pyrazole-3- carbonyl]-amino}-3-o-tolyl-propionic acid,

(S)-3-(2-Chloro-phenyl)-3-{[1 -(2-fluoro-phenyl)-5-((R)-2-hydroxy-3,3-dimethyl-butoxy)- 1 H-pyrazole-3-carbonyl]-amino}-propionic acid,

(S)-3-(2-Chloro-phenyl)-3-{[1 -(2-fluoro-phenyl)-5-((S)-2-hydroxy-3,3-dimethyl-butoxy)- 1 H-pyrazole-3-carbonyl]-amino}-propionic acid,

(S)-3-{[1 -(2-Fluoro-phenyl)-5-((R)-2-hydroxy-2,3,3-trimethyl-butoxy)-1 H-pyrazole-3- carbonyl]-amino}-3-p-tolyl-propionic acid,

(S)-3-{[1 -(2-Fluoro-phenyl)-5-((S)-2-hydroxy-2,3,3-trimethyl-butoxy)-1 H-pyrazole-3- carbonyl]-amino}-3-p-tolyl-propionic acid,

(S)-3-{[5-((R)-2-Hydroxy-3,3-dimethyl-butoxy)-1 -phenyl-1 H-pyrazole-3-carbonyl]- amino}-3-phenyl-propionic acid,

(S)-3-{[5-((S)-2-Hydroxy-3,3-dimethyl-butoxy)-1 -phenyl-1 H-pyrazole-3-carbonyl]- amino}-3-phenyl-propionic acid, (S)-3-{[1 -(2-Chloro-phenyl)-5-((R)-2-hydroxy-3,3-dimethyl-butoxy)-1 H-pyrazole-3- carbonyl]-amino}-3-phenyl-propionic acid, and

(S)-3-{[1 -(2-Chloro-phenyl)-5-((S)-2-hydroxy-3,3-dimethyl-butoxy)-1 H-pyrazole-3- carbonyl]-amino}-3-phenyl-propionic acid,

for the prevention and /or treatment of atrilar fibrillation.

A subject of the invention is the use of a compound of the formula I or a physiologically acceptable salt thereof, or a physiologically acceptable solvate of any of them, which is chosen from

(S)-3-{[1 -(2-Fluoro-phenyl)-5-methoxy-1 H-pyrazole-3-carbonyl]-amino}-3-o-tolyl- propionic acid,

3-(3-Fluoro-2-methyl-phenyl)-3-{[1 -(4-fluoro-phenyl)-5-hydroxy-1 H-pyrazole-3- carbonyl]-amino}-propionic acid,

(S)-3-[(5-Methoxy-1 -phenyl-1 H-pyrazole-3-carbonyl)-amino]-3-o-tolyl-propionic acid, 3-[(5-Hydroxy-1 -phenyl-1 H-pyrazole-3-carbonyl)-amino]-3-(2-methoxy-5- trifluoromethyl-phenyl)-propionic acid,

3-{[1 -(2-Fluoro-phenyl)-5-hydroxy-1 H-pyrazole-3-carbonyl]-amino}-3-(4- methanesulfonyl-phenyl)-propionic acid, (S)-3-{[5-Hydroxy-1 -(2-methanesulfonyl-phenyl)-1 H)-pyrazole-3-carbonyl]-amino}-3-o- tolyl-propionic acid,

(S)-3-{[1 -(2-Fluoro-phenyl)-5-((S)-2-hydroxy-3,3-dimethyl-butoxy)-1 H-pyrazole-3- carbonyl]-amino}-3-o-tolyl-propionic acid,

(S)-3-{[5-(3,3-Dimethyl-2-oxo-butoxy)-1 -(2-fluoro-phenyl)-1 H-pyrazole-3-carbonyl]- amino}-3-o-tolyl-propionic acid,

(S)-3-(2,4-Dichloro-phenyl)-3-{[5-(2-ethyl-2-hydroxy-butoxy)-1 -(2-fluoro-phenyl)-1 H- pyrazole-3-carbonyl]-amino}-propionic acid, (S)-3-(2,3-Dimethyl-phenyl)-3-{[1 -(2-fluoro-phenyl)-5-((R)-2-hydroxy-3,3-dimethyl- butoxy)-1 H-pyrazole-3-carbonyl]-amino}-propionic acid,

(S)-3-(2,4-Dimethyl-phenyl)-3-{[1 -(2-fluoro-phenyl)-5-((R)-2-hydroxy-3,3-dimethyl- butoxy)-1 H-pyrazole-3-carbonyl]-amino}-propionic acid,

(S)-3-(2,5-Dimethyl-phenyl)-3-{[1 -(2-fluoro-phenyl)-5-((R)-2-hydroxy-3,3-dimethyl- butoxy)-1 H-pyrazole-3-carbonyl]-amino}-propionic acid,

(S)-3-(2,3-Dichloro-phenyl)-3-{[1 -(2-fluoro-phenyl)-5-((R)-2-hydroxy-3,3-dimethyl- butoxy)-1 H-pyrazole-3-carbonyl]-amino}-propionic acid,

(S)-3-(2,4-Dichloro-phenyl)-3-{[1 -(2-fluoro-phenyl)-5-((R)-2-hydroxy-3,3-dimethyl- butoxy)-1 H-pyrazole-3-carbonyl]-amino}-propionic acid,

(S)-3-(2,5-Dichloro-phenyl)-3-{[1 -(2-fluoro-phenyl)-5-((R)-2-hydroxy-3,3-dimethyl- butoxy)-1 H-pyrazole-3-carbonyl]-amino}-propionic acid,

(S)-3-{[1 -(2-Fluoro-phenyl)-5-((R)-2-hydroxy-3,3-dimethyl-butoxy)-1 H-pyrazole-3- carbonyl]-amino}-3-(4-methoxy-2-nnethyl-phenyl)-propionic acid,

(S)-3-{[1 -(2-Fluoro-phenyl)-5-((R)-2-hydroxy-3,3-dimethyl-butoxy)-1 H-pyrazole-3- carbonyl]-amino}-3-(4-nnethoxy-phenyl)-propionic acid,

(S)-3-{[1 -(2-Fluoro-phenyl)-5-((R)-2-hydroxy-3,3-dimethyl-butoxy)-1 H-pyrazole-3- carbonyl]-amino}-3-(4-nnethanesulfonyl-phenyl)-propionic acid,

(S)-3-(2-Fluoro-phenyl)-3-{[1 -(2-fluoro-phenyl)-5-((R)-2-hydroxy-3,3-dimethyl-butoxy)- 1 H-pyrazole-3-carbonyl]-amino}-propionic acid,

(S)-3-{[1 -(2-Fluoro-phenyl)-5-((R)-2-hydroxy-3,3-dimethyl-butoxy)-1 H-pyrazole-3- carbonyl]-amino}-3-phenyl-propionic acid,

(S)-3-{[1 -(2-Fluoro-phenyl)-5-((R)-2-hydroxy-3,3-dimethyl-butoxy)-1 H-pyrazole-3- carbonyl]-amino}-3-(2-trifluoronnethyl-phenyl)-propionic acid,

(S)-3-{[1 -(2-Fluoro-phenyl)-5-((R)-2-hydroxy-3,3-dimethyl-butoxy)-1 H-pyrazole-3- carbonyl]-amino}-3-(4-trifluoronnethyl-phenyl)-propionic acid,

(S)-3-{[5-((R)-2-Hydroxy-3,3-dimethyl-butoxy)-1 -phenyl-1 H-pyrazole-3-carbonyl]- amino}-3-o-tolyl-propionic acid,

(S)-3-{[5-((R)-2-Hydroxy-3,3-dimethyl-butoxy)-1 -phenyl-1 H-pyrazole-3-carbonyl]- amino}-3-p-tolyl-propionic acid, (S)-3-(2,3-Dimethyl-phenyl)-3-{[5-((R)-2-hydroxy-3,3-dimethyl-butoxy)-1 -phenyl-1 H- pyrazole-3-carbonyl]-amino}-propionic acid,

(S)-3-(2-Chloro-phenyl)-3-{[5-((R)-2-hydroxy-3,3-dimethyl-butoxy)-1 -phenyl-1 H- pyrazole-3-carbonyl]-amino}-propionic acid,

(S)-3-(2,3-Dichloro-phenyl)-3-{[5-((R)-2-hydroxy-3,3-dimethyl-butoxy)-1 -phenyl-1 H- pyrazole-3-carbonyl]-amino}-propionic acid,

(S)-3-(2,4-Dichloro-phenyl)-3-{[5-((R)-2-hydroxy-3,3-dimethyl-butoxy)-1 -phenyl-1 H- pyrazole-3-carbonyl]-amino}-propionic acid,

(S)-3-(2,4-Dichloro-phenyl)-3-{[1 -(3-fluoro-phenyl)-5-((R)-2-hydroxy-3,3-dimethyl- butoxy)-1 H-pyrazole-3-carbonyl]-amino}-propionic acid,

(S)-3-{[1 -(3-Fluoro-phenyl)-5-((R)-2-hydroxy-3,3-dimethyl-butoxy)-1 H-pyrazole-3- carbonyl]-amino}-3-o-tolyl-propionic acid,

(S)-3-(2,4-Dimethyl-phenyl)-3-{[1 -(3-fluoro-phenyl)-5-((R)-2-hydroxy-3,3-dimethyl- butoxy)-1 H-pyrazole-3-carbonyl]-amino}-propionic acid,

(S)-3-{[1 -(2-Chloro-phenyl)-5-((R)-2-hydroxy-3,3-dimethyl-butoxy)-1 H-pyrazole-3- carbonyl]-amino}-3-o-tolyl-propionic acid,

(S)-3-{[1 -(2-Chloro-phenyl)-5-((R)-2-hydroxy-3,3-dimethyl-butoxy)-1 H-pyrazole-3- carbonyl]-amino}-3-nn-tolyl-propionic acid,

(S)-3-{[1 -(2-Chloro-phenyl)-5-((R)-2-hydroxy-3,3-dimethyl-butoxy)-1 H-pyrazole-3- carbonyl]-amino}-3-m-tolyl-propionic acid,

(S)-3-(2-Chloro-phenyl)-3-{[1 -(2-chloro-phenyl)-5-((R)-2-hydroxy-3,3-dimethyl-butoxy)- 1 H-pyrazole-3-carbonyl]-amino}-propionic acid,

(S)-3-{[1 -(2-Chloro-phenyl)-5-((R)-2-hydroxy-3,3-dimethyl-butoxy)-1 H-pyrazole-3- carbonyl]-amino}-3-(2,3-dichloro-phenyl)-propionic acid,

(S)-3-{[1 -(2-Chloro-phenyl)-5-((R)-2-hydroxy-3,3-dimethyl-butoxy)-1 H-pyrazole-3- carbonyl]-amino}-3-(2,4-dichloro-phenyl)-propionic acid,

(S)-3-{[1 -(2-Chloro-phenyl)-5-((R)-2-hydroxy-3,3-dimethyl-butoxy)-1 H-pyrazole-3- carbonyl]-amino}-3-phenyl-propionic acid,

(S)-3-{[1 -(4-Fluoro-phenyl)-5-((R)-2-hydroxy-3,3-dimethyl-butoxy)-1 H-pyrazole-3- carbonyl]-amino}-3-phenyl-propionic acid, (S)-3-{[1 -(4-Fluoro-phenyl)-5-((R)-2-hydroxy-3,3-dimethyl-butoxy)-1 H-pyrazole-3- carbonyl]-amino}-3-o-tolyl-propionic acid,

(S)-3-(2,3-Dimethyl-phenyl)-3-{[1 -(2-fluoro-phenyl)-5-((S)-2-hydroxy-3,3-dimethyl- butoxy)-1 H-pyrazole-3-carbonyl]-amino}-propionic acid,

(S)-3-(2,4-Dimethyl-phenyl)-3-{[1 -(2-fluoro-phenyl)-5-((S)-2-hydroxy-3,3-dimethyl- butoxy)-1 H-pyrazole-3-carbonyl]-amino}-propionic acid,

(S)-3-(2,5-Dimethyl-phenyl)-3-{[1 -(2-fluoro-phenyl)-5-((S)-2-hydroxy-3,3-dimethyl- butoxy)-1 H-pyrazole-3-carbonyl]-amino}-propionic acid,

(S)-3-(2,3-Dichloro-phenyl)-3-{[1 -(2-fluoro-phenyl)-5-((S)-2-hydroxy-3,3-dimethyl- butoxy)-1 H-pyrazole-3-carbonyl]-amino}-propionic acid,

(S)-3-(2,4-Dichloro-phenyl)-3-{[1 -(2-fluoro-phenyl)-5-((S)-2-hydroxy-3,3-dimethyl- butoxy)-1 H-pyrazole-3-carbonyl]-amino}-propionic acid,

(S)-3-(2,5-Dichloro-phenyl)-3-{[1 -(2-fluoro-phenyl)-5-((S)-2-hydroxy-3,3-dimethyl- butoxy)-1 H-pyrazole-3-carbonyl]-amino}-propionic acid,

(S)-3-{[1 -(2-Fluoro-phenyl)-5-((S)-2-hydroxy-3,3-dimethyl-butoxy)-1 H-pyrazole-3- carbonyl]-amino}-3-(4-methoxy-2-nnethyl-phenyl)-propionic acid,

(S)-3-{[1 -(2-Fluoro-phenyl)-5-((S)-2-hydroxy-3,3-dimethyl-butoxy)-1 H-pyrazole-3- carbonyl]-amino}-3-(4-nnethoxy-phenyl)-propionic acid,

(S)-3-{[1 -(2-Fluoro-phenyl)-5-((S)-2-hydroxy-3,3-dimethyl-butoxy)-1 H-pyrazole-3- carbonyl]-amino}-3-(4-nnethanesulfonyl-phenyl)-propionic acid,

(S)-3-(2-Fluoro-phenyl)-3-{[1 -(2-fluoro-phenyl)-5-((S)-2-hydroxy-3,3-dimethyl-butoxy)- 1 H-pyrazole-3-carbonyl]-amino}-propionic acid,

(S)-3-{[1 -(2-Fluoro-phenyl)-5-((S)-2-hydroxy-3,3-dimethyl-butoxy)-1 H-pyrazole-3- carbonyl]-amino}-3-phenyl-propionic acid,

(S)-3-{[1 -(2-Fluoro-phenyl)-5-((S)-2-hydroxy-3,3-dimethyl-butoxy)-1 H-pyrazole-3- carbonyl]-amino}-3-(2-trifluoronnethyl-phenyl)-propionic acid,

(S)-3-{[1 -(2-Fluoro-phenyl)-5-((S)-2-hydroxy-3,3-dimethyl-butoxy)-1 H-pyrazole-3- carbonyl]-amino}-3-(4-trifluoronnethyl-phenyl)-propionic acid,

(S)-3-{[5-((S)-2-Hydroxy-3,3-dimethyl-butoxy)-1 -phenyl-1 H-pyrazole-3-carbonyl]- amino}-3-o-tolyl-propionic acid, (S)-3-{[5-((S)-2-Hydroxy-3,3-dimethyl-butoxy)-1 -phenyl-1 H-pyrazole-3-carbonyl]- amino}-3-p-tolyl-propionic acid,

(S)-3-(2,3-Dimethyl-phenyl)-3-{[5-((S)-2-hydroxy-3,3-dimethyl-butoxy)-1 -phenyl-1 H- pyrazole-3-carbonyl]-amino}-propionic acid,

(S)-3-{[5-((S)-2-Hydroxy-3,3-dimethyl-butoxy)-1 -phenyl-1 H-pyrazole-3-carbonyl]- amino}-3-phenyl-propionic acid,

(S)-3-(2-Chloro-phenyl)-3-{[5-((S)-2-hydroxy-3,3-dimethyl-butoxy)-1 -phenyl-1 H- pyrazole-3-carbonyl]-amino}-propionic acid,

(S)-3-(2,3-Dichloro-phenyl)-3-{[5-((S)-2-hydroxy-3,3-dimethyl-butoxy)-1 -phenyl-1 H- pyrazole-3-carbonyl]-amino}-propionic acid,

(S)-3-(2,4-Dichloro-phenyl)-3-{[5-((S)-2-hydroxy-3,3-dimethyl-butoxy)-1 -phenyl-1 H- pyrazole-3-carbonyl]-amino}-propionic acid,

(S)-3-(2,4-Dichloro-phenyl)-3-{[1 -(3-fluoro-phenyl)-5-((S)-2-hydroxy-3,3-dimethyl- butoxy)-1 H-pyrazole-3-carbonyl]-amino}-propionic acid,

(S)-3-{[1 -(3-Fluoro-phenyl)-5-((S)-2-hydroxy-3,3-dimethyl-butoxy)-1 H-pyrazole-3- carbonyl]-amino}-3-o-tolyl-propionic acid,

(S)-3-(2,4-Dimethyl-phenyl)-3-{[1 -(3-fluoro-phenyl)-5-((S)-2-hydroxy-3,3-dimethyl- butoxy)-1 H-pyrazole-3-carbonyl]-amino}-propionic acid,

(S)-3-{[1 -(2-Chloro-phenyl)-5-((S)-2-hydroxy-3,3-dimethyl-butoxy)-1 H-pyrazole-3- carbonyl]-amino}-3-o-tolyl-propionic acid,

(S)-3-{[1 -(2-Chloro-phenyl)-5-((S)-2-hydroxy-3,3-dimethyl-butoxy)-1 H-pyrazole-3- carbonyl]-amino}-3-nn-tolyl-propionic acid,

(S)-3-(2-Chloro-phenyl)-3-{[1 -(2-chloro-phenyl)-5-((S)-2-hydroxy-3,3-dimethyl-butoxy)- 1 H-pyrazole-3-carbonyl]-amino}-propionic acid,

(S)-3-{[1 -(2-Chloro-phenyl)-5-((S)-2-hydroxy-3,3-dimethyl-butoxy)-1 H-pyrazole-3- carbonyl]-amino}-3-(2,3-dichloro-phenyl)-propionic acid,

(S)-3-{[1 -(2-Chloro-phenyl)-5-((S)-2-hydroxy-3,3-dimethyl-butoxy)-1 H-pyrazole-3- carbonyl]-amino}-3-(2,4-dichloro-phenyl)-propionic acid,

(S)-3-{[1 -(2-Chloro-phenyl)-5-((S)-2-hydroxy-3,3-dimethyl-butoxy)-1 H-pyrazole-3- carbonyl]-amino}-3-phenyl-propionic acid, (S)-3-{[1 -(4-Fluoro-phenyl)-5-((S)-2-hydroxy-3,3-dimethyl-butoxy)-1 H-pyrazole-3- carbonyl]-amino}-3-phenyl-propionic acid,

(S)-3-{[1 -(4-Fluoro-phenyl)-5-((S)-2-hydroxy-3,3-dimethyl-butoxy)-1 H-pyrazole-3- carbonyl]-amino}-3-o-tolyl-propionic acid,

(S)-3-{[1 -(2-Fluoro-phenyl)-5-((R)-2-hydroxy-2,3,3-trimethyl-butoxy)-1 H-pyrazole-3- carbonyl]-amino}-3-nn-tolyl-propionic acid,

(S)-3-{[1 -(3-Fluoro-phenyl)-5-((R)-2-hydroxy-2,3,3-trimethyl-butoxy)-1 H-pyrazole-3- carbonyl]-amino}-3-o-tolyl-propionic acid,

(S)-3-{[1 -(4-Fluoro-phenyl)-5-((R)-2-hydroxy-2,3,3-trimethyl-butoxy)-1 H-pyrazole-3- carbonyl]-amino}-3-o-tolyl-propionic acid,

(S)-3-{[1 -(2-Chloro-phenyl)-5-((R)-2-hydroxy-2,3,3-trimethyl-butoxy)-1 H-pyrazole-3- carbonyl]-amino}-3-o-tolyl-propionic acid,

(S)-3-{[5-((R)-2-Hydroxy-2,3,3-trimethyl-butoxy)-1 -phenyl-1 H-pyrazole-3-carbonyl]- amino}-3-o-tolyl-propionic acid,

(S)-3-{[1 -(2-Chloro-phenyl)-5-((R)-2-hydroxy-2,3,3-trimethyl-butoxy)-1 H-pyrazole-3- carbonyl]-amino}-3-nn-tolyl-propionic acid,

(S)-3-{[1 -(3-Fluoro-phenyl)-5-((R)-2-hydroxy-2,3,3-trimethyl-butoxy)-1 H-pyrazole-3- carbonyl]-amino}-3-nn-tolyl-propionic acid,

(S)-3-{[5-((R)-2-Hydroxy-2,3,3-trimethyl-butoxy)-1 -phenyl-1 H-pyrazole-3-carbonyl]- amino}-3-m-tolyl-propionic acid,

(S)-3-{[1 -(3-Fluoro-phenyl)-5-((R)-2-hydroxy-2,3,3-trimethyl-butoxy)-1 H-pyrazole-3- carbonyl]-amino}-3-p-tolyl-propionic acid,

(S)-3-{[1 -(4-Fluoro-phenyl)-5-((R)-2-hydroxy-2,3,3-trimethyl-butoxy)-1 H-pyrazole-3- carbonyl]-amino}-3-p-tolyl-propionic acid,

(S)-3-{[1 -(2-Chloro-phenyl)-5-((R)-2-hydroxy-2,3,3-trimethyl-butoxy)-1 H-pyrazole-3- carbonyl]-amino}-3-p-tolyl-propionic acid,

(S)-3-(2,3-Dimethyl-phenyl)-3-{[5-((R)-2-hydroxy-2,3,3-trimethyl-butoxy)-1 -phenyl-1 H- pyrazole-3-carbonyl]-amino}-propionic acid,

(S)-3-(2,3-Dimethyl-phenyl)-3-{[1 -(2-fluoro-phenyl)-5-((R)-2-hydroxy-2,3,3-trimethyl- butoxy)-1 H-pyrazole-3-carbonyl]-amino}-propionic acid, (S)-3-(2,3-Dimethyl-phenyl)-3-{[1 -(3-fluoro-phenyl)-5-((R)-2-hydroxy-2,3,3-trimethyl- butoxy)-1 H-pyrazole-3-carbonyl]-amino}-propionic acid,

(S)-3-(2,3-Dimethyl-phenyl)-3-{[1 -(4-fluoro-phenyl)-5-((R)-2-hydroxy-2,3,3-trimethyl- butoxy)-1 H-pyrazole-3-carbonyl]-amino}-propionic acid,

(S)-3-(2,4-Dimethyl-phenyl)-3-{[5-((R)-2-hydroxy-2,3,3-trimethyl-butoxy)-1 -phenyl-1 H- pyrazole-3-carbonyl]-amino}-propionic acid,

(S)-3-(2,4-Dimethyl-phenyl)-3-{[1 -(2-fluoro-phenyl)-5-((R)-2-hydroxy-2,3,3-trimethyl- butoxy)-1 H-pyrazole-3-carbonyl]-amino}-propionic acid,

(S)-3-(2,4-Dimethyl-phenyl)-3-{[1 -(3-fluoro-phenyl)-5-((R)-2-hydroxy-2,3,3-trimethyl- butoxy)-1 H-pyrazole-3-carbonyl]-amino}-propionic acid,

(S)-3-(2,4-Dimethyl-phenyl)-3-{[1 -(4-fluoro-phenyl)-5-((R)-2-hydroxy-2,3,3-trimethyl- butoxy)-1 H-pyrazole-3-carbonyl]-amino}-propionic acid,

(S)-3-{[1 -(2-Chloro-phenyl)-5-((R)-2-hydroxy-2,3,3-trimethyl-butoxy)-1 H-pyrazole-3- carbonyl]-amino}-3-(2,4-dinnethyl-phenyl)-propionic acid,

(S)-3-(2-Chloro-phenyl)-3-{[5-((R)-2-hydroxy-2,3,3-trimethyl-butoxy)-1 -phenyl-1 H- pyrazole-3-carbonyl]-amino}-propionic acid,

(S)-3-(2-Chloro-phenyl)-3-{[1 -(2-chloro-phenyl)-5-((R)-2-hydroxy-2,3,3-trimethyl- butoxy)-1 H-pyrazole-3-carbonyl]-amino}-propionic acid,

(S)-3-(2-Chloro-phenyl)-3-{[1 -(3-fluoro-phenyl)-5-((R)-2-hydroxy-2,3,3-trimethyl- butoxy)-1 H-pyrazole-3-carbonyl]-amino}-propionic acid,

(S)-3-(2-Chloro-phenyl)-3-{[1 -(4-fluoro-phenyl)-5-((R)-2-hydroxy-2,3,3-trimethyl- butoxy)-1 H-pyrazole-3-carbonyl]-amino}-propionic acid,

(S)-3-(2, 3-Dichloro-phenyl)-3-{[5-((R)-2-hydroxy-2, 3, 3-trimethyl-butoxy)-1 -phenyl-1 H- pyrazole-3-carbonyl]-amino}-propionic acid,

(S)-3-(2,3-Dichloro-phenyl)-3-{[1 -(2-fluoro-phenyl)-5-((R)-2-hydroxy-2,3,3-thmethyl- butoxy)-1 H-pyrazole-3-carbonyl]-amino}-propionic acid,

(S)-3-(2,3-Dichloro-phenyl)-3-{[1 -(3-fluoro-phenyl)-5-((R)-2-hydroxy-2,3,3-thmethyl- butoxy)-1 H-pyrazole-3-carbonyl]-amino}-propionic acid,

(S)-3-(2,3-Dichloro-phenyl)-3-{[1 -(4-fluoro-phenyl)-5-((R)-2-hydroxy-2,3,3-thmethyl- butoxy)-1 H-pyrazole-3-carbonyl]-amino}-propionic acid,

(S)-3-(2,4-Dichloro-phenyl)-3-{[5-((R)-2-hydroxy-2, 3, 3-thmethyl-butoxy)-1 -phenyl-1 H- pyrazole-3-carbonyl]-amino}-propionic acid, (S)-3-(2,4-Dichloro-phenyl)-3-{[1 -(2-fluoro-phenyl)-5-((R)-2-hydroxy-2,3,3-trimethyl- butoxy)-1 H-pyrazole-3-carbonyl]-amino}-propionic acid,

(S)-3-(2,4-Dichloro-phenyl)-3-{[1 -(3-fluoro-phenyl)-5-((R)-2-hydroxy-2,3,3-trimethyl- butoxy)-1 H-pyrazole-3-carbonyl]-amino}-propionic acid,

(S)-3-(2,4-Dichloro-phenyl)-3-{[1 -(4-fluoro-phenyl)-5-((R)-2-hydroxy-2,3,3-trimethyl- butoxy)-1 H-pyrazole-3-carbonyl]-amino}-propionic acid,

(S)-3-(2,5-Dichloro-phenyl)-3-{[5-((R)-2-hydroxy-2,3,3-trimethyl-butoxy)-1 -phenyl-1 H- pyrazole-3-carbonyl]-amino}-propionic acid,

(S)-3-(2,5-Dichloro-phenyl)-3-{[1 -(2-fluoro-phenyl)-5-((R)-2-hydroxy-2,3,3-trimethyl- butoxy)-1 H-pyrazole-3-carbonyl]-amino}-propionic acid,

(S)-3-{[1 -(2-Fluoro-phenyl)-5-((S)-2-hydroxy-2,3,3-trimethyl-butoxy)-1 H-pyrazole-3- carbonyl]-amino}-3-nn-tolyl-propionic acid,

(S)-3-{[1 -(3-Fluoro-phenyl)-5-((S)-2-hydroxy-2,3,3-trimethyl-butoxy)-1 H-pyrazole-3- carbonyl]-amino}-3-o-tolyl-propionic acid,

(S)-3-{[1 -(4-Fluoro-phenyl)-5-((S)-2-hydroxy-2,3,3-trimethyl-butoxy)-1 H-pyrazole-3- carbonyl]-amino}-3-o-tolyl-propionic acid,

(S)-3-{[1 -(2-Chloro-phenyl)-5-((S)-2-hydroxy-2,3,3-trimethyl-butoxy)-1 H-pyrazole-3- carbonyl]-amino}-3-o-tolyl-propionic acid,

(S)-3-{[5-((S)-2-Hydroxy-2,3,3-trimethyl-butoxy)-1 -phenyl-1 H-pyrazole-3-carbonyl]- amino}-3-o-tolyl-propionic acid,

(S)-3-{[1 -(2-Chloro-phenyl)-5-((S)-2-hydroxy-2,3,3-trimethyl-butoxy)-1 H-pyrazole-3- carbonyl]-amino}-3-nn-tolyl-propionic acid,

(S)-3-{[1 -(3-Fluoro-phenyl)-5-((S)-2-hydroxy-2,3,3-trimethyl-butoxy)-1 H-pyrazole-3- carbonyl]-amino}-3-m-tolyl-propionic acid,

(S)-3-{[5-((S)-2-Hydroxy-2,3,3-trimethyl-butoxy)-1 -phenyl-1 H-pyrazole-3-carbonyl]- amino}-3-nn-tolyl-propionic acid,

(S)-3-{[1 -(3-Fluoro-phenyl)-5-((S)-2-hydroxy-2,3,3-trimethyl-butoxy)-1 H-pyrazole-3- carbonyl]-amino}-3-p-tolyl-propionic acid,

(S)-3-{[1 -(4-Fluoro-phenyl)-5-((S)-2-hydroxy-2,3,3-trimethyl-butoxy)-1 H-pyrazole-3- carbonyl]-amino}-3-p-tolyl-propionic acid, (S)-3-{[1 -(2-Chloro-phenyl)-5-((S)-2-hydroxy-2,3,3-trimethyl-butoxy)-1 H-pyrazole-3- carbonyl]-amino}-3-p-tolyl-propionic acid,

(S)-3-(2,3-Dimethyl-phenyl)-3-{[5-((S)-2-hydroxy-2,3,3-trimethyl-butoxy)-1 -phenyl-1 H- pyrazole-3-carbonyl]-amino}-propionic acid,

(S)-3-(2,3-Dimethyl-phenyl)-3-{[1 -(2-fluoro-phenyl)-5-((S)-2-hydroxy-2,3,3-trimethyl- butoxy)-1 H-pyrazole-3-carbonyl]-amino}-propionic acid,

(S)-3-(2,3-Dimethyl-phenyl)-3-{[1 -(3-fluoro-phenyl)-5-((S)-2-hydroxy-2,3,3-trimethy^ butoxy)-1 H-pyrazole-3-carbonyl]-amino}-propionic acid,

(S)-3-(2,3-Dimethyl-phenyl)-3-{[1 -(4-fluoro-phenyl)-5-((S)-2-hydroxy-2,3,3-trimethyl- butoxy)-1 H-pyrazole-3-carbonyl]-amino}-propionic acid,

(S)-3-(2,4-Dimethyl-phenyl)-3-{[5-((S)-2-hydroxy-2,3,3-trimethyl-butoxy)-1 -phenyl-1 H- pyrazole-3-carbonyl]-amino}-propionic acid,

(S)-3-(2,4-Dimethyl-phenyl)-3-{[1 -(2-fluoro-phenyl)-5-((S)-2-hydroxy-2,3,3-trimethyl- butoxy)-1 H-pyrazole-3-carbonyl]-amino}-propionic acid,

(S)-3-(2,4-Dimethyl-phenyl)-3-{[1 -(3-fluoro-phenyl)-5-((S)-2-hydroxy-2,3,3-trimethyl- butoxy)-1 H-pyrazole-3-carbonyl]-amino}-propionic acid,

(S)-3-(2,4-Dimethyl-phenyl)-3-{[1 -(4-fluoro-phenyl)-5-((S)-2-hydroxy-2,3,3-trimethyl- butoxy)-1 H-pyrazole-3-carbonyl]-amino}-propionic acid,

(S)-3-{[1 -(2-Chloro-phenyl)-5-((S)-2-hydroxy-2,3,3-trimethyl-butoxy)-1 H-pyrazole-3- carbonyl]-amino}-3-(2,4-dinnethyl-phenyl)-propionic acid,

(S)-3-(2-Chloro-phenyl)-3-{[5-((S)-2-hydroxy-2,3,3-trimethyl-butoxy)-1 -phenyl-1 H- pyrazole-3-carbonyl]-amino}-propionic acid,

(S)-3-(2-Chloro-phenyl)-3-{[1 -(2-chloro-phenyl)-5-((S)-2-hydroxy-2,3,3-trimethyl- butoxy)-1 H-pyrazole-3-carbonyl]-amino}-propionic acid,

(S)-3-(2-Chloro-phenyl)-3-{[1 -(3-fluoro-phenyl)-5-((S)-2-hydroxy-2,3,3-trimethyl- butoxy)-1 H-pyrazole-3-carbonyl]-amino}-propionic acid,

(S)-3-(2-Chloro-phenyl)-3-{[1 -(4-fluoro-phenyl)-5-((S)-2-hydroxy-2,3,3-trimethyl- butoxy)-1 H-pyrazole-3-carbonyl]-amino}-propionic acid,

(S)-3-(2,3-Dichloro-phenyl)-3-{[5-((S)-2-hydroxy-2,3,3-trimethyl-butoxy)-1 -phenyl-1 H- pyrazole-3-carbonyl]-amino}-propionic acid,

(S)-3-(2,3-Dichloro-phenyl)-3-{[1 -(2-fluoro-phenyl)-5-((S)-2-hydroxy-2,3,3-trimethyl- butoxy)-1 H-pyrazole-3-carbonyl]-amino}-propionic acid, (S)-3-(2,3-Dichloro-phenyl)-3-{[1 -(3-fluoro-phenyl)-5-((S)-2-hydroxy-2,3,3-trimethyl- butoxy)-1 H-pyrazole-3-carbonyl]-amino}-propionic acid,

(S)-3-(2,3-Dichloro-phenyl)-3-{[1 -(4-fluoro-phenyl)-5-((S)-2-hydroxy-2,3,3-trimethyl- butoxy)-1 H-pyrazole-3-carbonyl]-amino}-propionic acid,

(S)-3-(2,4-Dichloro-phenyl)-3-{[5-((S)-2-hydroxy-2,3,3-trimethyl-butoxy)-1 -phenyl-1 H- pyrazole-3-carbonyl]-amino}-propionic acid,

(S)-3-(2,4-Dichloro-phenyl)-3-{[1 -(2-fluoro-phenyl)-5-((S)-2-hydroxy-2,3,3-trimethyl- butoxy)-1 H-pyrazole-3-carbonyl]-amino}-propionic acid,

(S)-3-(2,4-Dichloro-phenyl)-3-{[1 -(3-fluoro-phenyl)-5-((S)-2-hydroxy-2,3,3-trimethyl- butoxy)-1 H-pyrazole-3-carbonyl]-amino}-propionic acid,

(S)-3-(2,4-Dichloro-phenyl)-3-{[1 -(4-fluoro-phenyl)-5-((S)-2-hydroxy-2,3,3-trimethyl- butoxy)-1 H-pyrazole-3-carbonyl]-amino}-propionic acid,

(S)-3-(2, 5-Dichloro-phenyl)-3-{[5-((S)-2-hydroxy-2, 3, 3-trimethyl-butoxy)-1 -phenyl-1 H- pyrazole-3-carbonyl]-amino}-propionic acid,

(S)-3-(2,5-Dichloro-phenyl)-3-{[1 -(2-fluoro-phenyl)-5-((S)-2-hydroxy-2,3,3-trimethyl- butoxy)-1 H-pyrazole-3-carbonyl]-amino}-propionic acid,

(S)-3-{[5-((R)-2-Hydroxy-2,3-dimethyl-butoxy)-1 -phenyl-1 H-pyrazole-3-carbonyl]- amino}-3-o-tolyl-propionic acid,

(S)-3-{[1 -(3-Fluoro-phenyl)-5-((R)-2-hydroxy-2,3-dimethyl-butoxy)-1 H-pyrazole-3- carbonyl]-amino}-3-o-tolyl-propionic acid,

(S)-3-{[1 -(4-Fluoro-phenyl)-5-((R)-2-hydroxy-2,3-dimethyl-butoxy)-1 H-pyrazole-3- carbonyl]-amino}-3-o-tolyl-propionic acid,

(S)-3-{[1 -(2-Chloro-phenyl)-5-((R)-2-hydroxy-2,3-dimethyl-butoxy)-1 H-pyrazole-3- carbonyl]-amino}-3-o-tolyl-propionic acid,

(S)-3-{[5-((R)-2-Hydroxy-2,3-dimethyl-butoxy)-1 -phenyl-1 H-pyrazole-3-carbonyl]- amino}-3-phenyl-propionic acid,

(S)-3-(2-Chloro-phenyl)-3-{[1 -(2-fluoro-phenyl)-5-((R)-2-hydroxy-2,3-dimethyl-butoxy)- 1 H-pyrazole-3-carbonyl]-amino}-propionic acid,

(S)-3-(2-Chloro-phenyl)-3-{[1 -(3-fluoro-phenyl)-5-((R)-2-hydroxy-2,3-dimethyl-butoxy)- 1 H-pyrazole-3-carbonyl]-amino}-propionic acid, (S)-3-(2,3-Dichloro-phenyl)-3-{[5-((R)-2-hydroxy-2,3-dimethyl-butoxy)-1 -phenyl-1 H- pyrazole-3-carbonyl]-amino}-propionic acid,

(S)-3-(2,3-Dichloro-phenyl)-3-{[1 -(2-fluoro-phenyl)-5-((R)-2-hydroxy-2,3-dimethyl- butoxy)-1 H-pyrazole-3-carbonyl]-amino}-propionic acid,

S)-3-(2,3-Dichloro-phenyl)-3-{[1 -(3-fluoro-phenyl)-5-((R)-2-hydroxy-2,3-dimethyl- butoxy)-1 H-pyrazole-3-carbonyl]-amino}-propionic acid,

(S)-3-(2,4-Dichloro-phenyl)-3-{[5-((R)-2-hydroxy-2,3-dimethyl-butoxy)-1 -phenyl-1 H- pyrazole-3-carbonyl]-amino}-propionic acid,

(S)-3-(2,4-Dichloro-phenyl)-3-{[1 -(2-fluoro-phenyl)-5-((R)-2-hydroxy-2,3-dimethyl- butoxy)-1 H-pyrazole-3-carbonyl]-amino}-propionic acid,

(S)-3-{[1 -(2-Fluoro-phenyl)-5-((R)-2-hydroxy-2,3-dimethyl-butoxy)-1 H-pyrazole-3- carbonyl]-amino}-3-p-tolyl-propionic acid,

(S)-3-{[5-((R)-2-Hydroxy-2,3-dimethyl-butoxy)-1 -phenyl-1 H-pyrazole-3-carbonyl]- amino}-3-p-tolyl-propionic acid,

S)-3-(2,4-Dimethyl-phenyl)-3-{[5-((R)-2-hydroxy-2,3-dimethyl-butoxy)-1 -phenyl-1 H- pyrazole-3-carbonyl]-amino}-propionic acid,

(S)-3-(2,4-Dimethyl-phenyl)-3-{[1 -(2-fluoro-phenyl)-5-((R)-2-hydroxy-2,3-dimethyl- butoxy)-1 H-pyrazole-3-carbonyl]-amino}-propionic acid,

(S)-3-{[5-((S)-2-Hydroxy-2,3-dimethyl-butoxy)-1 -phenyl-1 H-pyrazole-3-carbonyl]- amino}-3-o-tolyl-propionic acid,

(S)-3-{[1 -(3-Fluoro-phenyl)-5-((S)-2-hydroxy-2,3-dimethyl-butoxy)-1 H-pyrazole-3- carbonyl]-amino}-3-o-tolyl-propionic acid,

(S)-3-{[1 -(4-Fluoro-phenyl)-5-((S)-2-hydroxy-2,3-dimethyl-butoxy)-1 H-pyrazole-3- carbonyl]-amino}-3-o-tolyl-propionic acid,

(S)-3-{[1 -(2-Chloro-phenyl)-5-((S)-2-hydroxy-2,3-dimethyl-butoxy)-1 H-pyrazole-3- carbonyl]-amino}-3-o-tolyl-propionic acid,

(S)-3-{[5-((S)-2-Hydroxy-2,3-dimethyl-butoxy)-1 -phenyl-1 H-pyrazole-3-carbonyl]- amino}-3-phenyl-propionic acid,

(S)-3-(2-Chloro-phenyl)-3-{[1 -(2-fluoro-phenyl)-5-((S)-2-hydroxy-2,3-dimethyl-butoxy)- 1 H-pyrazole-3-carbonyl]-amino}-propionic acid, (S)-3-(2-Chloro-phenyl)-3-{[1 -(3-fluoro-phenyl)-5-((S)-2-hydroxy-2,3-dimethyl-butoxy)- 1 H-pyrazole-3-carbonyl]-amino}-propionic acid,

(S)-3-(2,3-Dichloro-phenyl)-3-{[5-((S)-2-hydroxy-2,3-dimethyl-butoxy)-1 -phenyl-1 H- pyrazole-3-carbonyl]-amino}-propionic acid,

(S)-3-(2,3-Dichloro-phenyl)-3-{[1 -(2-fluoro-phenyl)-5-((S)-2-hydroxy-2,3-dimethyl- butoxy)-1 H-pyrazole-3-carbonyl]-amino}-propionic acid,

S)-3-(2,3-Dichloro-phenyl)-3-{[1 -(3-fluoro-phenyl)-5-((S)-2-hydroxy-2,3-dimethyl- butoxy)-1 H-pyrazole-3-carbonyl]-amino}-propionic acid,

(S)-3-(2,4-Dichloro-phenyl)-3-{[5-((S)-2-hydroxy-2,3-dimethyl-butoxy)-1 -phenyl-1 H- pyrazole-3-carbonyl]-amino}-propionic acid,

(S)-3-(2,4-Dichloro-phenyl)-3-{[1 -(2-fluoro-phenyl)-5-((S)-2-hydroxy-2,3-dimethyl- butoxy)-1 H-pyrazole-3-carbonyl]-amino}-propionic acid,

(S)-3-{[1 -(2-Fluoro-phenyl)-5-((S)-2-hydroxy-2,3-dimethyl-butoxy)-1 H-pyrazole-3- carbonyl]-amino}-3-p-tolyl-propionic acid,

(S)-3-{[5-((S)-2-Hydroxy-2,3-dimethyl-butoxy)-1 -phenyl-1 H-pyrazole-3-carbonyl]- amino}-3-p-tolyl-propionic acid,

S)-3-(2,4-Dimethyl-phenyl)-3-{[5-((S)-2-hydroxy-2,3-dimethyl-butoxy)-1 -phenyl-1 H- pyrazole-3-carbonyl]-amino}-propionic acid,

(S)-3-(2,4-Dimethyl-phenyl)-3-{[1 -(2-fluoro-phenyl)-5-((S)-2-hydroxy-2,3-dimethyl- butoxy)-1 H-pyrazole-3-carbonyl]-amino}-propionic acid,

(S)-3-{[1 -(2-Fluoro-phenyl)-5-(2-hydroxy-2,3-dimethyl-butoxy)-1 H-pyrazole-3-carbonyl]- amino}-3-o-tolyl-propionic acid,

(S)-3-(4-Fluoro-phenyl)-3-{[1 -(2-fluoro-phenyl)-5-((R)-2-hydroxy-2,3,3-trimethyl- butoxy)-1 H-pyrazole-3-carbonyl]-amino}-propionic acid,

3-Cyclohexyl-3-{[1 -(2-fluoro-phenyl)-5-((S)-2-hydroxy-2,3,3-trimethyl-butoxy)-1 H- pyrazole-3-carbonyl]-amino}-propionic acid,

(S)-3-(3-Chloro-phenyl)-3-{[1 -(2-fluoro-phenyl)-5-((R)-2-hydroxy-2,3,3-trimethyl- butoxy)-1 H-pyrazole-3-carbonyl]-amino}-propionic acid,

(S)-3-(2-Chloro-phenyl)-3-{[1 -(2-fluoro-phenyl)-5-(2-hydroxy-2,3-dimethyl-butoxy)-1 H- pyrazole-3-carbonyl]-amino}-propionic acid, (S)-3-(2,3-Dichloro-phenyl)-3-{[1 -(2-fluoro-phenyl)-5-((R)-2-hydroxy-3,3-dimethyl- butoxy)-1 H-pyrazole-3-carbonyl]-amino}-propionic acid,

(S)-3-(2-Chloro-phenyl)-3-{[5-(3,3-dimethyl-2-oxo-butoxy)-1 -(2-fluoro-phenyl)-1 H- pyrazole-3-carbonyl]-amino}-propionic acid,

(S)-3-(3-Cyano-phenyl)-3-{[1 -(2-fluoro-phenyl)-5-((R)-2-hydroxy-2,3,3-trimethyl- butoxy)-1 H-pyrazole-3-carbonyl]-amino}-propionic acid,

(S)-3-(3-Fluoro-phenyl)-3-{[1 -(2-fluoro-phenyl)-5-((R)-2-hydroxy-2,3,3-trimethyl- butoxy)-1 H-pyrazole-3-carbonyl]-amino}-propionic acid,

(S)-3-(3-Fluoro-phenyl)-3-{[1 -(2-fluoro-phenyl)-5-(2-hydroxy-2,3-dimethyl-butoxy)-1 H- pyrazole-3-carbonyl]-amino}-propionic acid,

(S)-3-{[1 -(2-Fluoro-phenyl)-5-((S)-2-hydroxy-2,3-dimethyl-butoxy)-1 H-pyrazole-3- carbonyl]-amino}-3-(2-nnethoxy-phenyl)-propionic acid,

(S)-3-{[1 -(2-Fluoro-phenyl)-5-((S)-2-hydroxy-2,3-dimethyl-butoxy)-1 H-pyrazole-3- carbonyl]-amino}-3-(2-trifluoronnethyl-phenyl)-propionic acid,

(S)-3-(3-Chloro-phenyl)-3-{[1 -(2-fluoro-phenyl)-5-(2-hydroxy-2,3-dimethyl-butoxy)-1 H- pyrazole-3-carbonyl]-amino}-propionic acid,

3-Cyclohexyl-3-{[1 -(2-fluoro-phenyl)-5-((R)-2-hydroxy-2,3-dimethyl-butoxy)-1 H- pyrazole-3-carbonyl]-amino}-propionic acid,

(S)-3-{[1 -(2-Fluoro-phenyl)-5-(2-hydroxy-2,3-dimethyl-butoxy)-1 H-pyrazole-3-carbonyl]- amino}-3-p-tolyl-propionic acid

(S)-3-{[1 -(2-Fluoro-phenyl)-5-((R)-2-hydroxy-3,3-dimethyl-butoxy)-1 H-pyrazole-3- carbonyl]-amino}-3-p-tolyl-propionic acid,

(S)-3-{[5-(3,3-Dimethyl-2-oxo-butoxy)-1 -(2-fluoro-phenyl)-1 H-pyrazole-3-carbonyl]- amino}-3-p-tolyl-propionic acid, (S)-3-{[1 -(2-Fluoro-phenyl)-5-((S)-2-hydroxy-3,3-dimethyl-butoxy)-1 H-pyrazole-3- carbonyl]-amino}-3-m-tolyl-propionic acid,

(S)-3-(4-Chloro-phenyl)-3-{[1 -(2-fluoro-phenyl)-5-((S)-2-hydroxy-3,3-dimethyl-butoxy)- 1 H-pyrazole-3-carbonyl]-amino}-propionic acid,

(S)-3-(3-Chloro-phenyl)-3-{[1 -(2-fluoro-phenyl)-5-((R)-2-hydroxy-3,3-dimethyl-butoxy)- 1 H-pyrazole-3-carbonyl]-amino}-propionic acid,

(S)-3-(3-Chloro-phenyl)-3-{[5-(3,3-dimethyl-2-oxo-butoxy)-1 -(2-fluoro-phenyl)-1 H- pyrazole-3-carbonyl]-amino}-propionic acid,

(S)-3-(3-Chloro-phenyl)-3-{[1 -(2-fluoro-phenyl)-5-((S)-2-hydroxy-2,3,3-trimethyl- butoxy)-1 H-pyrazole-3-carbonyl]-amino}-propionic acid,

(S)-3-{[1 -(2-Fluoro-phenyl)-5-((S)-2-hydroxy-2,3,3-trimethyl-butoxy)-1 H-pyrazole-3- carbonyl]-amino}-3-(2-trifluoronnethyl-phenyl)-propionic acid,

(S)-3-{[1 -(2-Fluoro-phenyl)-5-((S)-2-hydroxy-3,3-dimethyl-butoxy)-1 H-pyrazole-3- carbonyl]-amino}-3-p-tolyl-propionic acid,

(S)-3-{[1 -(2-Fluoro-phenyl)-5-(2-hydroxy-2,3-dimethyl-butoxy)-1 H-pyrazole-3-carbonyl]- amino}-3-(3-nnethoxy-phenyl)-propionic acid,

3-Cyclohexyl-3-{[1 -(2-fluoro-phenyl)-5-((S)-2-hydroxy-2,3-dimethyl-butoxy)-1 H- pyrazole-3-carbonyl]-amino}-propionic acid,

(S)-3-{[1 -(2-Fluoro-phenyl)-5-((R)-2-hydroxy-3,3-dimethyl-butoxy)-1 H-pyrazole-3- carbonyl]-amino}-3-nn-tolyl-propionic acid,

(S)-3-{[5-(3,3-Dimethyl-2-oxo-butoxy)-1 -(2-fluoro-phenyl)-1 H-pyrazole-3-carbonyl]- amino}-3-m-tolyl-propionic acid,

(S)-3-{[1 -(2-Fluoro-phenyl)-5-((R)-2-hydroxy-2,3-dimethyl-butoxy)-1 H-pyrazole-3- carbonyl]-amino}-3-(3-nnethoxy-phenyl)-propionic acid,

(S)-3-(3-Cyano-phenyl)-3-{[1 -(2-fluoro-phenyl)-5-(2-hydroxy-2,3-dimethyl-butoxy)-1 H- pyrazole-3-carbonyl]-amino}-propionic acid, (S)-3-(2,6-Difluoro-phenyl)-3-{[1 -(2-fluoro-phenyl)-5-(2-hydroxy-2,3-dimethyl-butoxy)- 1 H-pyrazole-3-carbonyl]-amino}-propionic acid,

(S)-3-(3-Chloro-phenyl)-3-{[1 -(2-fluoro-phenyl)-5-((S)-2-hydroxy-3,3-dimethyl-butoxy)- 1 H-pyrazole-3-carbonyl]-amino}-propionic acid,

(S)-3-{[1 -(2-Fluoro-phenyl)-5-((S)-2-hydroxy-2,3,3-trimethyl-butoxy)-1 H-pyrazole-3- carbonyl]-amino}-3-(2-nnethoxy-phenyl)-propionic acid,

(S)-3-{[1 -(2-Fluoro-phenyl)-5-(2-hydroxy-2,3-dimethyl-butoxy)-1 H-pyrazole-3-carbonyl]- amino}-3-(2-nnethoxy-phenyl)-propionic acid,

(S)-3-{[1 -(2-Fluoro-phenyl)-5-(2-hydroxy-2,3-dimethyl-butoxy)-1 H-pyrazole-3-carbonyl]- amino}-3-(2-trifluoronnethyl-phenyl)-propionic acid,

3-Cyclohexyl-3-{[1 -(2-fluoro-phenyl)-5-(2-hydroxy-2,3-dimethyl-butoxy)-1 H-pyrazole-3- carbonyl]-amino}-propionic acid,

3-{[1 -(2-Fluoro-phenyl)-5-(2-hydroxy-2,3-dimethyl-butoxy)-1 H-pyrazole-3-carbonyl]- amino}-5-methyl-hexanoic acid,

(R)-3-(4-Chloro-phenyl)-3-{[1 -(2-fluoro-phenyl)-5-(2-hydroxy-3,3-dimethyl-butoxy)-1 H- pyrazole-3-carbonyl]-amino}-propionic acid,

(S)-3-(2,6-Difluoro-phenyl)-3-{[1 -(2-fluoro-phenyl)-5-((S)-2-hydroxy-2,3-dimethyl- butoxy)-1 H-pyrazole-3-carbonyl]-amino}-propionic acid,

3-{[1 -(2-Fluoro-phenyl)-5-((S)-2-hydroxy-2,3,3-trimethyl-butoxy)-1 H-pyrazole-3- carbonyl]-amino}-4-phenyl-butyric acid,

(S)-3-(3-Fluoro-phenyl)-3-{[1 -(2-fluoro-phenyl)-5-((S)-2-hydroxy-2,3,3-trimethyl- butoxy)-1 H-pyrazole-3-carbonyl]-amino}-propionic acid,

3-Cyclohexyl-3-{[1 -(2-fluoro-phenyl)-5-((R)-2-hydroxy-2,3,3-trimethyl-butoxy)-1 H- pyrazole-3-carbonyl]-amino}-propionic acid,

3-{[1 -(2-Fluoro-phenyl)-5-((R)-2-hydroxy-2,3-dimethyl-butoxy)-1 H-pyrazole-3-carbonyl]- amino}-4-phenyl-butyric acid,

(S)-3-{[1 -(2-Fluoro-phenyl)-5-((R)-2-hydroxy-2,3-dimethyl-butoxy)-1 H-pyrazole-3- carbonyl]-amino}-3-(2-nnethoxy-phenyl)-propionic acid,

3-{[1 -(2-Fluoro-phenyl)-5-((R)-2-hydroxy-2,3-dimethyl-butoxy)-1 H-pyrazole-3-carbonyl]- amino}-5-nnethyl-hexanoic acid, (1 -{[1 -(2-Fluoro-phenyl)-5-((R)-2-hydroxy-2,3-dimethyl-butoxy)-1 H-pyrazole-3- carbonyl]-amino}-cyclopentyl)-acetic acid,

(1 -{[1 -(2-Fluoro-phenyl)-5-((S)-2-hydroxy-2,3-dimethyl-butoxy)-1 H-pyrazole-3- carbonyl]-amino}-cyclopentyl)-acetic acid,

3-{[1 -(2-Fluoro-phenyl)-5-((S)-2-hydroxy-2,3-dimethyl-butoxy)-1 H-pyrazole-3-carbonyl]- amino}-4-phenyl-butyric acid,

3-{[1 -(2-Fluoro-phenyl)-5-((R)-2-hydroxy-2,3-dimethyl-butoxy)-1 H-pyrazole-3-carbonyl]- amino}-2-phenyl-propionic acid,

(S)-3-(4-Chloro-phenyl)-3-{[1 -(2-fluoro-phenyl)-5-((R)-2-hydroxy-3,3-dimethyl-butoxy)- 1 H-pyrazole-3-carbonyl]-amino}-propionic acid,

3-{[1 -(2-Fluoro-phenyl)-5-(2-hydroxy-2,3-dimethyl-butoxy)-1 H-pyrazole-3-carbonyl]- amino}-4-phenyl-butyric acid,

3-{[1 -(2-Fluoro-phenyl)-5-((S)-2-hydroxy-2,3-dimethyl-butoxy)-1 H-pyrazole-3-carbonyl]- amino}-2-phenyl-propionic acid,

(S)-4-(4-Cyano-phenyl)-3-{[1 -(2-fluoro-phenyl)-5-((S)-2-hydroxy-2,3,3-trimethyl- butoxy)-1 H-pyrazole-3-carbonyl]-amino}-butyric acid,

(S)-4-(4-Cyano-phenyl)-3-{[1 -(2-fluoro-phenyl)-5-((S)-2-hydroxy-2,3-dimethyl-butoxy)- 1 H-pyrazole-3-carbonyl]-amino}-butyric acid,

(S)-3-(2-Fluoro-phenyl)-3-{[1 -(2-fluoro-phenyl)-5-((S)-2-hydroxy-2,3-dimethyl-butoxy)- 1 H-pyrazole-3-carbonyl]-amino}-propionic acid,

(S)-4-(4-Cyano-phenyl)-3-{[1 -(2-fluoro-phenyl)-5-(2-hydroxy-2,3-dimethyl-butoxy)-1 H- pyrazole-3-carbonyl]-amino}-butyric acid,

(S)-3-{[1 -(2-Fluoro-phenyl)-5-((S)-2-hydroxy-2,3-dimethyl-butoxy)-1 H-pyrazole-3- carbonyl]-amino}-4-phenyl-butyric acid,

(S)-3-{[1 -(2-Fluoro-phenyl)-5-(2-hydroxy-2,3-dimethyl-butoxy)-1 H-pyrazole-3-carbonyl]- amino}-4-phenyl-butyric acid,

(S)-3-(2,3-Dichloro-phenyl)-3-{[5-(3,3-dimethyl-2-oxo-butoxy)-1 -(2-fluoro-phenyl)-1 H- pyrazole-3-carbonyl]-amino}-propionic acid,

(S)-3-{[1 -(2-Fluoro-phenyl)-5-((S)-2-hydroxy-2,3-dimethyl-butoxy)-1 H-pyrazole-3- carbonyl]-amino}-3-(4-nnethoxy-phenyl)-propionic acid, (S)-3-{[1 -(2-Fluoro-phenyl)-5-((S)-2-hydroxy-2,3-dimethyl-butoxy)-1 H-pyrazole-3- carbonyl]-amino}-5-methyl-hexanoic acid,

(S)-3-{[1 -(2-Fluoro-phenyl)-5-(2-hydroxy-2,3-dimethyl-butoxy)-1 H-pyrazole-3-carbonyl]- amino}-5-nnethyl-hexanoic acid,

(1 -{[1 -(2-Fluoro-phenyl)-5-(2-hydroxy-2,3-dimethyl-butoxy)-1 H-pyrazole-3-carbonyl]- amino}-cyclopentyl)-acetic acid,

(S)-3-(4-Fluoro-phenyl)-3-{[1 -(2-fluoro-phenyl)-5-(2-hydroxy-2,3-dimethyl-butoxy)-1 H- pyrazole-3-carbonyl]-amino}-propionic acid,

(S)-3-(2,4-Dimethyl-phenyl)-3-{[1 -(2-fluoro-phenyl)-5-(2-hydroxy-2,3-dimethyl-butoxy)- 1 H-pyrazole-3-carbonyl]-amino}-propionic acid,

(S)-3-(2-Fluoro-phenyl)-3-{[1 -(2-fluoro-phenyl)-5-(2-hydroxy-2,3-dimethyl-butoxy)-1 H- pyrazole-3-carbonyl]-amino}-propionic acid,

(S)-3-(2,3-Dimethoxy-phenyl)-3-{[1 -(2-fluoro-phenyl)-5-(2-hydroxy-2,3-dimethyl- butoxy)-1 H-pyrazole-3-carbonyl]-amino}-propionic acid,

(S)-3-{[1 -(2-Fluoro-phenyl)-5-(2-hydroxy-2,3-dimethyl-butoxy)-1 H-pyrazole-3-carbonyl]- amino}-3-(4-nnethoxy-phenyl)-propionic acid,

(S)-3-{[1 -(2-Fluoro-phenyl)-5-((R)-2-hydroxy-2,3-dimethyl-butoxy)-1 H-pyrazole-3- carbonyl]-amino}-3-(4-nnethoxy-phenyl)-propionic acid,

3-{[1 -(2-Fluoro-phenyl)-5-((S)-2-hydroxy-2,3,3-trimethyl-butoxy)-1 H-pyrazole-3- carbonyl]-amino}-5-nnethyl-hexanoic acid,

(S)-3-{[1 -(2-Fluoro-phenyl)-5-((S)-2-hydroxy-2,3,3-trimethyl-butoxy)-1 H-pyrazole-3- carbonyl]-amino}-4-phenyl-butyric acid,

(1 -{[1 -(2-Fluoro-phenyl)-5-((R)-2-hydroxy-2,3,3-trimethyl-butoxy)-1 H-pyrazole-3- carbonyl]-amino}-cyclopentyl)-acetic acid,

(S)-3-(2-Fluoro-phenyl)-3-{[1 -(2-fluoro-phenyl)-5-((R)-2-hydroxy-2,3,3-trimethyl- butoxy)-1 H-pyrazole-3-carbonyl]-amino}-propionic acid,

(S)-3-(2,3-Dimethoxy-phenyl)-3-{[1 -(2-fluoro-phenyl)-5-((R)-2-hydroxy-2,3,3-trimethyl- butoxy)-1 H-pyrazole-3-carbonyl]-amino}-propionic acid,

(S)-3-{[1 -(2-Fluoro-phenyl)-5-((R)-2-hydroxy-2,3,3-trimethyl-butoxy)-1 H-pyrazole-3- carbonyl]-amino}-3-(3-nnethoxy-phenyl)-propionic acid, (S)-3-{[1 -(2-Fluoro-phenyl)-5-((R)-2-hydroxy-2,3-dimethyl-butoxy)-1 H-pyrazole-3- carbonyl]-amino}-3-o-tolyl-propionic acid,

(S)-3-{[1 -(2-Fluoro-phenyl)-5-((R)-2-hydroxy-2,3-dimethyl-butoxy)-1 H-pyrazole-3- carbonyl]-amino}-5-nnethyl-hexanoic acid,

(S)-3-(2-Fluoro-phenyl)-3-{[1 -(2-fluoro-phenyl)-5-((R)-2-hydroxy-2,3-dimethyl-butoxy)- 1 H-pyrazole-3-carbonyl]-amino}-propionic acid,

(S)-3-{[1 -(2-Fluoro-phenyl)-5-((R)-2-hydroxy-2,3-dimethyl-butoxy)-1 H-pyrazole-3- carbonyl]-amino}-3-(2-trifluoronnethyl-phenyl)-propionic acid,

(S)-3-{[1 -(2-Fluoro-phenyl)-5-((R)-2-hydroxy-2,3-dimethyl-butoxy)-1 H-pyrazole-3- carbonyl]-amino}-4-phenyl-butyric acid,

(S)-3-(3-Cyano-phenyl)-3-{[1 -(2-fluoro-phenyl)-5-((R)-2-hydroxy-2,3-dimethyl-butoxy)- 1 H-pyrazole-3-carbonyl]-amino}-propionic acid,

(S)-3-(2,3-Dimethoxy-phenyl)-3-{[1 -(2-fluoro-phenyl)-5-((R)-2-hydroxy-2,3-dimethyl- butoxy)-1 H-pyrazole-3-carbonyl]-amino}-propionic acid,

(S)-4-(4-Cyano-phenyl)-3-{[1 -(2-fluoro-phenyl)-5-((R)-2-hydroxy-2,3-dimethyl-butoxy)- 1 H-pyrazole-3-carbonyl]-amino}-butyric acid,

(S)-3-(2,6-Difluoro-phenyl)-3-{[1 -(2-fluoro-phenyl)-5-((R)-2-hydroxy-2,3-dimethyl- butoxy)-1 H-pyrazole-3-carbonyl]-amino}-propionic acid,

(S)-3-(3-Fluoro-phenyl)-3-{[1 -(2-fluoro-phenyl)-5-((R)-2-hydroxy-2,3-dimethyl-butoxy)- 1 H-pyrazole-3-carbonyl]-amino}-propionic acid,

3-{[1 -(2-Fluoro-phenyl)-5-((S)-2-hydroxy-2,3-dimethyl-butoxy)-1 H-pyrazole-3-carbonyl]- amino}-5-methyl-hexanoic acid,

(S)-3-(4-Fluoro-phenyl)-3-{[1 -(2-fluoro-phenyl)-5-((S)-2-hydroxy-2,3-dimethyl-butoxy)- 1 H-pyrazole-3-carbonyl]-amino}-propionic acid, (S)-3-(2-Chloro-phenyl)-3-{[1 -(2-fluoro-phenyl)-5-((S)-2-hydroxy-2,3-dimethyl-butoxy)- 1 H-pyrazole-3-carbonyl]-amino}-propionic acid,

(S)-3-(3-Cyano-phenyl)-3-{[1 -(2-fluoro-phenyl)-5-((S)-2-hydroxy-2,3-dimethyl-butoxy)- 1 H-pyrazole-3-carbonyl]-amino}-propionic acid,

(S)-3-{[1 -(2-Fluoro-phenyl)-5-((S)-2-hydroxy-2,3-dimethyl-butoxy)-1 H-pyrazole-3- carbonyl]-amino}-3-(3-nnethoxy-phenyl)-propionic acid,

(S)-3-(3-Fluoro-phenyl)-3-{[1 -(2-fluoro-phenyl)-5-((S)-2-hydroxy-2,3-dimethyl-butoxy)- 1 H-pyrazole-3-carbonyl]-amino}-propionic acid,

(S)-3-(3-Chloro-phenyl)-3-{[1 -(2-fluoro-phenyl)-5-((S)-2-hydroxy-2,3-dimethyl-butoxy)- 1 H-pyrazole-3-carbonyl]-amino}-propionic acid,

(S)-3-{[1 -(2-Fluoro-phenyl)-5-((S)-2-hydroxy-2,3,3-trimethyl-butoxy)-1 H-pyrazole-3- carbonyl]-amino}-5-nnethyl-hexanoic acid,

(1 -{[1 -(2-Fluoro-phenyl)-5-((S)-2-hydroxy-2,3,3-trimethyl-butoxy)-1 H-pyrazole-3- carbonyl]-amino}-cyclopentyl)-acetic acid,

(S)-3-(4-Fluoro-phenyl)-3-{[1 -(2-fluoro-phenyl)-5-((S)-2-hydroxy-2,3,3-trimethyl- butoxy)-1 H-pyrazole-3-carbonyl]-amino}-propionic acid,

(S)-3-(2-Fluoro-phenyl)-3-{[1 -(2-fluoro-phenyl)-5-((S)-2-hydroxy-2,3,3-trimethyl- butoxy)-1 H-pyrazole-3-carbonyl]-amino}-propionic acid,

(S)-3-(2,3-Dimethoxy-phenyl)-3-{[1 -(2-fluoro-phenyl)-5-((S)-2-hydroxy-2,3,3-trimethyl- butoxy)-1 H-pyrazole-3-carbonyl]-amino}-propionic acid,

(S)-3-{[1 -(2-Fluoro-phenyl)-5-((S)-2-hydroxy-2,3,3-trimethyl-butoxy)-1 H-pyrazole-3- carbonyl]-amino}-3-(3-nnethoxy-phenyl)-propionic acid,

(S)-3-{[1 -(2-Fluoro-phenyl)-5-((R)-2-hydroxy-2,3,3-trimethyl-butoxy)-1 H-pyrazole-3- carbonyl]-amino}-5-nnethyl-hexanoic acid,

(S)-3-{[1 -(2-Fluoro-phenyl)-5-((R)-2-hydroxy-2,3,3-trimethyl-butoxy)-1 H-pyrazole-3- carbonyl]-amino}-3-(2-trifluoronnethyl-phenyl)-propionic acid,

(S)-4-(4-Cyano-phenyl)-3-{[1 -(2-fluoro-phenyl)-5-((R)-2-hydroxy-2,3,3-trimethyl- butoxy)-1 H-pyrazole-3-carbonyl]-amino}-butyric acid,

(S)-3-{[1 -(2-Fluoro-phenyl)-5-((R)-2-hydroxy-2,3,3-trimethyl-butoxy)-1 H-pyrazole-3- carbonyl]-amino}-3-(4-nnethoxy-phenyl)-propionic acid, (S)-3-{[1 -(2-Fluoro-phenyl)-5-(2-hydroxy-2-phenyl-propoxy)-1 H-pyrazole-3-carbonyl]- amino}-3-o-tolyl-propionic acid,

1 -(2-Fluoro-phenyl)-5-methoxy-1 H-pyrazole-3-carboxylic acid {(S)-2-[(pyridin-2- ylmethyl)-carbannoyl]-1 -o-tolyl-ethyl}-annide; compound with trifluoro-acetic acid, 1 -(2-Fluoro-phenyl)-5-methoxy-1 H-pyrazole-3-carboxylic acid [(S)-2- (cyclopropylmethyl-carbannoyl)-1 -o-tolyl-ethyl]-annide,

1 -(2-Fluoro-phenyl)-5-methoxy-1 H-pyrazole-3-carboxylic acid {(S)-2-[(furan-2- ylmethyl)-carbannoyl]-1 -o-tolyl-ethyl}-annide,

1 -(2-Fluoro-phenyl)-5-methoxy-1 H-pyrazole-3-carboxylic acid [(S)-2-(3-dimethylamino- propylcarbamoyl)-1 -o-tolyl-ethyl]-amide;

1 -(2-Fluoro-phenyl)-5-methoxy-1 H-pyrazole-3-carboxylic acid [(S)-2-(1 -ethyl- propylcarbamoyl)-1 -o-tolyl-ethyl]-annide,

1 -(2-Fluoro-phenyl)-5-methoxy-1 H-pyrazole-3-carboxylic acid ((S)-2- cyclohexylcarbamoyl-1 -o-tolyl-ethyl)-annide,

1 -(2-Fluoro-phenyl)-5-methoxy-1 H-pyrazole-3-carboxylic acid [(S)-3-((S)-3-hydroxy- pyrrolidin-1 -yl)-3-oxo-1 -o-tolyl-propyl]-amide,

1 -(2-Fluoro-phenyl)-5-methoxy-1 H-pyrazole-3-carboxylic acid [(S)-1 -o-tolyl-2-((R)- 1 ,2,2-trinnethyl-propylcarbannoyl)-ethyl]-annide,

1 -(2-Fluoro-phenyl)-5-methoxy-1 H-pyrazole-3-carboxylic acid [(S)-3-((R)-3-hydroxy- pyrrolidin-1 -yl)-3-oxo-1 -o-tolyl-propyl]-amide,

1 -(2-Fluoro-phenyl)-5-methoxy-1 H-pyrazole-3-carboxylic acid [(S)-2-((S)-sec- butylcarbamoyl)-1 -o-tolyl-ethyl]-annide,

1 -(2-Fluoro-phenyl)-5-methoxy-1 H-pyrazole-3-carboxylic acid [(S)-3-((S)-3-hydroxy- piperidin-1 -yl)-3-oxo-1 -o-tolyl-propyl]-amide,

1 -(2-Fluoro-phenyl)-5-methoxy-1 H-pyrazole-3-carboxylic acid [(S)-2-(carbamoylnnethyl- methyl-carbannoyl)-1 -o-tolyl-ethyl]-annide,

1 -(2-Fluoro-phenyl)-5-methoxy-1 H-pyrazole-3-carboxylic acid [(S)-2-((R)-1 -cyclopropyl- ethylcarbamoyl)-1 -o-tolyl-ethyl]-annide,

1 -(2-Fluoro-phenyl)-5-methoxy-1 H-pyrazole-3-carboxylic acid [(S)-2-((S)-1 -cyclopropyl- ethylcarbamoyl)-1 -o-tolyl-ethyl]-amide,

1 -(2-Fluoro-phenyl)-5-methoxy-1 H-pyrazole-3-carboxylic acid ((S)-2- cyclobutylcarbamoyl-1 -o-tolyl-ethyl)-annide, 1 -(2-Fluoro-phenyl)-5-methoxy-1 H-pyrazole-3-carboxylic acid {(S)-2-[(pyridin-3- ylmethyl)-carbannoyl]-1 -o-tolyl-ethyl}-annide; compound with trifluoro-acetic acid, 1 -(2-Fluoro-phenyl)-5-methoxy-1 H-pyrazole-3-carboxylic acid ((S)-2- cyclopentylcarbamoyl-1 -o-tolyl-ethyl)-annide,

1 -(2-Fluoro-phenyl)-5-methoxy-1 H-pyrazole-3-carboxylic acid [(S)-2-(2-methoxy-1 - methyl-ethylcarbannoyl)-1 -o-tolyl-ethyl]-annide,

1 -(2-Fluoro-phenyl)-5-methoxy-1 H-pyrazole-3-carboxylic acid [(S)-2-(2,2-difluoro- ethylcarbamoyl)-1 -o-tolyl-ethyl]-annide,

1 -(2-Fluoro-phenyl)-5-methoxy-1 H-pyrazole-3-carboxylic acid [(S)-1 -o-tolyl-2-(2,2,2- trifluoro-ethylcarbamoyl)-ethyl]-annide,

1 -(2-Fluoro-phenyl)-5-methoxy-1 H-pyrazole-3-carboxylic acid [(S)-2-(2-cyclopropyl- ethylcarbamoyl)-1 -o-tolyl-ethyl]-annide,

1 -(2-Fluoro-phenyl)-5-methoxy-1 H-pyrazole-3-carboxylic acid {(S)-2-[(pyrimidin-5- ylmethyl)-carbannoyl]-1 -o-tolyl-ethyl}-annide,

1 -(2-Fluoro-phenyl)-5-methoxy-1 H-pyrazole-3-carboxylic acid ((S)-2-butylcarbamoyl-1 -

0- tolyl-ethyl)-amide,

1 - (2-Fluoro-phenyl)-5-methoxy-1 H-pyrazole-3-carboxylic acid {(S)-2-[(furan-3- ylmethyl)-carbannoyl]-1 -o-tolyl-ethyl}-annide,

1 -(2-Fluoro-phenyl)-5-methoxy-1 H-pyrazole-3-carboxylic acid {(S)-2-[(pyridin-4- ylmethyl)-carbannoyl]-1 -o-tolyl-ethyl}-annide; compound with trifluoro-acetic acid, 1 -(2-Fluoro-phenyl)-5-methoxy-1 H-pyrazole-3-carboxylic acid [(S)-2-(1 ,1 -dimethyl- propylcarbamoyl)-1 -o-tolyl-ethyl]-amide,

1 -(2-Fluoro-phenyl)-5-methoxy-1 H-pyrazole-3-carboxylic acid [(S)-2-((R)-sec- butylcarbamoyl)-1 -o-tolyl-ethyl]-amide,

1 -(2-Fluoro-phenyl)-5-methoxy-1 H-pyrazole-3-carboxylic acid ((S)-2- isobutylcarbamoyl-1 -o-tolyl-ethyl)-amide,

1 -(2-Fluoro-phenyl)-5-methoxy-1 H-pyrazole-3-carboxylic acid [(S)-1 -o-tolyl-2-((S)- 1 ,2,2-trimethyl-propylcarbamoyl)-ethyl]-amide,

1 -(2-Fluoro-phenyl)-5-methoxy-1 H-pyrazole-3-carboxylic acid [(S)-2-(1 -methoxymethyl- propylcarbamoyl)-1 -o-tolyl-ethyl]-amide,

1 -(2-Fluoro-phenyl)-5-methoxy-1 H-pyrazole-3-carboxylic acid ((S)-2-tert- butylcarbamoyl-1 -o-tolyl-ethyl)-amide, 1 -(2-Fluoro-phenyl)-5-methoxy-1 H-pyrazole-3-carboxylic acid [(S)-2- (5-methyl-1 H- pyrazol-3-ylcarbamoyl)-1 -o-tolyl-ethyl]-annide,

1 -(2-Fluoro-phenyl)-5-methoxy-1 H-pyrazole-3-carboxylic acid [(S)-2- (2,2-dimethyl- propylcarbamoyl)-1 -o-tolyl-ethyl]-annide,

1 -(2-Fluoro-phenyl)-5-methoxy-1 H-pyrazole-3-carboxylic acid [(S)-2- (3-hydroxy-2,2- dimethyl-propylcarbannoyl)-1 -o-tolyl-ethyl]-annide,

1 -(2-Fluoro-phenyl)-5-methoxy-1 H-pyrazole-3-carboxylic acid [(S)-2- (cyanomethyl- carbamoyl)-1 -o-tolyl-ethyl]-amide,

1 -(2-Fluoro-phenyl)-5-methoxy-1 H-pyrazole-3-carboxylic acid [(S)-2- ((R)-1 - hydroxymethyl-2-methyl-propylcarbamoyl)-1 -o-tolyl-ethyl]-amide,

1 -(2-Fluoro-phenyl)-5-methoxy-1 H-pyrazole-3-carboxylic acid {(S)-2- [(1 H-tetrazol-5- ylmethyl)-carbannoyl]-1 -o-tolyl-ethyl}-annide,

1 -(2-Fluoro-phenyl)-5-methoxy-1 H-pyrazole-3-carboxylic acid ((S)-2- isopropylcarbamoyl-1 -o-tolyl-ethyl)-annide,

1 -(2-Fluoro-phenyl)-5-methoxy-1 H-pyrazole-3-carboxylic acid [(S)-2- (1 -methyl-1 H- pyrazol-3-ylcarbamoyl)-1 -o-tolyl-ethyl]-annide,

1 -(2-Fluoro-phenyl)-5-methoxy-1 H-pyrazole-3-carboxylic acid [(S)-2- (2-oxo-pyrrolidin- 3-ylcarbamoyl)-1 -o-tolyl-ethyl]-annide,

1 -(2-Fluoro-phenyl)-5-methoxy-1 H-pyrazole-3-carboxylic acid [(S)-2- (5-methyl- isoxazol-3-ylcarbamoyl)-1 -o-tolyl-ethyl]-amide,

1 -(2-Fluoro-phenyl)-5-methoxy-1 H-pyrazole-3-carboxylic acid ((S)-2- cyclopropylcarbamoyl-1 -o-tolyl-ethyl)-annide,

1 -(2-Fluoro-phenyl)-5-methoxy-1 H-pyrazole-3-carboxylic acid {(S)-2- [(isoxazol-5- ylmethyl)-carbannoyl]-1 -o-tolyl-ethyl}-annide,

1 -(2-Fluoro-phenyl)-5-methoxy-1 H-pyrazole-3-carboxylic acid [(S)-2- (2-methoxy- ethylcarbamoyl)-1 -o-tolyl-ethyl]-annide,

1 -(2-Fluoro-phenyl)-5-methoxy-1 H-pyrazole-3-carboxylic acid [(S)-2- ((S)-1 - hydroxymethyl-2-nnethyl-propylcarbannoyl)-1 -o-tolyl-ethyl]-annide,

1 -(2-Fluoro-phenyl)-5-methoxy-1 H-pyrazole-3-carboxylic acid [(S)-2- ((S)-2-methoxy-1 - methyl-ethylcarbamoyl)-1 -o-tolyl-ethyl]-amide,

1 -(2-Fluoro-phenyl)-5-methoxy-1 H-pyrazole-3-carboxylic acid ((S)-2- {[(S)-1 - (tetrahydro-furan-2-yl)methyl]-carbannoyl}-1 -o-tolyl-ethyl)-annide and 1 -(2-Fluoro-phenyl)-5-methoxy-1 H-pyrazole-3-carboxylic acid [(S)-2-((R)-1 ,2-dimethyl- propylcarbamoyl)-1 -o-tolyl-ethyl]-annide,

for the treatment and/or prevention of atrial fibrillation.

The invention relates also to the use of a compound of the formula II, in any of its stereoisomeric forms or a mixture of stereoisomeric forms in any ratio, or a

wherein

A is chosen from the series consisting of C(R¹) and N;

D is chosen from the series consisting of C(R²) and N;

E is chosen from the series consisting of C(R³) and N; L is chosen from the series consisting of C(R⁴) and N;

where at least one and at most two of A, D, E or L is N;

G is chosen from the series consisting of R⁷¹-O-C(O)-, R⁷²-N(R⁷³)-C(O)- and tetrazol-5- yi;

R¹ is chosen from the series consisting of hydrogen, halogen, (Ci-C6)-alkyl, HO-, (Ci- C₆)-alkyl-O-, (Ci-C₆)-alkyl-S(0)_m- and NC-;

R² is chosen from the series consisting of hydrogen, halogen, (Ci-C₇)-alkyl, (C1-C-6)- alkyl-O-, (Ci-C₆)-alkyl-CO-, (Ci-C₆)-alkyl-CO-HN-, -NR¹²R¹³, Het²' (C₃-C₇)-cycloalkyl- C_sH_2s- and Ar-C₃H_2s-, wherein s is an integer chosen from the series consisting of 0, 1 , 2 and 3;

R³ is chosen from the series consisting of hydrogen, halogen, (Ci-C6)-alkyl, (C1-C-6)- alkyl-S(O)_m-, Het⁴-(O)_r, -NR¹²R¹³, Het², R¹¹-O-, R¹²-N(R¹³)-C(O)-O- and Het²-C(O)-O- and NC-, wherein s is an integer chosen from the series consisting of 0, 1 , 2 and 3 and wherein t is an integer chosen from the series consisting of 0 and 1 ;

R⁴ is chosen from the series consisting of hydrogen, halogen, (Ci-C6)-alkyl, (C1-C-6)- alkyl-O-, HO-, NR¹²R¹³, Het²;

R¹⁰ is chosen from the series consisting hydrogen, halogen, (Ci-C6)-alkyl, (C1-C-6)- alkyl-O-, (Ci-C₆)-alkyl-S(O)_m-, HO-, -NR¹²R¹³, Het², phenyl-C₃H₂s-(O)t-, wherein s is an integer chosen from the series consisting of 0, 1 , 2 and 3 and wherein t is an integer chosen from the series consisting of 0 and 1 ; or R¹ and R² or R² and R³ or form pyridyl;

or R¹ and R² are -C((Ci-C₃)-alkyl)=N-N((Ci-C₃)-alkyl)-;

or R² and R³ are -NH-CH=N-; with the proviso that one of R¹, R², R³, R⁴ or R¹⁰ is a cyclic substituent;

R¹¹ is chosen from the series consisting of hydrogen, R¹⁴, (C3-C₇)-cycloalkyl, Ar and Het³;

R¹² and R¹³ are independently of each other chosen from the series consisting of hydrogen and R¹⁵;

R¹⁴ is (Ci-Cio)-alkyl which is optionally substituted by one or more identical or different substituents chosen from the series consisting of halogen, HO-, R¹⁶-O-, oxo, (C3-C7)- cycloalkyl, Ar, Het¹, Het³, NC-, H₂N-C(O)-, (Ci-C₄)-alkyl-NH-C(O)-, di((Ci-C₄)-alkyl)N- C(O)-, Het¹-C(O)-, (Ci-C₄)-alkyl-C(O)-NH- and (Ci-C₄)-alkyl-S(0)_m-; R¹⁵ is (Ci-C6)-alkyl which is optionally substituted by one or more identical or different substituents chosen from the series consisting halogen, HO- and (Ci-C6)-alkyl-O-; R¹⁶ is (Ci-C6)-alkyl which is optionally substituted by one or more identical or different substituents chosen from the series consisting of HO-, (Ci-C₄)-alkyl-O- and NC-;

R³¹ is (Ci-Cio)-alkyl which is optionally substituted by one or more identical or different substituents chosen from the series consisting of halogen, (C3-C₇)-cycloalkyl, HO-, (Ci- C₆)-alkyl-O-, (Ci-C₆)-alkyl-S(0)_m- and NC-; R³² is chosen from the series consisting of phenyl and an aromatic 5-membered or 6- membered monocyclic heterocycle which comprises one, two or three identical or different ring heteroatoms chosen from the series consisting of nitrogen, oxygen and sulfur and is bonded via a ring carbon atom, wherein the phenyl and the heterocycle all are optionally substituted by one or more identical or different substituents chosen from the series consisting of halogen, (Ci-C₆)-alkyl, (C₃-C₇)-cycloalkyl, R³³, HO-, (Ci-C₆)- alkyl-O-, R³³-O-, R³³-(Ci-C₄)-alkyl-O-, -O-CH₂-O-, -O-CF₂-O-, (Ci-C₆)-alkyl-S(O)_m-, H₂N-S(O)₂-, (Ci-C₄)-alkyl-NH-S(O)₂-, di((Ci-C₄)-alkyl)N-S(O)₂-, H₂N-, (Ci-C₆)-alkyl-NH- , di((Ci-C₆)-alkyl)N-, Het¹, (Ci-C₄)-alkyl-C(O)-NH-, Ar-C(O)-NH-, (Ci-C₄)-alkyl-S(O)₂- NH- and NC-;

R³³ is chosen from the series consisting of phenyl and an aromatic 5-membered or 6- membered monocyclic heterocycle which comprises one, two or three identical or different ring heteroatoms chosen from the series consisting of nitrogen, oxygen and sulfur and is bonded via a ring carbon atom, wherein the phenyl and the heterocycle all are optionally substituted by one or more identical or different substituents chosen from the series consisting of halogen, (Ci-C6)-alkyl, (C3-C₇)-cycloalkyl, HO-, (Ci-C6)-alkyl-O- , (Ci-C₆)-alkyl-S(O)_m-, H₂N-S(O)₂-, (Ci-C₄)-alkyl-NH-S(O)₂-, di((Ci-C₄)-alkyl)N-S(O)₂- and NC-;

R⁴⁰ is chosen from the series consisting of hydrogen and (Ci-C₄)-alkyl; or R³⁰ and R⁴⁰ together are (CH₂)_X which is optionally substituted by one or more identical or different (Ci-C₄)-alkyl substituents, wherein x is an integer chosen from the series consisting of 2, 3, 4 and 5; R⁵⁰ is chosen from the series consisting of hydrogen, (Ci-C6)-alkyl, HO- and (d-Ce)- alkyl-O-;

R⁶⁰ is chosen from the series consisting of hydrogen and (Ci-C6)-alkyl; or R⁵⁰ and R⁶⁰ together are (CH₂)_y which is optionally substituted by one or more identical or different (Ci-C₄)-alkyl substituents, wherein y is an integer chosen from the series consisting of 2, 3, 4 and 5;

R⁷¹ is chosen from the series consisting of hydrogen and (Ci-Cs)-alkyl which is optionally substituted by one or more identical or different substituents chosen from the series consisting (Ci-C6)-alkyl-O- and (Ci-C6)-alkyl-C(O)-O-;

R⁷² is chosen from the series consisting of hydrogen, (Ci-C6)-alkyl, (C3-C6)-cycloalkyl, -CH₂-(CH₂)_b-(C₃-C₆)-cycloalkyl, Het⁴ and -(CH₂)_b-Het⁴, where alkyl or cycloalkyl is optionally substituted by one or more identical or different substituents chosen from the series consisting of halogen, HO-, HOOC-, (Ci-C₆)-alkyl-O- and (Ci-C₆)-alkyl-C(O)-O-, NC-, N((Ci-C₄)-alkyl)₂ and b is 0, 1 or 2;

R⁷³ is chosen from the series consisting of hydrogen, (Ci-C6)-alkyl;

or

R⁷² and R⁷³ together with the nitrogen atom to which they are bonded form a saturated 4-membered to 7-membered monocyclic heterocycle, which contain optionally one further ring heteroatom chosen from the series consisting of nitrogen, oxygen and sulfur, which is optionally substituted by one or more identical or different substituents chosen from the series consisting of halogen, (CrC₄)-alkyl, HO- and (Ci-C₄)-alkyl-O-;

Ar, independently of each other group Ar, is chosen from the series consisting of phenyl and an aromatic 5-membered or 6-membered monocyclic heterocycle which comprises one, two or three identical or different ring heteroatoms chosen from the series consisting of nitrogen, oxygen and sulfur and is bonded via a ring carbon atom, wherein the phenyl and the heterocycle all are optionally substituted by one or more identical or different substituents chosen from the series consisting of halogen, (C1-C-6)- alkyl, HO-(Ci-C₆)-alkyl, Het⁴, -(CH₂)_X-Phenyl, (Ci-C₆)-alkyl-O-, (C₃-C₇)-cycloalkyl- (CH₂)x-O-, -CF₃, -CO-(Ci-C₆)-alkyl, -NR¹²R¹³, Het², -CO-NR¹²R¹³, CO-Het², (Ci-C₆)- alkyl-S(O)_m-, H₂N-S(O)₂- and NC-;

and wherein phenyl may be substituted by -CH=CH-CH=CH-, -O-CH₂-O-, -O-CH₂- CH₂-O-, -O-CF₂-O- or -N((Ci-C₃)-alkyl)-CH=CH-;

Het¹, independently of each other group Het¹, is a saturated or unsaturated 4- membered to 8-membered monocyclic heterocycle which comprises a ring nitrogen atom via which Het¹ is bonded and optionally one or two identical or different further ring heteroatoms chosen from the series consisting of nitrogen, oxygen and sulfur, which is optionally substituted by one or more identical or different substituents chosen from the series consisting of halogen, (Ci-C₄)-alkyl, HO-, (Ci-C₄)-alkyl-O-, oxo and NC-

Het³, independently of each other group Het³, is a saturated 4-membered to 7- membered monocyclic heterocycle which comprises one or two identical or different ring heteroatoms chosen from the series consisting of nitrogen, oxygen and sulfur and is bonded via a ring carbon atom, which is optionally substituted by one or more identical or different substituents chosen from the series consisting of fluorine, (Ci-C₄)- alkyl and oxo; Het⁴, independently of each other group Het⁴, is a saturated or unsaturated 4- membered to 8-membered monocyclic heterocycle which comprises one to four ring heteroatoms chosen from the series consisting of nitrogen, oxygen and sulfur which is optionally substituted by one or more identical or different substituents chosen from the series consisting of halogen, (Ci-C₄)-alkyl, HO-, (Ci-C₄)-alkyl-O-, oxo and NC-; m, independently of each other number m, is an integer chosen from the series consisting of 0, 1 and 2; wherein all cycloalkyl groups, independently of each other, are optionally substituted by one or more identical or different substituents chosen from the series consisting of fluorine and (Ci-C₄)-alkyl; wherein all alkyl, C_sH_2s, C_uH_2u, (CH₂)_x and (CH₂)_y groups, independently of each other, and independently of any other substituents, are optionally substituted by one or more fluorine substituents;

for the prevention and/or treatment of atrial fibrillation.

Another embodiment is the use of a compound of the formula II, in any of its

stereoisomeric forms or a mixture of stereoisomeric forms in any ratio, or a

heteroatoms, wherein the phenyl and the heterocycle all are optionally substituted by one or more identical or different substituents chosen from the series consisting of halogen, (Ci-C₆)-alkyl, (C₃-C₇)-cycloalkyl, R^M, HO-, (Ci-C₆)-alkyl-0-, R -O-, R^M-(C C₄)-alkyl-O-, -O-CH₂-O-, -O-CF₂-O-, (Ci-C₆)-alkyl-S(O)_m-, di((Ci-C₄)-alkyl)N-S(O)₂-, H₂N-, di((Ci-C₆)-alkyl)N-, Het¹ , (Ci-C₄)-alkyl-C(O)-NH-, Ar-C(O)-NH- and NC-; R³³ is chosen from the series consisting of phenyl and an aromatic 6-membered monocyclic heterocycle which comprises one or two nitrogen atoms as ring

R⁴⁰ is hydrogen.

Another embodiment is the use of a compound of the formula II, in any of its

stereoisomeric forms or a mixture of stereoisomeric forms in any ratio, or a

physiologically acceptable salt thereof, or a physiologically acceptable solvate of any of them, as claimed in any one or more of claims 1 and 2, wherein

G is R⁷¹-O-C(O)-;

R³⁰ is R³²-C_uH_2u-, wherein u is 0;

R³² is chosen from the series consisting of phenyl, wherein the phenyl is optionally substituted by one or more identical or different substituents chosen from the series consisting of halogen, (Ci-C₆)-alkyl, (C₃-C₇)-cycloalkyl, R³³, HO-, (Ci-C₆)-alkyl-O-, R³³- O-, R³³-(Ci-C₄)-alkyl-O-, -O-CH₂-O-, -O-CF₂-O-, (Ci-C₆)-alkyl-S(O)_m-, di((d-C₄)- alkyl)N-S(O)₂-, H₂N-, di((Ci-C₆)-alkyl)N-, Het¹ , (Ci-C₄)-alkyl-C(O)-NH-, Ar-C(O)-NH- and NC-;

R³³ is chosen from the series consisting of phenyl, wherein the phenyl is optionally substituted by one or more identical or different substituents chosen from the series consisting of halogen, (Ci-C₆)-alkyl, (C₃-C₇)-cycloalkyl, HO-, (Ci-C₆)-alkyl-O-, (Ci-C₆)- alkyl-S(O)_m-, H₂N-S(O)₂-, di((Ci-C₄)-alkyl)N-S(O)₂- and NC-;

R⁴⁰ is hydrogen. Another embodiment is the use of a compound of the formula II, in any of its

stereoisomeric forms or a mixture of stereoisomeric forms in any ratio, or a

physiologically acceptable salt thereof, or a physiologically acceptable solvate of any of them, as claimed in any one or more of claims 1 to 3, wherein

R⁵⁰ is hydrogen;

R⁶⁰ is hydrogen.

Another embodiment is the use of a compound of the formula II, in any of its

stereoisomeric forms or a mixture of stereoisomeric forms in any ratio, or a

physiologically acceptable salt thereof, or a physiologically acceptable solvate of any of them, wherein formula I is selected from the series of subformulae 11-1 to II-7

-1 II-2

II-3

II-4 II-5

II-6 II-7

A further embodiment is the use of a compound of the formula 11-1 , in any of its stereoisomeric forms or a mixture of stereoisomeric forms in any ratio, or a

11-1

R² is Ar-C₃H_2s-, wherein s is an integer chosen from the series consisting of 0;

R³ is chosen from the series consisting of hydrogen, halogen, R¹¹-O-, HO-, (C1-C-6)- alkyl and (Ci-C₆)-alkyl-0-; preferred HO- and(Ci-C₆)-alkyl

R⁴ is hydrogen;

R¹⁰ is hydrogen.

A further embodiment is the use of a compound of the formula II, in any of its stereoisomeric forms or a mixture of stereoisomeric forms in any ratio, or a

R³ is R¹¹-O-, wherein R1 1 is hydrogen or (Ci-Cio)-alkyl. A further embodiment is the use of a compound of the formula II, in any of its stereoisomeric forms or a mixture of stereoisomeric forms in any ratio, or a

Another embodiment is the use of a compound of the formula II, or a physiologically acceptable salt thereof, or a physiologically acceptable solvate of any of them, chosen from

(S)-3-[(5-Methoxy-6-phenyl-pyridine-2-carbonyl)-amino]-3-o-tolyl-propionic acid (S)-3-(2,4-Dichloro-phenyl)-3-[(5-methoxy-6-phenyl-pyridine-2-carbonyl)-amino]- propionic acid

(S)-3-[(6-Chloro-5-methoxy-pyridine-2-carbonyl)-amino]-3-o-tolyl-propionic acid (S)-3-{[3-(4,6-Dimethoxy-pyrimidin-2-yloxy)-pyridine-2-carbonyl]-amino}-3-o-tolyl- propionic acid

(S)-3-[(6-Bromo-5-methoxy-pyridine-2-carbonyl)-amino]-3-o-tolyl-propionic acid (S)-3-{[4-(Pyrimidin-2-ylsulfanyl)-pyridine-2-carbonyl]-amino}-3-o-tolyl-propionic acid

(S)-3-[(6-Phenyl-pyridine-2-carbonyl)-amino]-3-o-tolyl-propionic acid

(S)-3-[(5-Phenyl-pyridine-2-carbonyl)-amino]-3-o-tolyl-propionic acid

(S)-3-{[5-(2-Chloro-phenyl)-pyridine-3-carbonyl]-amino}-3-o-tolyl-propionic acid

(S)-3-{[5-(2,3-Dichloro-phenyl)-pyridine-3-carbonyl]-amino}-3-o-tolyl-propionic acid (S)-3-{[5-(2,3-Dimethyl-phenyl)-pyridine-3-carbonyl]-amino}-3-o-tolyl-propionic acid (S)-3-o-Tolyl-3-[(6-m-tolyl-pyridine-2-carbonyl)-amino]-propionic acid

(S)-3-{[6-(2-Chloro-phenyl)-pyridine-2-carbonyl]-amino}-3-o-tolyl-propionic acid

(S)-3-{[6-(2-Fluoro-phenyl)-pyridine-2-carbonyl]-amino}-3-o-tolyl-propionic acid (S)-3-{[6-(2,3-Difluoro-phenyl)-pyridine-2-carbonyl]-annino}-3-o-tolyl-propionic acid (S)-3-{[6-(2,5-Difluoro-phenyl)-pyridine-2-carbonyl]-annino}-3-o-tolyl-propionic acid (S)-3-{[6-(4-Fluoro-2-methyl-phenyl)-pyridine-2-carbonyl]-amino}-3-o-tolyl-propionic acid

(S)-3-{[6-(2,3-Dimethyl-phenyl)-pyridine-2-carbonyl]-amino}-3-o-tolyl-propionic acid

(S)-3-{[6-(5-Fluoro-2-methyl-phenyl)-pyridine-2-carbonyl]-amino}-3-o-tolyl-propionic acid

(S)-3-{[6-(2-Methoxy-4-trifluoromethyl-phenyl)-pyridine-2-carbonyl]-amino}-3-o-tolyl- propionic acid

(S)-3-{[6-(4-Chloro-2-methoxy-phenyl)-pyridine-2-carbonyl]-amino}-3-o-tolyl- propionic acid

(S)-3-{[6-(2-Fluoro-5-methoxy-phenyl)-pyridine-2-carbonyl]-annino}-3-o-tolyl- propionic acid

(S)-3-{[6-(2-Fluoro-phenyl)-5-methoxy-pyridine-2-carbonyl]-annino}-3-o-tolyl- propionic acid

(S)-3-{[6-(2-Fluoro-5-methyl-phenyl)-pyridine-2-carbonyl]-amino}-3-o-tolyl-propionic acid

(S)-3-[(5-Methoxy-6-phenyl-pyridine-2-carbonyl)-amino]-3-p-tolyl-propionic acid (S)-3-[(5-Methoxy-6-o-tolyl-pyridine-2-carbonyl)-annino]-3-p-tolyl-propionic acid (S)-3-{[5-Methoxy-6-(2-trifluoromethyl-phenyl)-pyridine-2-carbonyl]-amino}-3-p-tolyl- propionic acid

(S)-3-{[6-(3-Fluoro-phenyl)-5-methoxy-pyridine-2-carbonyl]-annino}-3-p-tolyl- propionic acid

(S)-3-{[5-Methoxy-6-(2-methoxy-phenyl)-pyridine-2-carbonyl]-amino}-3-p-tolyl- propionic acid

(S)-3-{[6-(2-Chloro-phenyl)-5-methoxy-pyridine-2-carbonyl]-amino}-3-p-tolyl- propionic acid

(S)-3-{[6-(2-Fluoro-phenyl)-5-methoxy-pyridine-2-carbonyl]-annino}-3-p-tolyl- propionic acid

(S)-3-{[6-(2,4-Difluoro-phenyl)-5-methoxy-pyridine-2-carbonyl]-amino}-3-p-tolyl- propionic acid (S)-3-{[6-(2,3-Dichloro-phenyl)-5-methoxy-pyridine-2-carbonyl]-amino}-3-p-tolyl- propionic acid

(S)-3-{[6-(2-Chloro-5-trifluoromethyl-phenyl)-5-nnethoxy-pyridine-2-carbonyl]- amino}-3-p-tolyl-propionic acid

(S)-3-{[6-(3-Fluoro-2-methyl-phenyl)-5-methoxy-pyridine-2-carbonyl]-amino}-3-(2- fluoro-phenyl)-propionic acid

(S)-3-{[6-(2-Chloro-5-trifluoronnethyl-phenyl)-5-nnethoxy-pyridine-2-carbonyl]- amino}-3-(2-fluoro-phenyl)-propionic acid

(S)-3-{[6-(2,3-Difluoro-phenyl)-5-methoxy-pyridine-2-carbonyl]-annino}-3-p-tolyl- propionic acid

(S)-3-{[6-(2,5-Difluoro-phenyl)-5-methoxy-pyridine-2-carbonyl]-annino}-3-p-tolyl- propionic acid

(S)-3-{[6-(2,5-Dichloro-phenyl)-5-methoxy-pyridine-2-carbonyl]-annino}-3-p-tolyl- propionic acid

(S)-3-{[6-(3,5-Dimethyl-isoxazol-4-yl)-5-methoxy-pyridine-2-carbonyl]-amino}-3-p- tolyl-propionic acid

(S)-3-{[6-(4-Fluoro-2-methyl-phenyl)-5-methoxy-pyridine-2-carbonyl]-amino}-3-p- tolyl-propionic acid

(S)-3-{[6-(2,3-Dimethyl-phenyl)-5-methoxy-pyridine-2-carbonyl]-amino}-3-p-tolyl- propionic acid

(S)-3-[(3,2'-Dimethoxy-[2,3]bipyridinyl-6-carbonyl)-amino]-3-p-tolyl-propionic acid

(S)-3-{[6-(5-Fluoro-2-methyl-phenyl)-5-methoxy-pyridine-2-carbonyl]-amino}-3-p- tolyl-propionic acid

(S)-3-{[6-(4-Fluoro-2-methoxy-phenyl)-5-methoxy-pyridine-2-carbonyl]-amino}-3-p- tolyl-propionic acid

(S)-3-{[6-(5-Fluoro-2-methoxy-phenyl)-5-methoxy-pyridine-2-carbonyl]-amino}-3-p- tolyl-propionic acid

(S)-3-{[6-(2-Fluoro-5-methyl-phenyl)-5-methoxy-pyridine-2-carbonyl]-amino}-3-p- tolyl-propionic acid

(S)-3-{[6-(3-Chloro-2-methyl-phenyl)-5-methoxy-pyridine-2-carbonyl]-amino}-3-p- tolyl-propionic acid (S)-3-{[6-(3-Fluoro-2-methyl-phenyl)-5-methoxy-pyridine-2-carbonyl]-amino}-3-p- tolyl-propionic acid

(S)-3-{[6-(5-Chloro-2-fluoro-phenyl)-5-methoxy-pyridine-2-carbonyl]-annino}-3-p- tolyl-propionic acid

(S)-3-(2-Fluoro-phenyl)-3-[(5-methoxy-6-phenyl-pyridine-2-carbonyl)-amino]- propionic acid

(S)-3-{[6-(2,4-Dichloro-phenyl)-5-methoxy-pyridine-2-carbonyl]-annino}-3-(2-fluoro- phenyl)-propionic acid

(S)-3-(2-Fluoro-phenyl)-3-[(5-methoxy-6-o-tolyl-pyridine-2-carbonyl)-annino]- propionic acid

(S)-3-(2-Fluoro-phenyl)-3-{[5-methoxy-6-(2-trifluoronnethyl-phenyl)-pyridine-2- carbonyl]-amino}-propionic acid

(S)-3-(2-Fluoro-phenyl)-3-{[5-methoxy-6-(2-nnethoxy-phenyl)-pyridine-2-carbonyl]- amino}-propionic acid

(S)-3-{[6-(2-Chloro-phenyl)-5-methoxy-pyridine-2-carbonyl]-annino}-3-(2-fluoro- phenyl)-propionic acid

(S)-3-(2-Fluoro-phenyl)-3-{[6-(2-fluoro-phenyl)-5-methoxy-pyridine-2-carbonyl]- amino}-propionic acid

(S)-3-{[6-(2,4-Difluoro-phenyl)-5-methoxy-pyridine-2-carbonyl]-annino}-3-(2-fluoro- phenyl)-propionic acid

(S)-3-{[6-(2,3-Dichloro-phenyl)-5-methoxy-pyridine-2-carbonyl]-annino}-3-(2-fluoro- phenyl)-propionic acid

(S)-3-{[6-(2,3-Difluoro-phenyl)-5-methoxy-pyridine-2-carbonyl]-annino}-3-(2-fluoro- phenyl)-propionic acid

(S)-3-{[6-(2,5-Difluoro-phenyl)-5-methoxy-pyridine-2-carbonyl]-annino}-3-(2-fluoro- phenyl)-propionic acid

(S)-3-{[6-(4-Fluoro-2-methyl-phenyl)-5-methoxy-pyridine-2-carbonyl]-amino}-3-(2- fluoro-phenyl)-propionic acid

(S)-3-{[6-(3,5-Dimethyl-isoxazol-4-yl)-5-methoxy-pyridine-2-carbonyl]-amino}-3-(2- fluoro-phenyl)-propionic acid

(S)-3-{[6-(2,3-Dimethyl-phenyl)-5-methoxy-pyridine-2-carbonyl]-amino}-3-(2-fluoro- phenyl)-propionic acid (S)-3-[(3,2'-Dimethoxy-[2,3']bipyridinyl-6-carbonyl)-amino]-3-(2-fluoro-phenyl)- propionic acid

(S)-3-{[6-(5-Fluoro-2-methyl-phenyl)-5-methoxy-pyridine-2-carbonyl]-amino}-3-(2- fluoro-phenyl)-propionic acid

(S)-3-{[6-(4-Fluoro-2-methoxy-phenyl)-5-methoxy-pyridine-2-carbonyl]-amino}-3-(2- fluoro-phenyl)-propionic acid

(S)-3-{[6-(5-Fluoro-2-methoxy-phenyl)-5-methoxy-pyridine-2-carbonyl]-amino}-3-(2- fluoro-phenyl)-propionic acid

(S)-3-{[6-(2-Fluoro-5-methyl-phenyl)-5-methoxy-pyridine-2-carbonyl]-amino}-3-(2- fluoro-phenyl)-propionic acid

(S)-3-{[6-(3-Chloro-2-methyl-phenyl)-5-methoxy-pyridine-2-carbonyl]-amino}-3-(2- fluoro-phenyl)-propionic acid

(S)-3-{[6-(5-Chloro-2-fluoro-phenyl)-5-methoxy-pyridine-2-carbonyl]-annino}-3-(2- fluoro-phenyl)-propionic acid

(S)-3-{[6-(3-Chloro-2-fluoro-phenyl)-5-methoxy-pyridine-2-carbonyl]-annino}-3-(2- fluoro-phenyl)-propionic acid

(S)-3-(2-Fluoro-phenyl)-3-{[5-methoxy-6-(2-nnethyl-furan-3-yl)-pyridine-2-carbonyl]- amino}-propionic acid

(S)-3-{[6-(2-Chloro-3-methyl-phenyl)-5-methoxy-pyridine-2-carbonyl]-amino}-3-(2- fluoro-phenyl)-propionic acid

(S)-3-(2-Chloro-phenyl)-3-[(5-methoxy-6-phenyl-pyridine-2-carbonyl)-annino]- propionic acid

(S)-3-(2-Chloro-phenyl)-3-{[6-(2,4-dichloro-phenyl)-5-methoxy-pyridine-2-carbonyl]- amino}-propionic acid

(S)-3-(2-Chloro-phenyl)-3-{[6-(4-fluoro-phenyl)-5-methoxy-pyridine-2-carbonyl]- amino}-propionic acid

(S)-3-{[5-Methoxy-6-(3-trifluoromethyl-phenyl)-pyridine-2-carbonyl]-amino}-3-o-tolyl- propionic acid

(S)-3-{[6-(2,4-Dichloro-phenyl)-5-methoxy-pyridine-2-carbonyl]-amino}-3-o-tolyl- propionic acid

(S)-3-{[6-(4-Fluoro-phenyl)-5-methoxy-pyridine-2-carbonyl]-annino}-3-o-tolyl- propionic acid (S)-3-{[6-(4-Chloro-phenyl)-5-methoxy-pyridine-2-carbonyl]-annino}-3-o-tolyl- propionic acid

(S)-3-[(5-Methoxy-6-p-tolyl-pyridine-2-carbonyl)-annino]-3-o-tolyl-propionic acid (S)-3-{[6-(3-Chloro-phenyl)-5-methoxy-pyridine-2-carbonyl]-annino}-3-o-tolyl- propionic acid

(S)-3-{[5-Methoxy-6-(2-methoxy-phenyl)-pyridine-2-carbonyl]-amino}-3-o-tolyl- propionic acid

(S)-3-[(5-Methoxy-6-m-tolyl-pyridine-2-carbonyl)-amino]-3-o-tolyl-propionic acid (S)-3-{[6-(2-Chloro-phenyl)-5-methoxy-pyridine-2-carbonyl]-amino}-3-o-tolyl- propionic acid

(S)-3-{[6-(3,4-Difluoro-phenyl)-5-methoxy-pyridine-2-carbonyl]-amino}-3-o-tolyl- propionic acid

(S)-3-{[6-(2,5-Difluoro-phenyl)-5-methoxy-pyridine-2-carbonyl]-amino}-3-o-tolyl- propionic acid

(S)-3-{[6-(2,5-Dichloro-phenyl)-5-methoxy-pyridine-2-carbonyl]-amino}-3-o-tolyl- propionic acid

(S)-3-{[6-(3,5-Dimethyl-isoxazol-4-yl)-5-methoxy-pyridine-2-carbonyl]-amino}-3-o- tolyl-propionic acid

(S)-3-{[6-(2,3-Dimethyl-phenyl)-5-methoxy-pyridine-2-carbonyl]-amino}-3-o-tolyl- propionic acid

(S)-3-{[6-(2,4-Dimethyl-phenyl)-5-methoxy-pyridine-2-carbonyl]-amino}-3-o-tolyl- propionic acid

(S)-3-{[6-(4-Fluoro-2-methoxy-phenyl)-5-methoxy-pyridine-2-carbonyl]-amino}-3-o- tolyl-propionic acid

(S)-3-{[6-(2-Chloro-5-methyl-phenyl)-5-methoxy-pyridine-2-carbonyl]-amino}-3-o- tolyl-propionic acid

(S)-3-(2-Chloro-phenyl)-3-[(6-methoxy-5-o-tolyl-pyridine-3-carbonyl)-amino]- propionic acid

(S)-3-(2-Chloro-phenyl)-3-{[5-methoxy-6-(2-methoxy-phenyl)-pyridine-2-carbonyl]- amino}-propionic acid

(S)-3-(2-Chloro-phenyl)-3-[(5-methoxy-6-m-tolyl-pyridine-2-carbonyl)-amino]- propionic acid

(S)-3-(2-Chloro-phenyl)-3-{[6-(2-chloro-phenyl)-5-methoxy-pyridine-2-carbonyl]- amino}-propionic acid

(S)-3-(2-Chloro-phenyl)-3-{[6-(2-fluoro-phenyl)-5-methoxy-pyridine-2-carbonyl]- amino}-propionic acid

(S)-3-(2-Chloro-phenyl)-3-{[6-(2,4-difluoro-phenyl)-5-methoxy-pyridine-2-carbonyl]- amino}-propionic acid

(S)-3-(2-Chloro-phenyl)-3-{[6-(2,3-dichloro-phenyl)-5-methoxy-pyridine-2-carbonyl]- amino}-propionic acid

(S)-3-(2-Chloro-phenyl)-3-{[6-(2,3-difluoro-phenyl)-5-methoxy-pyridine-2-carbonyl]- amino}-propionic acid

(S)-3-(2-Chloro-phenyl)-3-{[6-(2,5-difluoro-phenyl)-5-methoxy-pyridine-2-carbonyl]- amino}-propionic acid

(S)-3-(2-Chloro-phenyl)-3-{[6-(4-fluoro-2-methyl-phenyl)-5-methoxy-pyridine-2- carbonyl]-amino}-propionic acid

(S)-3-(2-Chloro-phenyl)-3-{[6-(2,3-dimethyl-phenyl)-5-methoxy-pyridine-2-carbonyl]- amino}-propionic acid

(S)-3-(2-Chloro-phenyl)-3-[(3,2'-dimethoxy-[2,3]bipyridinyl-6-carbonyl)-amin propionic acid

(S)-3-(2-Chloro-phenyl)-3-{[6-(5-fluoro-2-methyl-phenyl)-5-methoxy-pyridine-2- carbonyl]-amino}-propionic acid

(S)-3-(2-Chloro-phenyl)-3-{[6-(4-fluoro-2-methoxy-phenyl)-5-methoxy-pyridine-2- carbonyl]-amino}-propionic acid

(S)-3-{[6-(4-Chloro-2-methoxy-phenyl)-5-methoxy-pyridine-2-carbonyl]-amino}-3-(2- chloro-phenyl)-propionic acid

(S)-3-(2-Chloro-phenyl)-3-{[6-(5-fluoro-2-methoxy-phenyl)-5-methoxy-pyridine-2- carbonyl]-amino}-propionic acid

(S)-3-(2-Chloro-phenyl)-3-{[6-(2-fluoro-5-trifluoromethyl-phenyl)-5-methoxy- pyridine-2-carbonyl]-amino}-propionic acid

(S)-3-{[5-Methoxy-6-(2-trifluoromethyl-phenyl)-pyridine-2-carbonyl]-amino}-3-o-tolyl- propionic acid (S)-3-{[6-(2,4-Difluoro-phenyl)-5-methoxy-pyridine-2-carbonyl]-amino}-3-o-tolyl- propionic acid

(S)-3-{[6-(4-Fluoro-2-methyl-phenyl)-5-methoxy-pyridine-2-carbonyl]-amino}-3-o- tolyl-propionic acid

(S)-3-[(3,2'-Dimethoxy-[2,3]bipyridinyl-6-carbonyl)-amino]-3-o-tolyl-propionic acid

(S)-3-[(3'-Fluoro-3-methoxy-[2,4']bipyridinyl-6-carbonyl)-amino]-3-o-tolyl-propionic acid

(S)-3-{[5-Methoxy-6-(2-methyl-furan-3-yl)-pyridine-2-carbonyl]-amino}-3-o-tolyl- propionic acid

(S)-3-{[6-(4-Cyano-2-fluoro-phenyl)-5-methoxy-pyridine-2-carbonyl]-amino}-3-o- tolyl-propionic acid

(S)-3-(2-Chloro-phenyl)-3-{[6-(2-fluoro-5-methoxy-phenyl)-5-methoxy-pyridine-2- carbonyl]-amino}-propionic acid

(S)-3-(2-Chloro-phenyl)-3-{[6-(2-fluoro-5-methyl-phenyl)-5-methoxy-pyridine-2- carbonyl]-amino}-propionic acid

(S)-3-{[6-(3-Chloro-2-methyl-phenyl)-5-methoxy-pyridine-2-carbonyl]-amino}-3-(2- chloro-phenyl)-propionic acid

(S)-3-(2-Chloro-phenyl)-3-{[6-(3-fluoro-2-methyl-phenyl)-5-methoxy-pyridine-2- carbonyl]-amino}-propionic acid

(S)-3-{[6-(5-Chloro-2-fluoro-phenyl)-5-methoxy-pyridine-2-carbonyl]-amino}-3-(2- chloro-phenyl)-propionic acid

(S)-3-(2-Chloro-phenyl)-3-[(3'-fluoro-3-methoxy-[2,4 bipyridinyl-6-carbonyl)-amino]- propionic acid

(S)-3-(2-Chloro-phenyl)-3-[(5-methoxy-6-pyrazin-2-yl-pyridine-2-carbonyl)-amino]- propionic acid

(S)-3-{[6-(3-Chloro-2-fluoro-phenyl)-5-methoxy-pyridine-2-carbonyl]-amino}-3-(2- chloro-phenyl)-propionic acid

(S)-3-(2-Chloro-phenyl)-3-{[5-methoxy-6-(2-methyl-furan-3-yl)-pyridine-2-carbonyl]- amino}-propionic acid

(S)-3-{[6-(2-Chloro-3-fluoro-phenyl)-5-methoxy-pyridine-2-carbonyl]-amino}-3-(2- chloro-phenyl)-propionic acid (S)-3-{[6-(2-Chloro-3-methyl-phenyl)-5-methoxy-pyridine-2-carbonyl]-amino}-3-(2- chloro-phenyl)-propionic acid

3-Biphenyl-4-yl-3-[(6-chloro-pyridine-2-carbonyl)-annino]-propionic acid

(S)-3-[(6-Chloro-pyridine-2-carbonyl)-amino]-3-o-tolyl-propionic acid

(S)-3-[(3,5-Diamino-6-chloro-pyrazine-2-carbonyl)-amino]-3-o-tolyl-propionic acid

3-Biphenyl-4-yl-3-[(3,5-diamino-6-chloro-pyrazine-2-carbonyl)-amino]-propionic acid

(S)-3-{[6-(2-Fluoro-phenyl)-pyridine-2-carbonyl]-amino}-3-phenyl-propionic acid (S)-3-(3-Fluoro-phenyl)-3-{[6-(2-fluoro-phenyl)-pyridine-2-carbonyl]-amino}- propionic acid

(S)-3-(2-Fluoro-phenyl)-3-{[6-(2-fluoro-phenyl)-pyridine-2-carbonyl]-amino}- propionic acid

(S)-3-(4-Fluoro-phenyl)-3-{[6-(2-fluoro-phenyl)-pyridine-2-carbonyl]-amino}- propionic acid

3-(2-Chloro-phenyl)-3-[(6-methoxy-quinoline-2-carbonyl)-amino]-propionic acid (S)-3-[(6-Methoxy-biphenyl-3-carbonyl)-amino]-3-o-tolyl-propionic acid

(S)-3-{[6-(2-Chloro-phenyl)-pyridine-2-carbonyl]-annino}-3-nn-tolyl-propionic acid (S)-3-{[6-(2-Fluoro-phenyl)-pyridine-2-carbonyl]-annino}-3-(4-nnethoxy-phenyl)- propionic acid

(S)-3-{[6-(2-Chloro-phenyl)-pyridine-2-carbonyl]-annino}-3-(2-fluoro-phenyl)- propionic acid

(S)-3-{[6-(2-Chloro-phenyl)-pyridine-2-carbonyl]-annino}-3-(4-fluoro-phenyl)- propionic acid

(S)-3-(3-Chloro-phenyl)-3-{[6-(2-fluoro-phenyl)-pyridine-2-carbonyl]-amino}- propionic acid

(S)-3-(4-Chloro-phenyl)-3-{[6-(2-fluoro-phenyl)-pyridine-2-carbonyl]-amino}- propionic acid

(S)-3-(4-Chloro-phenyl)-3-{[6-(2-chloro-phenyl)-pyridine-2-carbonyl]-annino}- propionic acid

(S)-3-(3-Chloro-phenyl)-3-{[6-(2-chloro-phenyl)-pyridine-2-carbonyl]-annino}- propionic acid

3-(2-Chloro-phenyl)-3-{[6-(2-chloro-phenyl)-pyridine-2-carbonyl]-amino}-propionic acid

(S)-3-{[6-(2-Fluoro-phenyl)-pyridine-2-carbonyl]-amino}-3-(3-trifluoromethyl-phenyl)- propionic acid

(S)-3-{[6-(2-Chloro-phenyl)-pyridine-2-carbonyl]-amino}-3-(2,4-dichloro-phenyl)- propionic acid

(S)-3-{[6-(2-Chloro-phenyl)-pyridine-2-carbonyl]-amino}-3-(4-trifluoromethyl- phenyl)-propionic acid

(S)-3-{[6-(2-Chloro-phenyl)-pyridine-2-carbonyl]-amino}-3-(3-trifluoromethyl- phenyl)-propionic acid

(S)-3-{[6-Bromo-5-(3,3-dimethyl-2-oxo-butoxy)-pyridine-2-carbonyl]-amino}-3-o- tolyl-propionic acid; for the treatment and/or prevention of atrial fibrillation.

(S)-3-[(5-Methoxy-6-phenyl-pyridine-2-carbonyl)-amino]-3-o-tolyl-propionic acid

(S)-3-{[6-(2-Fluoro-phenyl)-pyridine-2-carbonyl]-amino}-3-o-tolyl-propionic acid

(S)-3-o-Tolyl-3-[(6-m-tolyl-pyridine-2-carbonyl)-amino]-propionic acid

(S)-3-({6-[3-(1 -Hydroxy-1 -methyl-ethyl)-phenyl]-pyridine-2-carbonyl}-amino)-3-o- tolyl-propionic acid

(S)-3-(2,4-Dichloro-phenyl)-3-[(5-methoxy-6-phenyl-pyridine-2-carbonyl)-amino]- propionic acid

(S)-3-[(2,6-Dimethoxy-pyrimidine-4-carbonyl)-amino]-3-o-tolyl-propionic acid (S)-3-[(5-Phenyl-pyridine-2-carbonyl)-amino]-3-o-tolyl-propionic acid (S)-3-{[3-(4,6-Dimethoxy-pyrimidin-2-yloxy)-pyridine-2-carbonyl]-amino}-3-o-tolyl- propionic acid

(S)-3-{[4-(Pyrimidin-2-ylsulfanyl)-pyridine-2-carbonyl]-amino}-3-o-tolyl-propioni acid

(S)-3-{[5-(2,3-Dichloro-phenyl)-pyridine-3-carbonyl]-amino}-3-o-tolyl-propionic acid (S)-3-{[5-(2,3-Dimethyl-phenyl)-pyridine-3-carbonyl]-amino}-3-o-tolyl-propionic acid (S)-3-{[5-(2-Chloro-phenyl)-pyridine-3-carbonyl]-annino}-3-o-tolyl-propionic acid (S)-3-{[6-(2,3-Difluoro-phenyl)-pyridine-2-carbonyl]-annino}-3-o-tolyl-propionic acid

(S)-3-({5-Methoxy-6-[3-(5-methyl-[1 ,3,4]oxadiazol-2-yl)-phenyl]-pyridine-2- carbonyl}-amino)-3-o-tolyl-propionic acid

(S)-3-(2-Chloro-phenyl)-3-[(5-methoxy-6-naphthalen-2-yl-pyridine-2-carbonyl)- amino]-propionic acid

(S)-3-(2-Chloro-phenyl)-3-[(6-methoxy-5-naphthalen-2-yl-pyridine-3-carbonyl)- amino]-propionic acid

(S)-3-(2-Fluoro-phenyl)-3-{[5-methoxy-6-(1 ,3,5-trimethyl-1 H-pyrazol-4-yl)-pyndin 2-carbonyl]-amino}-propionic acid (S)-3-(2-Fluoro-phenyl)-3-{[5-methoxy-6-(1 -methyl-1 H-indol-5-yl)-pyridine-2- carbonyl]-amino}-propionic acid

(S)-3-{[6-(4-Chloro-phenyl)-5-methoxy-pyridine-2-carbonyl]-amino}-3-o-tolyl- propionic acid

(S)-3-{[6-(4-Chloro-phenyl)-5-methoxy-pyridine-2-carbonyl]-amino}-3-p-tolyl- propionic acid

(S)-3-{[6-(5-Acetyl-thiophen-2-yl)-5-methoxy-pyridine-2-carbonyl]-amino}-3-(2- chloro-phenyl)-propionic acid

for the prevention and/or treatment of atrial fibrillation.

The present invention relates to the use of compounds of the formula III, in any of its stereoisomeric forms or a mixture of stereoisomeric forms in any ratio, or a

wherein

A is chosen from the series consisting of C(R ) and N

D is chosen from the series consisting of N(R²), O and S;

E is chosen from the series consisting of C(R³) and N; G is chosen from the series consisting of R -O-C(O)-, R -N(R )-C(O)-, NC- and tetrazol-5-yl; R¹ is chosen from the series consisting of hydrogen, halogen, (Ci-C6)-alkyl, Ar, HO-, (Ci-C₆)-alkyl-O-, (Ci-C₆)-alkyl-S(O)_m- and NC-;

R² is chosen from the series consisting of (Ci-C₇)-alkyl, (C3-C₇)-cycloalkyl-C₃H_2s- and Ar-C₃H_2s-, wherein s is an integer chosen from the series consisting of 0, 1 , 2 and 3; or R² and R¹¹ together are -C(R¹⁸)=C(R¹⁹)-;

R³ is chosen from the series consisting of hydrogen, halogen, (Ci-C6)-alkyl, (d-Ce)- alkyl-O-, (Ci-C₆)-alkyl-S(O)_m- and NC-; R¹⁰ is chosen from the series consisting of R¹¹ , R¹²-N(R¹³)-C(O)- and Het²-C(O)-, R¹⁴- C(O)- and (Ci-C₄)-alkyl-S(O)_m-;

or R¹⁰ and R¹¹ form Het²;

R¹² and R¹³ are independently of each other chosen from the series consisting of hydrogen, R¹⁵ and Ar; R¹⁴ is (Ci-Cio)-alkyl which is optionally substituted by one or more identical or different substituents chosen from the series consisting of halogen, HO-, R¹⁶-O-, R¹⁷-O-, oxo, (C₃-C₇)-cycloalkyl, Ar, Het¹, Het³, NC-, H₂N-C(O)-, (Ci-C₄)-alkyl-NH-C(O)-, di((d-C₄)- alkyl)N-C(O)-, Het¹-C(O)-, (Ci-C₄)-alkyl-C(O)-NH- and (Ci-C₄)-alkyl-S(O)_m-;

R¹⁵ is (Ci-C6)-alkyl which is optionally substituted by one or more identical or different substituents chosen from the series consisting halogen, HO- and (Ci-C6)-alkyl-O-; R¹⁶ is (Ci-C6)-alkyl which is optionally substituted by one or more identical or different substituents chosen from the series consisting of HO-, (Ci-C₄)-alkyl-O- and NC-;

R¹⁷ is (C3-C₇)-cycloalkyl-C_uH2u- which is optionally substituted by one or more identical or different substituents chosen from the series consisting halogen, (Ci-C6)-alkyl, HO- and (Ci-C6)-alkyl-O-, wherein u is an integer chosen from the series consisting of 0, 1 , 2 and 3;

R¹⁸ is chosen from the series of hydrogen, halogen, (Ci-C6)-alkyl, HO- and (C1-C-6)- alkyl-O-;

R¹⁹ is chosen from the series of hydrogen, halogen, (Ci-C6)-alkyl, HO- and (C1-C-6)- alkyl-O-;

or R¹⁸ and R¹⁹ together are chosen from the series of -(CH₂)-(CH₂)-(CH₂)-, -(CH₂)- (CH₂)-(CH₂)-(CH₂)-, -(CH₂)-(CH)=(CH)- and -(CH)=(CH)-(CH)=(CH)-;

R³⁰ is chosen from the series consisting of R³¹ , (C3-C₇)-cycloalkyl, R³²-C_uH_2u- and Het³-C_uH_2u-, wherein u is an integer chosen from the series consisting of 0, 1 , 2 and 3; R³¹ is (Ci-Cio)-alkyl which is optionally substituted by one or more identical or different substituents chosen from the series consisting of halogen, (C3-C₇)-cycloalkyl, HO-, (Ci- C₆)-alkyl-O-, (Ci-C₆)-alkyl-S(O)_m- and NC-;

R³² is chosen from the series consisting of phenyl and an aromatic 5-membered or 6- membered monocyclic heterocycle which comprises one, two or three identical or different ring heteroatoms chosen from the series consisting of nitrogen, oxygen and sulfur and is bonded via a ring carbon atom, wherein the phenyl and the heterocycle all are optionally substituted by one or more identical or different substituents chosen from the series consisting of halogen, (Ci-C6)-alkyl, (C3-C₇)-cycloalkyl, R³³, HO-, (C1-C6)- alkyl-O-, R³³-O-, R³³-(Ci-C₄)-alkyl-O-, -O-CH₂-O-, -O-CF₂-O-, (Ci-C₆)-alkyl-S(O)_m-,

H₂N-S(O)₂-, (Ci-C₄)-alkyl-NH-S(O)₂-, di((Ci-C₄)-alkyl)N-S(O)₂-, H₂N-, (Ci-C₆)-alkyl-NH- , di((Ci-C₆)-alkyl)N-, Het¹ , (Ci-C₄)-alkyl-C(0)-NH-, Ar-C(O)-NH-, (Ci-C₄)-alkyl-S(0)₂- NH- and NC-;

R³³ is chosen from the series consisting of phenyl and an aromatic 5-membered or 6- membered monocyclic heterocycle which comprises one, two or three identical or different ring heteroatoms chosen from the series consisting of nitrogen, oxygen and sulfur and is bonded via a ring carbon atom, wherein the phenyl and the heterocycle all are optionally substituted by one or more identical or different substituents chosen from the series consisting of halogen, (Ci-C6)-alkyl, (C3-C₇)-cycloalkyl, HO-, (Ci-C-6)-alkyl-0- , (Ci-C₆)-alkyl-S(O)_m-, H₂N-S(O)₂-, (Ci-C₄)-alkyl-NH-S(O)₂-, di((Ci-C₄)-alkyl)N-S(0)₂- and NC-;

R⁵⁰ is chosen from the series consisting of hydrogen, (Ci-C6)-alkyl, HO- and (C1-C-6)- alkyl-O-;

R⁶⁰ is chosen from the series consisting of hydrogen and (Ci-C6)-alkyl; or R⁵⁰ and R⁶⁰ together are (CH₂)_y which is optionally substituted by one or more identical or different (Ci-C₄)-alkyl substituents, wherein y is an integer chosen from the series consisting of 2, 3, 4 and 5; or R³⁰ and R⁵⁰ together are (CH₂)_Z which is optionally substituted by one or more identical or different (Ci-C₄)-alkyl substituents, wherein z is an integer chosen from the series consisting of 2, 3, 4 and 5; R is chosen from the series consisting of hydrogen and (Ci-CsJ-alkyl which is optionally substituted by one or more identical or different substituents chosen from the series consisting (Ci-C6)-alkyl-O- and (Ci-C6)-alkyl-C(O)-O-; R⁷² is chosen from the series consisting of hydrogen, (Ci-C6)-alkyl, (C3-C6)-cycloalkyl, -CH₂-(CH₂)_b-(C3-C6)-cycloalkyl, Het⁴ and -(CH₂)_b-Het⁴, where alkyl or cycloalkyl is optionally substituted by one or more identical or different substituents chosen from the series consisting of halogen, HO-, HOOC-, (Ci-C₆)-alkyl-O- and (Ci-C₆)-alkyl-C(O)-O-, NC-, N((Ci-C₄)-alkyl)₂ and b is 0, 1 or 2;

R⁷³ is chosen from the series consisting of hydrogen, (Ci-C6)-alkyl;

or

Het² is a saturated 4-membered to 7-membered monocyclic heterocycle which comprises a ring nitrogen atom via which Het² is bonded and optionally one further ring heteroatom chosen from the series consisting of nitrogen, oxygen and sulfur, which is optionally substituted by one or more identical or different substituents chosen from the series consisting of halogen, (Ci-C₄)-alkyl, HO-, oxo and (Ci-C₄)-alkyl-O-; Het³, independently of each other group Het³, is a saturated 4-membered to 7- membered monocyclic heterocycle which comprises one or two identical or different ring heteroatoms chosen from the series consisting of nitrogen, oxygen and sulfur and is bonded via a ring carbon atom, which is optionally substituted by one or more identical or different substituents chosen from the series consisting of fluorine, (Ci-C₄)- alkyl and oxo;

Het⁴, independently of each other group Het⁴, is a saturated or unsaturated 4- membered to 8-membered monocyclic heterocycle which comprises one to four ring heteroatoms chosen from the series consisting of nitrogen, oxygen and sulfur which is optionally substituted by one or more identical or different substituents chosen from the series consisting of halogen, (Ci-C₄)-alkyl, HO-, (Ci-C₄)-alkyl-O-, oxo and NC-; m, independently of each other number m, is an integer chosen from the series consisting of 0, 1 and 2; wherein all cycloalkyl groups, independently of each other, are optionally substituted by one or more identical or different substituents chosen from the series consisting of fluorine and (Ci-C₄)-alkyl; wherein all alkyl, C_sH_2s, C_uH_2u, (CH₂)_X and (CH₂)_y groups, independently of each other, and independently of any other substituents, are optionally substituted by one or more fluorine substituents; for the prevention and/or treatment of atrial fibrillation.

A further preferred embodiment is the use of a compound of the formula III, in any of its stereoisomeric forms or a mixture of stereoisomeric forms in any ratio, or a physiologically acceptable salt thereof, or a physiologically acceptable solvate of any of them, wherein E is N.

A further preferred embodiment is the use of a compound of the formula III, in any of its stereoisomeric forms or a mixture of stereoisomeric forms in any ratio, or a physiologically acceptable salt thereof, or a physiologically acceptable solvate of any of them, wherein D is N(R²).

A further preferred embodiment is the use of a compound of the formula III, in any of its stereoisomeric forms or a mixture of stereoisomeric forms in any ratio, or a physiologically acceptable salt thereof, or a physiologically acceptable solvate of any of them, wherein

G is R⁷¹-O-C(O)- and R⁷²-N(R⁷³)-C(O)-;

R⁷¹ is chosen from the series consisting of hydrogen and (Ci-CsJ-alkyl;

R⁷² is chosen from the series consisting of hydrogen, (Ci-C6)-alkyl;

R⁷³ is chosen from the series consisting of hydrogen, (Ci-C6)-alkyl.

R⁵⁰ is hydrogen;

R⁶⁰ is hydrogen. A further preferred embodiment is the use of a compound of the formula III, in any of its stereoisomeric forms or a mixture of stereoisomeric forms in any ratio, or a physiologically acceptable salt thereof, or a physiologically acceptable solvate of any of them, wherein

A is chosen from the series consisting of C(R¹);

D is N(R²);

E is N;

R² is Ar-C₃H_2s-, wherein s is an integer chosen from the series consisting of 0 and 1 .

R³⁰ is R³²-C_uH_2u-, wherein u is an integer chosen from the series consisting of 0 and 1 ; R³² is chosen from the series consisting of phenyl and an aromatic 5-membered or 6- membered monocyclic heterocycle which comprises one, two or three identical or different ring heteroatoms chosen from the series consisting of nitrogen, oxygen and sulfur and is bonded via a ring carbon atom, wherein the phenyl and the heterocycle all are optionally substituted by one or more identical or different substituents chosen from the series consisting of halogen, (Ci-C6)-alkyl, (C3-C₇)-cycloalkyl, R³³, HO-, (C1-C-6)- alkyl-O-, R³³-O-, R³³-(Ci-C₄)-alkyl-O-, -O-CH2-O-, -O-CF2-O-, (Ci-C₆)-alkyl-S(O)_m-,

H₂N-S(O)₂-, (Ci-C₄)-alkyl-NH-S(O)₂-, di((Ci-C₄)-alkyl)N-S(O)₂-, H₂N-, (Ci-C₆)-alkyl-NH- , di((Ci-C₆)-alkyl)N-, Het¹, (Ci-C₄)-alkyl-C(O)-NH-, Ar-C(O)-NH-, (Ci-C₄)-alkyl-S(O)₂- NH- and NC-;

R⁴⁰ is hydrogen.

R² is Ar-C₃H_2s-, wherein s is an integer 0;

R³⁰ is R³²-C_uH_2u- wherein u is an integer 0;

R⁴⁰ is hydrogen.

A is chosen from the series consisting of C(R¹);

D is N(R²);

E is N;

R² and R¹¹ together are -C(R¹⁸)=C(R¹⁹)-.

R¹⁸ and R¹⁹ together are -(CH)=(CH)-(CH)=(CH)-.

A further preferred embodiment is the use of a compound of the formula III, or a physiologically acceptable salt thereof, or a physiologically acceptable solvate of any of them, chosen from

(S)-3-{[5-(Benzoyl-methyl-amino)-1 -phenyl-1 H-pyrazole-3-carbonyl]-amino}-3-(2- chloro-phenyl)-propionic acid,

(S)-3-{[5-(2-Hydroxy-3,3-dimethyl-butylannino)-1 -phenyl-1 H-pyrazole-3-carbonyl]- amino}-3-o-tolyl-propionic acid,

(S)-3-[(5-Benzoylamino-1 -phenyl-1 H-pyrazole-3-carbonyl)-amino]-3-(4-fluoro- phenyl)-propionic acid,

(S)-3-{[5-(Benzoyl-methyl-annino)-1 -phenyl-1 H-pyrazole-3-carbonyl]-amino}-3-(3- chloro-phenyl)-propionic acid,

(S)-3-{[5-(3,3-Dimethyl-2-oxo-butylannino)-1 -phenyl-1 H-pyrazole-3-carbonyl]- amino}-3-o-tolyl-propionic acid,

(S)-3-{[5-Amino-1 -(2-fluoro-phenyl)-1 H-pyrazole-3-carbonyl]-amino}-3-o-tolyl- propionic acid,

(S)-3-{[1 -Phenyl-5-(3-phenyl-ureido)-1 H-pyrazole-3-carbonyl]-amino}-3-o-tolyl- propionic acid,

{1 -[(5-Benzoylamino-1 -phenyl-1 H-pyrazole-3-carbonyl)-amino]-cyclopentyl}-acetic acid,

(S)-3-{[5-((S)-2-Hydroxy-3,3-dimethyl-butylamino)-1 -phenyl-1 H-pyrazole-3- carbonyl]-amino}-3-o-tolyl-propionic acid,

(S)-3-[(1 -Phenyl-5-pyrrolidin-1 -yl-1 H-pyrazole-3-carbonyl)-amino]-3-o-tolyl-propionic acid,

(S)-3-({5-[(2,2-Dimethyl-propionyl)-nnethyl-annino]-1 -phenyl-1 H-pyrazole-3- carbonyl}-amino)-3-o-tolyl-propionic acid,

(S)-3-{[5-(1 ,1 -Dioxo-1 lambda6-isothiazolidin-2-yl)-1 -phenyl-1 H-pyrazole-3- carbonyl]-amino}-3-o-tolyl-propionic acid,

(S)-3-[(5-Methanesulfonylamino-1 -phenyl-1 H-pyrazole-3-carbonyl)-amino]-3-o-tolyl- propionic acid,

(S)-3-(2,4-Dichloro-phenyl)-3-{[5-(2,2-dimethyl-propionylamino)-1 -phenyl-1 H- pyrazole-3-carbonyl]-amino}-propionic acid,

3-{[5-Amino-1 -(2-fluoro-phenyl)-1 H-pyrazole-3-carbonyl]-amino}-3-(4'-fluoro- biphenyl-4-yl)-propionic acid,

(S)-3-{[5-Amino-4-cyano-1 -(2-fluoro-phenyl)-1 H-pyrazole-3-carbonyl]-annino}-3-o- tolyl-propionic acid,

(S)-3-{[5-(2,2-Dimethyl-propionylannino)-1 -phenyl-1 H-pyrazole-3-carbonyl]-amino}- 3-o-tolyl-propionic acid,

3-{[5-Amino-1 -(2-fluoro-phenyl)-1 H-pyrazole-3-carbonyl]-amino}-3-(4-pyridin-2-yl- phenyl)-propionic acid,

(S)-3-{[1 -(2-Fluoro-phenyl)-5-pyrrolidin-1 -yl-1 H-pyrazole-3-carbonyl]-amino}-3-o- tolyl-propionic acid,

(S)-3-{[5-Amino-1 -(2-fluoro-phenyl)-1 H-pyrazole-3-carbonyl]-amino}-3-(2,3-dichloro- phenyl)-propionic acid,

3-[(5-Benzoylamino-1 -phenyl-1 H-pyrazole-3-carbonyl)-amino]-3-cyclohexyl- propionic acid,

(S)-3-[(5-Amino-1 -phenyl-1 H-pyrazole-3-carbonyl)-amino]-3-o-tolyl-propionic acid,

(S)-3-{[1 -(2-Fluoro-phenyl)-5-(2-oxo-pyrrolidin-1 -yl)-1 H-pyrazole-3-carbonyl]- amino}-3-o-tolyl-propionic acid,

(S)-3-{[1 -Phenyl-5-(pyridin-2-ylannino)-1 H-pyrazole-3-carbonyl]-amino}-3-o-tolyl- propionic acid,

(S)-3-{[5-((R)-2-Hydroxy-3,3-dimethyl-butylamino)-1 -phenyl-1 H-pyrazole-3- carbonyl]-amino}-3-o-tolyl-propionic acid,

(S)-3-[(4H-Benzo[4,5]imidazo[1 ,2-b]pyrazole-2-carbonyl)-amino]-3-o-tolyl-propionic acid,

(S)-3-({5-[2-((1 R,2S,5R)-2-lsopropyl-5-methyl-cyclohexyloxy)-acetylamino]-1 - phenyl-1 H-pyrazole-3-carbonyl}-amino)-3-o-tolyl-propionic acid,

(S)-3-{[5-(1 ,1 -Dioxo-1 lambda6-isothiazolidin-2-yl)-1 -(2-fluoro-phenyl)-1 H-pyrazole- 3-carbonyl]-amino}-3-o-tolyl-propionic acid,

(S)-3-{[5-(2-Hydroxy-2, 3, 3-thmethyl-butylamino)-1 -phenyl-1 H-pyrazole-3-carbonyl]- amino}-3-o-tolyl-propionic acid,

(S)-3-({5-[(2-Hydroxy-3,3-dimethyl-butyl)-methyl-amino]-1 -phenyl-1 H-pyrazole-3- carbonyl}-amino)-3-o-tolyl-propionic acid and

(S)-3-{[5-(Benzoyl-methyl-amino)-1 -phenyl-1 H-pyrazole-3-carbonyl]-amino}-3-o- tolyl-propionic acid.

A subject of the present invention is ther use a compound of the formula III-36, in any of its stereoisomeric forms or a mixture of stereoisomeric forms in any ratio, or a physiologically acceptable salt thereof, or a physiologically acceptable solvate of any of them,

In one embodiment of the invention, the group G is chosen from the series consisting of R⁷¹-O-C(O)-, R⁷²-N(R⁷³)-C(O)- and tetrazol-5-yl, in another embodiment from the series consisting of R⁷¹-O-C(O)- and R⁷²-N(R⁷³)-C(O)-, in another embodiment G is R⁷¹-O-C(O)-, and in another embodiment G is R⁷²-N(R⁷³)-C(O)-.

A subject of the invention also is the use of a compound of the formula III which is chosen from any of the specific compounds of the formula III which are disclosed herein, or is any one of the specific compounds of the formula III which are disclosed herein, irrespective thereof whether they are disclosed as a free compound and/or as a specific salt, or a physiologically acceptable salt thereof, or a physiologically

acceptable solvate of any of them, wherein the use of the compound of the formula III is a subject of the invention in any of its stereoisomeric forms or a mixture of

stereoisomeric forms in any ratio. For example, a subject of the invention is the use of a compound of the formula III which is chosen from

(S)-3-{[5-(2-Hydroxy-3,3-dimethyl-butylamino)-1 -phenyl-1 H-pyrazole-3-carbonyl]- amino}-3-o-tolyl-propionic acid,

(S)-3-[(5-Benzoylamino-1 -phenyl-1 H-pyrazole-3-carbonyl)-amino]-3-(4-fluoro- phenyl)-propionic acid, (S)-3-{[5-(Benzoyl-methyl-amino)-1 -phenyl-1 H-pyrazole-3-carbonyl]-amino}-3-(3- chloro-phenyl)-propionic acid,

3-{[5-Amino-1 -(2-fluoro-phenyl)-1 H-pyrazole-3-carbonyl]-amino}-3-(4-pyhdin-2-yl- phenyl)-propionic acid,

(S)-3-{[1 -(2-Fluoro-phenyl)-5-pyrrolidin-1 -yl-1 H-pyrazole-3-carbonyl]-amino}-3-o- tolyl-propionic acid, (S)-3-{[5-Amino-1 -(2-fluoro-phenyl)-1 H-pyrazole-3-carbonyl]-amino}-3-(2,3-dichloro- phenyl)-propionic acid,

(S)-3-{[5-(Benzoyl-methyl-amino)-1 -phenyl-1 H-pyrazole-3-carbonyl]-amino}-3-o- tolyl-propionic acid

or which is any one of these compounds, or a physiologically acceptable salt thereof, or a physiologically acceptable solvate of any of them, wherein the use of the compound of the formula III is a subject of the invention in any of its stereoisomeric forms or a mixture of stereoisomeric forms in any ratio, unless a specific

stereoisomeric form is specified with respect to any carbon atoms in the respective compound.

The present invention relates also to the use compounds of the formula IV, in any of its stereoisomeric forms or a mixture of stereoisomeric forms in any ratio, or a physiologically acceptable salt thereof, or a physiologically acceptable solvate of any of them,

wherein Ht is chosen from the series consisting of

G is chosen from the series consisting of R -O-C(O)-, R -N(R )-C(O)-, NC- and tetrazol-5-yl;

R¹ is chosen from the series consisting of hydrogen, halogen, (Ci-C6)-alkyl, CF₃, (C3- C₇)-cycloalkyl-C₃H₂s-, Ar-C₃H_2s-, Ar-O, (Ci-C₆)-alkyl-O-, (Ci-C₆)-alkyl-S(0)_m- and NC-; wherein s is an integer chosen from the series consisting of 0, 1 , 2 and 3; R² is chosen from the series consisting of hydrogen, halogen, (Ci-C6)-alkyl, CF₃, (Cr C₆)-alkyl-O-, (Ci-C₆)-alkyl-S(0)_m- and NC-;

R³ is chosen from the series consisting of hydrogen, (Ci-C6)-alkyl;

R⁴ is chosen from the series consisting of (Ci-C₇)-alkyl, (C3-C₇)-cycloalkyl-C₃H_2s- and Ar-C₃H_2s-, wherein s is an integer chosen from the series consisting of 0, 1 , 2 and 3;

R⁵ is chosen from the series consisting of hydrogen, halogen, (Ci-C6)-alkyl, (C1-C-6)- alkyl-O-, (Ci-C₆)-alkyl-S(0)_m- and NC-;

R¹⁰ is chosen from the series consisting of R^{1 1} , Het²-C(O)-, R¹⁴-C(O)- and (C1-C4)- alkyl-S(O)_m-; R^{1 1} is chosen from the series consisting of hydrogen, R¹⁴, (C3-C₇)-cycloalkyl, Ar and Het³;

R¹⁴ is (Ci-Cio)-alkyl which is optionally substituted by one or more identical or different substituents chosen from the series consisting of halogen, HO-, R¹⁶-O-, oxo, (C3-C7)- cycloalkyl, Ar, Het¹ , Het³, NC-, H₂N-C(O)-, (Ci-C₄)-alkyl-NH-C(O)-, di((Ci-C₄)-alkyl)N- C(O)-, Het¹-C(O)-, (Ci-C₄)-alkyl-C(O)-NH- and (Ci-C₄)-alkyl-S(0)_m-;

R is (Ci-Cio)-alkyl which is substituted by one or more identical or different

substituents chosen from the series consisting of halogen, (C3-C₇)-cycloalkyl, HO-, (Ci- C₆)-alkyl-O-, (Ci-C₆)-alkyl-S(0)_m- and NC-; R is chosen from the series consisting of phenyl and an aromatic 5-membered or 6- membered monocyclic heterocycle which comprises one, two or three identical or different ring heteroatoms chosen from the series consisting of nitrogen, oxygen and sulfur and is bonded via a ring carbon atom, wherein the phenyl and the heterocycle all are optionally substituted by one or more identical or different substituents chosen from the series consisting of halogen, (Ci-C6)-alkyl, (C3-C₇)-cycloalkyl, HO-, (Ci-C-6)-alkyl-0- , R³³-O-, R³³-(Ci-C₄)-alkyl-O-, -O-CH₂-O-, -O-CF₂-O-, (Ci-C₆)-alkyl-S(O)_m-, H₂N-S(O)₂-, (Ci-C₄)-alkyl-NH-S(O)₂-, di((Ci-C₄)-alkyl)N-S(O)₂-, H₂N-, (Ci-C₆)-alkyl-NH-, di((Ci-C₆)- alkyl)N-, Het¹, (Ci-C₄)-alkyl-C(O)-NH-, Ar-C(O)-NH-, (Ci-C₄)-alkyl-S(O)₂-NH- and NC-;

R³³ is chosen from the series consisting of phenyl and an aromatic 5-membered or 6- membered monocyclic heterocycle which comprises one, two or three identical or different ring heteroatoms chosen from the series consisting of nitrogen, oxygen and sulfur and is bonded via a ring carbon atom, wherein the phenyl and the heterocycle all are optionally substituted by one or more identical or different substituents chosen from the series consisting of halogen, (Ci-C6)-alkyl, (C3-C₇)-cycloalkyl, HO-, (Ci-C-6)-alkyl-0- , (Ci-C₆)-alkyl-S(O)_m-, H₂N-S(O)₂-, (Ci-C₄)-alkyl-NH-S(O)₂-, di((Ci-C₄)-alkyl)N-S(O)₂- and NC-; R⁴⁰ is chosen from the series consisting of hydrogen and (Ci-C₄)-alkyl; or R³⁰ and R⁴⁰ together are (CH₂)_X which is optionally substituted by one or more identical or different (Ci-C₄)-alkyl substituents, wherein x is an integer chosen from the series consisting of 2, 3, 4 and 5;

R⁵⁰ is chosen from the series consisting of hydrogen, (Ci-C6)-alkyl, HO- and (d-Ce)- alkyl-O-;

R⁶⁰ is chosen from the series consisting of hydrogen and (Ci-C6)-alkyl; or R and R together are (CH₂)_y which is optionally substituted by one or more identical or different (Ci-C₄)-alkyl substituents, wherein y is an integer chosen from the series consisting of 2, 3, 4 and 5; or R³⁰ and R⁵⁰ together are (CH₂)_Z which is optionally substituted by one or more identical or different (Ci-C₄)-alkyl substituents, wherein z is an integer chosen from the series consisting of 2, 3, 4 and 5;

R⁷¹ is chosen from the series consisting of hydrogen and (Ci-CsJ-alkyl which is optionally substituted by one or more identical or different substituents chosen from the series consisting (Ci-C6)-alkyl-O- and (Ci-C6)-alkyl-C(O)-O-;

R⁷² is chosen from the series consisting of hydrogen, (Ci-C6)-alkyl, (C3-C6)-cycloalkyl, -CH2-(CH₂)_b-(C3-C₆)-cycloalkyl, Het⁴ and -(CH₂)_b-Het⁴, where alkyl or cycloalkyl is optionally substituted by one or more identical or different substituents chosen from the series consisting of halogen, HO-, HOOC-, (Ci-C₆)-alkyl-O- and (Ci-C₆)-alkyl-C(O)-O-, NC-, N((Ci-C₄)-alkyl)₂ and b is 0, 1 or 2;

R⁷³ is chosen from the series consisting of hydrogen, (Ci-C6)-alkyl;

or

Ar, independently of each other group Ar, is chosen from the series consisting of phenyl and an aromatic 5-membered or 6-membered monocyclic heterocycle which comprises one, two or three identical or different ring heteroatoms chosen from the series consisting of nitrogen, oxygen and sulfur and is bonded via a ring carbon atom, wherein the phenyl and the heterocycle all are optionally substituted by one or more identical or different substituents chosen from the series consisting of halogen, (Ci-Ce)- alkyl, (Ci-C₆)-alkyl-0-, -O-CH₂-O-, O-CH₂-CH₂-O-, -O-CF₂-O-, (Ci-C₆)-alkyl-S(O)_m-, H₂N-S(O)₂-, CF₃ and NC-;

Het¹ , independently of each other group Het¹ , is a saturated or unsaturated 4- membered to 8-mennbered monocyclic heterocycle which comprises a ring nitrogen atom via which Het¹ is bonded and optionally one or two identical or different further ring heteroatoms chosen from the series consisting of nitrogen, oxygen and sulfur, which is optionally substituted by one or more identical or different substituents chosen from the series consisting of halogen, (Ci-C₄)-alkyl, HO-, (Ci-C₄)-alkyl-O-, oxo and NC-;

Het² is a saturated 4-membered to 7-membered monocyclic heterocycle which comprises a ring nitrogen atom via which Het² is bonded and optionally one further ring heteroatom chosen from the series consisting of nitrogen, oxygen and sulfur, which is optionally substituted by one or more identical or different substituents chosen from the series consisting of halogen, (Ci-C₄)-alkyl, HO-, oxo and (Ci-C₄)-alkyl-O-;

Het³, independently of each other group Het³, is a saturated 4-membered to 7- membered monocyclic heterocycle which comprises one or two identical or different ring heteroatoms chosen from the series consisting of nitrogen, oxygen and sulfur and is bonded via a ring carbon atom, which is optionally substituted by one or more identical or different substituents chosen from the series consisting of fluorine, (Ci-C₄)- alkyl and oxo; Het⁴, independently of each other group Het⁴, is a saturated or unsaturated 4- membered to 8-mennbered monocyclic heterocycle which comprises one to four ring heteroatoms chosen from the series consisting of nitrogen, oxygen and sulfur which is optionally substituted by one or more identical or different substituents chosen from the series consisting of halogen, (Ci-C₄)-alkyl, HO-, (Ci-C₄)-alkyl-O-, oxo and NC-; m, independently of each other number m, is an integer chosen from the series consisting of 0, 1 and 2; wherein all cycloalkyl groups, independently of each other, are optionally substituted by one or more identical or different substituents chosen from the series consisting of fluorine and (Ci-C₄)-alkyl; wherein all alkyl, C_sH_2s, C_uH_2u, (CH₂)_x and (CH₂)_y groups, independently of each other, and independently of any other substituents, are optionally substituted by one or more fluorine substituents; for the treatment and/or prevention of atrrial fibrillation.

A further preferred embodiment is the use of a compound of the formula IV, in any of its stereoisomeric forms or a mixture of stereoisomeric forms in any ratio, or a physiologically acceptable salt thereof, or a physiologically acceptable solvate of any of them, wherein

Ht is chosen from the series consisting of

R¹ is chosen from the series consisting of hydrogen, halogen, (Ci-C6)-alkyl, CF₃, (C3- C₇)-cycloalkyl-C₃H_2s-, Ar-C₃H_2s-, Ar-O, (Ci-C6)-alkyl-O-; wherein s is an integer chosen from the series consisting of 0, 1 , 2 and 3;

R² is chosen from the series consisting of hydrogen, halogen, (Ci-C6)-alkyl, CF₃, (Cr C₆)-alkyl-O- and NC-; R³ is chosen from the series consisting of hydrogen, (Ci-C6)-alkyl;

R⁵ is chosen from the series consisting of hydrogen, halogen, (Ci-C6)-alkyl, (C1-C-6)- alkyl-O-, and NC-.

R³⁰ is R³²-C_uH_2u-, wherein u is an integer chosen from the series consisting of 0 and 1 ; R³² is chosen from the series consisting of phenyl and an aromatic 5-membered or 6- membered monocyclic heterocycle which comprises one, two or three identical or different ring heteroatoms chosen from the series consisting of nitrogen, oxygen and sulfur and is bonded via a ring carbon atom, wherein the phenyl and the heterocycle all are optionally substituted by one or more identical or different substituents chosen from the series consisting of halogen, (Ci-C6)-alkyl, (C3-C₇)-cycloalkyl, HO-, (Ci-C-6)-alkyl-0- , R³³-O-, R³³-(Ci-C₄)-alkyl-O-, -O-CH2-O-, -O-CF2-O-, (Ci-C₆)-alkyl-S(O)_m-, H₂N-S(O)₂-, (Ci-C₄)-alkyl-NH-S(O)₂-, di((Ci-C₄)-alkyl)N-S(O)₂-, H₂N-, (Ci-C₆)-alkyl-NH-, di((Ci-C₆)- alkyl)N-, Het¹, (Ci-C₄)-alkyl-C(O)-NH-, Ar-C(O)-NH-, (Ci-C₄)-alkyl-S(O)₂-NH- and NC-; R³³ is chosen from the series consisting of phenyl and an aromatic 5-membered or 6- membered monocyclic heterocycle which comprises one, two or three identical or different ring heteroatoms chosen from the series consisting of nitrogen, oxygen and sulfur and is bonded via a ring carbon atom, wherein the phenyl and the heterocycle all are optionally substituted by one or more identical or different substituents chosen from the series consisting of halogen, (Ci-C6)-alkyl, (C3-C₇)-cycloalkyl, HO-, (Ci-C6)-alkyl-O- , (Ci-C₆)-alkyl-S(O)_m-, H₂N-S(O)₂-, (Ci-C₄)-alkyl-NH-S(O)₂-, di((Ci-C₄)-alkyl)N-S(O)₂- and NC-;

R⁴⁰ is hydrogen. A further preferred embodiment is the use of a compound of the formula IV, in any of its stereoisomeric forms or a mixture of stereoisomeric forms in any ratio, or a physiologically acceptable salt thereof, or a physiologically acceptable solvate of any of them, wherein

G is R⁷¹-O-C(O)- and R⁷²-N(R⁷³)-C(O)-;

R⁷¹ is chosen from the series consisting of hydrogen and (Ci-CsJ-alkyl;

R⁷² is chosen from the series consisting of hydrogen, (Ci-C6)-alkyl;

R⁷³ is chosen from the series consisting of hydrogen, (Ci-C6)-alkyl.

R⁵⁰ is hydrogen;

R⁶⁰ is hydrogen.

R³⁰ is R³²-C_uH_2u- wherein u is an integer 0;

R⁴⁰ is hydrogen,

A further preferred embodiment is the use of a compound of the formula IV, in any of its stereoisomeric forms or a mixture of stereoisomeric forms in any ratio, or a physiologically acceptable salt thereof, or a physiologically acceptable solvate of any of them, wherein the compound is chosen from (S)-3-[(2-Phenyl-1 H-imidazole-4-carbonyl)-annino]-3-o-tolyl-propionic acid (S)-3-[(5-Phenyl-isoxazole-3-carbonyl)-amino]-3-o-tolyl-propionic acid

3-Cyclohexyl-3-[(5-methyl-2-phenyl-oxazole-4-carbonyl)-annino]-propionic acid 3-[(5-Methyl-2-phenyl-oxazole-4-carbonyl)-amino]-4-phenyl-butyric acid

(S)-3-[(5-Methyl-2-phenyl-oxazole-4-carbonyl)-amino]-3-o-tolyl-propionic acid

(S)-3-[(1 -lsopropyl-1 H-indazole-3-carbonyl)-amino]-3-o-tolyl-propionic acid

(S)-3-(2-Fluoro-phenyl)-3-[(5-methyl-2-phenyl-oxazole-4-carbonyl)-annino]-propionic acid

(S)-3-(3-Fluoro-phenyl)-3-[(5-methyl-2-phenyl-oxazole-4-carbonyl)-annino]-propionic acid

(S)-3-(4-Fluoro-phenyl)-3-[(5-methyl-2-phenyl-oxazole-4-carbonyl)-annino]-propionic acid

(S)-3-{[2-(2-Fluoro-phenyl)-5-methyl-oxazole-4-carbonyl]-annino}-3-phenyl-propionic acid

(R)-3-{[3-(2-Fluoro-phenyl)-[1 ,2,4]oxadiazole-5-carbonyl]-annino}-4-phenyl-butync acid (S)-3-{[5-(2-Fluoro-phenyl)-[1 ,2,4]oxadiazole-3-carbonyl]-amino}-3-p-tolyl-propionic acid

(R)-3-{[5-(2-Fluoro-phenyl)-[1 ,2,4]oxadiazole-3-carbonyl]-annino}-4-phenyl-butync acid (S)-3-{[5-(2-Fluoro-phenyl)-[1 ,2,4]oxadiazole-3-carbonyl]-annino}-3-phenyl-butync acid (S)-3-{[5-(2-Fluoro-phenyl)-[1 ,2,4]oxadiazole-3-carbonyl]-annino}-3-o-tolyl-propionic acid

(S)-3-{[5-(2-Fluoro-phenyl)-[1 ,2,4]oxadiazole-3-carbonyl]-amino}-3-m-tolyl-propionic acid

(S)-3-(2-Fluoro-phenyl)-3-{[5-(2-fluoro-phenyl)-[1 ,2,4]oxadiazole-3-carbonyl]-annino}- propionic acid

(S)-3-(3-Fluoro-phenyl)-3-{[5-(2-fluoro-phenyl)-[1 ,2,4]oxadiazole-3-carbonyl]-annino}- propionic acid

(S)-3-(4-Fluoro-phenyl)-3-{[5-(2-fluoro-phenyl)-[1 ,2,4]oxadiazole-3-carbonyl]-annino}- propionic acid

(S)-3-{[5-(2,3-Difluoro-phenyl)-[1 ,2,4]oxadiazo

acid

(S)-3-[(1 -Ethyl-5-phenyl-1 H-pyrazole-3-carbonyl)-amino]-3-o-tolyl-propionic acid (S)-3-[(5-lsopropyl-2-phenyl-oxazole-4-carbonyl)-amino]-3-phenyl-propionic acid

(S)-3-(4-Methoxy-phenyl)-3-[(5-methyl-2-phenyl-oxazole-4-carbonyl)-amino]-propionic acid

(S)-3-(3-Methoxy-phenyl)-3-[(5-methyl-2-phenyl-oxazole-4-carbonyl)-amino]-propionic acid

(S)-3-{[2-(2-Fluoro-phenyl)-5-methyl-oxazole-4-carbonyl]-annino}-3-o-tolyl-propionic acid

(S)-3-{[5-(4-Chloro-phenyl)-isoxazole-3-carbonyl]-amino}-3-o-tolyl-propionic acid (S)-3-{[2-(2-Fluoro-phenyl)-5-methyl-oxazole-4-carbonyl]-amino}-3-m-tolyl-propionic acid

(S)-3-(3-Chloro-phenyl)-3-[(5-methyl-2-phenyl-oxazole-4-carbonyl)-amino]-propionic acid

(R)-3-{[2-(2-Fluoro-phenyl)-5-methyl-oxazole-4-carbonyl]-annino}-4-phenyl-butyric acid (S)-3-{[2-(2-Fluoro-phenyl)-5-methyl-oxazole-4-carbonyl]-annino}-3-phenyl-butyric acid (S)-3-{3-[3-(2-Fluoro-phenyl)-[1 ,2,4]oxadiazol-5-yl]-propionylannino}-3-phenyl-propionic acid

(S)-3-(2-Chloro-phenyl)-3-[(5-methyl-2-phenyl-oxazole-4-carbonyl)-amino]-propionic acid

(S)-3-{[1 -(2-Chloro-phenyl)-5-methyl-1 H-[1 ,2,4]triazole-3-carbonyl]-amino}-3-phenyl- propionic acid

3-Cyclohexyl-3-[(5-isopropyl-2-phenyl-oxazole-4-carbonyl)-amino]-propionic acid (S)-3-(2-Fluoro-phenyl)-3-{[2-(2-fluoro-phenyl)-5-methyl-oxazole-4-carbonyl]-amino}- propionic acid

(S)-3-(3-Fluoro-phenyl)-3-{[2-(2-fluoro-phenyl)-5-methyl-oxazole-4-carbonyl]-annino}- propionic acid

(S)-3-(4-Fluoro-phenyl)-3-{[2-(2-fluoro-phenyl)-5-methyl-oxazole-4-carbonyl]-annino}- propionic acid

(S)-3-{[5-(2,3-Difluoro-phenyl)-[1 ,2,4]oxadiazole-3-carbonyl]-amino}-3-p-tolyl-propionic acid

(S)-3-{[5-(2,3-Difluoro-phenyl)-[1 ,2,4]oxadiazole-3-carbonyl]-amino}-3-m-tolyl-propionic acid (S)-3-{[5-(2,3-Difluoro-phenyl)-[1 ,2,4]oxadiazole-3-carbonyl]-amino}-3-phenyl-butyric acid

(R)-3-{[5-(2,3-Difluoro-phenyl)-[1 ,2,4]oxadiazole-3-carbonyl]-amino}-4-phenyl-butyric acid

(S)-3-{[5-(2,3-Difluoro-phenyl)-[1 ,2,4]oxadiazole-3-carbonyl]-annino}-3-o-tolyl-propionic acid

(S)-3-{[5-(2,3-Difluoro-phenyl)-[1 ,2,4]oxadiazole-3-carbonyl]-amino}-3-(2-fluoro- phenyl)-propionic acid

(S)-3-{[5-(2,3-Difluoro-phenyl)-[1 ,2,4]oxadiazole-3-carbonyl]-annino}-3-(4-fluoro- phenyl)-propionic acid

3-[(5-lsopropyl-2-phenyl-oxazole-4-carbonyl)-amino]-4-phenyl-butyric acid

(S)-3-[(5-Dimethylsulfamoyl-2-methyl-furan-3-carbonyl)-amino]-3-o-tolyl-propionic acid (S)-3-(2-Fluoro-phenyl)-3-[(5-isopropyl-2-phenyl-oxazole-4-carbonyl)-amino]-propionic acid

(S)-3-(4-Fluoro-phenyl)-3-[(5-isopropyl-2-phenyl-oxazole-4-carbonyl)-amino]-propionic acid

(R)-3-{3-[3-(2-Fluoro-phenyl)-[1 ,2,4]oxadiazol-5-yl]-propionylamino}-4-phenyl-butyric acid

(S)-3-{3-[3-(2-Fluoro-phenyl)-[1 ,2,4]oxadiazol-5-yl]-propionylamino}-3-m-tolyl-propionic acid

(S)-3-{3-[3-(2-Fluoro-phenyl)-[1 ,2,4]oxadiazol-5-yl]-propionylamino}-3-phenyl-butyric acid

(S)-3-{3-[3-(2-Fluoro-phenyl)-[1 ,2,4]oxadiazol-5-yl]-propionylamino}-3-p-tolyl-propionic acid

(S)-3-{3-[3-(2-Fluoro-phenyl)-[1 ,2,4]oxadiazol-5-yl]-propionylamino}-3-o-tolyl-propionic acid

(S)-Cyclohexyl-{[5-(4-trifluoronnethyl-pyridin-3-yl)-[1 ,2,4]oxadiazole-3-carbonyl]-amino}- acetic acid

(S)-3-{[1 -(2-Chloro-phenyl)-5-methyl-1 H-[1 ,2,4]triazole-3-carbonyl]-amino}-3-p-tolyl- propionic acid

(S)-3-{[1 -(2-Chloro-phenyl)-5-ethyl-1 H-[1 ,2,4]triazole-3-carbonyl]-amino}-3-phenyl- propionic acid (S)-3-{[1 -(2-Chlorc-phenyl)-5-methyl-1 H-[1 ,2,4]triazole-3-carbonyl]-amino}-3-o-tolyl- propionic acid

(S)-3-(4-Fluoro-phenyl)-3-{3-[3-(2-fluoro-phenyl)-[1 ,2,4]oxadiazol-5-yl]- propionylamino}-propionic acid

(S)-3-(2-Fluoro-phenyl)-3-{3-[3-(2-fluoro-phenyl)-[1 ,2,4]oxadiazol-5-yl]- propionylamino}-propionic acid

(S)-3-(3-Fluoro-phenyl)-3-{3-[3-(2-fluoro-phenyl)-[1 ,2,4]oxadiazol-5-yl]- propionylamino}-propionic acid

(S)-3-(3-Chloro-phenyl)-3-{[2-(2-fluoro-phenyl)-5-methyl-oxazole-4-carbonyl]-annino}- propionic acid

3-(2-Chloro-phenyl)-3-{[2-(2-fluoro-phenyl)-5-methyl-oxazole-4-carbonyl]-amino}- propionic acid

(S)-3-(4-Chloro-phenyl)-3-{[2-(2-fluoro-phenyl)-5-methyl-oxazole-4-carbonyl]-amino}- propionic acid

(S)-3-{[1 -Methyl-4-(propane-1 -sulfonylamino)-1 H-pyrazole-3-carbonyl]-amino}-3-o- tolyl-propionic acid

(S)-3-[(5-lsopropyl-2-phenyl-oxazole-4-carbonyl)-amino]-3-(3-nnethoxy-phenyl)- propionic acid

(S)-3-(2,3-Dimethoxy-phenyl)-3-[(5-methyl-2-phenyl-oxazole-4-carbonyl)-amino]- propionic acid

(S)-3-(2-Chloro-phenyl)-3-[(5-isopropyl-2-phenyl-oxazole-4-carbonyl)-amino]-propionic acid

3-Cyclohexyl-3-[(2-phenyl-5-trifluoromethyl-oxazole-4-carbonyl)-amino]-propionic acid (S)-3-[(1 ,5-Diphenyl-1 H-[1 ,2,4]triazole-3-carbonyl)-annino]-3-phenyl-propionic acid (S)-3-{[1 -(2-Chloro-phenyl)-5-ethyl-1 H-[1 ,2,4]triazole-3-carbonyl]-amino}-3-o-tolyl- propionic acid

(S)-3-{[1 -(2-Chloro-phenyl)-5-ethyl-1 H-[1 ,2,4]triazole-3-carbonyl]-amino}-3-p-tolyl- propionic acid

(S)-3-[(1 -Benzyl-1 H-indazole-3-carbonyl)-amino]-3-o-tolyl-propionic acid

(S)-3-{3-[3-(2-Fluoro-phenyl)-[1 ,2,4]oxadiazol-5-yl]-propionylamino}-3-(4-nnethoxy- phenyl)-propionic acid (S)-3-(3-Chloro-phenyl)-3-{3-[3-(2-fluoro-phenyl)-[1 ,2,4]oxadiazol-5-yl]- propionylamino}-propionic acid

(S)-3-(2,4-Dichloro-phenyl)-3-[(5-methyl-2-phenyl-oxazole-4-carbonyl)-amino]- propionic acid

(S)-3-(2,3-Dichloro-phenyl)-3-[(5-methyl-2-phenyl-oxazole-4-carbonyl)-amino]- propionic acid

(S)-3-[(2-Phenyl-5-trifluoromethyl-oxazole-4-carbonyl)-amino]-3-o-tolyl-propionic acid (S)-3-[(5-Methyl-2-phenyl-oxazole-4-carbonyl)-amino]-3-(2-trifluoromethyl-phenyl)- propionic acid

(S)-3-(3-Fluoro-phenyl)-3-[(2-phenyl-5-trifluoronnethyl-oxazole-4-carbonyl)-annino]- propionic acid

(S)-3-{[5-(2-Fluoro-phenyl)-[1 ,2,4]oxadiazole-3-carbonyl]-annino}-3-(2-tnfluoronnethyl- phenyl)-propionic acid

(S)-3-{[5-(2-Fluoro-phenyl)-[1 ,2,4]oxadiazole-3-carbonyl]-amino}-3-(3-trifluoromethyl- phenyl)-propionic acid

(S)-3-{[1 -(2-Chloro-phenyl)-5-cyclopropyl-1 H-[1 ,2,4]triazole-3-carbonyl]-amino}-3-o- tolyl-propionic acid

(S)-3-{[1 -(2-Chloro-phenyl)-5-cyclopropyl-1 H-[1 ,2,4]triazole-3-carbonyl]-amino}-3-p- tolyl-propionic acid

(S)-3-[(1 ,5-Diphenyl-1 H-[1 ,2,4]triazole-3-carbonyl)-annino]-3-o-tolyl-propionic acid

(S)-3-{[1 -(2-Chloro-phenyl)-5-isopropyl-1 H-[1 ,2,4]triazole-3-carbonyl]-amino}-3-p-tolyl- propionic acid

3-[(1 ,5-Diphenyl-1 H-[1 ,2,4]triazole-3-carbonyl)-amino]-4-phenyl-butyric acid

(S)-3-{[1 -(2-Chloro-phenyl)-5-isopropyl-1 H-[1 ,2,4]triazole-3-carbonyl]-amino}-3-o-tolyl- propionic acid

(S)-3-{[1 -(2-Chloro-phenyl)-5-propyl-1 H-[1 ,2,4]triazole-3-carbonyl]-amino}-3-p-tolyl- propionic acid

(S)-3-{[1 -(2-Chloro-phenyl)-5-propyl-1 H-[1 ,2,4]triazole-3-carbonyl]-amino}-3-o-tolyl- propionic acid

(S)-3-[(1 ,5-Diphenyl-1 H-[1 ,2,4]triazole-3-carbonyl)-annino]-3-(2-fluoro-phenyl)-propionic acid (S)-3-[(1 ,5-Diphenyl-1 H-[1 ,2,4]triazole-3-carbonyl)-annino]-3-(4-fluoro-phenyl)-propionic acid

(S)-3-{[2-(2-Fluoro-phenyl)-5-methyl-oxazole-4-carbonyl]-amino}-3-(3-trifluoromethyl- phenyl)-propionic acid

(S)-3-{[2-(2-Fluoro-phenyl)-5-methyl-oxazole-4-carbonyl]-amino}-3-(4-trifluoromethyl- phenyl)-propionic acid

(S)-3-(2,3-Dichloro-phenyl)-3-{[2-(2-fluoro-phenyl)-5-methyl-oxazole-4-carbonyl]- amino}-propionic acid

(S)-3-{[4-(2,2-Dimethyl-propane-1 -sulfonylamino)-1 -methyl-1 H-pyrazole-3-carbonyl]- amino}-3-o-tolyl-propionic acid

(S)-3-(3-Chloro-phenyl)-3-[(2-phenyl-5-trifluoromethyl-oxazole-4-carbonyl)-amino]- propionic acid

(S)-3-(2-Chloro-phenyl)-3-[(2-phenyl-5-trifluoromethyl-oxazole-4-carbonyl)-amino]- propionic acid

(S)-3-[(1 -Benzyl-5-phenyl-1 H-pyrazole-3-carbonyl)-amino]-3-o-tolyl-propionic acid (S)-3-(4-Chloro-phenyl)-2-{[5-(4-trifluoromethyl-pyndin-3-yl)-[1 ,2,4]oxadiazole-3- carbonyl]-amino}-propionic acid

(S)-3-{[1 -Ethyl-5-(2-propyl-piperidine-1 -carbonyl)-1 H-pyrazole-3-carbonyl]-amino}-3- phenyl-propionic acid

(S)-3-{[5-(2,3-Difluoro-phenyl)-[1 ,2,4]oxadiazole-3-carbonyl]-amino}-3-(2- trifluoronnethyl-phenyl)-propionic acid

(S)-3-[(1 ,5-Diphenyl-1 H-[1 ,2,4]triazole-3-carbonyl)-amino]-3-(3-methoxy-phenyl)- propionic acid

(S)-3-(2,3-Dichloro-phenyl)-3-[(5-isopropyl-2-phenyl-oxazole-4-carbonyl)-amino]- propionic acid

(S)-3-(3-Chloro-phenyl)-3-[(1 ,5-diphenyl-1 H-[1 ,2,4]triazole-3-carbonyl)-amino]- propionic acid

(S)-3-(2,4-Dichloro-phenyl)-3-[(5-isopropyl-2-phenyl-oxazole-4-carbonyl)-amino]- propionic acid

(S)-3-(2-Chloro-phenyl)-3-[(1 ,5-diphenyl-1 H-[1 ,2,4]triazole-3-carbonyl)-amino]- propionic acid (S)-3-{[1 -(2,6-Dichloro-phenyl)-5-ethyl-1 H-[1 ,2,4]triazole-3-carbonyl]-amino}-3-p-tolyl- propionic acid

(S)-3-{[1 -(2,6-Dichloro-phenyl)-5-ethyl-1 H-[1 ,2,4]triazole-3-carbonyl]-amino}-3-o-tolyl- propionic acid

(S)-3-[(4-Cyclohexylmethanesulfonylannino-1 -methyl-1 H-pyrazole-3-carbonyl)-amino]- 3-phenyl-propionic acid

(S)-3-{3-[3-(2-Fluoro-phenyl)-[1 ,2,4]oxadiazol-5-yl]-propionylamino}-3-(2- trifluoronnethyl-phenyl)-propionic acid

(S)-3-{3-[3-(2-Fluoro-phenyl)-[1 ,2,4]oxadiazol-5-yl]-propionylamino}-3-(4- trifluoronnethyl-phenyl)-propionic acid

(S)-3-(2,3-Dichloro-phenyl)-3-{3-[3-(2-fluoro-phenyl)-[1 ,2,4]oxadiazol-5-yl]- propionylamino}-propionic acid

(S)-3-{3-[3-(2-Fluoro-phenyl)-[1 ,2,4]oxadiazol-5-yl]-propionylamino}-3-(3- trifluoronnethyl-phenyl)-propionic acid

(S)-3-{[1 -Ethyl-5-(2-propyl-piperidine-1 -carbonyl)-1 H-pyrazole-3-carbonyl]-amino}-3-o- tolyl-propionic acid

(S)-3-{[1 -Ethyl-5-(2-propyl-piperidine-1 -carbonyl)-1 H-pyrazole-3-carbonyl]-amino}-3-p- tolyl-propionic acid

(S)-3-{[1 -Ethyl-5-(2-propyl-piperidine-1 -carbonyl)-1 H-pyrazole-3-carbonyl]-amino}-3-m- tolyl-propionic acid

(S)-3-[(1 -Methyl-4-phenylmethanesulfonylannino-1 H-pyrazole-3-carbonyl)-amino]-3-o- tolyl-propionic acid

(S)-3-{[1 -(4-Fluoro-benzyl)-5-phenyl-1 H-pyrazole-3-carbonyl]-amino}-3-o-tolyl- propionic acid

(S)-3-[(4-Cyclohexylmethanesulfonylannino-1 -methyl-1 H-pyrazole-3-carbonyl)-amino]- 3-o-tolyl-propionic acid

(S)-3-(2,3-Dimethoxy-phenyl)-3-[(2-phenyl-5-trifluoronnethyl-oxazole-4-carbonyl)- amino]-propionic acid

(S)-3-{[1 -Methyl-4-(2-phenyl-ethanesulfonylamino)-1 H-pyrazole-3-carbonyl]-amino}-3- o-tolyl-propionic acid

(S)-3-(2,3-Dichloro-phenyl)-3-[(2-phenyl-5-trifluoromethyl-oxazole-4-carbonyl)-amino]- propionic acid (S)-3-(2,4-Dichloro-phenyl)-3-[(2-phenyl-5-trifluoromethyl-oxazole-4-carbonyl)-amino]- propionic acid

(S)-3-(2,3-Dichloro-phenyl)-3-[(1 ,5-diphenyl-1 H-[1 ,2,4]triazole-3-carbonyl)-amino]- propionic acid

(S)-3-(2,4-Dichloro-phenyl)-3-[(1 ,5-diphenyl-1 H-[1 ,2,4]triazole-3-carbonyl)-amino]- propionic acid,

for prevention and/or treatment of atrial fibrillation.

A subject of the invention also is the use of a compound of the formula IV which is chosen from any of the specific compounds of the formula IV which are disclosed herein, or is any one of the specific compounds of the formula IV which are disclosed herein, irrespective thereof whether they are disclosed as a free compound and/or as a specific salt, or a physiologically acceptable salt thereof, or a physiologically

acceptable solvate of any of them, wherein the use of the compound of the formula IV is a subject of the invention in any of its stereoisomeric forms or a mixture of stereoisomeric forms in any ratio. For example, a subject of the invention is the use of a compound of the formula IV which is chosen from (S)-3-[(2-Phenyl-1 H-imidazole-4-carbonyl)-amino]-3-o-tolyl-propionic acid

(S)-3-[(5-Phenyl-isoxazole-3-carbonyl)-amino]-3-o-tolyl-propionic acid

3-Cyclohexyl-3-[(5-methyl-2-phenyl-oxazole-4-carbonyl)-amino]-propionic acid

3-[(5-Methyl-2-phenyl-oxazole-4-carbonyl)-amino]-4-phenyl-butyric acid

(S)-3-[(5-Methyl-2-phenyl-oxazole-4-carbonyl)-amino]-3-o-tolyl-propionic acid

(S)-3-[(1 -lsopropyl-1 H-indazole-3-carbonyl)-amino]-3-o-tolyl-propionic acid

(S)-3-(2-Fluoro-phenyl)-3-[(5-methyl-2-phenyl-oxazole-4-carbonyl)-amino]-propionic acid

(S)-3-(3-Fluoro-phenyl)-3-[(5-methyl-2-phenyl-oxazole-4-carbonyl)-amino]-propionic acid

(S)-3-(4-Fluoro-phenyl)-3-[(5-methyl-2-phenyl-oxazole-4-carbonyl)-amino]-propionic acid (S)-3-{[2-(2-Fluoro-phenyl)-5-methyl-oxazole-4-carbonyl]-annino}-3-phenyl-propionic acid

(S)-3-{[5-(2-Fluoro-phenyl)-[1 ,2,4]oxadiazole-3-carbonyl]-annino}-3-nn-tolyl-propionic acid

(S)-3-{[5-(2,3-Difluoro-phenyl)-[1 ,2,4]oxadiazo

acid

(S)-3-[(1 -Ethyl-5-phenyl-1 H-pyrazole-3-carbonyl)-amino]-3-o-tolyl-propionic acid (S)-3-[(5-lsopropyl-2-phenyl-oxazole-4-carbonyl)-amino]-3-phenyl-propionic acid (S)-3-(4-Methoxy-phenyl)-3-[(5-methyl-2-phenyl-oxazole-4-carbonyl)-amino]-propionic acid

(S)-3-{[2-(2-Fluoro-phenyl)-5-methyl-oxazole-4-carbonyl]-amino}-3-o-tolyl-propionic acid

(S)-3-(3-Chloro-phenyl)-3-[(5-methyl-2-phenyl-oxazole-4-carbonyl)-amino]-propionic acid (R)-3-{[2-(2-Fluoro-phenyl)-5-methyl-oxazole-4-carbonyl]-annino}-4-phenyl-butyric acid (S)-3-{[2-(2-Fluoro-phenyl)-5-methyl-oxazole-4-carbonyl]-annino}-3-phenyl-butyric acid (S)-3-{3-[3-(2-Fluoro-phenyl)-[1 ,2,4]oxadiazol-5-yl]-propionylamino}-3-phenyl-propionic acid

3-Cyclohexyl-3-[(5-isopropyl-2-phenyl-oxazole-4-carbonyl)-amino]-propionic acid (S)-3-(2-Fluoro-phenyl)-3-{[2-(2-fluoro-phenyl)-5-methyl-oxazole-4-carbonyl]-annino}- propionic acid

(S)-3-(3-Fluoro-phenyl)-3-{[2-(2-fluoro-phenyl)-5-methyl-oxazole-4-carbonyl]-amino}- propionic acid

(S)-3-{[5-(2,3-Difluoro-phenyl)-[1 ,2,4]oxadiazole-3-carbonyl]-amino}-3-m-tolyl-propionic acid

(S)-3-{[5-(2,3-Difluoro-phenyl)-[1 ,2,4]oxadiazole-3-carbonyl]-amino}-3-phenyl-butyric acid

(S)-3-{[5-(2,3-Difluoro-phenyl)-[1 ,2,4]oxadiazole-3-carbonyl]-amino}-3-o-tolyl-propionic acid

(S)-3-{[5-(2,3-Difluoro-phenyl)-[1 ,2,4]oxadiazole-3-carbonyl]-amino}-3-(4-fluoro- phenyl)-propionic acid

3-[(5-lsopropyl-2-phenyl-oxazole-4-carbonyl)-amino]-4-phenyl-butyric acid

(S)-3-{[1 -(2-Chloro-phenyl)-5-ethyl-1 H-[1 ,2,4]triazole-3-carbonyl]-amino}-3-phenyl- propionic acid

(S)-3-{[1 -(2-Chloro-phenyl)-5-methyl-1 H-[1 ,2,4]triazole-3-carbonyl]-amino}-3-o-tolyl- propionic acid

(S)-3-(3-Chloro-phenyl)-3-{[2-(2-fluoro-phenyl)-5-methyl-oxazole-4-carbonyl]-amino}- propionic acid

3-(2-Chloro-phenyl)-3-{[2-(2-fluoro-phenyl)-5-methyl-oxazole-4-carbonyl]-amino}- propionic acid (S)-3-(4-Chloro-phenyl)-3-{[2-(2-fluoro-phenyl)-5-methyl-oxazole-4-carbonyl]-annino}- propionic acid

(S)-3-[(1 -Benzyl-1 H-indazole-3-carbonyl)-amino]-3-o-tolyl-propionic acid

(S)-3-{3-[3-(2-Fluoro-phenyl)-[1 ,2,4]oxadiazol-5-yl]-propionylamino}-3-(4-nnethoxy- phenyl)-propionic acid

(S)-3-(3-Chloro-phenyl)-3-{3-[3-(2-fluoro-phenyl)-[1 ,2,4]oxadiazol-5-yl]- propionylamino}-propionic acid

(S)-3-(3-Fluoro-phenyl)-3-[(2-phenyl-5-trifluoromethyl-oxazole-4-carbonyl)-amino]- propionic acid

(S)-3-{[5-(2-Fluoro-phenyl)-[1 ,2,4]oxadiazole-3-carbonyl]-amino}-3-(2-thfluoronnethyl- phenyl)-propionic acid (S)-3-{[5-(2-Fluoro-phenyl)-[1 ,2,4]oxadiazole-3-carbonyl]-amino}-3-(3-trifluoromethyl- phenyl)-propionic acid

(S)-3-[(1 ,5-Diphenyl-1 H-[1 ,2,4]triazole-3-carbonyl)-annino]-3-o-tolyl-propionic acid (S)-3-{[1 -(2-Chloro-phenyl)-5-isopropyl-1 H-[1 ,2,4]triazole-3-carbonyl]-amino}-3-p-tolyl- propionic acid

3-[(1 ,5-Diphenyl-1 H-[1 ,2,4]triazole-3-carbonyl)-annino]-4-phenyl-butync acid

(S)-3-[(1 ,5-Diphenyl-1 H-[1 ,2,4]triazole-3-carbonyl)-annino]-3-(2-fluoro-phenyl)-propionic acid

(S)-3-[(1 ,5-Diphenyl-1 H-[1 ,2,4]triazole-3-carbonyl)-annino]-3-(4-fluoro-phenyl)-propionic acid

(S)-3-(2-Chloro-phenyl)-3-[(2-phenyl-5-trifluoromethyl-oxazole-4-carbonyl)-amino]- propionic acid (S)-3-[(1 -Benzyl-5-phenyl-1 H-pyrazole-3-carbonyl)-amino]-3-o-tolyl-propionic acid (S)-3-(4-Chloro-phenyl)-2-{[5-(4-trifluoromethyl-pyridin-3-yl)-[1 ,2,4]oxadiazole-3- carbonyl]-amino}-propionic acid

(S)-3-(2-Chloro-phenyl)-3-[(1 ,5-diphenyl-1 H-[1 ,2,4]triazole-3-carbonyl)-amino]- propionic acid

(S)-3-{[1 -(2,6-Dichloro-phenyl)-5-ethyl-1 H-[1 ,2,4]triazole-3-carbonyl]-amino}-3-p-tolyl- propionic acid

(S)-3-[(4-Cyclohexylmethanesulfonylamino-1 -nnethyl-1 H-pyrazole-3-carbonyl)-amino]- 3-phenyl-propionic acid

(S)-3-{3-[3-(2-Fluoro-phenyl)-[1 ,2,4]oxadiazol-5-yl]-propionylamino}-3-(2- trifluoromethyl-phenyl)-propionic acid

(S)-3-{3-[3-(2-Fluoro-phenyl)-[1 ,2,4]oxadiazol-5-yl]-propionylamino}-3-(4- trifluoromethyl-phenyl)-propionic acid

(S)-3-{3-[3-(2-Fluoro-phenyl)-[1 ,2,4]oxadiazol-5-yl]-propionylamino}-3-(3- trifluoromethyl-phenyl)-propionic acid (S)-3-{[1 -Ethyl-5-(2-propyl-piperidine-1 -carbonyl)-1 H-pyrazole-3-carbonyl]-amino}-3-o- tolyl-propionic acid

(S)-3-[(4-Cyclohexylmethanesulfonylamino-1 -methyl-1 H-pyrazole-3-carbonyl)-amino]- 3-o-tolyl-propionic acid

(S)-3-(2,3-Dimethoxy-phenyl)-3-[(2-phenyl-5-trifluoromethyl-oxazole-4-carbonyl)- amino]-propionic acid

(S)-3-(2,3-Dichloro-phenyl)-3-[(2-phenyl-5-trifluoromethyl-oxazole-4-carbonyl)-amino]- propionic acid

(S)-3-(2,4-Dichloro-phenyl)-3-[(2-phenyl-5-trifluoromethyl-oxazole-4-carbonyl)-amino]- propionic acid

(S)-3-(2,4-Dichloro-phenyl)-3-[(1 ,5-diphenyl-1 H-[1 ,2,4]triazole-3-carbonyl)-amino]- propionic acid

or which is any one of these compounds, or a physiologically acceptable salt thereof, or a physiologically acceptable solvate of any of them, wherein the use of the compound of the formula IV is a subject of the invention in any of its stereoisomeric forms or a mixture of stereoisomeric forms in any ratio, unless a specific

stereoisomeric form is specified with respect to any carbon atoms in the respective compound. For example, another subject of the invention is the use if a compound of the formula IV which is chosen from

(S)-3-[(2-Phenyl-1 H-imidazole-4-carbonyl)-amino]-3-o-tolyl-propionic acid

(S)-3-[(5-Methyl-2-phenyl-oxazole-4-carbonyl)-amino]-3-o-tolyl-propionic acid

(S)-3-[(1 -lsopropyl-1 H-indazole-3-carbonyl)-amino]-3-o-tolyl-propionic acid

(R)-3-{[5-(2-Fluoro-phenyl)-[1 ,2,4]oxadiazole-3-carbonyl]-amino}-4-phenyl-butyric acid (S)-3-[(1 -Ethyl-5-phenyl-1 H-pyrazole-3-carbonyl)-amino]-3-o-tolyl-propionic acid (S)-3-{[2-(2-Fluoro-phenyl)-5-methyl-oxazole-4-carbonyl]-amino}-3-o-tolyl-propionic acid

(R)-3-{[2-(2-Fluoro-phenyl)-5-methyl-oxazole-4-carbonyl]-amino}-4-phenyl-butyric acid (S)-3-(3-Fluoro-phenyl)-3-{[2-(2-fluoro-phenyl)-5-methyl-oxazole-4-carbonyl]-amino}- propionic acid

(S)-3-[(1 ,5-Diphenyl-1 H-[1 ,2,4]triazole-3-carbonyl)-amino]-3-phenyl-propionic acid (S)-3-{[1 -(2-Chloro-phenyl)-5-ethyl-1 H-[1 ,2,4]triazole-3-carbonyl]-amino}-3-o-tolyl- propionic acid

(S)-3-[(1 -Benzyl-1 H-indazole-3-carbonyl)-amino]-3-o-tolyl-propionic acid

(S)-3-(2,3-Dichloro-phenyl)-3-[(5-methyl-2-phenyl-oxazole-4-carbonyl)-amino]- propionic acid (S)-3-[(1 ,5-Diphenyl-1 H-[1 ,2,4]triazole-3-carbonyl)-annino]-3-o-tolyl-propionic acid (S)-3-{[1 -(2-Chloro-phenyl)-5-isopropyl-1 H-[1 ,2,4]triazole-3-carbonyl]-amino}-3-p-tolyl- propionic acid

(S)-3-[(1 -Benzyl-5-phenyl-1 H-pyrazole-3-carbonyl)-amino]-3-o-tolyl-propionic acid (S)-3-[(1 ,5-Diphenyl-1 H-[1 ,2,4]triazole-3-carbonyl)-amino]-3-(3-methoxy-phenyl)- propionic acid

(S)-3-{[1 -Ethyl-5-(2-propyl-piperidine-1 -carbonyl)-1 H-pyrazole-3-carbonyl]-amino}-3-o- tolyl-propionic acid (S)-3-(2,3-Dichloro-phenyl)-3-[(1 ,5-diphenyl-1 H-[1 ,2,4]triazole-3-carbonyl)-amino]- propionic acid

(S)-3-(2,4-Dichloro-phenyl)-3-[(1 ,5-diphenyl-1 H-[1 ,2,4]triazole-3-carbonyl)-amino]- propionic acid.

The present invention relates also to the use of compounds of the formulae Va and Vb, in any of its stereoisomeric forms or a mixture of stereoisomeric forms in any ratio, or a physiologically acceptable salt thereof, or a physiologically acceptable solvate of any of them,

wherein

R¹ is chosen from the series consisting of hydrogen, halogen, (Ci-C6)-alkyl, CF₃, (C3- C₇)-cycloalkyl-C₃H₂s-, Ar-C₃H_2s-, Ar-O, (Ci-C₆)-alkyl-O-, (Ci-C₆)-alkyl-S(O)_m- and NC-; wherein s is an integer chosen from the series consisting of 0, 1 , 2 and 3;

R² is chosen from the series consisting of hydrogen, halogen, (Ci-C6)-alkyl, CF₃, HO-, (Ci-C₆)-alkyl-O-, and NC-; R¹⁰ is chosen from the series consisting of R^{1 1} , Het²-C(O)-, R¹⁴-C(O)- and (Ci-C )- alkyl-S(O)_m-;

R¹⁶ is (Ci-C6)-alkyl which is optionally substituted by one or more identical or different substituents chosen from the series consisting of HO-, (Ci-C₄)-alkyl-O- and NC-; R³⁰ is chosen from the series consisting of R³¹ , (C3-C₇)-cycloalkyl, R³²-C_uH_2u- and

Het³-C_uH_2u-, wherein u is an integer chosen from the series consisting of 0, 1 , 2 and 3;

R³² is chosen from the series consisting of phenyl and an aromatic 5-membered or 6- membered monocyclic heterocycle which comprises one, two or three identical or different ring heteroatoms chosen from the series consisting of nitrogen, oxygen and sulfur and is bonded via a ring carbon atom, wherein the phenyl and the heterocycle all are optionally substituted by one or more identical or different substituents chosen from the series consisting of halogen, (Ci-C6)-alkyl, (C3-C₇)-cycloalkyl, R³³, HO-, (C1-C-6)- alkyl-O-, R³³-O-, R³³-(Ci-C₄)-alkyl-O-, -O-CH2-O-, -O-CF2-O-, (Ci-C₆)-alkyl-S(O)_m-, H₂N-S(O)₂-, (Ci-C₄)-alkyl-NH-S(O)₂-, di((Ci-C₄)-alkyl)N-S(O)₂-, H₂N-, (Ci-C₆)-alkyl-NH- , di((Ci-C₆)-alkyl)N-, Het¹ , (Ci-C₄)-alkyl-C(O)-NH-, (Ci-C₄)-alkyl-S(0)₂-NH- and NC-; R is chosen from the series consisting of phenyl and an aromatic 5-membered or 6- membered monocyclic heterocycle which comprises one, two or three identical or different ring heteroatoms chosen from the series consisting of nitrogen, oxygen and sulfur and is bonded via a ring carbon atom, wherein the phenyl and the heterocycle all are optionally substituted by one or more identical or different substituents chosen from the series consisting of halogen, (Ci-C6)-alkyl, (C3-C₇)-cycloalkyl, HO-, (Ci-C-6)-alkyl-0- , (Ci-C₆)-alkyl-S(O)_m-, H₂N-S(O)₂-, (Ci-C₄)-alkyl-NH-S(O)₂-, di((Ci-C₄)-alkyl)N-S(O)₂- and NC-; R⁴⁰ is chosen from the series consisting of hydrogen and (Ci-C₄)-alkyl; or R³⁰ and R⁴⁰ together are (CH₂)_X which is optionally substituted by one or more identical or different (Ci-C₄)-alkyl substituents, wherein x is an integer chosen from the series consisting of 2, 3, 4 and 5;

R⁶⁰ is chosen from the series consisting of hydrogen and (Ci-C6)-alkyl; or R⁵⁰ and R⁶⁰ together are (CH₂)_y which is optionally substituted by one or more identical or different (Ci-C₄)-alkyl substituents, wherein y is an integer chosen from the series consisting of 2, 3, 4 and 5; R⁷¹ is chosen from the series consisting of hydrogen and (Ci-Cs)-alkyl which is optionally substituted by one or more identical or different substituents chosen from the series consisting (Ci-C6)-alkyl-O- and (Ci-C6)-alkyl-C(O)-O-;

R⁷² is chosen from the series consisting of hydrogen, (Ci-C6)-alkyl, (C3-C6)-cycloalkyl, -CH₂-(CH₂)_b-(C₃-C₆)-cycloalkyl, Het⁴ and -(CH₂)_b-Het⁴, where alkyl or cycloalkyl is optionally substituted by one or more identical or different substituents chosen from the series consisting of halogen, HO-, HOOC-, (Ci-C₆)-alkyl-0- and (Ci-C₆)-alkyl-C(O)-O-, NC-, N((Ci-C₄)-alkyl)₂ and b is 0, 1 or 2;

R⁷³ is chosen from the series consisting of hydrogen, (Ci-C6)-alkyl;

or

Ar, independently of each other group Ar, is chosen from the series consisting of phenyl and an aromatic 5-membered or 6-membered monocyclic heterocycle which comprises one, two or three identical or different ring heteroatoms chosen from the series consisting of nitrogen, oxygen and sulfur and is bonded via a ring carbon atom, wherein the phenyl and the heterocycle all are optionally substituted by one or more identical or different substituents chosen from the series consisting of halogen, (C1-C-6)- alkyl, (Ci-C₆)-alkyl-O-, -O-CH2-O-, -O-CH₂-CH₂-, O-O-CF2-O-, CF₃, (d-C₆)-alkyl- S(O)_m-, H₂N-S(O)₂- and NC-;

and wherein phenyl may be substituted by -CH=CH-CH=CH-, -O-CH2-O-, -O-CH₂- CH2-O-, -O-CF₂-O- or -N((Ci-C₃)-alkyl)-CH=CH-;

Het¹, independently of each other group Het¹, is a saturated or unsaturated 4- membered to 8-membered monocyclic heterocycle which comprises a ring nitrogen atom via which Het¹ is bonded and optionally one or two identical or different further ring heteroatoms chosen from the series consisting of nitrogen, oxygen and sulfur, which is optionally substituted by one or more identical or different substituents chosen from the series consisting of halogen, (Ci-C₄)-alkyl, HO-, (Ci-C₄)-alkyl-O-, oxo and NC-; Het² is a saturated 4-membered to 7-membered monocyclic heterocycle which comprises a ring nitrogen atom via which Het² is bonded and optionally one further ring heteroatom chosen from the series consisting of nitrogen, oxygen and sulfur, which is optionally substituted by one or more identical or different substituents chosen from the series consisting of halogen, (CrC₄)-alkyl, HO- and (Ci-C₄)-alkyl-O-;

Het³, independently of each other group Het³, is a saturated 4-membered to 7- membered monocyclic heterocycle which comprises one or two identical or different ring heteroatoms chosen from the series consisting of nitrogen, oxygen and sulfur and is bonded via a ring carbon atom, which is optionally substituted by one or more identical or different substituents chosen from the series consisting of fluorine, (Ci-C₄)- alkyl and oxo;

for the prevention and/or treatment of atrial fibrillation.

A further preferred embodiment is use of a compound of the formulae Va and Vb, in any of its stereoisomeric forms or a mixture of stereoisomeric forms in any ratio, or a physiologically acceptable salt thereof, or a physiologically acceptable solvate of any of them, wherein R¹ is chosen from the series consisting of hydrogen, halogen, CF₃ and (Ci-C₄)-alkyl; R² is chosen from the series consisting of hydrogen, halogen, CF₃ and (Ci-C₄)-alkyl.

A further preferred embodiment is use of a compound of the formulae Va and Vb, in any of its stereoisomeric forms or a mixture of stereoisomeric forms in any ratio, or a physiologically acceptable salt thereof, or a physiologically acceptable solvate of any of them, wherein

H₂N-S(O)₂-, (Ci-C₄)-alkyl-NH-S(O)₂-, di((Ci-C₄)-alkyl)N-S(O)₂-, H₂N-, (Ci-C₆)-alkyl-NH- , di((Ci-C₆)-alkyl)N-, Het¹, (Ci-C₄)-alkyl-C(O)-NH-, (Ci-C₄)-alkyl-S(O)₂-NH- and NC-; R³³ is chosen from the series consisting of phenyl and an aromatic 5-membered or 6- membered monocyclic heterocycle which comprises one, two or three identical or different ring heteroatoms chosen from the series consisting of nitrogen, oxygen and sulfur and is bonded via a ring carbon atom, wherein the phenyl and the heterocycle all are optionally substituted by one or more identical or different substituents chosen from the series consisting of halogen, (Ci-C6)-alkyl, (C3-C₇)-cycloalkyl, HO-, (Ci-C-6)-alkyl-0- , (Ci-C₆)-alkyl-S(O)_m-, H₂N-S(O)₂-, (Ci-C₄)-alkyl-NH-S(O)₂-, di((Ci-C₄)-alkyl)N-S(O)₂- and NC-;

R⁴⁰ is hydrogen.

A further preferred embodiment is use of a compound of the formulae Va and Vb, in any of its stereoisomeric forms or a mixture of stereoisomeric forms in any ratio, or a physiologically acceptable salt thereof, or a physiologically acceptable solvate of any of them, wherein G is FT-O-C(O)- and R -N(R'^d)-C(0)-;

R⁷¹ is chosen from the series consisting of hydrogen and (Ci-CsJ-alkyl;

R⁷² is chosen from the series consisting of hydrogen, (Ci-C6)-alkyl;

R⁷³ is chosen from the series consisting of hydrogen, (Ci-C6)-alkyl.

R⁵⁰ is hydrogen;

R⁶⁰ is hydrogen.

R³⁰ is R³²-C_uH_2u- wherein u is an integer 0;

R⁴⁰ is hydrogen.

A further preferred embodiment is use of a compound of the formulae Va and Vb, or a physiologically acceptable salt thereof, or a physiologically acceptable solvate of any of them, chosen from

(R)-4-Phenyl-3-[(4-phenyl-thiazole-2-carbonyl)-amino]-butyric acid

3-(4'-Fluoro-biphenyl-4-yl)-3-[(2-phenyl-thiazole-4-carbonyl)-amino]-propionic acid (S)-3-[(4-Phenyl-thiazole-2-carbonyl)-amino]-3-m-tolyl-propionic acid

(S)-3-Phenyl-3-[(4-phenyl-thiazole-2-carbonyl)-amino]-butyric acid

(S)-3-{[2-(4-Methoxy-phenyl)-thiazole-4-carbonyl]-amino}-3-o-tolyl-propionic acid (S)-3-{[2-(3,5-Dimethyl-pyrazol-1 -yl)-thiazole-4-carbonyl]-amino}-3-o-tolyl-propionic acid

(S)-3-[(2-Pyridin-4-yl-thiazole-4-carbonyl)-amino]-3-o-tolyl-propionic acid (S)-3-[(2-Pyrazin-2-yl-thiazole-4-carbonyl)-amino]-3-o-tolyl-propionic acid (S)-3-{[2-(3-Methyl-5-trifluoromethyl-pyrazol-1 -yl)-thiazole-4-carbonyl]-amino}-3-o-tolyl- propionic acid

(S)-3-o-Tolyl-3-[(2-p-tolyl-thiazole-4-carbonyl)-amino]-propionic acid

(S)-3-[(4-Phenyl-thiazole-2-carbonyl)-amino]-3-p-tolyl-propionic acid

(S)-3-(2,3-Dichloro-phenyl)-3-[(2-o-tolyl-thiazole-4-carbonyl)-amino]-propioni acid (S)-3-(2,3-Dichloro-phenyl)-3-[(2-phenyl-thiazole-4-carbonyl)-amino]-propion acid (S)-3-(2,3-Dichloro-phenyl)-3-{[2-(2,3-dichloro-phenyl)-thiazole-4-carbonyl]-am propionic acid

(S)-3-(2,3-Dichloro-phenyl)-3-{[2-(2-fluoro-phenyl)-thiazole-4-carbonyl]-amino}- propionic acid

(S)-3-(2,3-Dichloro-phenyl)-3-{[2-(4-thfluoromethyl-phenyl)-thiazole-4-carbonyl]- amino}-propionic acid

(S)-3-(2,3-Dimethoxy-phenyl)-3-[(2-o-tolyl-thiazole-4-carbonyl)-amino]-propionic acid (S)-3-(2,3-Dimethoxy-phenyl)-3-[(2-phenyl-thiazole-4-carbonyl)-amino]-propionic acid (S)-3-(2,3-Dimethoxy-phenyl)-3-{[2-(2-fluoro-phenyl)-thiazole-4-carbonyl]-amino}- propionic acid

(S)-3-(2,3-Dimethoxy-phenyl)-3-{[2-(4-trifluoromethyl-phenyl)-thiazole-4-carbonyl]- amino}-propionic acid

(S)-3-(2,4-Dichloro-phenyl)-3-[(2-o-tolyl-thiazole-4-carbonyl)-amino]-propionic acid (S)-3-(2,4-Dichloro-phenyl)-3-[(2-phenyl-thiazole-4-carbonyl)-amino]-propionic acid (S)-3-(2,4-Dichloro-phenyl)-3-{[2-(2,3-dichloro-phenyl)-thiazole-4-carbonyl]-amino}- propionic acid

(S)-3-(2,4-Dichloro-phenyl)-3-{[2-(2-fluoro-phenyl)-thiazole-4-carbonyl]-amino}- propionic acid

(S)-3-(2,4-Dichloro-phenyl)-3-{[2-(4-thfluoromethyl-phenyl)-thiazole-4-carbonyl]- amino}-propionic acid

(S)-3-(2-Chloro-phenyl)-3-[(2-o-tolyl-thiazole-4-carbonyl)-amino]-propionic acid

(S)-3-(2-Chloro-phenyl)-3-[(2-phenyl-thiazole-4-carbonyl)-amino]-propionic acid (S)-3-(2-Chloro-phenyl)-3-{[2-(2,3-dichloro-phenyl)-thiazole-4-carbonyl]-amino}- propionic acid (S)-3-(2-Chloro-phenyl)-3-{[2-(2-chloro-phenyl)-thiazole-4-carbonyl]-amino}-propionic acid

(S)-3-(2-Chloro-phenyl)-3-{[2-(2-fluoro-phenyl)-thiazole-4-carbonyl]-amino}-propionic acid

(S)-3-(2-Chloro-phenyl)-3-{[2-(3-chloro-phenyl)-thiazole-4-carbonyl]-amino}-propionic acid

(S)-3-(2-Chloro-phenyl)-3-{[2-(4-chloro-phenyl)-thiazole-4-carbonyl]-amino}-propionic acid

(S)-3-(2-Chloro-phenyl)-3-{[2-(4-trifluoromethyl-phenyl)-thiazole-4-carbonyl]-amino}- propionic acid

(S)-3-(2-Fluoro-phenyl)-3-[(2-o-tolyl-thiazole-4-carbonyl)-amino]-propionic acid (S)-3-(2-Fluoro-phenyl)-3-[(2-phenyl-thiazole-4-carbonyl)-amino]-propionic acid (S)-3-(2-Fluoro-phenyl)-3-{[2-(2-fluoro-phenyl)-thiazole-4-carbonyl]-amino}-propionic acid

(S)-3-(2-Fluoro-phenyl)-3-{[2-(4-trifluoromethyl-phenyl)-thiazole-4-carbonyl]-amino}- propionic acid

(S)-3-(2-Trifluoromethyl-phenyl)-3-{[2-(4-trifluoromethyl-phenyl)-thiazole-4-carbonyl]- amino}-propionic acid

(S)-3-(3-Chloro-phenyl)-3-[(2-o-tolyl-thiazole-4-carbonyl)-amino]-propionic acid (S)-3-(3-Chloro-phenyl)-3-[(2-phenyl-thiazole-4-carbonyl)-amino]-propionic acid (S)-3-(3-Chloro-phenyl)-3-{[2-(2,3-dichloro-phenyl)-thiazole-4-carbonyl]-amino}- propionic acid

(S)-3-(3-Chloro-phenyl)-3-{[2-(2-chloro-phenyl)-thiazole-4-carbonyl]-amino}-propionic acid

(S)-3-(3-Chloro-phenyl)-3-{[2-(2-fluoro-phenyl)-thiazole-4-carbonyl]-amino}-propionic acid

(S)-3-(3-Chloro-phenyl)-3-{[2-(3-chloro-phenyl)-thiazole-4-carbonyl]-amino}-propionic acid

(S)-3-(3-Chloro-phenyl)-3-{[2-(4-chloro-phenyl)-thiazole-4-carbonyl]-amino}-propionic acid

(S)-3-(3-Chloro-phenyl)-3-{[2-(4-trifluoromethyl-phenyl)-thiazole-4-carbonyl]-amino}- propionic acid (S)-3-(3-Fluoro-phenyl)-3-[(2-o-tolyl-thiazole-4-carbonyl)-amino]-propionic acid

(S)-3-(3-Fluoro-phenyl)-3-[(2-phenyl-thiazole-4-carbonyl)-amino]-propionic acid (S)-3-(3-Fluoro-phenyl)-3-{[2-(2-fluoro-phenyl)-thiazole-4-carbonyl]-amino}-propionic acid

(S)-3-(3-Fluoro-phenyl)-3-{[2-(4-trifluoromethyl-phenyl)-thiazole-4-carbonyl]-amino}- propionic acid

(S)-3-(4-Fluoro-phenyl)-3-[(4-phenyl-thiazole-2-carbonyl)-amino]-propionic acid (S)-3-(3-Methoxy-phenyl)-3-[(2-phenyl-thiazole-4-carbonyl)-amino]-propionic acid (S)-3-(2-Fluoro-phenyl)-3-[(4-phenyl-thiazole-2-carbonyl)-amino]-propionic acid (S)-3-(4-Fluoro-phenyl)-3-[(2-o-tolyl-thiazole-4-carbonyl)-amino]-propionic acid

(S)-3-(3-Fluoro-phenyl)-3-[(4-phenyl-thiazole-2-carbonyl)-amino]-propionic acid (S)-3-(4-Fluoro-phenyl)-3-{[2-(2-fluoro-phenyl)-thiazole-4-carbonyl]-amino}-propionic acid

(S)-{[2-(3-Chloro-phenyl)-thiazole-4-carbonyl]-amino}-cyclohexyl-acetic acid

(S)-3-(4-Chloro-phenyl)-2-[(2-phenyl-thiazole-4-carbonyl)-amino]-propionic acid (S)-3-(4-Methoxy-phenyl)-3-[(2-phenyl-thiazole-4-carbonyl)-amino]-propionic acid (S)-3-(4-Methoxy-phenyl)-3-{[2-(4-trifluoromethyl-phenyl)-thiazole-4-carbonyl]-amino}- propionic acid

(S)-3-[(2-o-Tolyl-thiazole-4-carbonyl)-amino]-3-(2-trifluoromethyl-phenyl)-propionic acid (S)-3-[(2-Phenyl-thiazole-4-carbonyl)-amino]-3-(2-trifluoromethyl-phenyl)-propionic acid (S)-3-[(2-Phenyl-thiazole-4-carbonyl)-amino]-3-o-tolyl-propionic acid

(S)-3-{[2-(2,3-Dichloro-phenyl)-thiazol

propionic acid

(S)-3-(3-Chloro-phenyl)-3-[(4-phenyl-thiazole-2-carbonyl)-amino]-propionic acid (S)-3-{[2-(2,3-Dichloro-phenyl)-thiazole-4-carbonyl]-amino}-3-(2-trifluoromethyl- phenyl)-propionic acid

(S)-3-{[2-(2,3-Dichloro-phenyl)-thiazole-4-carbonyl]-amino}-3-(3-fluoro-phenyl)- propionic acid

3-(2-Chloro-phenyl)-3-[(4-phenyl-thiazole-2-carbonyl)-amino]-propionic acid

(S)-3-(4-Chloro-phenyl)-3-[(4-phenyl-thiazole-2-carbonyl)-amino]-propionic acid (S)-3-[(4-Methyl-2-p-tolyl-thiazole-5-carbonyl)-amino]-3-o-tolyl-propionic acid

(S)-3-{[2-(2,3-Dichloro-phenyl)-thiazole-4-carbonyl]-amino}-3-o-tolyl-propionic acid (S)-3-(4-Chloro-phenyl)-2- (2-o-tolyl-thiazole-4-carbonyl)-amino]-propionic acid

(S)-3-{[2-(2-Chloro-phenyl -thiazole-4-carbonyl]-amino}-3-(2,3-dichloro-phenyl)- propionic acid

(S)-3-{[2-(2-Chloro-phenyl -thiazole-4-carbonyl]-amino}-3-(2,3-dinnethoxy-phenyl)- propionic acid

(S)-3-{[2-(2-Chloro-phenyl -thiazole-4-carbonyl]-amino}-3-(2,4-dichloro-phenyl)- propionic acid

(S)-3-{[2-(2-Chloro-phenyl -thiazole-4-carbonyl]-amino}-3-(2-fluoro-phenyl)-propionic acid

(S)-3-{[2-(2-Chloro-phenyl -thiazole-4-carbonyl]-amino}-3-(2-thfluoronnethyl-phenyl)- propionic acid

(S)-3-{[2-(2-Chloro-phenyl -thiazole-4-carbonyl]-amino}-3-(3-fluoro-phenyl)-propionic acid

(S)-3-{[2-(2-Chloro-phenyl -thiazole-4-carbonyl]-amino}-3-(3-methoxy-phenyl)- propionic acid

(S)-3-{[2-(2-Chloro-phenyl -thiazole-4-carbonyl]-amino}-3-(4-fluoro-phenyl)-propionic acid

(S)-3-(4-Chloro-phenyl)-2- ;[2-(2-chloro-phenyl)-thiazole-4-carbonyl]-amino}-propionic acid

(S)-3-{[2-(2-Chloro-phenyl -thiazole-4-carbonyl]-amino}-3-o-tolyl-propionic acid

(S)-3-{[2-(2-Chloro-phenyl -thiazole-4-carbonyl]-amino}-3-phenyl-propionic acid (S)-3-{[2-(2-Fluoro-phenyi; -thiazole-4-carbonyl]-amino}-3-(2-thfluoronnethyl-phenyl)- propionic acid

(S)-3-{[2-(2-Fluoro-phenyi; -thiazole-4-carbonyl]-amino}-3-(3-nnethoxy-phenyl)-propionic acid

(S)-3-{[2-(2-Fluoro-phenyi; -thiazole-4-carbonyl]-amino}-3-(4-nnethoxy-phenyl)-propionic acid

(S)-3-{[2-(2-Fluoro-phenyi; -thiazole-4-carbonyl]-amino}-3-o-tolyl-propionic acid

(S)-3-{[2-(2-Fluoro-phenyi; -thiazole-4-carbonyl]-amino}-3-phenyl-propionic acid

(S)-3-{[2-(3-Chloro-phenyl -thiazole-4-carbonyl]-amino}-3-(2,3-dichloro-phenyl)- propionic acid (S)-3-{[2-(3-Chloro-phenyl)-thiazole-4-carbonyl]-amino}-3-(2,3-dimethoxy-phenyl)- propionic acid

(S)-3-{[2-(3-Chloro-phenyl)-thiazole-4-carbonyl]-amino}-3-(2,4-dichloro-phenyl)- propionic acid

(S)-3-{[2-(3-Chloro-phenyl)-thiazole-4-carbonyl]-amino}-3-(2-fluoro-phenyl)-propionic acid

(S)-3-{[2-(3-Chloro-phenyl)-thiazole-4-carbonyl]-amino}-3-(2-trifluoromethyl-phenyl)- propionic acid

(S)-3-{[2-(3-Chloro-phenyl)-thiazole-4-carbonyl]-amino}-3-(3-fluoro-phenyl)-propionic acid

(S)-3-(2,3-Dichloro-phenyl)-3-[(4-phenyl-thiazole-2-carbonyl)-amino]-propion acid (S)-3-(2,4-Dichloro-phenyl)-3-[(4-pheny^ acid (S)-3-[(4-Phenyl-thiazole-2-carbonyl)-amino]-3-(4-trifluoromethyl-phenyl)-propionic acid (S)-3-{[2-(3-Chloro-phenyl)-thiazole-4-carbonyl]-amino}-3-o-tolyl-propionic acid

(S)-3-[(4-Phenyl-thiazole-2-carbonyl)-amino]-3-(3-trifluoromethyl-phenyl)-propionic acid (S)-3-{[2-(4-Chloro-phenyl)-thiazole-4-carbonyl]-amino}-3-(2,3-dichloro-phen propionic acid

(S)-3-{[2-(4-Chloro-phenyl)-thiazole-4-carbonyl]-amino}-3-(2,3-dimethoxy-phenyl)- propionic acid

(S)-3-{[2-(4-Chloro-phenyl)-thiazole-4-carbonyl]-amino}-3-(2,4-dichloro-phenyl)- propionic acid

(3S,4R)-4-Phenyl-1 -[4-(4-trifluoromethyl-phenyl)-thiazole-2-carbonyl]-pyrrolidine-3- carboxylic acid

(S)-3-{[2-(4-Chloro-phenyl)-thiazole-4-carbonyl]-amino}-3-(2-trifluoromethyl-phenyl)- propionic acid

(S)-3-{[2-(4-Chloro-phenyl)-thiazole-4-carbonyl]-amino}-3-(3-fluoro-phenyl)-propionic acid

(S)-3-{[2-(4-Chloro-phenyl)-thiazole-4-carbonyl]-amino}-3-(3-methoxy-phenyl)- propionic acid

(S)-3-(4-Chloro-phenyl)-2-{[2-(4-trifluoromethyl-phenyl)-thiazole-4-carbonyl]-amino}- propionic acid (S)-3-{[2-(4-Chloro-phenyl)-thiazole-4-carbonyl]-amino}-3-(4-nnethoxy-phenyl)- propionic acid

(S)-3-{[2-(4-Chloro-phenyl)-thiazole-4-carbonyl]-amino}-3-o-tolyl-propionic acid

(S)-3-{[2-(4-Chloro-phenyl)-thiazole-4-carbonyl]-amino}-3-phenyl-propionic acid (S)-3-o-Tolyl-3-[(2-o-tolyl-thiazole-4-carbonyl)-amino]-propionic acid

(S)-3-o-Tolyl-3-{[2-(4-trifluoromethyl-phenyl)-thiazole-4-carbonyl]-amino}-propionic acid (S)-3-Phenyl-3-[(2-o-tolyl-thiazole-4-carbonyl)-amino]-propionic acid

2-Phenyl-3-[(2-o-tolyl-thiazole-4-carbonyl)-amino]-propionic acid

2- Phenyl-3-[(2-phenyl-thiazole-4-carbonyl)-amino]-propionic acid

3-{[2-(2,3-Dichloro-phenyl)-thiazole-4-carbonyl]-amino}-2-phenyl-propionic acid

3- {[2-(2,3-Dichloro-phenyl)-thiazole-4-carbonyl]-amino}-4-phenyl-butyric acid

3-{[2-(2-Chloro-phenyl)-thiazole-4-carbonyl]-amino}-2-phenyl-propionic acid

3-{[2-(2-Chloro-phenyl)-thiazole-4-carbonyl]-amino}-3-cyclohexyl-propionic acid 3-{[2-(2-Chloro-phenyl)-thiazole-4-carbonyl]-amino}-4-phenyl-butyric acid

3-{[2-(2-Fluoro-phenyl)-thiazole-4-carbonyl]-amino}-2-phenyl-propionic acid

3-{[2-(2-Fluoro-phenyl)-thiazole-4-carbonyl]-amino}-4-phenyl-butyric acid

3-{[2-(3-Chloro-phenyl)-thiazole-4-carbonyl]-amino}-2-phenyl-propionic acid

3-{[2-(3-Chloro-phenyl)-thiazole-4-carbonyl]-amino}-3-cyclohexyl-propionic acid 3-{[2-(3-Chloro-phenyl)-thiazole-4-carbonyl]-amino}-4-phenyl-butyric acid

3-{[2-(4-Chloro-phenyl)-thiazole-4-carbonyl]-amino}-3-cyclohexyl-propionic acid 3-{[2-(4-Chloro-phenyl)-thiazole-4-carbonyl]-amino}-4-phenyl-butyric acid

3-Cyclohexyl-3-[(2-o-tolyl-thiazole-4-carbonyl)-amino]-propionic acid

3-Cyclohexyl-3-[(2-phenyl-thiazole-4-carbonyl)-amino]-propionic acid

3-Cyclohexyl-3-{[2-(2,3-dichloro-phenyl)-thiazole-4-carbonyl]-amino}-propionic acid 3-Cyclohexyl-3-{[2-(2-fluoro-phenyl)-thiazole-4-carbonyl]-amino}-propionic acid

3- Cyclohexyl-3-{[2-(4-trifluoromethyl-phenyl)-thiazole-4-carbonyl]-amino}-propionic acid

4- Phenyl-3-[(2-o-tolyl-thiazole-4-carbonyl)-amino]-butyric acid

4-Phenyl-3-[(2-phenyl-thiazole-4-carbonyl)-amino]-butync acid

4-Phenyl-3-{[2-(4-trifluoromethyl-phenyl)-thiazole-4-carbonyl]-amino}-butyric acid (S)-3-[(4-Phenyl-thiazole-2-carbonyl)-amino]-3-o-tolyl-propionic acid;

for the prevention and/or treatment of atrial fibrillation. The present invention relates to the use of the compounds of the formula VI,

The compound of formula VI is known as Boceprevir (lUPAC name: (1 R,2S,5S)-A/- [(2≡)-4-amino-1 -cyclobutyl-3,4-dioxobutan-2-yl)]- 3-{(2S)-2-[(tert- butylcarbamoyl)amino]-3,3-dimethylbutanoyl}- 6,6-dimethyl-3-azabicyclo[3.1 .0]hexane- 2-carboxamide) and is an inhibitor of HCV NS3/4a protease and intended for the treatment of hepatitis C virus infection. Boceprevir and related compounds and their preparation are described in WO0208244, WO03062265, US7012066, US7772178 and WO20061 13942.

The present invention relates to the use of the compounds of the formula VII,

The compound of formula VII is known as Telaprevir (lUPAC name: (1 S,3aR,6aS)-2- [(2S)-2-[[(2S)-2-Cyclohexyl-2-(pyrazine-2-carbonylamino)acetyl]amino]-3,3- dimethylbutanoyl]-/V-[(3S)-1 -(cyclopropylamino)-l ,2-dioxohexan-3-yl]-3,3a,4,5,6,6a- hexahydro-1 H-cyclopenta[c]pyrrole-1 -carboxamide) and is an inhibitor of HCV NS3/4a protease and intended for the treatment of hepatitis C virus infection. Telaprevir and related compounds and their preparation are described in WO9817679, WO9950230, WO2001074768, WO2003087092, WO2003035060, WO2003006490,

WO2004092162, WO2004092161 , WO2005028502, WO2005007681 ,

WO2007022459, WO2005035525, WO2007016589. WO2007022459 discloses specifically methods for preparation of Telaprevir.

If structural elements such as groups, substituents or numbers, for example, can occur several times in the compounds of the formulae I to VII, they are all independent of each other and can in each case have any of the indicated meanings, and they can in each case be identical to or different from any other such element. In a dialkylamino group, for example, the alkyl groups can be identical or different.

Physiologically acceptable salts, including pharmaceutically utilizable salts, of the compounds of the formulae I to VII, generally comprise a nontoxic salt component. They can contain inorganic or organic salt components. Such salts can be formed, for example, from compounds of the formulae I to VII which contain an acidic group, for example a carboxylic acid group (hydroxycarbonyl group, HO-C(O)-), and nontoxic inorganic or organic bases. Suitable bases are, for example, alkali metal compounds or alkaline earth metal compounds, such as sodium hydroxide, potassium hydroxide, sodium carbonate or sodium hydrogencarbonate, or ammonia, organic amino compounds and quaternary ammonium hydroxides. Reactions of compounds of the formulae I to VII with bases for the preparation of the salts are in general carried out according to customary procedures in a solvent or diluent. Examples of salts of acidic groups thus are sodium, potassium, magnesium or calcium salts or ammonium salts which can also carry one or more organic groups on the nitrogen atom. Compounds of the formulae I to VII which contain a basic, i.e. protonatable, group, for example an amino group or a basic heterocycle, can be present in the form of their acid addition salts with physiologically acceptable acids, for example as salt with hydrogen chloride, hydrogen bromide, phosphoric acid, sulfuric acid, acetic acid, benzoic acid,

methanesulfonic acid, p-toluenesulfonic acid, which in general can be prepared from the compounds of the formulae I to VII by reaction with an acid in a solvent or diluent according to customary procedures. If the compounds of the formulae I to VII simultaneously contain an acidic and a basic group in the molecule, the invention also includes internal salts (betaines, zwitterions) in addition to the salt forms mentioned. The present invention also comprises all salts of the compounds of the formulae I to VII which, because of low physiological tolerability, are not directly suitable for use as a pharmaceutical, but are suitable as intermediates for chemical reactions or for the preparation of physiologically acceptable salts, for example by means of anion exchange or cation exchange. The present invention also comprises all solvates of the compounds of the formulae I to VII and their salts, including physiologically acceptable solvates, such as hydrates, i.e. adducts with water, and adducts with alcohols like (Ci- C₄)-alkanols, as well as active metabolites of compounds of the formula I and prodrugs of the compounds of the formulae I to VII, i.e. compounds which in vitro may not necessarily exhibit pharmacological activity but which in vivo are converted into pharmacologically active compounds of the formulae I to VII, for example compounds which are converted by metabolic hydrolysis into a compound of the formulae I to VII, such as compounds in which a carboxylic acid group is present in esterified form or in the form of an amide.

The pharmaceutical compositions and medicaments according to the invention normally contain from about 0.5 to about 90 percent by weight of compounds of the formulae I to VII and/or physiologically acceptable salts and/or solvates thereof, and an amount of active ingredient of the formulae I to VII and/or its physiologically acceptable salt and/or solvate which in general is from about 0.2 mg to about 1 .5 g, particularly from about 0.2 mg to about 1 g, more particularly from about 0.5 mg to about 0.5 g, for example from about 1 mg to about 0.3 g, per unit dose. Depending on the kind of the pharmaceutical composition and other particulars of the specific case, the amount may deviate from the indicated ones. The production of the pharmaceutical compositions and medicaments can be carried out in a manner known per se. For this, the compounds of the formulae I to VII and/or their physiologically acceptable salts and/or solvates are mixed together with one or more solid or liquid vehicles and/or excipients, if desired also in combination with one or more other pharmaceutical active

compounds such as those mentioned above, and brought into a suitable form for dosage and administration, which can then be used in human medicine or veterinary medicine.

As vehicles, which may also be looked upon as diluents or bulking agents, and excipients suitable organic and inorganic substances can be used which do not react in an undesired manner with the compounds of the formulae I to VII. As examples of types of excipients, or additives, which can be contained in the pharmaceutical compositions and medicaments, lubricants, preservatives, thickeners, stabilizers, disintegrants, wetting agents, agents for achieving a depot effect, emulsifiers, salts, for example for influencing the osmotic pressure, buffer substances, colorants, flavorings and aromatic substances may be mentioned. Examples of vehicles and excipients are water, vegetable oils, waxes, alcohols such as ethanol, isopropanol, 1 ,2-propanediol, benzyl alcohols, glycerol, polyols, polyethylene glycols or polypropylene glycols, glycerol triacetate, polyvinylpyrrolidone, gelatin, cellulose, carbohydrates such as lactose or starch like corn starch, sodium chloride, stearic acid and its salts such as magnesium stearate, talc, lanolin, petroleum jelly, or mixtures thereof, for example saline or mixtures of water with one or more organic solvents such as mixtures of water with alcohols. For oral and rectal use, pharmaceutical forms such as, for example, tablets, film-coated tablets, sugar-coated tablets, granules, hard and soft gelatin capsules, suppositories, solutions, including oily, alcoholic or aqueous solutions, syrups, juices or drops, furthermore suspensions or emulsions, can be used. For parenteral use, for example by injection or infusion, pharmaceutical forms such as solutions, for example aqueous solutions, can be used. For topical use,

pharmaceutical forms such as ointments, creams, pastes, lotions, gels, sprays, foams, aerosols, solutions or powders can be used. Further suitable pharmaceutical forms are, for example, implants and patches and forms adapted to inhalation. The

compounds of the formulae I to VII and their physiologically acceptable salts can also be lyophilized and the obtained lyophilizates used, for example, for the production of injectable compositions. In particular for topical application, also liposomal

compositions are suitable. The pharmaceutical compositions and medicaments can also contain one or more other active ingredients and/or, for example, one or more vitamins.

As usual, the dosage of the compounds of the formulae I to VII depends on the circumstances of the specific case and is adjusted by the physician according to the customary rules and procedures. It depends, for example, on the compound of the formulae I to VII administered and its potency and duration of action, on the nature and severity of the individual syndrome, on the sex, age, weight and the individual responsiveness of the human or animal to be treated, on whether the treatment is acute or chronic or prophylactic, or on whether further pharmaceutical active

compounds are administered in addition to a compound of the formulae I to VII.

Normally, in the case of administration to an adult weighing about 75 kg, a dose from about 0.1 mg to about 100 mg per kg per day, in particular from about 1 mg to about 20 mg per kg per day, for example from about 1 mg to about 10 mg per kg per day (in each case in mg per kg of body weight), is administered. The daily dose can be administered in the form of a single dose or divided into a number of individual doses, for example two, three or four individual doses. The administration can also be carried out continuously, for example by continuous injection or infusion. Depending on the individual behavior in a specific case, it may be necessary to deviate upward or downward from the indicated dosages.

The following examples illustrate the invention. Pharmacological tests

Cathepsin A inhibitory activity

Recombinant human cathepsin A (residues 29-480, with a C-terminal 10-His tag; R&D Systems, # 1049-SE) was proteolytically activated with recombinant human cathepsin L (R&D Systems, # 952-CY). Briefly, cathepsin A was incubated at 10 g/ml with cathepsin L at 1 g/ml in activation buffer (25 mM 2-(morpholin-4-yl)-ethanesulfonic acid (MES), pH 6.0, containing 5 mM dithiothreitol (DTT)) for 15 min at 37 °C.

Cathepsin L activity was then stopped by the addition of the cysteine protease inhibitor E-64 (N-(trans-epoxysuccinyl)-L-leucine-4-guanidinobutylamide; Sigma-Aldrich, # E3132; dissolved in activation buffer/DMSO) to a final concentration of 10 μΜ.

The activated cathepsin A was diluted in assay buffer (25 mM MES, pH 5.5, containing 5 mM DTT) and mixed with the test compound (dissolved in assay buffer containing (v/v) 3 % DMSO) or, in the control experiments, with the vehicle in a multiple assay plate. After incubation for 15 min at room temperature, as substrate then bradykinin carrying an N-terminal ^®Bodipy FL (4,4-difluoro-5,7-dimethyl-4-bora-3a,4a-diaza-s- indacene-3-propionyl) label (JPT Peptide Technologies GmbH; dissolved in assay buffer) was added to the mixture. The final concentration of cathepsin A was 833 ng/ml and the final concentration of labeled bradykinin 2 μΜ. After incubation for 15 min at room temperature the reaction was stopped by the addition of stop buffer (130 mM 2- (4-(2-hydroxy-ethyl)-piperazin-1 -yl)-ethanesulfonic acid, pH 7.4, containing (v/v) 0.013 % ^®Triton X-100, 0.13 % Coating Reagent 3 (Caliper Life Sciences), 6.5 % DMSO and 20 μΜ ebelactone B (Sigma, # E0886)). Uncleaved substrate and product were then separated by a microfluidic capillary electrophoresis on a LabChip^® 3000 Drug Discovery System (12-Sipper-Chip; Caliper Life Sciences) and quantified by determination of the respective peak areas. Substrate turnover was calculated by dividing product peak area by the sum of substrate and product peak areas, and the enzyme activity and the inhibitory effect of the test compound thus quantified. From the percentage of inhibition of cathepsin A activity observed with the test compound at several concentrations, the inhibitory

concentration IC₅o, i.e. the concentration which effects 50 % inhibition of enzyme activity was, calculated. IC₅o values of various example compounds are given in Table 1 , wherein "A" means an IC₅o value of less than 0.1 μΜ, "B" means an IC₅o value between 0.1 μΜ and 1 μΜ, and "C" means an IC₅o value between 1 μΜ and 30 μΜ.

In vivo antihypertrophic and renoprotective activity

The in vivo pharmacological activity of the compounds of the invention can be investigated, for example, in the model of DOCA-salt sensitive rats with unilateral nephrectomy. Briefly, in this model unilateral nephrectomy of the left kidney (UNX) is performed on Sprague Dawley rats of 150 g to 200 g of body weight. After the operation as well as at the beginning of each of the following weeks 30 mg/kg of body weight of DOCA (desoxycorticosterone acetate) are administered to the rats by subcutaneous injection. The nephrectomized rats treated with DOCA are supplied with drinking water containing 1 % of sodium chloride (UNX/DOCA rats). The UNX/DOCA rats develop high blood pressure, endothelial dysfunction, myocardial hypertrophy and fibrosis as well as renal dysfunction. In the test group (UNX/DOCA Test) and the placebo group (UNX/DOCA Placebo), which consist of randomized UNX/DOCA rats, the rats are treated orally by gavage in two part administrations at 6 a.m. and 6 p.m. with the daily dose of the test compound (for example 10 mg/kg of body weight dissolved in vehicle) or with vehicle only, respectively. In a control group (control), which consists of animals which have not been subjected to UNX and DOCA administration, the animals receive normal drinking water and are treated with vehicle only. After five weeks of treatment, systolic blood pressure (SBP) and heart rate (HR) are measured non-invasively via the tail cuff method. For determination of albuminuria and creatinine, 24 h urine is collected on metabolic cages. Endothelial function is assessed in excised rings of the thoracic aorta as described previously (W. Linz et al., JRAAS (Journal of the renin-angiotensin-aldosterone system) 7 (2006), 155-161 ). As a measure of myocardial hypertrophy and fibrosis, heart weight, left ventricular weight and the relation of hydroxyproline and proline are determined in excised hearts.

Test methods for atrial fibrillation

Animal model

Zucker diabetic fatty-rats (ZDF/G mi -fa/fa, n=40) and their age matched lean littermates (male, 200 - 250g body weight, 10 weeks old, LEAN, n=20) were purchased from Charles River and housed three per cage under standardized conditions (room temperature 24°C, relative humidity 60%, lighting times 12 hours dark/light cycle). They had free access to a standardized diet, sodium content 0.2 %, Altromin, Lage,

Germany) and tap drinking water.

ZDF-rats were randomized in 2 groups: placebo treated ZDF-rats (ZDF-placebo, n=20) and CathA-inhibitor treated ZDF-rats (ZDF-SAR, n=20) and administered daily via oral gavage (50 mg/kg/d, Vehicle: 0,5% HEC / Tween 5%, volume administered: 1 ml/kg). ZDF-placebo rats were treated with vehicle only.

After 38 weeks, animals were anesthetized and cardiac function was assessed by cardiac magnet resonance imaging (MRI). One week later, electrophysiological measurements were performed in open chest experiments and the animals were sacrificed.

All animal studies conform with the guide for the Care and Use of laboratory Animals published by the US National Institutes of Health (NIH Publication No. 85-23, revised 1996).

Electrophysiological studies

All measurements were performed during general anesthesia by intraperitoneal injection of pentobarbital at the age of 9.5 months. Surface ECG (lead II) was recorded via subcutaneous needle electrodes. To analyze atrial conduction, a custom made mapping electrode with 4^*5 unipolar electrodes (1 .0mm interelectrode distance) was placed on the LA free wall. Unipolar signals were recorded using a custom made channel mapping amplifier (filtering bandwidth 0.1 -408Hz, sampling rate 1 kHz, A D resolution 16 bits). Unipolar pacing was performed from the surface of the right atrial (pulse width of 1 ms at twice the diastolic threshold). Maps from 5 consecutive beats were analyzed. Local activation times were identified by maximum negative dV/dt in each unipolar electrogram. Local activation time differences were calculated between neighboring electrodes (conduction times). Conduction times of > 3ms (equivalent to conduction velocities < 33cm/s) were considered as being prolonged.¹⁹ Total-atrial activation time was defined as the time difference between the right atrial activation time, visualized by a custom made multiple action potential (MAP)-catheter (Franz-like electrode) next to the pacing electrode, and the latest left atrial activation time recorded by the mapping electrode during right atrial-pacing (cycle length: 150ms). Atrial effective refractory period (AERP) was measured at a basic cycle length of 150ms at the free wall of the LA. The mean of 3 AERP measurements was used for analysis.

Susceptibility to AT/AF induced by repetitive 1 s bursts of stimuli (very rapid pacing, cycle length: 10 ms). When atrial electrograms showed a rapid atrial rate, cycle length < 70ms and duration >5 beats, AT/AF was diagnosed. The duration of the longest of three subsequent episode of AT/AF induced during this protocol was measured and was taken as AF/AT-du ration.

Magnetic resonance imaging (MRI)

All scans were acquired with a 7-T magnetic resonance imaging (MRI) scanner (Bio Spec 70/30) in all rats at the age of 9.5 months (anesthesia: Isoflurane). Multi-slice short-axis cine imaging was performed from the upper left atrial roof to the apex with a slice thickness of 1 .2 mm and an inter-slice gab of 0 mm. Orthogonal long axis cine imaging of the whole heart, two chamber and four chamber views, were acquired. Boundaries of the left ventricle and left atrium were obtained in each short-axis image. The LV-volumes were then determined by Simpson's rule. LA-area was manually encircled. The point of insertion of the mitral valve leaflets was taken as the

atrioventricular border. Pulmonary veins were excluded at their ostia and the left atrial appendage was excluded at its base. All dimensions were measured throughout the cardiac cycle. The cardiac cycle was divided into 10 equal phases with an interphase time difference of the spontaneous cycle length / 10. The MRI-images of all LAs were analyzed by the same blinded investigator.

LV-enddiastolic volume (LVedV) and end-systolic volume (LVesV) were derived from the LA-volume/time curves for maximal and minimal values. LV-ejection fraction (EF) was subsequently computed. Minimal LA- (LA min) and maximal LA-volume (LAmax) and their difference (cyclical change volume) were determined from the LA- volume/time curves. The minimal volume at the end of rapid passive emptying (LAre) and the volume before active emptying (LApc) were determined from the volume-time curves as described elsewhere.²¹ LA-emptying function parameters (total percent emptying ((LAmax-LAmin)/LAmax), active percent emptying ((LApc-LAmin)/LApc), passive percent emptying ((LAmax-LAre)/LAmax) were computed according to Jarvinen et al.. ²⁰ Measurement of LV-pressure and blood pressure

LV-enddiastolic pressure (LVedP) was measured in anaesthetized rats using Millar Tip catheters (Millar Instruments Inc, Houston, USA) introduced from the right arteria carotis and advanced into the left ventricle. In conscious rats, blood pressure was measured using the tailcuff method.

Gene expression analysis

Gene expression analysis was performed by realtime PCR. Total RNA was extracted from whole LA by homogenizing in RLT buffer and by using RNeasy Mini columns (Qiagen, Hidlen, Germany). Genomic DNA impurities were removed by DNase treatment (DNA removal kit; Ambion, Austin, TX), and cDNA was synthesized by reverse transcription (Life Science Technologies, Darmstadt, Germany). Quantitative real-time RT-PCR was performed using the Taqman primers on an ABI Prism 7500 Sequence Detector (Applied Biosystems, Foster City, CA) and c(t) values obtained by using a respective software (SDS version 1 .9). Gene expression was normalized to glyceraldehyde-3-phosphate dehydrogenase (GAPDH) as housekeeping gene.

Detailed information on probes is provided in supp. Table 1 . For each analysis, mean values were used from 8-10 animals per group. CathepsinA activity, angiotensin and bradykinin degradation

LA tissue was homogenized in 25mM MES pH 5.5 containing 10μΜ E64.

Homogenates were then mixed with the compound or DMSO in a multiple assay plate. After incubation for 15 minutes at room temperature a bradykinin peptide carrying a N- terminal BodipyFL label (Jerini Peptide Technology) was added to the assay mixture to a final concentration of 2μΜ. After incubation for 15min at room temperature the reaction was stopped by the addition of 130mM Hepes pH 7.4 containing 0.013% Triton X-100, 0.13% Coating Reagent (Caliper Life Sciences), 6.5% DMSO and 20μΜ ebelactone B (Sigma, #E0886). Uncleaved substrate and product were then separated by a microfluidic capillary electrophoresis on a LabChip® 3000 Drug Discovery System (12-Sipper-Chip, Caliper Life Sciences) and quantified by determination of the respective peak areas. Substrate turnover was calculated by dividing product peak area by the sum of substrate and product peak areas. The difference in bradykinin turnover in the presence and absence of compound was used to quantify CathA- activity. Angiotensin was quantified in LA preperations by ELISA.

Histology and connexins

Hearts were rapidly removed, trimmed free from non cardiac tissues and weighed. Thereafter, separated LA was fixed in buffered 4% formaldehyde for 24h and

imbedded in paraffin for histological evaluation. Tissue sections of 5μηη were fixed at 56°C overnight, deparaffinized, rehydrated and stained with hematoxylin and eosin (H&E) to determine cardiomyocyte diameter and cell distances. To visualize tissue fibrosis amount, the sections were stained with Picro-Sirius Red. The percentage of the LA consisting of interstitial collagen was calculated as the ratio of Picro-Sirius-Red positively stained area over total LA tissue area, excluding blood vessels and the epi- and endocardial plane, using ImageJ 1 .37a (National Institute of Health, USA). Fibrosis was quantified on three sections per atrium (6-8 fields per section).

Immunostaining for connexin43 (Cx43) in formalin fixed left atrial tissue from 9 LEAN, 9 ZDF-placebo and 8 ZDF-SAR rats was performed like described elsewhere.²² Briefly, expression of Cx43 at the lateral and polar membrane of cardiomyocytes from rat atria was investigated. Per animal 2-3 sections were analyzed, and per section 5-10 cells, so that each data point of the columns is representing 100-250 cells.

Blood

The concentration of BNP32 (fluorescent ELISA) and osteopontin was determined in plasma using a radio immunoassay (Phoenix Pharmaceuticals Inc., USA).

Statistical Analysis

The data are expressed as mean±SEM. Statistical significance was assessed by analysis of variance (ANOVA), followed by the unpaired Student's t tests (two-tailed) for 2 groups. If necessary, Dunnett's test was employed. P-values of <0.05 were considered statistically significant.

Results

(S)-3-{[1 -(2-Fluoro-phenyl)-5-methoxy-1 H-pyrazole-3-carbonyl]-amino}-3-o-tolyl- propionic acid (SAR, i.e. example 129 in compound table 1 ) was tested on atrial emptying function and atrial electrical and structural arrhythmogenic remodeling in old Zucker Diabetic Fatty rats (ZDF), an animal model for T2D.

Figure legends

Figure 1 : CathepsinA-activity (SAR-sensitive bradykinin turnover) in (A) atrial and (B) ventricular preparations in LEAN, in ZDFplacebo and in ZDF-SAR.

Figure 2: Atrial electrophysiological measurements in rats. (A) AF-duration induced by burst-pacing (top) and representative atrial electrograms in ZDF-placebo and in LEAN (bottom). (B) Total atrial activation time, (C) areas of slow conduction and (D) left atrial effective refractory period (LAERP) at a stimulation frequency of 400/min (basic cycle lengths (BCL): 150ms) are shown at the right. Figure 3: Atrial emptying function in rats. (A) representative makroskopic and MRI- images and (B) LA-volume/time curves showing the % maximal phasic LA-volume change in LEAN and in ZDF-placebo. Cardiac cycle is divided in 10 phases. (A: minimal LA-volume, B: maximal LA-volume, C: minimal volume at the end of rapid passive emptying, D: max volume before active emptying.) (C) Total percent emptying, (D) passive percent emptying and (E) active percent emptying determined out of the LA-volume/time curve are shown at the right.

Figure 4: Atria histological analysis. Representative histological images of (A) s^'irius red stained and (B) H&E stained left atrial preperations in LEAN, ZDF-placebo and ZDF-SAR. Results for (C) tissue fibrosis amount, (D) myocyte diameter and (E) myocyte distances are shown at the right.

Figure 5: Atrial connexin 43 expression. Representative immunohistochemical staining for Cx43 in left atrial preperations in (A) LEAN, (B) ZDF-placebo and (C) ZDF-SAR. Quantification of positively stained (D) lateral and (E) polar cardiomyocyte membrane.

Figure 6: (A) Total bradykinin turnover and (B) angiotnesin II content of left atrial tissue in LEAN, ZDF-placebo and ZDF-SAR.

Figure 7: Table 1.

Figure 8: Table 2.

Atrial-selective increase in Cathepsin A Activity in ZDF

LA CathA-activity was significantly increased in ZDF-placebo, and this increase was inhibited by SAR treatment. In contrast, LV CathA-activity was not significantly changed in ZDF-placebo and not further modified by SAR treatment (Figure 1).

Metabolic and hemodynamics parameters

Metabolic and hemodynamic parameters from these experiments are summarized in Table 1. At the age of 9.5 months, increased concentration of glucose and HbAl c in serum of ZDF-placebo was accompanied with severe signs of nephropathy and dyslipidemia. SAR-treatment did not change metabolic parameters or renal function in ZDF-rats at the age of 9.5 months. Cardiac hypertrophy index, expressed as heart weight / 10Og body weight, was neither elevated in hearts from ZDF-placebo nor from SAR-treated ZDF-rats in comparison to LEAN. Body weights between untreated and SAR-treated ZDF-rats were not different. However, LEAN were heavier than ZDF-rats. LV-EF and LV-dimensions determined by MRI did not differ between the different groups, but LV-enddiastolic pressure was increased in ZDF-placebo, indicating the development of moderate diastolic dysfunction with preserved systolic function in old ZDF-rats. Blood pressure measured in conscious rats (tail-cuff-methode) revealed no differences between ZDF-placebo and LEAN, but heart rate tended to be reduced in ZDF-rats. SAR-treatment in old ZDF-rats did not significantly change blood pressure nor heart rate in ZDF-rats. Lower LVedP and plasma BNP-levels (121 .3±1 .5 ng/ml vs.159.9±1 1 .3 ng/ml in ZDF) were preserved in SAR-treated ZDF-rats. LA-dimensions determined by LA-volume/heart weight indices did not differ between the groups.

Atrial electrophysiology

Short episodes of AF/AT could be induced in all rats investigated in our study. The median duration of AF/AT was increased in ZDF-placebo in comparison to LEAN (Figure 2). AERP was prolonged in ZDF-placebo when compared to LEAN. Total atrial activation time was significantly longer in ZDF-placebo compared to LEAN and the percentage of regions with slow conduction during rapid pacing was increased in ZDF- placebo compared to LEAN. SAR-treatment did not attenuate AERP-prolongation in ZDF-rats but reduced median AF/AT-du ration in ZDF-rats by reducing total atrial activation time and the percentage of regions with slow conduction.

LA-emptying function

LA-emptying function parameters are shown in figure 3. LA-fractional shortening was reduced in ZDF-placebo when compared to LEAN. Global LA-emptying function as assessed by total percent emptying was not changed. In contrast, active percent emptying was diminished in old ZDF-placebo compared to LEAN. SAR-treatment attenuated changes in LA-fractional shortening and active percent emptying. During the MRI-scan, heart rate was lower in ZDF-placebo and ZDF-SAR compared to LEAN (261 ±3.34 bpm, 260±5.67 bpm and 281 ±5.37 bpm respectively) (p<0.05). However, since atrial emptying function is inversely correlated to heart rate, this would even underestimate the differences between LEAN and ZDF-placebo and ZDF-SAR and would not influence the comparison between ZDF-placebo and ZDF-SAR.

LA-structural remodeling

In sirius red-stained sections, the degree of atrial tissue fibrosis was increased in ZDF- placebo LA when compared to LEAN (shown in Fig. 4) as were myocyte diameters and myocyte-myocyte distances within bundles as a measure of enhanced extracellular LA matrix formation. SAR-treatment in ZDF-rats prevented the increase in myocyte- myocyte distances and total atrial tissue fibrosis but did not modify increased cell- diameter in ZDF-rats.

SAR reduced LA gene-expression of the profibrotic and proinflammatory adhesion protein osteopontin which was highly upregulated in ZDF-placebo when compared to LEAN (Table 2). Osteopontin plasma concentration was significantly reduced in SAR- ZDF (8,4±0.4 ng/ml, p<0.01 ) when compared to ZDF-placebo (12.1 ±1 .4 ng/ml). Other profibrotic markers like TGF-βΙ and MMP2 and Col1 a1 gene expression were clearly detectable but kept unchanged on mRNA level in ZDF-placebo or ZDF-SAR.

Cx 43

In figure 5, the pattern of Cx43 immunostaining in LA tissue is shown. Lateral Cx43 immunostaining was significantly enhanced in ZDF-placebo, whereas polar staining was unchanged. Lateralization of Cx43 was significantly attenuated by SAR. Overall Cx43 mRNA was not altered in ZDF-placebo when compared to LEAN and not further altered by SAR. Components of the RAAS and the kinin-kallikrinin system

LA total bradykinin-degrading activity was increased in ZDF-placebo compared to LEAN and reduced to LEAN values in ZDF-SAR (Figure 6A). LA tissue angiotensin II levels were not modulated, neither in ZDF nor in SAR-treated ZDF when compared to LEAN. (B). Increased serum ACE-activity was observed in both, ZDF-placebo

(107.1 ±2.1 , p<0.01 ) and ZDF-SAR rats (109.1 ±1 .5, p<0.01 ) when compared to LEAN (90.3±0.9, p<0.01 ). In LA-tissue, ACE, chymase or ATRa and ATRb mRNA expression were unchanged in ZDF-placebo with no effect of SAR treatment (Table 2). In ZDF-rats, a rat model for T2D, susceptibility to AF was increased and LA-emptying function parameters were impaired while LV systolic function remained unchanged. These findings were accompanied by upregulation of the lysosomal enzyme CathA in LA. Inhibition of CathA by SAR attenuated arrhythmogenic and functional atrial remodeling without influencing T2D-related metabolic changes, blood pressure, LV- systolic function, plasma ACE-activity or LA angiotensin II levels in ZDF. CathA- inhibition reduced serum BNP-levels, LA gene expression of profibrotic and

proinflammatory factor osteopontin, and bradykinin-degrading activity.

In ZDF, increased susceptibility to AF was associated with longer total atrial activation times, more areas of local atrial conduction slowing and prolonged AERP when compared to LEAN. AERP prolongation has been reported in animal models for CHF²³ and dilated atria¹⁹ and there are reports of action potential prolongation leading to polymorphic atrial tachycardia that degenerates into AF.²⁴ Local heterogeneities in conduction have been demonstrated to underlie the high AF susceptibility in

structurally remodeled atria in a variety of animal models.^19,23 In ZDF-rats, myocyte- myocyte distances in the atrial myocardium as a measure of enhanced extracellular matrix formation were increased as were myocyte diameters. Additionally, enhanced ANP expression in LA of ZDF may contribute to atrial amyloidosis.^25,26 Cx43

lateralization was more pronounced in atria of old ZDF-rats compared to LEAN, a finding also reported in patients with AF and various animal models for AF.^22,27,28 These structural atrial changes together with the disorganization of connexins resulted in disruption of side to side electrical connections between muscle bundles obviously accounting for the impaired atrial conduction properties and increased susceptibility to AT/AF observed in old ZDF-rats compared to LEAN. This arrhythmogenic substrate and these structural alterations of the extracellular matrix occurred without any changes in LA-dimensions in ZDF-rats. ZDF rats showed moderate signs for diastolic ventricular dysfunction with fully preserved systolic function. Additionally, we found an impairment of active LA- emptying function in ZDF-rats suggestive for a LA-hypocontractility in ZDF-rats. Those findings are in line with impairment of LA-emptying function revealed by

echocardiography in patients with type 1 diabetes and preserved LV-function.³² Potentially, impaired LA-emptying function reduces exercise tolerance in diabetic patients.⁷'⁸'⁹

Atrial contractile dysfunction reduces local blood flow velocity increasing the risk for thrombus formation. A similar reduction of contractile function with unchanged or prolonged AERP was found in CHF-dogs³³ and in goats with dilated atria.³⁴ Increased interstitial fibrosis amount in old ZDF rats could account for abnormal myocardial stiffness and ultimately for atrial dysfunction. Another possibility is altered energetics of myofilaments as also found in patients with AF.³⁵ In this report, we identify a relevant role of CathA for the LA-remodeling process in T2D. LA, but not LV-CathA activity was increased in ZDF compared to LEAN. The novel CathA inhibitor SAR attenuated functional and arrhythmogenic atrial remodeling characterized by increased tissue fibrosis, myocyte-myocyte distances and

lateralization of Cx43. Smaller myocyte-myocyte distances and attenuation of lateralization of Cx43 increase coupling between the atrial bundles network and are likely involved in the reduction of AF/AT-du ration and conduction disturbances in ZDF- SAR compared to ZDF-placebo. LA total tissue fibrosis amount was not influenced and analysis of differential gene expression of common profibrotic markers did not reveal pronounced changes by SAR.

This suggests, that not the overall fibrosis amount, but fibrosis-distribution as represented by myocyte-myocyte distances is the most important factor for the development of the arrhythmogenic substrate in T2D.

LA-gene expression and plasma concentration of the profibrotic and proinflammatory marker osteopontin (OPN) was markedly increased in ZDF-rats and CathA-inhibition by SAR was associated with a reduction in LA gene expression and plasma

concentration of OPN. OPN is a secreted multifunctional phosphoprotein, which plays an important role in the pathogenesis and fibrosis formation and inflammation in CHF and diabetic cardiopathy.³⁶ Its expression is accelerated by mechanical stress including pressure/volume loading and angiotensin II infusion in rats.^37,38 OPN knockout prevented diastolic dysfunction and interstitial fibrosis following myocardial infarction.³⁹ Additionally, streptozotocin-induced diabetic cardiomyopathy and cardiac fibrosis were attenuated in OPN-deficient mice, suggesting that OPN is a key factor for the remodeling process in the heart especially under diabetic conditions.⁴⁰ Both, CathA and OPN are involved in inflammation occurring rapidly (within 24h) after onset of ventricular tachypacing in dogs. However, these inflammatory changes are transient and disappear gradually.⁴¹ In line with this, we did not observe indicators for enhanced inflammation in ZDF rats. However, inflammatory processes might well have contributed to extracellular matrix changes at an early stage of T2D in ZDF. Thus, inhibition of OPN expression by SAR may be of value in the treatment and prevention of diabetic atrial cardiomyopathy.

Angiotensin I and bradykinin have been described as substrates for CathA in vitro.¹¹ CathA-inhibition by SAR resulted in a pronounced decrease in bradykinin-degrading activity in LA homogenates which may well explain the observed atrial protective effects of CathA-inhibtion in ZDF-rats. Bradykinin displays positive inotropic effects in isolated LA preparation of the guinea pig heart, which could explain the attenuation of LA emptying function in SAR-treated ZDF.⁴² Increase of bradykinin has been shown to be beneficial in neovascularization in ischemic tissue, attenuation of cardiac

hypertrophy and fibrosis ⁴³ Besides this, atrial tissue angiotensin II concentration and gene expression of different players of the local RAAS were not modified by SAR, suggesting a mode of action different to simple modulation of local RAAS. Contrary to established targets in the cardiac renin-angiotensin and kinin system like angiotensin converting enzyme, CathA is only weakly expressed in the vasculature and has an acidic pH optimum of activity.¹¹ Both factors likely exclude this enzyme from systemic peptide hormone turnover. CathA gene expression and activity in LA were increased in old ZDF rats. CathA- inhibition attenuated increased myocyte-myocyte-distances and lateralization of Cx43. CathA-inhibition decreased bradykinin-degrading activity in LA homogenates and attenuated elevated LA-gene expression and plasma level of profibrotic and

proinflammatory marker OPN which might explain the protective effect of SAR. This was associated with reduced susceptibility to AF and improved LA-emptying function parameters. The atrial protective effect of CathA-inhibition was neither associated with changes in markers of the RAAS, blood pressure, ventricular or renal function nor with changes in LA-dimensions. These findings provide evidence for CathA playing a role for cardiac and especially atrial remodeling in T2D.

Most available antiarrhythmic drugs used for the maintenance of sinus rhythm (SR) are blocker of different cardiac ion channels. Failure of current pharmacological therapy for AF in maintaining SR may be due to complex and progressive arrhythmogenic atrial remodeling. Thereby, early identification and diagnosis of atrial arrhythmogenic substrates opens the opportunity for early pharmacological interventions upon or even before the onset of AF in order to delay or prevent the development of an

arrhythmogenic substrate in the atrium. CathA inhibition is feasible in an animal model and provides protection against diabetes-induced atrial arrythmogenic remodeling. SAR may be a promising target for upstream therapy in diabetes and may be effective in maintaining SR and mechanical atrial emptying function and the prevention of stroke.

The synthesis and physical and pharmacological data of compounds given in Example tables 1 , 2, 3, 4 and 5 are described in WO201 1092187, WO2012101 197,

WO2012101 199, WO2013072327 and WO2013072328.

Example Table 1 . Example compounds of the formula I

ExCompound Name

ample

1 3-{[1 -(2,5-Dimethyl-phenyl)-5-hydroxy-1 H-pyrazole-3-carbonyl]-amino}-3-(4- fluoro-phenyl)-propionic acid

2 3-[(5-Hydroxy-1 -phenyl-1 H-pyrazole-3-carbonyl)-amino]-hexanoic acid

3 3-[(5-Hydroxy-1 -phenyl-1 H-pyrazole-3-carbonyl)-amino]-3-(4-methoxy- phenyl)-propionic acid

4 3-[(5-Hydroxy-1 -phenyl-1 H-pyrazole-3-carbonyl)-amino]-3-methyl-butyric acid

5 {1 -[(5-Hydroxy-1 -phenyl-1 H-pyrazole-3-carbonyl)-amino]-cyclopentyl}-acetic acid

6 3-(3-tert-Butoxy-phenyl)-3-[(5-hydroxy-1 -phenyl-1 H-pyrazole-3-carbonyl)- amino]-propionic acid

7 3-(3-tert-Butoxy-phenyl)-3-{[1 -(2,5-dimethyl-phenyl)-5-hydroxy-1 H-pyrazole-3- carbonyl]-amino}-propionic acid

8 3-{[1 -(2,5-Dimethyl-phenyl)-5-hydroxy-1 H-pyrazole-3-carbonyl]-amino}-3- methyl-butyric acid

9 3-[(5-Hydroxy-1 -phenyl-1 H-pyrazole-3-carbonyl)-amino]-3-(3-methoxy- phenyl)-propionic acid

10 3-(3-Chloro-phenyl)-3-[(5-hydroxy-1 -phenyl-1 H-pyrazole-3-carbonyl)-amino]- propionic acid

1 1 3-(3,4-Dimethoxy-phenyl)-3-[(5-hydroxy-1 -phenyl-1 H-pyrazole-3-carbonyl)- amino]-propionic acid

12 3-[(5-Hydroxy-1 -phenyl-1 H-pyrazole-3-carbonyl)-amino]-3-(4- thfluoromethoxy-phenyl)-propionic acid

13 3-[(5-Hydroxy-1 -phenyl-1 H-pyrazole-3-carbonyl)-amino]-4-methyl-pentanoic acid

14 3-[(5-Hydroxy-1 -phenyl-1 H-pyrazole-3-carbonyl)-amino]-heptanoic acid ExCompound Name

ample

15 3-[(5-Hydroxy-1 -phenyl-1 H-pyrazole-3-carbonyl)-amino]-5-phenyl-pentanoic acid

16 3-[(5-Hydroxy-1 -phenyl-1 H-pyrazole-3-carbonyl)-amino]-3-pyridin-3-yl- propionic acid

17 3-Cyclopropyl-3-[(5-hydroxy-1 -phenyl-1 H-pyrazole-3-carbonyl)-amino]- propionic acid

18 3-Cyclohexyl-3-[(5-hydroxy-1 -phenyl-1 H-pyrazole-3-carbonyl)-amino]- propionic acid

19 3-[(5-Hydroxy-1 -phenyl-1 H-pyrazole-3-carbonyl)-amino]-5-methyl-hexanoic acid

20 3-(2-Chloro-phenyl)-3-[(5-hydroxy-1 -phenyl-1 H-pyrazole-3-carbonyl)-amino]- propionic acid

21 3-[(5-Hydroxy-1 -phenyl-1 H-pyrazole-3-carbonyl)-amino]-3-o-tolyl-propionic acid

22 3-(4-Ethyl-phenyl)-3-[(5-hydroxy-1 -phenyl-1 H-pyrazole-3-carbonyl)-amino]- propionic acid

23 3-(4-tert-Butoxy-phenyl)-3-[(5-hydroxy-1 -phenyl-1 H-pyrazole-3-carbonyl)- amino]-propionic acid

24 3-[(5-Hydroxy-1 -phenyl-1 H-pyrazole-3-carbonyl)-amino]-3-(4-isopropyl- phenyl)-propionic acid

25 3-[(5-Hydroxy-1 -phenyl-1 H-pyrazole-3-carbonyl)-amino]-3-(4-methoxy-2,3- dimethyl-phenyl)-propionic acid

26 3-{[1 -(2,5-Dimethyl-phenyl)-5-hydroxy-1 H-pyrazole-3-carbonyl]-amino}- hexanoic acid

27 3-{[1 -(2,5-Dimethyl-phenyl)-5-hydroxy-1 H-pyrazole-3-carbonyl]-amino}-3-(4- methoxy-phenyl)-propionic acid ExCompound Name

ample

28 3-{[1 -(2,5-Dimethyl-phenyl)-5-hydroxy-1 H-pyrazole-3-carbonyl]-amino}-3-(3- methoxy-phenyl)-propionic acid

29 3-(3-Chloro-phenyl)-3-{[1 -(2,5-dimethyl-phenyl)-5-hydroxy-1 H-pyrazole-3- carbonyl]-amino}-propionic acid

30 3-(3,4-Dimethoxy-phenyl)-3-{[1 -(2,5-dimethyl-phenyl)-5-hydroxy-1 H-pyrazole- 3-carbonyl]-amino}-propionic acid

31 3-{[1 -(2,5-Dimethyl-phenyl)-5-hydroxy-1 H-pyrazole-3-carbonyl]-amino}-3-(4- trifluoromethoxy-phenyl)-propionic acid

32 3-{[1 -(2,5-Dimethyl-phenyl)-5-hydroxy-1 H-pyrazole-3-carbonyl]-amino}-4- methyl-pentanoic acid

33 3-{[1 -(2,5-Dimethyl-phenyl)-5-hydroxy-1 H-pyrazole-3-carbonyl]-amino}- heptanoic acid

34 3-{[1 -(2,5-Dimethyl-phenyl)-5-hydroxy-1 H-pyrazole-3-carbonyl]-amino}-5- phenyl-pentanoic acid

35 3-{[1 -(2,5-Dimethyl-phenyl)-5-hydroxy-1 H-pyrazole-3-carbonyl]-amino}-3- pyridin-3-yl-propionic acid

36 3-Cyclopropyl-3-{[1 -(2,5-dimethyl-phenyl)-5-hydroxy-1 H-pyrazole-3-carbonyl]- amino}-propionic acid

37 3-Cyclohexyl-3-{[1 -(2,5-dimethyl-phenyl)-5-hydroxy-1 H-pyrazole-3-carbonyl]- amino}-propionic acid

38 3-{[1 -(2,5-Dimethyl-phenyl)-5-hydroxy-1 H-pyrazole-3-carbonyl]-amino}-5- methyl-hexanoic acid

39 3-(2-Chloro-phenyl)-3-{[1 -(2,5-dimethyl-phenyl)-5-hydroxy-1 H-pyrazole-3- carbonyl]-amino}-propionic acid

40 3-{[1 -(2,5-Dimethyl-phenyl)-5-hydroxy-1 H-pyrazole-3-carbonyl]-amino}-3-o- tolyl-propionic acid ExCompound Name

ample

41 3-{[1 -(2,5-Dimethyl-phenyl)-5-hydroxy-1 H-pyrazole-3-carbonyl]-amino}-3-(4- ethyl-phenyl)-propionic acid

42 (1 -{[1 -(2,5-Dimethyl-phenyl)-5-hydroxy-1 H-pyrazole-3-carbonyl]-amino}- cyclopentyl)-acetic acid

43 3-{[1 -(2,5-Dimethyl-phenyl)-5-hydroxy-1 H-pyrazole-3-carbonyl]-amino}-3- (tetrahydro-pyran-4-yl)-propionic acid

44 3-Cyclopentyl-3-{[1 -(2,5-dimethyl-phenyl)-5-hydroxy-1 H-pyrazole-3-carbonyl]- amino}-propionic acid

45 3-(4-Chloro-phenyl)-3-{[1 -(2,5-dimethyl-phenyl)-5-hydroxy-1 H-pyrazole-3- carbonyl]-amino}-propionic acid

46 3-{[1 -(2,5-Dimethyl-phenyl)-5-hydroxy-1 H-pyrazole-3-carbonyl]-amino}-3-(4- isobutyl-phenyl)-propionic acid

47 3-(3,4-Difluoro-phenyl)-3-{[1 -(2,5-dimethyl-phenyl)-5-hydroxy-1 H-pyrazole-3- carbonyl]-amino}-propionic acid

48 3-(3,4-Dichloro-phenyl)-3-{[1 -(2,5-dimethyl-phenyl)-5-hydroxy-1 H-pyrazole-3- carbonyl]-amino}-propionic acid

49 3-{[1 -(2,5-Dimethyl-phenyl)-5-hydroxy-1 H-pyrazole-3-carbonyl]-amino}-3-(3- fluoro-phenyl)-propionic acid

50 3-{[1 -(2,5-Dimethyl-phenyl)-5-hydroxy-1 H-pyrazole-3-carbonyl]-amino}-3-p- tolyl-propionic acid

51 3-{[1 -(2,5-Dimethyl-phenyl)-5-hydroxy-1 H-pyrazole-3-carbonyl]-amino}-3-m- tolyl-propionic acid

52 3-(4-Cyano-phenyl)-3-{[1 -(2,5-dimethyl-phenyl)-5-hydroxy-1 H-pyrazole-3- carbonyl]-amino}-propionic acid

53 3-{[1 -(2,5-Dimethyl-phenyl)-5-hydroxy-1 H-pyrazole-3-carbonyl]-amino}-3-(3- trifluoromethyl-phenyl)-propionic acid ExCompound Name

ample

54 3-{[1 -(2,5-Dimethyl-phenyl)-5-hydroxy-1 H-pyrazole-3-carbonyl]-amino}-3-(3- fluoro-4-methoxy-phenyl)-propionic acid

55 3-Biphenyl-4-yl-3-{[1 -(2,5-dimethyl-phenyl)-5-hydroxy-1 H-pyrazole-3- carbonyl]-amino}-propionic acid

56 3-(3,5-Difluoro-phenyl)-3-{[1 -(2,5-dimethyl-phenyl)-5-hydroxy-1 H-pyrazole-3- carbonyl]-amino}-propionic acid

57 3-{[1 -(2,5-Dimethyl-phenyl)-5-hydroxy-1 H-pyrazole-3-carbonyl]-amino}-3-(4- trifluoromethyl-phenyl)-propionic acid

58 3-(4-Chloro-phenyl)-3-[(5-hydroxy-1 -phenyl-1 H-pyrazole-3-carbonyl)-amino]- propionic acid

59 3-(3,5-Bis-trifluoromethyl-phenyl)-3-[(5-hydroxy-1 -phenyl-1 H-pyrazole-3- carbonyl)-amino]-propionic acid

60 3-(3,4-Difluoro-phenyl)-3-[(5-hydroxy-1 -phenyl-1 H-pyrazole-3-carbonyl)- amino]-propionic acid

61 3-(4-Fluoro-phenyl)-3-[(5-hydroxy-1 -phenyl-1 H-pyrazole-3-carbonyl)-amino]- propionic acid

62 3-(3,4-Dichloro-phenyl)-3-[(5-hydroxy-1 -phenyl-1 H-pyrazole-3-carbonyl)- amino]-propionic acid

63 3-(3-Fluoro-phenyl)-3-[(5-hydroxy-1 -phenyl-1 H-pyrazole-3-carbonyl)-amino]- propionic acid

64 3-[(5-Hydroxy-1 -phenyl-1 H-pyrazole-3-carbonyl)-amino]-3-p-tolyl-propionic acid

65 3-[(5-Hydroxy-1 -phenyl-1 H-pyrazole-3-carbonyl)-amino]-3-m-tolyl-propionic acid

66 3-(4-tert-Butyl-phenyl)-3-[(5-hydroxy-1 -phenyl-1 H-pyrazole-3-carbonyl)- amino]-propionic acid ExCompound Name

ample

67 3-[(5-Hydroxy-1 -phenyl-1 H-pyrazole-3-carbonyl)-amino]-3-(3-trifluoromethyl- phenyl)-propionic acid

68 3-(3-Fluoro-4-methoxy-phenyl)-3-[(5-hydroxy-1 -phenyl-1 H-pyrazole-3- carbonyl)-amino]-propionic acid

69 3-Biphenyl-4-yl-3-[(5-hydroxy-1 -phenyl-1 H-pyrazole-3-carbonyl)-amino]- propionic acid

70 3-(3,5-Difluoro-phenyl)-3-[(5-hydroxy-1 -phenyl-1 H-pyrazole-3-carbonyl)- amino]-propionic acid

71 3-[(5-Hydroxy-1 -phenyl-1 H-pyrazole-3-carbonyl)-amino]-3-(4-trifluoromethyl- phenyl)-propionic acid

72 3-{[1 -(3-Chloro-4-fluoro-phenyl)-5-hydroxy-1 H-pyrazole-3-carbonyl]-amino}-3- (4-fluoro-phenyl)-propionic acid

73 3-{[1 -(4-Chloro-phenyl)-5-hydroxy-1 H-pyrazole-3-carbonyl]-amino}-3-(4- fluoro-phenyl)-propionic acid

74 (S)-3-{[1 -(3-Fluoro-phenyl)-5-hydroxy-1 H-pyrazole-3-carbonyl]-amino}-3-o- tolyl-propionic acid

75 (S)-3-{[1 -(3-Chloro-phenyl)-5-hydroxy-1 H-pyrazole-3-carbonyl]-amino}-3-o- tolyl-propionic acid

76 (S)-3-{[1 -(4-Fluoro-phenyl)-5-hydroxy-1 H-pyrazole-3-carbonyl]-amino}-3-o- tolyl-propionic acid

77 (S)-3-{[1 -(2-Chloro-phenyl)-5-hydroxy-1 H-pyrazole-3-carbonyl]-amino}-3-o- tolyl-propionic acid

78 3-{[1 -(3,5-Dimethyl-phenyl)-5-hydroxy-1 H-pyrazole-3-carbonyl]-amino}-3-o- tolyl-propionic acid

79 3-{[1 -(4-Chloro-phenyl)-5-hydroxy-1 H-pyrazole-3-carbonyl]-amino}-3-o-tolyl- propionic acid ExCompound Name

ample

80 3-{[1 -(3-Chloro-4-fluoro-phenyl)-5-hydroxy-1 H-pyrazole-3-carbonyl]-amino}-3- o-tolyl-propionic acid

81 (S)-3-{[1 -(2-Fluoro-phenyl)-5-hydroxy-1 H-pyrazole-3-carbonyl]-amino}-3-o- tolyl-propionic acid

82 (S)-3-[(5-Hydroxy-1 -phenyl-1 H-pyrazole-3-carbonyl)-amino]-3-o-tolyl- propionic acid

83 (R)-3-[(5-Hydroxy-1 -phenyl-1 H-pyrazole-3-carbonyl)-amino]-3-o-tolyl- propionic acid

84 3-(2,4-Dimethyl-phenyl)-3-[(5-hydroxy-1 -phenyl-1 H-pyrazole-3-carbonyl)- amino]-propionic acid

85 3-(4-Fluoro-2-methyl-phenyl)-3-[(5-hydroxy-1 -phenyl-1 H-pyrazole-3- carbonyl)-amino]-propionic acid

86 3-(2,4-Difluoro-phenyl)-3-{[1 -(4-fluoro-phenyl)-5-hydroxy-1 H-pyrazole-3- carbonyl]-amino}-propionic acid

87 (S)-3-{[5-Hydroxy-1 -(4-methoxy-phenyl)-1 H-pyrazole-3-carbonyl]-amino}-3-o- tolyl-propionic acid

88 3-{[1 -(3-Chloro-4-fluoro-phenyl)-5-hydroxy-1 H-pyrazole-3-carbonyl]-amino}-3- (2-fluoro-4-methoxy-phenyl)-propionic acid

89 3-(2,4-Dimethyl-phenyl)-3-{[1 -(4-fluoro-phenyl)-5-hydroxy-1 H-pyrazole-3- carbonyl]-amino}-propionic acid

90 3-(2-Fluoro-4-methoxy-phenyl)-3-{[1 -(4-fluoro-phenyl)-5-hydroxy-1 H-pyrazole- 3-carbonyl]-amino}-propionic acid

91 3-{[1 -(3-Chloro-4-fluoro-phenyl)-5-hydroxy-1 H-pyrazole-3-carbonyl]-amino}-3- (2,4-dimethyl-phenyl)-propionic acid

92 3-(2-Fluoro-4-methoxy-phenyl)-3-[(5-hydroxy-1 -phenyl-1 H-pyrazole-3- carbonyl)-amino]-propionic acid ExCompound Name

ample

93 (S)-3-{[1 -(2-Fluoro-phenyl)-5-hydroxy-1 H-pyrazole-3-carbonyl]-amino}-3-o- tolyl-propionic acid methyl ester

94 (S)-3-{[5-Hydroxy-1 -(3-methoxy-phenyl)-1 H-pyrazole-3-carbonyl]-amino}-3-o- tolyl-propionic acid

95 (S)-3-(2,4-Dichloro-phenyl)-3-[(5-hydroxy-1 -phenyl-1 H-pyrazole-3-carbonyl)- amino]-propionic acid

96 (S)-3-(2-Fluoro-phenyl)-3-[(5-hydroxy-1 -phenyl-1 H-pyrazole-3-carbonyl)- amino]-propionic acid

97 (S)-3-[(5-Hydroxy-1 -phenyl-1 H-pyrazole-3-carbonyl)-amino]-3-(2- trifluoromethyl-phenyl)-propionic acid

98 (S)-3-(4-Chloro-phenyl)-3-[(5-hydroxy-1 -phenyl-1 H-pyrazole-3-carbonyl)- amino]-propionic acid

99 (S)-3-[(5-Hydroxy-1 -phenyl-1 H-pyrazole-3-carbonyl)-amino]-3-(4- trifluoromethyl-phenyl)-propionic acid

100 (S)-3-[(5-Hydroxy-1 -phenyl-1 H-pyrazole-3-carbonyl)-amino]-3-(2-methoxy- phenyl)-propionic acid

101 (S)-3-(4-Cyano-phenyl)-3-[(5-hydroxy-1 -phenyl-1 H-pyrazole-3-carbonyl)- amino]-propionic acid

102 3-[(5-Hydroxy-1 -phenyl-1 H-pyrazole-3-carbonyl)-amino]-3-(4-phenoxy- phenyl)-propionic acid

103 (S)-3-(2,6-Difluoro-phenyl)-3-[(5-hydroxy-1 -phenyl-1 H-pyrazole-3-carbonyl)- amino]-propionic acid

104 3-(4'-Fluoro-biphenyl-4-yl)-3-[(5-hydroxy-1 -phenyl-1 H-pyrazole-3-carbonyl)- amino]-propionic acid

105 3-[(5-Hydroxy-1 -phenyl-1 H-pyrazole-3-carbonyl)-amino]-3-(4-imidazol-1 -yl- phenyl)-propionic acid ExCompound Name

ample

106 (S)-3-{[1 -(2-Chloro-phenyl)-5-hydroxy-1 H-pyrazole-3-carbonyl]-amino}-3-(2,4- dichloro-phenyl)-propionic acid

107 (S)-3-{[1 -(2-Chloro-phenyl)-5-hydroxy-1 H-pyrazole-3-carbonyl]-amino}-3-(2- fluoro-phenyl)-propionic acid

108 (S)-3-{[1 -(2-Chloro-phenyl)-5-hydroxy-1 H-pyrazole-3-carbonyl]-amino}-3-(2- trifluoromethyl-phenyl)-propionic acid

109 (S)-3-(4-Chloro-phenyl)-3-{[1 -(2-chloro-phenyl)-5-hydroxy-1 H-pyrazole-3- carbonyl]-amino}-propionic acid

1 10 (S)-3-{[1 -(2-Chloro-phenyl)-5-hydroxy-1 H-pyrazole-3-carbonyl]-amino}-3-(4- trifluoromethyl-phenyl)-propionic acid

1 1 1 (S)-3-{[1 -(2-Chloro-phenyl)-5-hydroxy-1 H-pyrazole-3-carbonyl]-amino}-3-(2- methoxy-phenyl)-propionic acid

1 12 (S)-3-{[1 -(2-Chloro-phenyl)-5-hydroxy-1 H-pyrazole-3-carbonyl]-amino}-3-(4- cyano-phenyl)-propionic acid

1 13 3-{[1 -(2-Chloro-phenyl)-5-hydroxy-1 H-pyrazole-3-carbonyl]-amino}-3-(4- phenoxy-phenyl)-propionic acid

1 14 (S)-3-{[1 -(2-Chloro-phenyl)-5-hydroxy-1 H-pyrazole-3-carbonyl]-amino}-3-(2,6- difluoro-phenyl)-propionic acid

1 15 3-{[1 -(2-Chloro-phenyl)-5-hydroxy-1 H-pyrazole-3-carbonyl]-amino}-3-(4'- fluoro-biphenyl-4-yl)-propionic acid

1 16 3-{[1 -(2-Chloro-phenyl)-5-hydroxy-1 H-pyrazole-3-carbonyl]-amino}-3-(4- imidazol-1 -yl-phenyl)-propionic acid

1 17 (S)-3-(2,4-Dichloro-phenyl)-3-{[1 -(2-fluoro-phenyl)-5-hydroxy-1 H-pyrazole-3- carbonyl]-amino}-propionic acid

1 18 (S)-3-(2-Fluoro-phenyl)-3-{[1 -(2-fluoro-phenyl)-5-hydroxy-1 H-pyrazole-3- carbonyl]-amino}-propionic acid ExCompound Name

ample

1 19 (S)-3-{[1 -(2-Fluoro-phenyl)-5-hydroxy-1 H-pyrazole-3-carbonyl]-amino}-3-(2- trifluoromethyl-phenyl)-propionic acid

120 (S)-3-(4-Chloro-phenyl)-3-{[1 -(2-fluoro-phenyl)-5-hydroxy-1 H-pyrazole-3- carbonyl]-amino}-propionic acid

121 (S)-3-{[1 -(2-Fluoro-phenyl)-5-hydroxy-1 H-pyrazole-3-carbonyl]-amino}-3-(4- trifluoromethyl-phenyl)-propionic acid

122 (S)-3-{[1 -(2-Fluoro-phenyl)-5-hydroxy-1 H-pyrazole-3-carbonyl]-amino}-3-(2- methoxy-phenyl)-propionic acid

123 (S)-3-(4-Cyano-phenyl)-3-{[1 -(2-fluoro-phenyl)-5-hydroxy-1 H-pyrazole-3- carbonyl]-amino}-propionic acid

124 3-{[1 -(2-Fluoro-phenyl)-5-hydroxy-1 H-pyrazole-3-carbonyl]-amino}-3-(4- phenoxy-phenyl)-propionic acid

125 (S)-3-(2,6-Difluoro-phenyl)-3-{[1 -(2-fluoro-phenyl)-5-hydroxy-1 H-pyrazole-3- carbonyl]-amino}-propionic acid

126 3-(4'-Fluoro-biphenyl-4-yl)-3-{[1 -(2-fluoro-phenyl)-5-hydroxy-1 H-pyrazole-3- carbonyl]-amino}-propionic acid

127 3-{[1 -(2-Fluoro-phenyl)-5-hydroxy-1 H-pyrazole-3-carbonyl]-amino}-3-(4- imidazol-1 -yl-phenyl)-propionic acid

128 (S)-3-{[1 -(2-Fluoro-phenyl)-5-hydroxy-1 H-pyrazole-3-carbonyl]-amino}-3-o- tolyl-propionic acid ethyl ester

129 (S)-3-{[1 -(2-Fluoro-phenyl)-5-methoxy-1 H-pyrazole-3-carbonyl]-amino}-3-o- tolyl-propionic acid

130 (S)-3-{[1 -(5-Chloro-pyridin-2-yl)-5-hydroxy-1 H-pyrazole-3-carbonyl]-amino}-3- o-tolyl-propionic acid

131 (S)-3-{[1 -(2-Chloro-pyridin-4-yl)-5-hydroxy-1 H-pyrazole-3-carbonyl]-amino}-3- o-tolyl-propionic acid ExCompound Name

ample

132 3-{[1 -(2-Chloro-phenyl)-5-hydroxy-1 H-pyrazole-3-carbonyl]-amino}-3-(2- fluoro-4-methoxy-phenyl)-propionic acid

133 3-(2-Fluoro-4-methoxy-phenyl)-3-{[1 -(2-fluoro-phenyl)-5-hydroxy-1 H-pyrazole- 3-carbonyl]-amino}-propionic acid

134 3-(4-Ethyl-phenyl)-3-{[1 -(2-fluoro-phenyl)-5-hydroxy-1 H-pyrazole-3-carbonyl]- amino}-propionic acid

135 (S)-3-{[1 -(2-Chloro-phenyl)-5-hydroxy-1 H-pyrazole-3-carbonyl]-amino}-3-p- tolyl-propionic acid

136 (S)-3-{[1 -(2-Fluoro-phenyl)-5-hydroxy-1 H-pyrazole-3-carbonyl]-amino}-3-(6- methoxy-pyridin-3-yl)-propionic acid

137 (S)-3-[(5-Hydroxy-1 -phenyl-1 H-pyrazole-3-carbonyl)-amino]-3-pyridin-3-yl- propionic acid

138 (S)-3-{[5-Hydroxy-1 -(4-trifluoromethyl-pyrimidin-2-yl)-1 H-pyrazole-3-carbonyl]- amino}-3-o-tolyl-propionic acid

139 (S)-3-{[1 -(2-Chloro-phenyl)-5-hydroxy-1 H-pyrazole-3-carbonyl]-amino}-3-(6- methoxy-pyridin-3-yl)-propionic acid

140 (S)-3-{[1 -(2-Fluoro-phenyl)-5-hydroxy-1 H-pyrazole-3-carbonyl]-amino}-3- pyridin-3-yl-propionic acid

141 (S)-3-[(5-Hydroxy-1 -pyridin-4-yl-1 H-pyrazole-3-carbonyl)-amino]-3-o-tolyl- propionic acid

142 3-{[1 -(2-Chloro-phenyl)-5-hydroxy-1 H-pyrazole-3-carbonyl]-amino}-3-(4- fluoro-2-methyl-phenyl)-propionic acid

143 (S)-3-[(5-Hydroxy-1 -pyridin-3-yl-1 H-pyrazole-3-carbonyl)-amino]-3-o-tolyl- propionic acid

144 (S)-3-[(5-Hydroxy-1 -phenyl-1 H-pyrazole-3-carbonyl)-amino]-3-(6-methoxy- pyridin-3-yl)-propionic acid ExCompound Name

ample

145 (S)-3-{[1 -(2-Chloro-phenyl)-5-hydroxy-1 H-pyrazole-3-carbonyl]-amino}-3- pyridin-3-yl-propionic acid

146 (S)-3-(4'-Fluoro-biphenyl-4-yl)-3-{[1 -(2-fluoro-phenyl)-5-hydroxy-1 H-pyrazole- 3-carbonyl]-amino}-propionic acid

147 (R)-3-(4'-Fluoro-biphenyl-4-yl)-3-{[1 -(2-fluoro-phenyl)-5-hydroxy-1 H-pyrazole- 3-carbonyl]-amino}-propionic acid

148 (S)-3-{[1 -(2-Chloro-phenyl)-5-hydroxy-1 H-pyrazole-3-carbonyl]-amino}-3-(4'- fluoro-biphenyl-4-yl)-propionic acid

149 (R)-3-{[1 -(2-Chloro-phenyl)-5-hydroxy-1 H-pyrazole-3-carbonyl]-amino}-3-(4'- fluoro-biphenyl-4-yl)-propionic acid

150 3-Biphenyl-4-yl-3-{[1 -(2-fluoro-phenyl)-5-hydroxy-1 H-pyrazole-3-carbonyl]- amino}-propionic acid

151 3-Biphenyl-4-yl-3-[(5-hydroxy-1 -pyridin-4-yl-1 H-pyrazole-3-carbonyl)-amino]- propionic acid

152 3-{[1 -(2-Chloro-phenyl)-5-hydroxy-1 H-pyrazole-3-carbonyl]-amino}-3-(4- phenoxy-phenyl)-propionic acid ethyl ester

153 3-(4'-Fluoro-biphenyl-4-yl)-3-{[1 -(2-fluoro-phenyl)-5-hydroxy-1 H-pyrazole-3- carbonyl]-amino}-propionic acid ethyl ester

154 3-{[1 -(2-Chloro-phenyl)-5-hydroxy-1 H-pyrazole-3-carbonyl]-amino}-3-(4'- fluoro-biphenyl-4-yl)-propionic acid ethyl ester

155 3-{[1 -(2-Fluoro-phenyl)-5-hydroxy-1 H-pyrazole-3-carbonyl]-amino}-3-(4- phenoxy-phenyl)-propionic acid ethyl ester

156 3-{[1 -(2-Fluoro-phenyl)-5-hydroxy-1 H-pyrazole-3-carbonyl]-amino}-3-(3'- methoxy-biphenyl-4-yl)-propionic acid

157 3-{[1 -(2-Chloro-phenyl)-5-hydroxy-1 H-pyrazole-3-carbonyl]-amino}-3-(3'- methoxy-biphenyl-4-yl)-propionic acid ExCompound Name

ample

158 3-Benzo[1 ,3]dioxol-4-yl-3-[(5-hydroxy-1 -phenyl-1 H-pyrazole-3-carbonyl)- amino]-propionic acid

159 (S)-3-(2-Bromo-phenyl)-3-[(5-hydroxy-1 -phenyl-1 H-pyrazole-3-carbonyl)- amino]-propionic acid

160 (S)-3-(3-Cyano-phenyl)-3-[(5-hydroxy-1 -phenyl-1 H-pyrazole-3-carbonyl)- amino]-propionic acid

161 3-(2,4-Dimethoxy-phenyl)-3-[(5-hydroxy-1 -phenyl-1 H-pyrazole-3-carbonyl)- amino]-propionic acid

162 3-(2-Chloro-4-methoxy-phenyl)-3-[(5-hydroxy-1 -phenyl-1 H-pyrazole-3- carbonyl)-amino]-propionic acid

163 (S)-3-(4-Fluoro-phenyl)-3-[(5-hydroxy-1 -phenyl-1 H-pyrazole-3-carbonyl)- amino]-propionic acid

164 (S)-3-(2,3-Dichloro-phenyl)-3-[(5-hydroxy-1 -phenyl-1 H-pyrazole-3-carbonyl)- amino]-propionic acid

165 (S)-3-[(5-Hydroxy-1 -phenyl-1 H-pyrazole-3-carbonyl)-amino]-3-(3-methoxy- phenyl)-propionic acid

166 (S)-3-(3-Fluoro-phenyl)-3-[(5-hydroxy-1 -phenyl-1 H-pyrazole-3-carbonyl)- amino]-propionic acid

167 (S)-3-(3-Chloro-phenyl)-3-[(5-hydroxy-1 -phenyl-1 H-pyrazole-3-carbonyl)- amino]-propionic acid

168 3-(2,3-Dichloro-phenyl)-3-[(5-hydroxy-1 -phenyl-1 H-pyrazole-3-carbonyl)- amino]-propionic acid

169 (2R,3R)-2-Hydroxy-3-[(5-hydroxy-1 -phenyl-1 H-pyrazole-3-carbonyl)-amino]-3- (2-methoxy-phenyl)-propionic acid

170 (S)-3-(2,3-Dimethoxy-phenyl)-3-[(5-hydroxy-1 -phenyl-1 H-pyrazole-3- carbonyl)-amino]-propionic acid ExCompound Name

ample

171 3-(3'-Fluoro-biphenyl-4-yl)-3-[(5-hydroxy-1 -phenyl-1 H-pyrazole-3-carbonyl)- amino]-propionic acid

172 3-(3-Chloro-2-fluoro-phenyl)-3-[(5-hydroxy-1 -phenyl-1 H-pyrazole-3-carbonyl)- amino]-propionic acid

173 3-[3-(4-Chloro-phenoxy)-phenyl]-3-[(5-hydroxy-1 -phenyl-1 H-pyrazole-3- carbonyl)-amino]-propionic acid

174 3-Benzo[1 ,3]dioxol-4-yl-3-{[1 -(2,4-difluoro-phenyl)-5-hydroxy-1 H-pyrazole-3- carbonyl]-amino}-propionic acid

175 (S)-3-(2-Bromo-phenyl)-3-{[1 -(2,4-difluoro-phenyl)-5-hydroxy-1 H-pyrazole-3- carbonyl]-amino}-propionic acid

176 (S)-3-(4-Cyano-phenyl)-3-{[1 -(2,4-difluoro-phenyl)-5-hydroxy-1 H-pyrazole-3- carbonyl]-amino}-propionic acid

177 (S)-3-{[1 -(2,4-Difluoro-phenyl)-5-hydroxy-1 H-pyrazole-3-carbonyl]-amino}-3- (2-methoxy-phenyl)-propionic acid

178 3-(5-Chloro-2-methoxy-phenyl)-3-{[1 -(2,4-difluoro-phenyl)-5-hydroxy-1 H- pyrazole-3-carbonyl]-amino}-propionic acid

179 3-(2-Chloro-4-methoxy-phenyl)-3-{[1 -(2,4-difluoro-phenyl)-5-hydroxy-1 H- pyrazole-3-carbonyl]-amino}-propionic acid

180 (S)-3-{[1 -(2,4-Difluoro-phenyl)-5-hydroxy-1 H-pyrazole-3-carbonyl]-amino}-3- (4-fluoro-phenyl)-propionic acid

181 (S)-3-(2,3-Dichloro-phenyl)-3-{[1 -(2,4-difluoro-phenyl)-5-hydroxy-1 H-pyrazole- 3-carbonyl]-amino}-propionic acid

182 (S)-3-{[1 -(2,4-Difluoro-phenyl)-5-hydroxy-1 H-pyrazole-3-carbonyl]-amino}-3- (3-methoxy-phenyl)-propionic acid

183 (S)-3-{[1 -(2,4-Difluoro-phenyl)-5-hydroxy-1 H-pyrazole-3-carbonyl]-amino}-3- (3-fluoro-phenyl)-propionic acid ExCompound Name

ample

184 (S)-3-(3-Chloro-phenyl)-3-{[1 -(2,4-difluoro-phenyl)-5-hydroxy-1 H-pyrazole-3- carbonyl]-amino}-propionic acid

185 (S)-3-{[1 -(2,4-Difluoro-phenyl)-5-hydroxy-1 H-pyrazole-3-carbonyl]-amino}-3- (4-trifluoromethyl-phenyl)-propionic acid

186 3-(2,3-Dichloro-phenyl)-3-{[1 -(2,4-difluoro-phenyl)-5-hydroxy-1 H-pyrazole-3- carbonyl]-amino}-propionic acid

187 3-{[1 -(2,4-Difluoro-phenyl)-5-hydroxy-1 H-pyrazole-3-carbonyl]-amino}-3-(4- trifluoromethoxy-phenyl)-propionic acid

188 (2R,3R)-3-{[1 -(2,4-Difluoro-phenyl)-5-hydroxy-1 H-pyrazole-3-carbonyl]- amino}-2-hydroxy-3-(2-methoxy-phenyl)-propionic acid

189 (S)-3-{[1 -(2,4-Difluoro-phenyl)-5-hydroxy-1 H-pyrazole-3-carbonyl]-amino}-3- (2,3-dimethoxy-phenyl)-propionic acid

190 (S)-3-{[1 -(2,4-Difluoro-phenyl)-5-hydroxy-1 H-pyrazole-3-carbonyl]-amino}-3- m-tolyl-propionic acid

191 3-{[1 -(2,4-Difluoro-phenyl)-5-hydroxy-1 H-pyrazole-3-carbonyl]-amino}-3-(2,3- dimethyl-phenyl)-propionic acid

192 3-(3-Chloro-2-fluoro-phenyl)-3-{[1 -(2,4-difluoro-phenyl)-5-hydroxy-1 H- pyrazole-3-carbonyl]-amino}-propionic acid

193 3-(2-Chloro-3-trifluoromethyl-phenyl)-3-{[1 -(2,4-difluoro-phenyl)-5-hydroxy- 1 H-pyrazole-3-carbonyl]-amino}-propionic acid

194 3-{[1 -(2,4-Difluoro-phenyl)-5-hydroxy-1 H-pyrazole-3-carbonyl]-amino}-3-(4- ethyl-phenyl)-propionic acid

195 3-{[1 -(2,4-Difluoro-phenyl)-5-hydroxy-1 H-pyrazole-3-carbonyl]-amino}-3-(2,4- dimethyl-phenyl)-propionic acid

196 3-{[1 -(2,4-Difluoro-phenyl)-5-hydroxy-1 H-pyrazole-3-carbonyl]-amino}-3-(4- fluoro-2-methyl-phenyl)-propionic acid ExCompound Name

ample

197 3-Biphenyl-4-yl-3-{[1 -(2,4-difluoro-phenyl)-5-hydroxy-1 H-pyrazole-3-carbonyl]- amino}-propionic acid

198 (S)-3-{[1 -(2,4-Difluoro-phenyl)-5-hydroxy-1 H-pyrazole-3-carbonyl]-amino}-3- (2-trifluoromethyl-phenyl)-propionic acid

199 3-{[1 -(2,4-Difluoro-phenyl)-5-hydroxy-1 H-pyrazole-3-carbonyl]-amino}-3-(4- phenoxy-phenyl)-propionic acid

200 (S)-3-(4-Chloro-phenyl)-3-{[1 -(2,4-difluoro-phenyl)-5-hydroxy-1 H-pyrazole-3- carbonyl]-amino}-propionic acid

201 (S)-3-(2,4-Dichloro-phenyl)-3-{[1 -(2,4-difluoro-phenyl)-5-hydroxy-1 H-pyrazole- 3-carbonyl]-amino}-propionic acid

202 3-{[1 -(2,4-Difluoro-phenyl)-5-hydroxy-1 H-pyrazole-3-carbonyl]-amino}-3-(4'- fluoro-biphenyl-4-yl)-propionic acid

203 3-{[1 -(2-Chloro-phenyl)-5-hydroxy-1 H-pyrazole-3-carbonyl]-amino}-3-(4- methoxy-2-methyl-phenyl)-propionic acid

204 (S)-3-(2-Bromo-phenyl)-3-{[1 -(2-chloro-phenyl)-5-hydroxy-1 H-pyrazole-3- carbonyl]-amino}-propionic acid

205 (S)-3-{[1 -(2-Chloro-phenyl)-5-hydroxy-1 H-pyrazole-3-carbonyl]-amino}-3-(3- cyano-phenyl)-propionic acid

206 3-{[1 -(2-Chloro-phenyl)-5-hydroxy-1 H-pyrazole-3-carbonyl]-amino}-3-(3- trifluoromethyl-phenyl)-propionic acid

207 3-{[1 -(2-Chloro-phenyl)-5-hydroxy-1 H-pyrazole-3-carbonyl]-amino}-3-(2,4- dimethoxy-phenyl)-propionic acid

208 3-{[1 -(2-Chloro-phenyl)-5-hydroxy-1 H-pyrazole-3-carbonyl]-amino}-3-(2- fluoro-phenyl)-propionic acid

209 3-(5-Chloro-2-methoxy-phenyl)-3-{[1 -(2-chloro-phenyl)-5-hydroxy-1 H- pyrazole-3-carbonyl]-amino}-propionic acid ExCompound Name

ample

210 3-(2-Chloro-4-methoxy-phenyl)-3-{[1 -(2-chloro-phenyl)-5-hydroxy-1 H- pyrazole-3-carbonyl]-amino}-propionic acid

21 1 (S)-3-{[1 -(2-Chloro-phenyl)-5-hydroxy-1 H-pyrazole-3-carbonyl]-amino}-3-(4- fluoro-phenyl)-propionic acid

212 (S)-3-{[1 -(2-Chloro-phenyl)-5-hydroxy-1 H-pyrazole-3-carbonyl]-amino}-3-(2,3- dichloro-phenyl)-propionic acid

213 (S)-3-{[1 -(2-Chloro-phenyl)-5-hydroxy-1 H-pyrazole-3-carbonyl]-amino}-3-(3- methoxy-phenyl)-propionic acid

214 (S)-3-(3-Chloro-phenyl)-3-{[1 -(2-chloro-phenyl)-5-hydroxy-1 H-pyrazole-3- carbonyl]-amino}-propionic acid

215 3-{[1 -(2-Chloro-phenyl)-5-hydroxy-1 H-pyrazole-3-carbonyl]-amino}-3-(4- trifluoromethoxy-phenyl)-propionic acid

216 (2R,3R)-3-{[1 -(2-Chloro-phenyl)-5-hydroxy-1 H-pyrazole-3-carbonyl]-amino}-2- hydroxy-3-(2-methoxy-phenyl)-propionic acid

217 (S)-3-{[1 -(2-Chloro-phenyl)-5-hydroxy-1 H-pyrazole-3-carbonyl]-amino}-3-m- tolyl-propionic acid

218 (S)-3-{[1 -(2-Chloro-phenyl)-5-hydroxy-1 H-pyrazole-3-carbonyl]-amino}-3-(3- trifluoromethyl-phenyl)-propionic acid

219 3-{[1 -(2-Chloro-phenyl)-5-hydroxy-1 H-pyrazole-3-carbonyl]-amino}-3-(3'- fluoro-biphenyl-4-yl)-propionic acid

220 3-{[1 -(2-Chloro-phenyl)-5-hydroxy-1 H-pyrazole-3-carbonyl]-amino}-3-(2,3- dimethyl-phenyl)-propionic acid

221 3-{[1 -(2-Chloro-phenyl)-5-hydroxy-1 H-pyrazole-3-carbonyl]-amino}-3-(2- fluoro-3-trifluoromethyl-phenyl)-propionic acid

222 3-(3-Chloro-2-fluoro-phenyl)-3-{[1 -(2-chloro-phenyl)-5-hydroxy-1 H-pyrazole-3- carbonyl]-amino}-propionic acid ExCompound Name

ample

223 3-{[1 -(2-Chloro-phenyl)-5-hydroxy-1 H-pyrazole-3-carbonyl]-amino}-3-(2- chloro-3-trifluoromethyl-phenyl)-propionic acid

224 3-{[1 -(2-Chloro-phenyl)-5-hydroxy-1 H-pyrazole-3-carbonyl]-amino}-3-(4-ethyl- phenyl)-propionic acid

225 3-{[1 -(2-Chloro-phenyl)-5-hydroxy-1 H-pyrazole-3-carbonyl]-amino}-3-(2,4- dimethyl-phenyl)-propionic acid

226 3-Biphenyl-4-yl-3-{[1 -(2-chloro-phenyl)-5-hydroxy-1 H-pyrazole-3-carbonyl]- amino}-propionic acid

227 3-{[1 -(2-Chloro-phenyl)-5-hydroxy-1 H-pyrazole-3-carbonyl]-amino}-3-(3,4- dichloro-phenyl)-propionic acid

228 3-Benzo[1 ,3]dioxol-4-yl-3-{[1 -(2-fluoro-phenyl)-5-hydroxy-1 H-pyrazole-3- carbonyl]-amino}-propionic acid

229 3-(3-Benzyloxy-phenyl)-3-{[1 -(2-fluoro-phenyl)-5-hydroxy-1 H-pyrazole-3- carbonyl]-amino}-propionic acid

230 (S)-3-(3-Cyano-phenyl)-3-{[1 -(2-fluoro-phenyl)-5-hydroxy-1 H-pyrazole-3- carbonyl]-amino}-propionic acid

231 3-{[1 -(2-Fluoro-phenyl)-5-hydroxy-1 H-pyrazole-3-carbonyl]-amino}-3-(3- trifluoromethyl-phenyl)-propionic acid

232 3-(2,4-Dimethoxy-phenyl)-3-{[1 -(2-fluoro-phenyl)-5-hydroxy-1 H-pyrazole-3- carbonyl]-amino}-propionic acid

233 3-(2-Fluoro-phenyl)-3-{[1 -(2-fluoro-phenyl)-5-hydroxy-1 H-pyrazole-3- carbonyl]-amino}-propionic acid

234 3-(5-Chloro-2-methoxy-phenyl)-3-{[1 -(2-fluoro-phenyl)-5-hydroxy-1 H- pyrazole-3-carbonyl]-amino}-propionic acid

235 3-(2-Chloro-4-methoxy-phenyl)-3-{[1 -(2-fluoro-phenyl)-5-hydroxy-1 H- pyrazole-3-carbonyl]-amino}-propionic acid ExCompound Name

ample

236 (S)-3-(4-Fluoro-phenyl)-3-{[1 -(2-fluoro-phenyl)-5-hydroxy-1 H-pyrazole-3- carbonyl]-amino}-propionic acid

237 (S)-3-{[1 -(2-Fluoro-phenyl)-5-hydroxy-1 H-pyrazole-3-carbonyl]-amino}-3-(3- methoxy-phenyl)-propionic acid

238 3- {[1 -(2-Fluoro-phenyl)-5-hydroxy-1 H-pyrazole-3-carbonyl]-amino}-3-(2-fluoro-

4- trifluoromethyl-phenyl)-propionic acid

239 3-{[1 -(2-Fluoro-phenyl)-5-hydroxy-1 H-pyrazole-3-carbonyl]-amino}-3-(4- trifluoromethoxy-phenyl)-propionic acid

240 (2R,3R)-3-{[1 -(2-Fluoro-phenyl)-5-hydroxy-1 H-pyrazole-3-carbonyl]-amino}-2- hydroxy-3-(2-methoxy-phenyl)-propionic acid

241 (S)-3-{[1 -(2-Fluoro-phenyl)-5-hydroxy-1 H-pyrazole-3-carbonyl]-amino}-3-(3- trifluoromethyl-phenyl)-propionic acid

242 3-(3'-Fluoro-biphenyl-4-yl)-3-{[1 -(2-fluoro-phenyl)-5-hydroxy-1 H-pyrazole-3- carbonyl]-amino}-propionic acid

243 3-(4-Chloro-2-fluoro-phenyl)-3-{[1 -(2-fluoro-phenyl)-5-hydroxy-1 H-pyrazole-3- carbonyl]-amino}-propionic acid

244 3-(3-Chloro-2-fluoro-phenyl)-3-{[1 -(2-fluoro-phenyl)-5-hydroxy-1 H-pyrazole-3- carbonyl]-amino}-propionic acid

245 3-(2-Chloro-3-trifluoromethyl-phenyl)-3-{[1 -(2-fluoro-phenyl)-5-hydroxy-1 H- pyrazole-3-carbonyl]-amino}-propionic acid

246 3-[3-(4-Chloro-phenoxy)-phenyl]-3-{[1 -(2-fluoro-phenyl)-5-hydroxy-1 H- pyrazole-3-carbonyl]-amino}-propionic acid

247 3-(2,4-Dimethyl-phenyl)-3-{[1 -(2-fluoro-phenyl)-5-hydroxy-1 H-pyrazole-3- carbonyl]-amino}-propionic acid

248 3-(4-Fluoro-2-methyl-phenyl)-3-{[1 -(2-fluoro-phenyl)-5-hydroxy-1 H-pyrazole-3- carbonyl]-amino}-propionic acid ExCompound Name

ample

249 3-Benzo[1 ,3]dioxol-4-yl-3-{[1 -(3-chloro-phenyl)-5-hydroxy-1 H-pyrazole-3- carbonyl]-amino}-propionic acid

250 3-{[1 -(3-Chloro-phenyl)-5-hydroxy-1 H-pyrazole-3-carbonyl]-amino}-3-(4- methoxy-2-methyl-phenyl)-propionic acid

251 (S)-3-(2-Bromo-phenyl)-3-{[1 -(3-chloro-phenyl)-5-hydroxy-1 H-pyrazole-3- carbonyl]-amino}-propionic acid

252 (S)-3-{[1 -(3-Chloro-phenyl)-5-hydroxy-1 H-pyrazole-3-carbonyl]-amino}-3-(3- cyano-phenyl)-propionic acid

253 (S)-3-{[1 -(3-Chloro-phenyl)-5-hydroxy-1 H-pyrazole-3-carbonyl]-amino}-3-(2- methoxy-phenyl)-propionic acid

254 3-{[1 -(3-Chloro-phenyl)-5-hydroxy-1 H-pyrazole-3-carbonyl]-amino}-3-(2- fluoro-phenyl)-propionic acid

255 3-(5-Chloro-2-methoxy-phenyl)-3-{[1 -(3-chloro-phenyl)-5-hydroxy-1 H- pyrazole-3-carbonyl]-amino}-propionic acid

256 (S)-3-{[1 -(3-Chloro-phenyl)-5-hydroxy-1 H-pyrazole-3-carbonyl]-amino}-3-(4- trifluoromethyl-phenyl)-propionic acid

257 3-{[1 -(3-Chloro-phenyl)-5-hydroxy-1 H-pyrazole-3-carbonyl]-amino}-3-(2,3- dichloro-phenyl)-propionic acid

258 (S)-3-{[1 -(3-Chloro-phenyl)-5-hydroxy-1 H-pyrazole-3-carbonyl]-amino}-3-m- tolyl-propionic acid

259 (S)-3-{[1 -(3-Chloro-phenyl)-5-hydroxy-1 H-pyrazole-3-carbonyl]-amino}-3-(3- trifluoromethyl-phenyl)-propionic acid

260 3-{[1 -(3-Chloro-phenyl)-5-hydroxy-1 H-pyrazole-3-carbonyl]-amino}-3-(3'- fluoro-biphenyl-4-yl)-propionic acid

261 3-{[1 -(3-Chloro-phenyl)-5-hydroxy-1 H-pyrazole-3-carbonyl]-amino}-3-(2,3- dimethyl-phenyl)-propionic acid ExCompound Name

ample

262 3-(3-Chloro-2-fluoro-phenyl)-3-{[1 -(3-chloro-phenyl)-5-hydroxy-1 H-pyrazole-3- carbonyl]-amino}-propionic acid

263 3-{[1 -(3-Chloro-phenyl)-5-hydroxy-1 H-pyrazole-3-carbonyl]-amino}-3-(2- chloro-3-trifluoromethyl-phenyl)-propionic acid

264 3-{[1 -(3-Chloro-phenyl)-5-hydroxy-1 H-pyrazole-3-carbonyl]-amino}-3-(4-ethyl- phenyl)-propionic acid

265 (S)-3-{[1 -(3-Chloro-phenyl)-5-hydroxy-1 H-pyrazole-3-carbonyl]-amino}-3-(2,6- difluoro-phenyl)-propionic acid

266 (S)-3-{[1 -(3-Chloro-phenyl)-5-hydroxy-1 H-pyrazole-3-carbonyl]-amino}-3-(2,4- dichloro-phenyl)-propionic acid

267 3-{[1 -(3-Chloro-phenyl)-5-hydroxy-1 H-pyrazole-3-carbonyl]-amino}-3-(4'- fluoro-biphenyl-4-yl)-propionic acid

268 (S)-3-{[1 -(3-Chloro-phenyl)-5-hydroxy-1 H-pyrazole-3-carbonyl]-amino}-3- pyridin-3-yl-propionic acid

269 (S)-3-{[1 -(3-Chloro-phenyl)-5-hydroxy-1 H-pyrazole-3-carbonyl]-amino}-3-(6- methoxy-pyridin-3-yl)-propionic acid

270 (S)-3-(2-Bromo-phenyl)-3-{[1 -(4-chloro-phenyl)-5-hydroxy-1 H-pyrazole-3- carbonyl]-amino}-propionic acid

271 (S)-3-{[1 -(4-Chloro-phenyl)-5-hydroxy-1 H-pyrazole-3-carbonyl]-amino}-3-(3- cyano-phenyl)-propionic acid

272 (S)-3-{[1 -(4-Chloro-phenyl)-5-hydroxy-1 H-pyrazole-3-carbonyl]-amino}-3-(4- cyano-phenyl)-propionic acid

273 3-{[1 -(4-Chloro-phenyl)-5-hydroxy-1 H-pyrazole-3-carbonyl]-amino}-3-(2,4- dimethoxy-phenyl)-propionic acid

274 (S)-3-{[1 -(4-Chloro-phenyl)-5-hydroxy-1 H-pyrazole-3-carbonyl]-amino}-3-(2- methoxy-phenyl)-propionic acid ExCompound Name

ample

275 3-(5-Chloro-2-methoxy-phenyl)-3-{[1 -(4-chloro-phenyl)-5-hydroxy-1 H- pyrazole-3-carbonyl]-amino}-propionic acid

276 (S)-3-{[1 -(4-Chloro-phenyl)-5-hydroxy-1 H-pyrazole-3-carbonyl]-amino}-3-(4- fluoro-phenyl)-propionic acid

277 (S)-3-{[1 -(4-Chloro-phenyl)-5-hydroxy-1 H-pyrazole-3-carbonyl]-amino}-3-(2,3- dichloro-phenyl)-propionic acid

278 (S)-3-{[1 -(4-Chloro-phenyl)-5-hydroxy-1 H-pyrazole-3-carbonyl]-amino}-3-(3- methoxy-phenyl)-propionic acid

279 (S)-3-{[1 -(4-Chloro-phenyl)-5-hydroxy-1 H-pyrazole-3-carbonyl]-amino}-3-(3- fluoro-phenyl)-propionic acid

280 (S)-3-(3-Chloro-phenyl)-3-{[1 -(4-chloro-phenyl)-5-hydroxy-1 H-pyrazole-3- carbonyl]-amino}-propionic acid

281 3-{[1 -(4-Chloro-phenyl)-5-hydroxy-1 H-pyrazole-3-carbonyl]-amino}-3-(2,3- dichloro-phenyl)-propionic acid

282 (2R,3R)-3-{[1 -(4-Chloro-phenyl)-5-hydroxy-1 H-pyrazole-3-carbonyl]-amino}-2- hydroxy-3-(2-methoxy-phenyl)-propionic acid

283 (S)-3-{[1 -(4-Chloro-phenyl)-5-hydroxy-1 H-pyrazole-3-carbonyl]-amino}-3-(2,3- dimethoxy-phenyl)-propionic acid

284 (S)-3-{[1 -(4-Chloro-phenyl)-5-hydroxy-1 H-pyrazole-3-carbonyl]-amino}-3-m- tolyl-propionic acid

285 (S)-3-{[1 -(4-Chloro-phenyl)-5-hydroxy-1 H-pyrazole-3-carbonyl]-amino}-3-(3- trifluoromethyl-phenyl)-propionic acid

286 3-(4-Chloro-2-fluoro-phenyl)-3-{[1 -(4-chloro-phenyl)-5-hydroxy-1 H-pyrazole-3- carbonyl]-amino}-propionic acid

287 3-{[1 -(4-Chloro-phenyl)-5-hydroxy-1 H-pyrazole-3-carbonyl]-amino}-3-(2,3- dimethyl-phenyl)-propionic acid ExCompound Name

ample

288 3-(3-Chloro-2-fluoro-phenyl)-3-{[1 -(4-chloro-phenyl)-5-hydroxy-1 H-pyrazole-3- carbonyl]-amino}-propionic acid

289 3-{[1 -(4-Chloro-phenyl)-5-hydroxy-1 H-pyrazole-3-carbonyl]-amino}-3-(2- chloro-3-trifluoromethyl-phenyl)-propionic acid

290 3-[3-(4-Chloro-phenoxy)-phenyl]-3-{[1 -(4-chloro-phenyl)-5-hydroxy-1 H- pyrazole-3-carbonyl]-amino}-propionic acid

291 3-{[1 -(4-Chloro-phenyl)-5-hydroxy-1 H-pyrazole-3-carbonyl]-amino}-3-(2,4- dimethyl-phenyl)-propionic acid

292 3-{[1 -(4-Chloro-phenyl)-5-hydroxy-1 H-pyrazole-3-carbonyl]-amino}-3-(4- fluoro-2-methyl-phenyl)-propionic acid

293 (S)-3-{[1 -(4-Chloro-phenyl)-5-hydroxy-1 H-pyrazole-3-carbonyl]-amino}-3-(2- fluoro-phenyl)-propionic acid

294 3-{[1 -(4-Chloro-phenyl)-5-hydroxy-1 H-pyrazole-3-carbonyl]-amino}-3-(4- phenoxy-phenyl)-propionic acid

295 (S)-3-{[1 -(4-Chloro-phenyl)-5-hydroxy-1 H-pyrazole-3-carbonyl]-amino}-3-(2,6- difluoro-phenyl)-propionic acid

296 (S)-3-(4-Chloro-phenyl)-3-{[1 -(4-chloro-phenyl)-5-hydroxy-1 H-pyrazole-3- carbonyl]-amino}-propionic acid

297 (S)-3-{[1 -(4-Chloro-phenyl)-5-hydroxy-1 H-pyrazole-3-carbonyl]-amino}-3-(2,4- dichloro-phenyl)-propionic acid

298 (S)-3-{[1 -(4-Chloro-phenyl)-5-hydroxy-1 H-pyrazole-3-carbonyl]-amino}-3- pyridin-3-yl-propionic acid

299 (S)-3-{[1 -(4-Chloro-phenyl)-5-hydroxy-1 H-pyrazole-3-carbonyl]-amino}-3-(6- methoxy-pyridin-3-yl)-propionic acid

300 3-Benzo[1 ,3]dioxol-4-yl-3-{[1 -(3-fluoro-phenyl)-5-hydroxy-1 H-pyrazole-3- carbonyl]-amino}-propionic acid ExCompound Name

ample

301 3-(3-Chloro-phenyl)-3-{[1 -(3-fluoro-phenyl)-5-hydroxy-1 H-pyrazole-3- carbonyl]-amino}-propionic acid

302 (S)-3-(2-Bromo-phenyl)-3-{[1 -(3-fluoro-phenyl)-5-hydroxy-1 H-pyrazole-3- carbonyl]-amino}-propionic acid

303 (S)-3-(3-Cyano-phenyl)-3-{[1 -(3-fluoro-phenyl)-5-hydroxy-1 H-pyrazole-3- carbonyl]-amino}-propionic acid

304 3-{[1 -(3-Fluoro-phenyl)-5-hydroxy-1 H-pyrazole-3-carbonyl]-amino}-3-(3- trifluoromethyl-phenyl)-propionic acid

305 (S)-3-(4-Cyano-phenyl)-3-{[1 -(3-fluoro-phenyl)-5-hydroxy-1 H-pyrazole-3- carbonyl]-amino}-propionic acid

306 3-(2,4-Dimethoxy-phenyl)-3-{[1 -(3-fluoro-phenyl)-5-hydroxy-1 H-pyrazole-3- carbonyl]-amino}-propionic acid

307 (S)-3-{[1 -(3-Fluoro-phenyl)-5-hydroxy-1 H-pyrazole-3-carbonyl]-amino}-3-(2- methoxy-phenyl)-propionic acid

308 3-(2-Fluoro-phenyl)-3-{[1 -(3-fluoro-phenyl)-5-hydroxy-1 H-pyrazole-3- carbonyl]-amino}-propionic acid

309 3-(5-Chloro-2-methoxy-phenyl)-3-{[1 -(3-fluoro-phenyl)-5-hydroxy-1 H- pyrazole-3-carbonyl]-amino}-propionic acid

310 3-(2-Chloro-4-methoxy-phenyl)-3-{[1 -(3-fluoro-phenyl)-5-hydroxy-1 H- pyrazole-3-carbonyl]-amino}-propionic acid

31 1 (S)-3-(4-Fluoro-phenyl)-3-{[1 -(3-fluoro-phenyl)-5-hydroxy-1 H-pyrazole-3- carbonyl]-amino}-propionic acid

312 (S)-3-(3-Fluoro-phenyl)-3-{[1 -(3-fluoro-phenyl)-5-hydroxy-1 H-pyrazole-3- carbonyl]-amino}-propionic acid

313 (S)-3-{[1 -(3-Fluoro-phenyl)-5-hydroxy-1 H-pyrazole-3-carbonyl]-amino}-3-(4- trifluoromethyl-phenyl)-propionic acid ExCompound Name

ample

314 3-(2,3-Dichloro-phenyl)-3-{[1 -(3-fluoro-phenyl)-5-hydroxy-1 H-pyrazole-3- carbonyl]-amino}-propionic acid

315 3-{[1 -(3-Fluoro-phenyl)-5-hydroxy-1 H-pyrazole-3-carbonyl]-amino}-3-(4- trifluoromethoxy-phenyl)-propionic acid

316 (2R,3R)-3-{[1 -(3-Fluoro-phenyl)-5-hydroxy-1 H-pyrazole-3-carbonyl]-amino}-2- hydroxy-3-(2-methoxy-phenyl)-propionic acid

317 (S)-3-{[1 -(3-Fluoro-phenyl)-5-hydroxy-1 H-pyrazole-3-carbonyl]-amino}-3-m- tolyl-propionic acid

318 (S)-3-{[1 -(3-Fluoro-phenyl)-5-hydroxy-1 H-pyrazole-3-carbonyl]-amino}-3-(3- trifluoromethyl-phenyl)-propionic acid

319 3-(3'-Fluoro-biphenyl-4-yl)-3-{[1 -(3-fluoro-phenyl)-5-hydroxy-1 H-pyrazole-3- carbonyl]-amino}-propionic acid

320 3-(4-Chloro-2-fluoro-phenyl)-3-{[1 -(3-fluoro-phenyl)-5-hydroxy-1 H-pyrazole-3- carbonyl]-amino}-propionic acid

321 3-(2,5-Dimethyl-phenyl)-3-{[1 -(3-fluoro-phenyl)-5-hydroxy-1 H-pyrazole-3- carbonyl]-amino}-propionic acid

322 3-(3-Chloro-2-fluoro-phenyl)-3-{[1 -(3-fluoro-phenyl)-5-hydroxy-1 H-pyrazole-3- carbonyl]-amino}-propionic acid

323 3-(2-Chloro-3-trifluoromethyl-phenyl)-3-{[1 -(3-fluoro-phenyl)-5-hydroxy-1 H- pyrazole-3-carbonyl]-amino}-propionic acid

324 3-(4-Ethyl-phenyl)-3-{[1 -(3-fluoro-phenyl)-5-hydroxy-1 H-pyrazole-3-carbonyl]- amino}-propionic acid

325 3-(2,4-Dimethyl-phenyl)-3-{[1 -(3-fluoro-phenyl)-5-hydroxy-1 H-pyrazole-3- carbonyl]-amino}-propionic acid

326 3-(4-Fluoro-2-methyl-phenyl)-3-{[1 -(3-fluoro-phenyl)-5-hydroxy-1 H-pyrazole-3- carbonyl]-amino}-propionic acid ExCompound Name

ample

327 3-Biphenyl-4-yl-3-{[1 -(3-fluoro-phenyl)-5-hydroxy-1 H-pyrazole-3-carbonyl]- amino}-propionic acid

328 3-(3,4-Dichloro-phenyl)-3-{[1 -(3-fluoro-phenyl)-5-hydroxy-1 H-pyrazole-3- carbonyl]-amino}-propionic acid

329 (S)-3-{[1 -(3-Fluoro-phenyl)-5-hydroxy-1 H-pyrazole-3-carbonyl]-amino}-3-(2- trifluoromethyl-phenyl)-propionic acid

330 3-{[1 -(3-Fluoro-phenyl)-5-hydroxy-1 H-pyrazole-3-carbonyl]-amino}-3-(4- phenoxy-phenyl)-propionic acid

331 (S)-3-(4-Chloro-phenyl)-3-{[1 -(3-fluoro-phenyl)-5-hydroxy-1 H-pyrazole-3- carbonyl]-amino}-propionic acid

332 (S)-3-(2,4-Dichloro-phenyl)-3-{[1 -(3-fluoro-phenyl)-5-hydroxy-1 H-pyrazole-3- carbonyl]-amino}-propionic acid

333 3-(4'-Fluoro-biphenyl-4-yl)-3-{[1 -(3-fluoro-phenyl)-5-hydroxy-1 H-pyrazole-3- carbonyl]-amino}-propionic acid

334 (S)-3-{[1 -(3-Fluoro-phenyl)-5-hydroxy-1 H-pyrazole-3-carbonyl]-amino}-3- pyridin-3-yl-propionic acid

335 (S)-3-{[1 -(3-Fluoro-phenyl)-5-hydroxy-1 H-pyrazole-3-carbonyl]-amino}-3-(6- methoxy-pyridin-3-yl)-propionic acid

336 3-Benzo[1 ,3]dioxol-4-yl-3-{[1 -(4-fluoro-phenyl)-5-hydroxy-1 H-pyrazole-3- carbonyl]-amino}-propionic acid

337 3-{[1 -(4-Fluoro-phenyl)-5-hydroxy-1 H-pyrazole-3-carbonyl]-amino}-3-(4- methoxy-2-methyl-phenyl)-propionic acid

338 3-(3-Chloro-phenyl)-3-{[1 -(4-fluoro-phenyl)-5-hydroxy-1 H-pyrazole-3- carbonyl]-amino}-propionic acid

339 (S)-3-(2-Bromo-phenyl)-3-{[1 -(4-fluoro-phenyl)-5-hydroxy-1 H-pyrazole-3- carbonyl]-amino}-propionic acid ExCompound Name

ample

340 (S)-3-(3-Cyano-phenyl)-3-{[1 -(4-fluoro-phenyl)-5-hydroxy-1 H-pyrazole-3- carbonyl]-amino}-propionic acid

341 (S)-3-(4-Cyano-phenyl)-3-{[1 -(4-fluoro-phenyl)-5-hydroxy-1 H-pyrazole-3- carbonyl]-amino}-propionic acid

342 (S)-3-{[1 -(4-Fluoro-phenyl)-5-hydroxy-1 H-pyrazole-3-carbonyl]-amino}-3-(2- methoxy-phenyl)-propionic acid

343 3-(2-Fluoro-phenyl)-3-{[1 -(4-fluoro-phenyl)-5-hydroxy-1 H-pyrazole-3- carbonyl]-amino}-propionic acid

344 3-(5-Chloro-2-methoxy-phenyl)-3-{[1 -(4-fluoro-phenyl)-5-hydroxy-1 H- pyrazole-3-carbonyl]-amino}-propionic acid

345 3-(2-Chloro-4-methoxy-phenyl)-3-{[1 -(4-fluoro-phenyl)-5-hydroxy-1 H- pyrazole-3-carbonyl]-amino}-propionic acid

346 (S)-3-(4-Fluoro-phenyl)-3-{[1 -(4-fluoro-phenyl)-5-hydroxy-1 H-pyrazole-3- carbonyl]-amino}-propionic acid

347 (S)-3-(2,3-Dichloro-phenyl)-3-{[1 -(4-fluoro-phenyl)-5-hydroxy-1 H-pyrazole-3- carbonyl]-amino}-propionic acid

348 (S)-3-{[1 -(4-Fluoro-phenyl)-5-hydroxy-1 H-pyrazole-3-carbonyl]-amino}-3-(3- methoxy-phenyl)-propionic acid

349 (S)-3-(3-Fluoro-phenyl)-3-{[1 -(4-fluoro-phenyl)-5-hydroxy-1 H-pyrazole-3- carbonyl]-amino}-propionic acid

350 (S)-3-(3-Chloro-phenyl)-3-{[1 -(4-fluoro-phenyl)-5-hydroxy-1 H-pyrazole-3- carbonyl]-amino}-propionic acid

351 (S)-3-{[1 -(4-Fluoro-phenyl)-5-hydroxy-1 H-pyrazole-3-carbonyl]-amino}-3-(4- trifluoromethyl-phenyl)-propionic acid

352 3-(2,3-Dichloro-phenyl)-3-{[1 -(4-fluoro-phenyl)-5-hydroxy-1 H-pyrazole-3- carbonyl]-amino}-propionic acid ExCompound Name

ample

353 (S)-3-(2,3-Dimethoxy-phenyl)-3-{[1 -(4-fluoro-phenyl)-5-hydroxy-1 H-pyrazole- 3-carbonyl]-amino}-propionic acid

354 (S)-3-{[1 -(4-Fluoro-phenyl)-5-hydroxy-1 H-pyrazole-3-carbonyl]-amino}-3-m- tolyl-propionic acid

355 (S)-3-{[1 -(4-Fluoro-phenyl)-5-hydroxy-1 H-pyrazole-3-carbonyl]-amino}-3-(3- trifluoromethyl-phenyl)-propionic acid

356 3-(3'-Fluoro-biphenyl-4-yl)-3-{[1 -(4-fluoro-phenyl)-5-hydroxy-1 H-pyrazole-3- carbonyl]-amino}-propionic acid

357 3-(4-Chloro-2-fluoro-phenyl)-3-{[1 -(4-fluoro-phenyl)-5-hydroxy-1 H-pyrazole-3- carbonyl]-amino}-propionic acid

358 3-(2,3-Dimethyl-phenyl)-3-{[1 -(4-fluoro-phenyl)-5-hydroxy-1 H-pyrazole-3- carbonyl]-amino}-propionic acid

359 3-(2,5-Dimethyl-phenyl)-3-{[1 -(4-fluoro-phenyl)-5-hydroxy-1 H-pyrazole-3- carbonyl]-amino}-propionic acid

360 3-{[1 -(4-Fluoro-phenyl)-5-hydroxy-1 H-pyrazole-3-carbonyl]-amino}-3-(2-fluoro- 3-trifluoromethyl-phenyl)-propionic acid

361 3-(3-Chloro-2-fluoro-phenyl)-3-{[1 -(4-fluoro-phenyl)-5-hydroxy-1 H-pyrazole-3- carbonyl]-amino}-propionic acid

362 3-(2-Chloro-3-trifluoromethyl-phenyl)-3-{[1 -(4-fluoro-phenyl)-5-hydroxy-1 H- pyrazole-3-carbonyl]-amino}-propionic acid

363 3-(4-Ethyl-phenyl)-3-{[1 -(4-fluoro-phenyl)-5-hydroxy-1 H-pyrazole-3-carbonyl]- amino}-propionic acid

364 3-(4-Fluoro-2-methyl-phenyl)-3-{[1 -(4-fluoro-phenyl)-5-hydroxy-1 H-pyrazole-3- carbonyl]-amino}-propionic acid

365 3-Biphenyl-4-yl-3-{[1 -(4-fluoro-phenyl)-5-hydroxy-1 H-pyrazole-3-carbonyl]- amino}-propionic acid ExCompound Name

ample

366 (S)-3-(2-Fluoro-phenyl)-3-{[1 -(4-fluoro-phenyl)-5-hydroxy-1 H-pyrazole-3- carbonyl]-amino}-propionic acid

367 (S)-3-{[1 -(4-Fluoro-phenyl)-5-hydroxy-1 H-pyrazole-3-carbonyl]-amino}-3-(2- trifluoromethyl-phenyl)-propionic acid

368 (S)-3-(2,6-Difluoro-phenyl)-3-{[1 -(4-fluoro-phenyl)-5-hydroxy-1 H-pyrazole-3- carbonyl]-amino}-propionic acid

369 (S)-3-(4-Chloro-phenyl)-3-{[1 -(4-fluoro-phenyl)-5-hydroxy-1 H-pyrazole-3- carbonyl]-amino}-propionic acid

370 (S)-3-(2,4-Dichloro-phenyl)-3-{[1 -(4-fluoro-phenyl)-5-hydroxy-1 H-pyrazole-3- carbonyl]-amino}-propionic acid

371 3-(4'-Fluoro-biphenyl-4-yl)-3-{[1 -(4-fluoro-phenyl)-5-hydroxy-1 H-pyrazole-3- carbonyl]-amino}-propionic acid

372 (S)-3-{[1 -(4-Fluoro-phenyl)-5-hydroxy-1 H-pyrazole-3-carbonyl]-amino}-3- pyridin-3-yl-propionic acid

373 3-[(5-Hydroxy-1 -phenyl-1 H-pyrazole-3-carbonyl)-amino]-3-(4-methoxy-2- methyl-phenyl)-propionic acid

374 (S)-3-[(5-Hydroxy-1 -phenyl-1 H-pyrazole-3-carbonyl)-amino]-3-(4-methoxy- phenyl)-propionic acid

375 3-(5-Chloro-2-methoxy-phenyl)-3-[(5-hydroxy-1 -phenyl-1 H-pyrazole-3- carbonyl)-amino]-propionic acid

376 (S)-3-[(5-Hydroxy-1 -phenyl-1 H-pyrazole-3-carbonyl)-amino]-3-m-tolyl- propionic acid

377 3-(2,3-Dimethyl-phenyl)-3-[(5-hydroxy-1 -phenyl-1 H-pyrazole-3-carbonyl)- amino]-propionic acid

378 3-(2,5-Dimethyl-phenyl)-3-[(5-hydroxy-1 -phenyl-1 H-pyrazole-3-carbonyl)- amino]-propionic acid ExCompound Name

ample

379 3-{[1 -(2,4-Difluoro-phenyl)-5-hydroxy-1 H-pyrazole-3-carbonyl]-amino}-3-(4- methoxy-2-methyl-phenyl)-propionic acid

380 3-(3-Chloro-phenyl)-3-{[1 -(2,4-difluoro-phenyl)-5-hydroxy-1 H-pyrazole-3- carbonyl]-amino}-propionic acid

381 (S)-3-(3-Cyano-phenyl)-3-{[1 -(2,4-difluoro-phenyl)-5-hydroxy-1 H-pyrazole-3- carbonyl]-amino}-propionic acid

382 (S)-3-{[1 -(2,4-Difluoro-phenyl)-5-hydroxy-1 H-pyrazole-3-carbonyl]-amino}-3- (4-methoxy-phenyl)-propionic acid

383 3-{[1 -(2,4-Difluoro-phenyl)-5-hydroxy-1 H-pyrazole-3-carbonyl]-amino}-3-(2,4- dimethoxy-phenyl)-propionic acid

384 3-{[1 -(2,4-Difluoro-phenyl)-5-hydroxy-1 H-pyrazole-3-carbonyl]-amino}-3-(3'- fluoro-biphenyl-4-yl)-propionic acid

385 3-{[1 -(2,4-Difluoro-phenyl)-5-hydroxy-1 H-pyrazole-3-carbonyl]-amino}-3-(2- fluoro-3-trifluoromethyl-phenyl)-propionic acid

386 3-[3-(4-Chloro-phenoxy)-phenyl]-3-{[1 -(2,4-difluoro-phenyl)-5-hydroxy-1 H- pyrazole-3-carbonyl]-amino}-propionic acid

387 (S)-3-{[1 -(2,4-Difluoro-phenyl)-5-hydroxy-1 H-pyrazole-3-carbonyl]-amino}-3- (2-fluoro-phenyl)-propionic acid

388 (S)-3-(2,6-Difluoro-phenyl)-3-{[1 -(2,4-difluoro-phenyl)-5-hydroxy-1 H-pyrazole- 3-carbonyl]-amino}-propionic acid

389 (S)-3-{[1 -(2,4-Difluoro-phenyl)-5-hydroxy-1 H-pyrazole-3-carbonyl]-amino}-3- pyridin-3-yl-propionic acid

390 (S)-3-{[1 -(2,4-Difluoro-phenyl)-5-hydroxy-1 H-pyrazole-3-carbonyl]-amino}-3- (6-methoxy-pyridin-3-yl)-propionic acid

391 3-(3-Chloro-phenyl)-3-{[1 -(2-chloro-phenyl)-5-hydroxy-1 H-pyrazole-3- carbonyl]-amino}-propionic acid ExCompound Name

ample

392 (S)-3-{[1 -(2-Chloro-phenyl)-5-hydroxy-1 H-pyrazole-3-carbonyl]-amino}-3-(4- methoxy-phenyl)-propionic acid

393 (S)-3-{[1 -(2-Chloro-phenyl)-5-hydroxy-1 H-pyrazole-3-carbonyl]-amino}-3-(3- fluoro-phenyl)-propionic acid

394 (S)-3-{[1 -(2-Chloro-phenyl)-5-hydroxy-1 H-pyrazole-3-carbonyl]-amino}-3-(2,3- dimethoxy-phenyl)-propionic acid

395 3-{[1 -(2-Fluoro-phenyl)-5-hydroxy-1 H-pyrazole-3-carbonyl]-amino}-3-(4- methoxy-2-methyl-phenyl)-propionic acid

396 3-(3-Chloro-phenyl)-3-{[1 -(2-fluoro-phenyl)-5-hydroxy-1 H-pyrazole-3- carbonyl]-amino}-propionic acid

397 (S)-3-(2-Bromo-phenyl)-3-{[1 -(2-fluoro-phenyl)-5-hydroxy-1 H-pyrazole-3- carbonyl]-amino}-propionic acid

398 (S)-3-{[1 -(2-Fluoro-phenyl)-5-hydroxy-1 H-pyrazole-3-carbonyl]-amino}-3-(4- methoxy-phenyl)-propionic acid

399 (S)-3-(2,3-Dichloro-phenyl)-3-{[1 -(2-fluoro-phenyl)-5-hydroxy-1 H-pyrazole-3- carbonyl]-amino}-propionic acid

400 (S)-3-(3-Fluoro-phenyl)-3-{[1 -(2-fluoro-phenyl)-5-hydroxy-1 H-pyrazole-3- carbonyl]-amino}-propionic acid

401 (S)-3-(3-Chloro-phenyl)-3-{[1 -(2-fluoro-phenyl)-5-hydroxy-1 H-pyrazole-3- carbonyl]-amino}-propionic acid

402 3-(2,3-Dichloro-phenyl)-3-{[1 -(2-fluoro-phenyl)-5-hydroxy-1 H-pyrazole-3- carbonyl]-amino}-propionic acid

403 (S)-3-(2,3-Dimethoxy-phenyl)-3-{[1 -(2-fluoro-phenyl)-5-hydroxy-1 H-pyrazole- 3-carbonyl]-amino}-propionic acid

404 (S)-3-{[1 -(2-Fluoro-phenyl)-5-hydroxy-1 H-pyrazole-3-carbonyl]-amino}-3-m- tolyl-propionic acid ExCompound Name

ample

405 3-(2,3-Dimethyl-phenyl)-3-{[1 -(2-fluoro-phenyl)-5-hydroxy-1 H-pyrazole-3- carbonyl]-amino}-propionic acid

406 3-(2,5-Dimethyl-phenyl)-3-{[1 -(2-fluoro-phenyl)-5-hydroxy-1 H-pyrazole-3- carbonyl]-amino}-propionic acid

407 3-(3,4-Dichloro-phenyl)-3-{[1 -(2-fluoro-phenyl)-5-hydroxy-1 H-pyrazole-3- carbonyl]-amino}-propionic acid

408 3-(3-Chloro-phenyl)-3-{[1 -(3-chloro-phenyl)-5-hydroxy-1 H-pyrazole-3- carbonyl]-amino}-propionic acid

409 (S)-3-{[1 -(3-Chloro-phenyl)-5-hydroxy-1 H-pyrazole-3-carbonyl]-amino}-3-(4- methoxy-phenyl)-propionic acid

410 (S)-3-{[1 -(3-Chloro-phenyl)-5-hydroxy-1 H-pyrazole-3-carbonyl]-amino}-3-(4- cyano-phenyl)-propionic acid

41 1 (S)-3-{[1 -(3-Chloro-phenyl)-5-hydroxy-1 H-pyrazole-3-carbonyl]-amino}-3-(4- fluoro-phenyl)-propionic acid

412 (S)-3-{[1 -(3-Chloro-phenyl)-5-hydroxy-1 H-pyrazole-3-carbonyl]-amino}-3-(2,3- dichloro-phenyl)-propionic acid

413 (S)-3-{[1 -(3-Chloro-phenyl)-5-hydroxy-1 H-pyrazole-3-carbonyl]-amino}-3-(3- methoxy-phenyl)-propionic acid

414 (S)-3-{[1 -(3-Chloro-phenyl)-5-hydroxy-1 H-pyrazole-3-carbonyl]-amino}-3-(3- fluoro-phenyl)-propionic acid

415 (S)-3-(3-Chloro-phenyl)-3-{[1 -(3-chloro-phenyl)-5-hydroxy-1 H-pyrazole-3- carbonyl]-amino}-propionic acid

416 (2R,3R)-3-{[1 -(3-Chloro-phenyl)-5-hydroxy-1 H-pyrazole-3-carbonyl]-amino}-2- hydroxy-3-(2-methoxy-phenyl)-propionic acid

417 (S)-3-{[1 -(3-Chloro-phenyl)-5-hydroxy-1 H-pyrazole-3-carbonyl]-amino}-3-(2,3- dimethoxy-phenyl)-propionic acid ExCompound Name

ample

418 3-{[1 -(3-Chloro-phenyl)-5-hydroxy-1 H-pyrazole-3-carbonyl]-amino}-3-(2- fluoro-3-trifluoromethyl-phenyl)-propionic acid

419 3-{[1 -(3-Chloro-phenyl)-5-hydroxy-1 H-pyrazole-3-carbonyl]-amino}-3-(2,4- dimethyl-phenyl)-propionic acid

420 3-{[1 -(3-Chloro-phenyl)-5-hydroxy-1 H-pyrazole-3-carbonyl]-amino}-3-(4- fluoro-2-methyl-phenyl)-propionic acid

421 3-Biphenyl-4-yl-3-{[1 -(3-chloro-phenyl)-5-hydroxy-1 H-pyrazole-3-carbonyl]- amino}-propionic acid

422 (S)-3-{[1 -(3-Chloro-phenyl)-5-hydroxy-1 H-pyrazole-3-carbonyl]-amino}-3-(2- fluoro-phenyl)-propionic acid

423 (S)-3-{[1 -(4-Chloro-phenyl)-5-hydroxy-1 H-pyrazole-3-carbonyl]-amino}-3-(4- methoxy-phenyl)-propionic acid

424 3-(2-Chloro-4-methoxy-phenyl)-3-{[1 -(4-chloro-phenyl)-5-hydroxy-1 H- pyrazole-3-carbonyl]-amino}-propionic acid

425 3-{[1 -(4-Chloro-phenyl)-5-hydroxy-1 H-pyrazole-3-carbonyl]-amino}-3-(4'- fluoro-biphenyl-4-yl)-propionic acid

426 3-{[1 -(3-Fluoro-phenyl)-5-hydroxy-1 H-pyrazole-3-carbonyl]-amino}-3-(4- methoxy-2-methyl-phenyl)-propionic acid

427 (S)-3-{[1 -(3-Fluoro-phenyl)-5-hydroxy-1 H-pyrazole-3-carbonyl]-amino}-3-(4- methoxy-phenyl)-propionic acid

428 (S)-3-(2,3-Dichloro-phenyl)-3-{[1 -(3-fluoro-phenyl)-5-hydroxy-1 H-pyrazole-3- carbonyl]-amino}-propionic acid

429 (S)-3-{[1 -(3-Fluoro-phenyl)-5-hydroxy-1 H-pyrazole-3-carbonyl]-amino}-3-(3- methoxy-phenyl)-propionic acid

430 (S)-3-(3-Chloro-phenyl)-3-{[1 -(3-fluoro-phenyl)-5-hydroxy-1 H-pyrazole-3- carbonyl]-amino}-propionic acid ExCompound Name

ample

431 (S)-3-(2,3-Dimethoxy-phenyl)-3-{[1 -(3-fluoro-phenyl)-5-hydroxy-1 H-pyrazole- 3-carbonyl]-amino}-propionic acid

432 3-(2,3-Dimethyl-phenyl)-3-{[1 -(3-fluoro-phenyl)-5-hydroxy-1 H-pyrazole-3- carbonyl]-amino}-propionic acid

433 (S)-3-(2-Fluoro-phenyl)-3-{[1 -(3-fluoro-phenyl)-5-hydroxy-1 H-pyrazole-3- carbonyl]-amino}-propionic acid

434 (S)-3-(2,6-Difluoro-phenyl)-3-{[1 -(3-fluoro-phenyl)-5-hydroxy-1 H-pyrazole-3- carbonyl]-amino}-propionic acid

435 (S)-3-{[1 -(4-Fluoro-phenyl)-5-hydroxy-1 H-pyrazole-3-carbonyl]-amino}-3-(4- methoxy-phenyl)-propionic acid

436 3-(2,4-Dimethoxy-phenyl)-3-{[1 -(4-fluoro-phenyl)-5-hydroxy-1 H-pyrazole-3- carbonyl]-amino}-propionic acid

437 3-{[1 -(4-Fluoro-phenyl)-5-hydroxy-1 H-pyrazole-3-carbonyl]-amino}-3-(4- phenoxy-phenyl)-propionic acid

438 (S)-3-{[1 -(4-Fluoro-phenyl)-5-hydroxy-1 H-pyrazole-3-carbonyl]-amino}-3-(6- methoxy-pyridin-3-yl)-propionic acid

439 3-Biphenyl-4-yl-3-{[1 -(2-chloro-pyridin-4-yl)-5-hydroxy-1 H-pyrazole-3- carbonyl]-amino}-propionic acid

440 3-Biphenyl-4-yl-3-[(5-hydroxy-1 -pyridin-3-yl-1 H-pyrazole-3-carbonyl)-amino]- propionic acid

441 3-(2-Fluoro-6-methoxy-phenyl)-3-[(5-hydroxy-1 -phenyl-1 H-pyrazole-3- carbonyl)-amino]-propionic acid

442 3-[(5-Hydroxy-1 -phenyl-1 H-pyrazole-3-carbonyl)-amino]-3-(2-phenoxy- phenyl)-propionic acid

443 3-(5-Fluoro-2-trifluoromethyl-phenyl)-3-[(5-hydroxy-1 -phenyl-1 H-pyrazole-3- carbonyl)-amino]-propionic acid ExCompound Name

ample

444 3-(2,5-Dichloro-phenyl)-3-[(5-hydroxy-1 -phenyl-1 H-pyrazole-3-carbonyl)- amino]-propionic acid

445 (S)-3-[(5-Hydroxy-1 -phenyl-1 H-pyrazole-3-carbonyl)-amino]-3-p-tolyl- propionic acid

446 (S)-3-(2-Chloro-phenyl)-3-[(5-hydroxy-1 -phenyl-1 H-pyrazole-3-carbonyl)- amino]-propionic acid

447 3-{[1 -(2,4-Difluoro-phenyl)-5-hydroxy-1 H-pyrazole-3-carbonyl]-amino}-3-(3- fluoro-2-methyl-phenyl)-propionic acid

448 3-(2-Chloro-4-dimethylamino-phenyl)-3-{[1 -(2,4-difluoro-phenyl)-5-hydroxy- 1 H-pyrazole-3-carbonyl]-amino}-propionic acid

449 3-{[1 -(2,4-Difluoro-phenyl)-5-hydroxy-1 H-pyrazole-3-carbonyl]-amino}-3-(2- fluoro-6-methoxy-phenyl)-propionic acid

450 3-(2,2-Difluoro-benzo[1 ,3]dioxol-4-yl)-3-{[1 -(2,4-difluoro-phenyl)-5-hydroxy- 1 H-pyrazole-3-carbonyl]-amino}-propionic acid

451 3-(2,5-Difluoro-phenyl)-3-{[1 -(2,4-difluoro-phenyl)-5-hydroxy-1 H-pyrazole-3- carbonyl]-amino}-propionic acid

452 3-{[1 -(2,4-Difluoro-phenyl)-5-hydroxy-1 H-pyrazole-3-carbonyl]-amino}-3-(5- fluoro-2-trifluoromethyl-phenyl)-propionic acid

453 3-{[1 -(2,4-Difluoro-phenyl)-5-hydroxy-1 H-pyrazole-3-carbonyl]-amino}-3-(5- fluoro-2-methoxy-phenyl)-propionic acid

454 (S)-3-{[1 -(2,4-Difluoro-phenyl)-5-hydroxy-1 H-pyrazole-3-carbonyl]-amino}-3-p- tolyl-propionic acid

455 3-{[1 -(2-Chloro-phenyl)-5-hydroxy-1 H-pyrazole-3-carbonyl]-amino}-3-(3- fluoro-2-methyl-phenyl)-propionic acid ExCompound Name

ample

456 3-(2-Chloro-4-dimethylamino-phenyl)-3-{[1 -(2-chloro-phenyl)-5-hydroxy-1 H- pyrazole-3-carbonyl]-amino}-propionic acid; compound with trifluoro-acetic acid

457 3-{[1 -(2-Chloro-phenyl)-5-hydroxy-1 H-pyrazole-3-carbonyl]-amino}-3-(2- fluoro-6-methoxy-phenyl)-propionic acid

458 3-(2-Chloro-5-fluoro-phenyl)-3-{[1 -(2-chloro-phenyl)-5-hydroxy-1 H-pyrazole-3- carbonyl]-amino}-propionic acid

459 3-{[1 -(2-Chloro-phenyl)-5-hydroxy-1 H-pyrazole-3-carbonyl]-amino}-3-(2,5- difluoro-phenyl)-propionic acid

460 3-{[1 -(2-Chloro-phenyl)-5-hydroxy-1 H-pyrazole-3-carbonyl]-amino}-3-(5- fluoro-2-thfluoromethyl-phenyl)-propionic acid

461 3-{[1 -(2-Chloro-phenyl)-5-hydroxy-1 H-pyrazole-3-carbonyl]-amino}-3-(5- fluoro-2-methyl-phenyl)-propionic acid

462 3-{[1 -(2-Chloro-phenyl)-5-hydroxy-1 H-pyrazole-3-carbonyl]-amino}-3-(2,5- dichloro-phenyl)-propionic acid

463 3-(2-Chloro-4-dimethylamino-phenyl)-3-{[1 -(3-chloro-phenyl)-5-hydroxy-1 H- pyrazole-3-carbonyl]-amino}-propionic acid

464 3-{[1 -(3-Chloro-phenyl)-5-hydroxy-1 H-pyrazole-3-carbonyl]-amino}-3-(2,2- difluoro-benzo[1 ,3]dioxol-4-yl)-propionic acid

465 3-{[1 -(3-Chloro-phenyl)-5-hydroxy-1 H-pyrazole-3-carbonyl]-amino}-3-(2,5- difluoro-phenyl)-propionic acid

466 3-{[1 -(3-Chloro-phenyl)-5-hydroxy-1 H-pyrazole-3-carbonyl]-amino}-3-(5- fluoro-2-thfluoromethyl-phenyl)-propionic acid

467 3-{[1 -(3-Chloro-phenyl)-5-hydroxy-1 H-pyrazole-3-carbonyl]-amino}-3-(2- trifluoromethylsulfanyl-phenyl)-propionic acid ExCompound Name

ample

468 3-{[1 -(4-Chloro-phenyl)-5-hydroxy-1 H-pyrazole-3-carbonyl]-amino}-3-(3- fluoro-2-methyl-phenyl)-propionic acid

469 3-{[1 -(4-Chloro-phenyl)-5-hydroxy-1 H-pyrazole-3-carbonyl]-amino}-3-(2- fluoro-6-methoxy-phenyl)-propionic acid

470 3-(2-Chloro-5-fluoro-phenyl)-3-{[1 -(4-chloro-phenyl)-5-hydroxy-1 H-pyrazole-3- carbonyl]-amino}-propionic acid

471 3-{[1 -(4-Chloro-phenyl)-5-hydroxy-1 H-pyrazole-3-carbonyl]-amino}-3-(2,2- difluoro-benzo[1 ,3]dioxol-4-yl)-propionic acid

472 3-{[1 -(4-Chloro-phenyl)-5-hydroxy-1 H-pyrazole-3-carbonyl]-amino}-3-(2,5- difluoro-phenyl)-propionic acid

473 3-{[1 -(4-Chloro-phenyl)-5-hydroxy-1 H-pyrazole-3-carbonyl]-amino}-3-(5- fluoro-2-trifluoromethyl-phenyl)-propionic acid

474 (S)-3-(2-Chloro-phenyl)-3-{[1 -(4-chloro-phenyl)-5-hydroxy-1 H-pyrazole-3- carbonyl]-amino}-propionic acid

475 3-(2-Chloro-5-fluoro-phenyl)-3-{[1 -(2-fluoro-phenyl)-5-hydroxy-1 H-pyrazole-3- carbonyl]-amino}-propionic acid

476 3-(2,2-Difluoro-benzo[1 ,3]dioxol-4-yl)-3-{[1 -(2-fluoro-phenyl)-5-hydroxy-1 H- pyrazole-3-carbonyl]-amino}-propionic acid

477 3-{[1 -(2-Fluoro-phenyl)-5-hydroxy-1 H-pyrazole-3-carbonyl]-amino}-3-(5-fluoro- 2-trifluoromethyl-phenyl)-propionic acid

478 3-(5-Fluoro-2-methyl-phenyl)-3-{[1 -(2-fluoro-phenyl)-5-hydroxy-1 H-pyrazole-3- carbonyl]-amino}-propionic acid

479 3-(2,5-Dichloro-phenyl)-3-{[1 -(2-fluoro-phenyl)-5-hydroxy-1 H-pyrazole-3- carbonyl]-amino}-propionic acid

480 (S)-3-{[1 -(2-Fluoro-phenyl)-5-hydroxy-1 H-pyrazole-3-carbonyl]-amino}-3-p- tolyl-propionic acid ExCompound Name

ample

481 3-{[1 -(2-Fluoro-phenyl)-5-hydroxy-1 H-pyrazole-3-carbonyl]-amino}-3-(4- pyridin-2-yl-phenyl)-propionic acid

482 3-(3-Fluoro-2-methyl-phenyl)-3-{[1 -(3-fluoro-phenyl)-5-hydroxy-1 H-pyrazole-3- carbonyl]-amino}-propionic acid

483 3-(2-Chloro-5-fluoro-phenyl)-3-{[1 -(3-fluoro-phenyl)-5-hydroxy-1 H-pyrazole-3- carbonyl]-amino}-propionic acid

484 3-(2,2-Difluoro-benzo[1 ,3]dioxol-4-yl)-3-{[1 -(3-fluoro-phenyl)-5-hydroxy-1 H- pyrazole-3-carbonyl]-amino}-propionic acid

485 3-(2,5-Difluoro-phenyl)-3-{[1 -(3-fluoro-phenyl)-5-hydroxy-1 H-pyrazole-3- carbonyl]-amino}-propionic acid

486 3-{[1 -(3-Fluoro-phenyl)-5-hydroxy-1 H-pyrazole-3-carbonyl]-amino}-3-(5-fluoro- 2-trifluoromethyl-phenyl)-propionic acid

487 3-(5-Fluoro-2-methyl-phenyl)-3-{[1 -(3-fluoro-phenyl)-5-hydroxy-1 H-pyrazole-3- carbonyl]-amino}-propionic acid

488 3-(2,5-Dichloro-phenyl)-3-{[1 -(3-fluoro-phenyl)-5-hydroxy-1 H-pyrazole-3- carbonyl]-amino}-propionic acid

489 (S)-3-{[1 -(3-Fluoro-phenyl)-5-hydroxy-1 H-pyrazole-3-carbonyl]-amino}-3-p- tolyl-propionic acid

490 3-(2-Chloro-4-dimethylamino-phenyl)-3-{[1 -(4-fluoro-phenyl)-5-hydroxy-1 H- pyrazole-3-carbonyl]-amino}-propionic acid

491 3-(2,2-Difluoro-benzo[1 ,3]dioxol-4-yl)-3-{[1 -(4-fluoro-phenyl)-5-hydroxy-1 H- pyrazole-3-carbonyl]-amino}-propionic acid

492 3-(5-Fluoro-2-methyl-phenyl)-3-{[1 -(4-fluoro-phenyl)-5-hydroxy-1 H-pyrazole-3- carbonyl]-amino}-propionic acid

493 3-(2,5-Dichloro-phenyl)-3-{[1 -(4-fluoro-phenyl)-5-hydroxy-1 H-pyrazole-3- carbonyl]-amino}-propionic acid ExCompound Name

ample

494 3-(3-Fluoro-2-methyl-phenyl)-3-[(5-hydroxy-1 -phenyl-1 H-pyrazole-3- carbonyl)-amino]-propionic acid

495 3-(2-Chloro-5-fluoro-phenyl)-3-[(5-hydroxy-1 -phenyl-1 H-pyrazole-3-carbonyl)- amino]-propionic acid

496 3-(2,2-Difluoro-benzo[1 ,3]dioxol-4-yl)-3-[(5-hydroxy-1 -phenyl-1 H-pyrazole-3- carbonyl)-amino]-propionic acid

497 3-(5-Fluoro-2-methyl-phenyl)-3-[(5-hydroxy-1 -phenyl-1 H-pyrazole-3- carbonyl)-amino]-propionic acid

498 3-(5-Fluoro-2-methoxy-phenyl)-3-[(5-hydroxy-1 -phenyl-1 H-pyrazole-3- carbonyl)-amino]-propionic acid

499 3-[(5-Hydroxy-1 -phenyl-1 H-pyrazole-3-carbonyl)-amino]-3-(4-pyridin-2-yl- phenyl)-propionic acid; compound with trifluoro-acetic acid

500 3-(2,5-Dichloro-phenyl)-3-{[1 -(2,4-difluoro-phenyl)-5-hydroxy-1 H-pyrazole-3- carbonyl]-amino}-propionic acid

501 3-{[1 -(2,4-Difluoro-phenyl)-5-hydroxy-1 H-pyrazole-3-carbonyl]-amino}-3-(4- pyridin-2-yl-phenyl)-propionic acid; compound with trifluoro-acetic acid

502 (S)-3-(2-Chloro-phenyl)-3-{[1 -(2,4-difluoro-phenyl)-5-hydroxy-1 H-pyrazole-3- carbonyl]-amino}-propionic acid

503 3-{[1 -(2-Chloro-phenyl)-5-hydroxy-1 H-pyrazole-3-carbonyl]-amino}-3-(2,2- difluoro-benzo[1 ,3]dioxol-4-yl)-propionic acid

504 3-{[1 -(2-Chloro-phenyl)-5-hydroxy-1 H-pyrazole-3-carbonyl]-amino}-3-(5- fluoro-2-methoxy-phenyl)-propionic acid

505 3-{[1 -(2-Chloro-phenyl)-5-hydroxy-1 H-pyrazole-3-carbonyl]-amino}-3-(4- morpholin-4-yl-phenyl)-propionic acid

506 3-{[1 -(2-Chloro-phenyl)-5-hydroxy-1 H-pyrazole-3-carbonyl]-amino}-3-(4- pyridin-2-yl-phenyl)-propionic acid ExCompound Name

ample

507 (S)-3-(2-Chloro-phenyl)-3-{[1 -(2-chloro-phenyl)-5-hydroxy-1 H-pyrazole-3- carbonyl]-amino}-propionic acid

508 3-{[1 -(3-Chloro-phenyl)-5-hydroxy-1 H-pyrazole-3-carbonyl]-amino}-3-(3- fluoro-2-methyl-phenyl)-propionic acid

509 3-(2-Chloro-5-fluoro-phenyl)-3-{[1 -(3-chloro-phenyl)-5-hydroxy-1 H-pyrazole-3- carbonyl]-amino}-propionic acid

510 3-{[1 -(3-Chloro-phenyl)-5-hydroxy-1 H-pyrazole-3-carbonyl]-amino}-3-(5- fluoro-2-methyl-phenyl)-propionic acid

51 1 3-{[1 -(3-Chloro-phenyl)-5-hydroxy-1 H-pyrazole-3-carbonyl]-amino}-3-(2,5- dichloro-phenyl)-propionic acid

512 (S)-3-{[1 -(3-Chloro-phenyl)-5-hydroxy-1 H-pyrazole-3-carbonyl]-amino}-3-p- tolyl-propionic acid

513 3-{[1 -(3-Chloro-phenyl)-5-hydroxy-1 H-pyrazole-3-carbonyl]-amino}-3-(4- pyridin-2-yl-phenyl)-propionic acid

514 (S)-3-(2-Chloro-phenyl)-3-{[1 -(3-chloro-phenyl)-5-hydroxy-1 H-pyrazole-3- carbonyl]-amino}-propionic acid

515 3-{[1 -(4-Chloro-phenyl)-5-hydroxy-1 H-pyrazole-3-carbonyl]-amino}-3-(4- pyridin-2-yl-phenyl)-propionic acid

516 3-(3-Fluoro-2-methyl-phenyl)-3-{[1 -(2-fluoro-phenyl)-5-hydroxy-1 H-pyrazole-3- carbonyl]-amino}-propionic acid

517 3-(2,5-Difluoro-phenyl)-3-{[1 -(2-fluoro-phenyl)-5-hydroxy-1 H-pyrazole-3- carbonyl]-amino}-propionic acid

518 3-{[1 -(2-Fluoro-phenyl)-5-hydroxy-1 H-pyrazole-3-carbonyl]-amino}-3-(4- morpholin-4-yl-phenyl)-propionic acid

519 (S)-3-(2-Chloro-phenyl)-3-{[1 -(2-fluoro-phenyl)-5-hydroxy-1 H-pyrazole-3- carbonyl]-amino}-propionic acid ExCompound Name

ample

520 3-(5-Fluoro-2-methoxy-phenyl)-3-{[1 -(3-fluoro-phenyl)-5-hydroxy-1 H-pyrazole- 3-carbonyl]-amino}-propionic acid

521 3-{[1 -(3-Fluoro-phenyl)-5-hydroxy-1 H-pyrazole-3-carbonyl]-amino}-3-(4- pyridin-2-yl-phenyl)-propionic acid

522 (S)-3-(2-Chloro-phenyl)-3-{[1 -(3-fluoro-phenyl)-5-hydroxy-1 H-pyrazole-3- carbonyl]-amino}-propionic acid

523 3-(3-Fluoro-2-methyl-phenyl)-3-{[1 -(4-fluoro-phenyl)-5-hydroxy-1 H-pyrazole-3- carbonyl]-amino}-propionic acid

524 3-(2-Chloro-5-fluoro-phenyl)-3-{[1 -(4-fluoro-phenyl)-5-hydroxy-1 H-pyrazole-3- carbonyl]-amino}-propionic acid

525 3-(5-Fluoro-2-methoxy-phenyl)-3-{[1 -(4-fluoro-phenyl)-5-hydroxy-1 H-pyrazole- 3-carbonyl]-amino}-propionic acid

526 (S)-3-{[1 -(4-Fluoro-phenyl)-5-hydroxy-1 H-pyrazole-3-carbonyl]-amino}-3-p- tolyl-propionic acid

527 3-{[1 -(4-Fluoro-phenyl)-5-hydroxy-1 H-pyrazole-3-carbonyl]-amino}-3-(4- pyridin-2-yl-phenyl)-propionic acid

528 (S)-3-(2-Chloro-phenyl)-3-{[1 -(4-fluoro-phenyl)-5-hydroxy-1 H-pyrazole-3- carbonyl]-amino}-propionic acid

529 2,2-Dimethyl-propionic acid (S)-3-{[1 -(2-fluoro-phenyl)-5-hydroxy-1 H- pyrazole-3-carbonyl]-amino}-3-o-tolyl-propionyloxymethyl ester

530 (R)-3-{[1 -(2-Fluoro-phenyl)-5-hydroxy-1 H-pyrazole-3-carbonyl]-amino}-3- phenyl-butyric acid methyl ester

531 3-{[1 -(2-Fluoro-phenyl)-5-hydroxy-1 H-pyrazole-3-carbonyl]-amino}-3-[4-(6- methoxy-pyridin-3-yl)-phenyl]-propionic acid

532 (S)-3-[(5-Hydroxy-1 -o-tolyl-1 H-pyrazole-3-carbonyl)-amino]-3-o-tolyl-propionic acid ExCompound Name

ample

533 (S)-3-[(1 -Benzyl-5-hydroxy-1 H-pyrazole-3-carbonyl)-amino]-3-o-tolyl-propionic acid

534 (S)-3-[(5-Methoxy-1 -phenyl-1 H-pyrazole-3-carbonyl)-amino]-3-o-tolyl- propionic acid

535 3-{[1 -(2-Fluoro-phenyl)-5-hydroxy-1 H-pyrazole-3-carbonyl]-amino}-3-phenyl- propionic acid

536 3-(4'-Fluoro-biphenyl-4-yl)-3-[(5-hydroxy-1 -o-tolyl-1 H-pyrazole-3-carbonyl)- amino]-propionic acid

537 (S)-3-{[5-Hydroxy-1 -(2-trifluoromethyl-phenyl)-1 H-pyrazole-3-carbonyl]- amino}-3-o-tolyl-propionic acid

538 3- [(1 -Benzyl-5-hydroxy-1 H-pyrazole-3-carbonyl)-amino]-3-(4'-fluoro-biphenyl-

4- yl)-propionic acid

539 3-(2'-Chloro-biphenyl-4-yl)-3-[(5-hydroxy-1 -phenyl-1 H-pyrazole-3-carbonyl)- amino]-propionic acid

540 3-(3'-Chloro-biphenyl-4-yl)-3-{[1 -(2-chloro-phenyl)-5-hydroxy-1 H-pyrazole-3- carbonyl]-amino}-propionic acid

541 3-(3'-Chloro-biphenyl-4-yl)-3-{[1 -(2-fluoro-phenyl)-5-hydroxy-1 H-pyrazole-3- carbonyl]-amino}-propionic acid

542 3-(2'-Chloro-biphenyl-4-yl)-3-{[1 -(2-fluoro-phenyl)-5-hydroxy-1 H-pyrazole-3- carbonyl]-amino}-propionic acid

543 3-(4'-Fluoro-biphenyl-4-yl)-3-{[1 -(2-fluoro-phenyl)-5-methoxy-1 H-pyrazole-3- carbonyl]-amino}-propionic acid

544 3-(4'-Fluoro-biphenyl-4-yl)-3-[(5-methoxy-1 -phenyl-1 H-pyrazole-3-carbonyl)- amino]-propionic acid

545 3-[(5-Hydroxy-1 -phenyl-1 H-pyrazole-3-carbonyl)-amino]-3-(3-methoxy- biphenyl-4-yl)-propionic acid ExCompound Name

ample

546 3-[(5-Hydroxy-1 -phenyl-1 H-pyrazole-3-carbonyl)-amino]-3-(4-methoxy-2- trifluoromethyl-phenyl)-propionic acid

547 3-(2-Fluoro-5-methoxy-phenyl)-3-[(5-hydroxy-1 -phenyl-1 H-pyrazole-3- carbonyl)-amino]-propionic acid

548 3-[(5-Hydroxy-1 -phenyl-1 H-pyrazole-3-carbonyl)-amino]-3-(2-methoxy-5- trifluoromethyl-phenyl)-propionic acid

549 3-[(5-Hydroxy-1 -phenyl-1 H-pyrazole-3-carbonyl)-amino]-3-(4-methoxy- biphenyl-3-yl)-propionic acid

550 3-{[1 -(2-Fluoro-phenyl)-5-hydroxy-1 H-pyrazole-3-carbonyl]-amino}-3-(4- [1 ,2,4]triazol-1 -yl-phenyl)-propionic acid

551 3-{[1 -(2-Fluoro-phenyl)-5-hydroxy-1 H-pyrazole-3-carbonyl]-amino}-3-(3- methoxy-biphenyl-4-yl)-propionic acid

552 3-{[1 -(2-Fluoro-phenyl)-5-hydroxy-1 H-pyrazole-3-carbonyl]-amino}-3-(4- methoxy-2-trifluoromethyl-phenyl)-propionic acid

553 3-(2-Fluoro-5-methoxy-phenyl)-3-{[1 -(2-fluoro-phenyl)-5-hydroxy-1 H-pyrazole- 3-carbonyl]-amino}-propionic acid

554 3-{[1 -(2-Fluoro-phenyl)-5-hydroxy-1 H-pyrazole-3-carbonyl]-amino}-3-(2- methoxy-5-trifluoromethyl-phenyl)-propionic acid

555 3-(2-Fluoro-4-methyl-phenyl)-3-{[1 -(2-fluoro-phenyl)-5-hydroxy-1 H-pyrazole-3- carbonyl]-amino}-propionic acid

556 3-{[1 -(2-Fluoro-phenyl)-5-hydroxy-1 H-pyrazole-3-carbonyl]-amino}-3-(4- methoxy-biphenyl-3-yl)-propionic acid

557 3-{[1 -(2-Chloro-phenyl)-5-hydroxy-1 H-pyrazole-3-carbonyl]-amino}-3-(4- [1 ,2,4]triazol-1 -yl-phenyl)-propionic acid

558 3-{[1 -(2-Chloro-phenyl)-5-hydroxy-1 H-pyrazole-3-carbonyl]-amino}-3-(3- methoxy-biphenyl-4-yl)-propionic acid ExCompound Name

ample

559 3-{[1 -(2-Chloro-phenyl)-5-hydroxy-1 H-pyrazole-3-carbonyl]-amino}-3-(2- fluoro-5-methoxy-phenyl)-propionic acid

560 3-{[1 -(2-Chloro-phenyl)-5-hydroxy-1 H-pyrazole-3-carbonyl]-amino}-3-(2- methoxy-5-trifluoromethyl-phenyl)-propionic acid

561 3-{[1 -(2-Chloro-phenyl)-5-hydroxy-1 H-pyrazole-3-carbonyl]-amino}-3-(2- fluoro-4-methyl-phenyl)-propionic acid

562 3-{[1 -(2-Chloro-phenyl)-5-hydroxy-1 H-pyrazole-3-carbonyl]-amino}-3-(4- methoxy-biphenyl-3-yl)-propionic acid

563 3-[(5-Hydroxy-1 -phenyl-1 H-pyrazole-3-carbonyl)-amino]-3-(4-[1 ,2,4]triazol-1 - yl-phenyl)-propionic acid

564 3-(2-Fluoro-4-methyl-phenyl)-3-[(5-hydroxy-1 -phenyl-1 H-pyrazole-3- carbonyl)-amino]-propionic acid

565 3-[(5-Hydroxy-1 -phenyl-1 H-pyrazole-3-carbonyl)-amino]-3-(4-pyrrolidin-1 -yl- phenyl)-propionic acid

566 3-{[1 -(2-Fluoro-phenyl)-5-hydroxy-1 H-pyrazole-3-carbonyl]-amino}-3-(4- pyrrolidin-1 -yl-phenyl)-propionic acid

567 3-{[1 -(2-Chloro-phenyl)-5-hydroxy-1 H-pyrazole-3-carbonyl]-amino}-3-(4- methoxy-2-trifluoromethyl-phenyl)-propionic acid

568 3-{[1 -(2-Chloro-phenyl)-5-hydroxy-1 H-pyrazole-3-carbonyl]-amino}-3-(4- pyrrolidin-1 -yl-phenyl)-propionic acid

569 3-(4'-Fluoro-biphenyl-4-yl)-3-{[5-hydroxy-1 -(2-thfluoromethyl-phenyl)-1 H- pyrazole-3-carbonyl]-amino}-propionic acid

570 (S)-3-{[1 -(2-Fluoro-phenyl)-5-hydroxy-1 H-pyrazole-3-carbonyl]-amino}-3-o- tolyl-propionic acid isopropyl ester

571 (S)-3-{[1 -(2-Fluoro-phenyl)-5-hydroxy-1 H-pyrazole-3-carbonyl]-amino}-3-o- tolyl-propionic acid propyl ester ExCompound Name

ample

572 (S)-3-[(1 -Cyclopentyl-5-hydroxy-1 H-pyrazole-3-carbonyl)-amino]-3-o-tolyl- propionic acid

573 (S)-3-[(1 -Cyclohexyl-5-hydroxy-1 H-pyrazole-3-carbonyl)-amino]-3-o-tolyl- propionic acid

574 3-[(1 -Cyclopentyl-5-hydroxy-1 H-pyrazole-3-carbonyl)-amino]-3-(4'-fluoro- biphenyl-4-yl)-propionic acid

575 3-[(1 -Cyclohexyl-5-hydroxy-1 H-pyrazole-3-carbonyl)-amino]-3-(4'-fluoro- biphenyl-4-yl)-propionic acid

576 3-{[1 -(2-Fluoro-phenyl)-5-hydroxy-1 H-pyrazole-3-carbonyl]-amino}-3-(4'- trifluoromethyl-biphenyl-4-yl)-propionic acid

577 (S)-3-{[1 -(2-Fluoro-phenyl)-5-hydroxy-1 H-pyrazole-3-carbonyl]-amino}-3-o- tolyl-propionic acid butyl ester

578 3-[(5-Hydroxy-1 -phenyl-1 H-pyrazole-3-carbonyl)-amino]-3-(4-pyrazol-1 -yl- phenyl)-propionic acid

579 3-[(5-Hydroxy-1 -phenyl-1 H-pyrazole-3-carbonyl)-amino]-3-(4'-trifluoromethyl- biphenyl-4-yl)-propionic acid

580 3-{[1 -(2-Chloro-phenyl)-5-hydroxy-1 H-pyrazole-3-carbonyl]-amino}-3-(4- pyrazol-1 -yl-phenyl)-propionic acid

581 3-{[1 -(2-Chloro-phenyl)-5-hydroxy-1 H-pyrazole-3-carbonyl]-amino}-3-(4'- trifluoromethyl-biphenyl-4-yl)-propionic acid

582 3-{[1 -(2-Fluoro-phenyl)-5-hydroxy-1 H-pyrazole-3-carbonyl]-amino}-3-(4- pyrazol-1 -yl-phenyl)-propionic acid

583 3-(2'-Fluoro-biphenyl-4-yl)-3-[(5-hydroxy-1 -phenyl-1 H-pyrazole-3-carbonyl)- amino]-propionic acid

584 3-(2'-Fluoro-biphenyl-4-yl)-3-{[1 -(2-fluoro-phenyl)-5-hydroxy-1 H-pyrazole-3- carbonyl]-amino}-propionic acid ExCompound Name

ample

585 3-{[1 -(2-Chloro-phenyl)-5-hydroxy-1 H-pyrazole-3-carbonyl]-amino}-3-(2'- fluoro-biphenyl-4-yl)-propionic acid

586 (S)-3-{[1 -(3,5-Difluoro-phenyl)-5-hydroxy-1 H-pyrazole-3-carbonyl]-amino}-3-o- tolyl-propionic acid

587 3-{[1 -(3,5-Difluoro-phenyl)-5-hydroxy-1 H-pyrazole-3-carbonyl]-amino}-3-(4'- fluoro-biphenyl-4-yl)-propionic acid

588 (S)-3-{[1 -(2,6-Difluoro-phenyl)-5-hydroxy-1 H-pyrazole-3-carbonyl]-amino}-3-o- tolyl-propionic acid

589 (S)-3-{[1 -(3-Chloro-2-fluoro-phenyl)-5-hydroxy-1 H-pyrazole-3-carbonyl]- amino}-3-o-tolyl-propionic acid

590 3-{[1 -(3-Chloro-2-fluoro-phenyl)-5-hydroxy-1 H-pyrazole-3-carbonyl]-amino}-3- (4'-fluoro-biphenyl-4-yl)-propionic acid

591 3-(2'-Chloro-biphenyl-4-yl)-3-{[1 -(2-chloro-phenyl)-5-hydroxy-1 H-pyrazole-3- carbonyl]-amino}-propionic acid

592 3-{[1 -(2-Fluoro-phenyl)-5-hydroxy-4-methyl-1 H-pyrazole-3-carbonyl]-amino}- 3-o-tolyl-propionic acid

593 (S)-3-{[4-Chloro-1 -(2-fluoro-phenyl)-5-methoxy-1 H-pyrazole-3-carbonyl]- amino}-3-o-tolyl-propionic acid

594 (S)-3-{[4-Bromo-1 -(2-fluoro-phenyl)-5-methoxy-1 H-pyrazole-3-carbonyl]- amino}-3-o-tolyl-propionic acid

595 (S)-3-{[4-Fluoro-1 -(2-fluoro-phenyl)-5-methoxy-1 H-pyrazole-3-carbonyl]- amino}-3-o-tolyl-propionic acid

596 (S)-3-(2,3-Dichloro-phenyl)-3-[(5-methoxy-1 -phenyl-1 H-pyrazole-3-carbonyl)- amino]-propionic acid

597 3-[(5-Methoxy-1 -phenyl-1 H-pyrazole-3-carbonyl)-amino]-3-(4-pyridin-2-yl- phenyl)-propionic acid ExCompound Name

ample

598 3-{[1 -(2-Fluoro-phenyl)-5-methoxy-1 H-pyrazole-3-carbonyl]-amino}-3-(4- pyridin-2-yl-phenyl)-propionic acid

599 (S)-3-{[1 -(2,5-Difluoro-phenyl)-5-hydroxy-1 H-pyrazole-3-carbonyl]-amino}-3-o- tolyl-propionic acid

600 3-[(5-Hydroxy-1 -phenyl-1 H-pyrazole-3-carbonyl)-amino]-3-(4- methanesulfonyl-phenyl)-propionic acid

601 (S)-3-{[5-Hydroxy-1 -(3-sulfamoyl-phenyl)-1 H-pyrazole-3-carbonyl]-amino}-3- o-tolyl-propionic acid

602 (S)-3-{[5-Hydroxy-1 -(4-sulfamoyl-phenyl)-1 H-pyrazole-3-carbonyl]-amino}-3- o-tolyl-propionic acid

603 3-{[1 -(2-Fluoro-phenyl)-5-hydroxy-1 H-pyrazole-3-carbonyl]-amino}-3-(4- methanesulfonyl-phenyl)-propionic acid

604 3-{[2-(2-Fluoro-phenyl)-5-methoxy-4-methyl-2H-pyrazole-3-carbonyl]-amino}- 3-o-tolyl-propionic acid

605 3-{[1 -(2-Fluoro-phenyl)-5-methoxy-4-methyl-1 H-pyrazole-3-carbonyl]-amino}- 3-o-tolyl-propionic acid

606 3-(4'-Fluoro-biphenyl-4-yl)-3-{[5-hydroxy-1 -(3-sulfamoyl-phenyl)-1 H-pyrazole- 3-carbonyl]-amino}-propionic acid

607 (S)-3-{[5-Hydroxy-1 -(2-methanesulfonyl-phenyl)-1 H-pyrazole-3-carbonyl]- amino}-3-o-tolyl-propionic acid

608 (S)-3-{[1 -(2-Chloro-phenyl)-5-methoxy-1 H-pyrazole-3-carbonyl]-amino}-3-o- tolyl-propionic acid

609 (S)-3-{[1 -(3-Fluoro-phenyl)-5-methoxy-1 H-pyrazole-3-carbonyl]-amino}-3-o- tolyl-propionic acid

610 (S)-3-{[1 -(2,5-Difluoro-phenyl)-5-methoxy-1 H-pyrazole-3-carbonyl]-amino}-3- o-tolyl-propionic acid ExCompound Name

ample

61 1 (S)-3-[(1 -tert-Butyl-5-methoxy-1 H-pyrazole-3-carbonyl)-amino]-3-o-tolyl- propionic acid

612 (S)-3-{[5-Cyclopropylmethoxy-1 -(2-fluoro-phenyl)-1 H-pyrazole-3-carbonyl]- amino}-3-o-tolyl-propionic acid

613 Pyrrolidine-1 -carboxylic acid 5-((S)-2-carboxy-1 -o-tolyl-ethylcarbamoyl)-2-(2- fluoro-phenyl)-2H-pyrazol-3-yl ester

614 (S)-3-{[5-Dimethylcarbamoyloxy-1 -(2-fluoro-phenyl)-1 H-pyrazole-3-carbonyl]- amino}-3-o-tolyl-propionic acid

615 (S)-3-{[5-Dimethylcarbamoylmethoxy-1 -(2-fluoro-phenyl)-1 H-pyrazole-3- carbonyl]-amino}-3-o-tolyl-propionic acid

616 (S)-3-{[1 -(2-Fluoro-phenyl)-5-(2-oxo-2-pyrrolidin-1 -yl-ethoxy)-1 H-pyrazole-3- carbonyl]-amino}-3-o-tolyl-propionic acid

617 (S)-3-{[1 -(2-Fluoro-phenyl)-5-(2-methoxy-ethoxy)-1 H-pyrazole-3-carbonyl]- amino}-3-o-tolyl-propionic acid

618 (S)-3-{[1 -(2-Fluoro-phenyl)-5-methoxy-1 H-pyrazole-3-carbonyl]-amino}-3-o- tolyl-propionic acid ethyl ester

619 Piperidine-1 -carboxylic acid 5-((S)-2-carboxy-1 -o-tolyl-ethylcarbamoyl)-2-(2- fluoro-phenyl)-2H-pyrazol-3-yl ester

620 (S)-3-{[1 -(2-Fluoro-phenyl)-5-(methyl-phenyl-carbamoyloxy)-1 H-pyrazole-3- carbonyl]-amino}-3-o-tolyl-propionic acid

621 (S)-3-[(5-Ethoxy-1 -phenyl-1 H-pyrazole-3-carbonyl)-amino]-3-o-tolyl-propionic acid

622 (S)-3-[(5-Cyclopropylmethoxy-1 -phenyl-1 H-pyrazole-3-carbonyl)-amino]-3-o- tolyl-propionic acid

623 (S)-3-{[1 -(2-Fluoro-phenyl)-5-(2-trifluoromethyl-benzyloxy)-1 H-pyrazole-3- carbonyl]-amino}-3-o-tolyl-propionic acid ExCompound Name

ample

624 (S)-3-{[1 -(2-Fluoro-phenyl)-5-(3-trifluoromethyl-benzyloxy)-1 H-pyrazole-3- carbonyl]-amino}-3-o-tolyl-propionic acid

625 (S)-3-{[1 -(2-Fluoro-phenyl)-5-phenethyloxy-1 H-pyrazole-3-carbonyl]-amino}-3- o-tolyl-propionic acid

626 (S)-3-{[5-Cyclopentyloxy-1 -(2-fluoro-phenyl)-1 H-pyrazole-3-carbonyl]-amino}- 3-o-tolyl-propionic acid

627 (S)-3-{[1 -(2-Fluoro-phenyl)-5-(tetrahydro-pyran-4-ylmethoxy)-1 H-pyrazole-3- carbonyl]-amino}-3-o-tolyl-propionic acid

628 (S)-3-{[5-[2-(3,5-Dimethyl-isoxazol-4-yl)-ethoxy]-1 -(2-fluoro-phenyl)-1 H- pyrazole-3-carbonyl]-amino}-3-o-tolyl-propionic acid

629 (S)-3-{[1 -(2-Fluoro-phenyl)-5-(pyridin-4-ylmethoxy)-1 H-pyrazole-3-carbonyl]- amino}-3-o-tolyl-propionic acid

630 (S)-3-{[1 -(2-Fluoro-phenyl)-5-isopropoxy-1 H-pyrazole-3-carbonyl]-amino}-3-o- tolyl-propionic acid

631 (S)-3-{[5-Cyclohexyloxy-1 -(2-fluoro-phenyl)-1 H-pyrazole-3-carbonyl]-amino}- 3-o-tolyl-propionic acid

632 (S)-3-{[5-(2,2-Dimethyl-propoxy)-1 -(2-fluoro-phenyl)-1 H-pyrazole-3-carbonyl]- amino}-3-o-tolyl-propionic acid

633 (S)-3-{[1 -(2-Fluoro-phenyl)-5-isobutoxy-1 H-pyrazole-3-carbonyl]-amino}-3-o- tolyl-propionic acid

634 (S)-3-{[5-Cyclopropylmethoxy-1 -(2,6-difluoro-phenyl)-1 H-pyrazole-3- carbonyl]-amino}-3-o-tolyl-propionic acid

635 (S)-3-{[5-(2-Cyano-benzyloxy)-1 -(2-fluoro-phenyl)-1 H-pyrazole-3-carbonyl]- amino}-3-o-tolyl-propionic acid

636 (S)-3-{[1 -(2-Fluoro-phenyl)-5-(2-hydroxy-2-phenyl-propoxy)-1 H-pyrazole-3- carbonyl]-amino}-3-p-tolyl-propionic acid ExCompound Name

ample

637 (S)-3-{[5-[2-(2-Ethoxy-ethoxy)-ethoxy]-1 -(2-fluoro-phenyl)-1 H-pyrazole-3- carbonyl]-amino}-3-o-tolyl-propionic acid

638 (S)-3-{[5-Cyclohexylmethoxy-1 -(2-fluoro-phenyl)-1 H-pyrazole-3-carbonyl]- amino}-3-o-tolyl-propionic acid

639 (S)-3-({1 -(2-Fluoro-phenyl)-5-[2-(2-oxo-pyrrolidin-1 -yl)-ethoxy]-1 H-pyrazole-3- carbonyl}-amino)-3-o-tolyl-propionic acid

640 (S)-3-{[1 -(2-Fluoro-phenyl)-5-(pyridin-2-ylmethoxy)-1 H-pyrazole-3-carbonyl]- amino}-3-o-tolyl-propionic acid

641 (S)-3-{[1 -(2-Fluoro-phenyl)-5-(3-fluoro-propoxy)-1 H-pyrazole-3-carbonyl]- amino}-3-o-tolyl-propionic acid

642 (S)-3-{[1 -(2-Fluoro-phenyl)-5-(tetrahydro-furan-2-ylmethoxy)-1 H-pyrazole-3- carbonyl]-amino}-3-o-tolyl-propionic acid

643 (S)-3-{[1 -(2-Fluoro-phenyl)-5-(3-methyl-isoxazol-5-ylmethoxy)-1 H-pyrazole-3- carbonyl]-amino}-3-o-tolyl-propionic acid

644 (S)-3-{[5-(2,6-Difluoro-benzyloxy)-1 -(2-fluoro-phenyl)-1 H-pyrazole-3- carbonyl]-amino}-3-o-tolyl-propionic acid

645 (S)-3-{[5-(2,2-Difluoro-cyclopropylmethoxy)-1 -(2-fluoro-phenyl)-1 H-pyrazole- 3-carbonyl]-amino}-3-o-tolyl-propionic acid

646 (S)-3-{[1 -(2-Fluoro-phenyl)-5-(2-methyl-thiazol-4-ylmethoxy)-1 H-pyrazole-3- carbonyl]-amino}-3-o-tolyl-propionic acid

647 (S)-3-{[1 -(2-Fluoro-phenyl)-5-(isoxazol-3-ylmethoxy)-1 H-pyrazole-3-carbonyl]- amino}-3-o-tolyl-propionic acid

648 (S)-3-{[5-Cyclobutoxy-1 -(2-fluoro-phenyl)-1 H-pyrazole-3-carbonyl]-amino}-3- o-tolyl-propionic acid

649 (S)-3-{[5-Cyclobutylmethoxy-1 -(2-fluoro-phenyl)-1 H-pyrazole-3-carbonyl]- amino}-3-o-tolyl-propionic acid ExCompound Name

ample

650 (S)-3-{[1 -(2-Fluoro-phenyl)-5-(tetrahydro-furan-3-ylmethoxy)-1 H-pyrazole-3- carbonyl]-amino}-3-o-tolyl-propionic acid

651 (S)-3-{[5-Benzyloxy-1 -(2-fluoro-phenyl)-1 H-pyrazole-3-carbonyl]-amino}-3-o- tolyl-propionic acid

652 (S)-3-{[1 -(2-Fluoro-phenyl)-5-((R)-5-oxo-pyrrolidin-2-ylmethoxy)-1 H-pyrazole- 3-carbonyl]-amino}-3-o-tolyl-propionic acid

653 (S)-3-{[1 -(2-Fluoro-phenyl)-5-(tetrahydro-pyran-2-ylmethoxy)-1 H-pyrazole-3- carbonyl]-amino}-3-o-tolyl-propionic acid

654 (S)-3-{[1 -(2-Fluoro-phenyl)-5-((S)-5-oxo-pyrrolidin-2-ylmethoxy)-1 H-pyrazole- 3-carbonyl]-amino}-3-o-tolyl-propionic acid

655 (S)-3-{[1 -(2-Fluoro-phenyl)-5-(3-methoxy-benzyloxy)-1 H-pyrazole-3-carbonyl]- amino}-3-o-tolyl-propionic acid

656 (S)-3-{[1 -(2-Fluoro-phenyl)-5-(1 -methyl-1 H-pyrazol-3-ylmethoxy)-1 H-pyrazole- 3-carbonyl]-amino}-3-o-tolyl-propionic acid

657 (S)-3-{[1 -(2-Fluoro-phenyl)-5-(5-methyl-isoxazol-3-ylmethoxy)-1 H-pyrazole-3- carbonyl]-amino}-3-o-tolyl-propionic acid

658 (S)-3-{[1 -(2-Fluoro-phenyl)-5-(isoxazol-5-ylmethoxy)-1 H-pyrazole-3-carbonyl]- amino}-3-o-tolyl-propionic acid

659 (S)-3-{[5-(3,3-Dimethyl-butoxy)-1 -(2-fluoro-phenyl)-1 H-pyrazole-3-carbonyl]- amino}-3-o-tolyl-propionic acid

660 (S)-3-{[1 -(2-Fluoro-phenyl)-5-hexyloxy-1 H-pyrazole-3-carbonyl]-amino}-3-o- tolyl-propionic acid

661 1 -(2-Fluoro-phenyl)-5-methoxy-1 H-pyrazole-3-carboxylic acid ((S)-2- carbamoyl-1 -o-tolyl-ethyl)-amide

662 (S)-3-{[5-Ethoxy-1 -(2-fluoro-phenyl)-1 H-pyrazole-3-carbonyl]-amino}-3-o-tolyl- propionic acid ExCompound Name

ample

663 (S)-3-{[1 -(2-Fluoro-phenyl)-5-(3-methyl-oxetan-3-ylmethoxy)-1 H-pyrazole-3- carbonyl]-amino}-3-o-tolyl-propionic acid

664 3-(3-Fluoro-2-methyl-phenyl)-3-{[1 -(2-fluoro-phenyl)-5-methoxy-1 H-pyrazole- 3-carbonyl]-amino}-propionic acid

665 (S)-3-{[1 -(2-Fluoro-phenyl)-5-methoxy-1 H-pyrazole-3-carbonyl]-amino}-3- phenyl-propionic acid

666 3-(2,4-Dimethyl-phenyl)-3-{[1 -(2-fluoro-phenyl)-5-methoxy-1 H-pyrazole-3- carbonyl]-amino}-propionic acid

667 (S)-3-{[1 -(2-Fluoro-phenyl)-5-methoxy-1 H-pyrazole-3-carbonyl]-amino}-3-(2- methoxy-phenyl)-propionic acid

668 (S)-3-(4-Cyano-phenyl)-3-{[1 -(2-fluoro-phenyl)-5-methoxy-1 H-pyrazole-3- carbonyl]-amino}-propionic acid

669 (S)-3-{[1 -(2-Fluoro-phenyl)-5-methoxy-1 H-pyrazole-3-carbonyl]-amino}-3-(3- methoxy-phenyl)-propionic acid

670 (S)-3-{[1 -(2-Fluoro-phenyl)-5-methoxy-1 H-pyrazole-3-carbonyl]-amino}-3-m- tolyl-propionic acid

671 (S)-3-(4-Chloro-phenyl)-3-{[1 -(2-fluoro-phenyl)-5-methoxy-1 H-pyrazole-3- carbonyl]-amino}-propionic acid

672 3-{[1 -(2-Fluoro-phenyl)-5-methoxy-1 H-pyrazole-3-carbonyl]-amino}-3-(4- methoxy-2-methyl-phenyl)-propionic acid

673 (S)-3-(2,4-Dichloro-phenyl)-3-{[1 -(2-fluoro-phenyl)-5-methoxy-1 H-pyrazole-3- carbonyl]-amino}-propionic acid

674 (S)-3-{[1 -(2-Fluoro-phenyl)-5-methoxy-1 H-pyrazole-3-carbonyl]-amino}-3-(4- trifluoromethyl-phenyl)-propionic acid

675 (S)-3-{[1 -(2-Fluoro-phenyl)-5-methoxy-1 H-pyrazole-3-carbonyl]-amino}-3-p- tolyl-propionic acid ExCompound Name

ample

676 (S)-3-(2-Chloro-phenyl)-3-{[1 -(2-fluoro-phenyl)-5-methoxy-1 H-pyrazole-3- carbonyl]-amino}-propionic acid

677 3-(4-Fluoro-2-methyl-phenyl)-3-{[1 -(2-fluoro-phenyl)-5-methoxy-1 H-pyrazole- 3-carbonyl]-amino}-propionic acid

678 3-(4-Fluoro-phenyl)-3-{[1 -(2-fluoro-phenyl)-5-methoxy-1 H-pyrazole-3- carbonyl]-amino}-propionic acid

679 (S)-3-(2-Fluoro-phenyl)-3-{[1 -(2-fluoro-phenyl)-5-methoxy-1 H-pyrazole-3- carbonyl]-amino}-propionic acid

680 (S)-3-{[1 -(2-Fluoro-phenyl)-5-methoxy-1 H-pyrazole-3-carbonyl]-amino}-3-(2- trifluoromethyl-phenyl)-propionic acid

681 (S)-3-(2,3-Dichloro-phenyl)-3-{[1 -(2-fluoro-phenyl)-5-methoxy-1 H-pyrazole-3- carbonyl]-amino}-propionic acid

682 3-(2,3-Dimethyl-phenyl)-3-{[1 -(2-fluoro-phenyl)-5-methoxy-1 H-pyrazole-3- carbonyl]-amino}-propionic acid

683 3-(2,5-Dichloro-phenyl)-3-{[1 -(2-fluoro-phenyl)-5-methoxy-1 H-pyrazole-3- carbonyl]-amino}-propionic acid

684 3-{[5-Cyclopropylmethoxy-1 -(2-fluoro-phenyl)-1 H-pyrazole-3-carbonyl]- amino}-3-(3-fluoro-2-methyl-phenyl)-propionic acid

685 (S)-3-{[5-Cyclopropylmethoxy-1 -(2-fluoro-phenyl)-1 H-pyrazole-3-carbonyl]- amino}-3-phenyl-propionic acid

686 3-{[5-Cyclopropylmethoxy-1 -(2-fluoro-phenyl)-1 H-pyrazole-3-carbonyl]- amino}-3-(2,4-dimethyl-phenyl)-propionic acid

687 (S)-3-{[5-Cyclopropylmethoxy-1 -(2-fluoro-phenyl)-1 H-pyrazole-3-carbonyl]- amino}-3-(2-methoxy-phenyl)-propionic acid

688 (S)-3-(4-Cyano-phenyl)-3-{[5-cyclopropylmethoxy-1 -(2-fluoro-phenyl)-1 H- pyrazole-3-carbonyl]-amino}-propionic acid ExCompound Name

ample

689 (S)-3-{[5-Cyclopropylmethoxy-1 -(2-fluoro-phenyl)-1 H-pyrazole-3-carbonyl]- amino}-3-(3-methoxy-phenyl)-propionic acid

690 (S)-3-{[5-Cyclopropylmethoxy-1 -(2-fluoro-phenyl)-1 H-pyrazole-3-carbonyl]- amino}-3-m-tolyl-propionic acid

691 (S)-3-(4-Chloro-phenyl)-3-{[5-cyclopropylmethoxy-1 -(2-fluoro-phenyl)-1 H- pyrazole-3-carbonyl]-amino}-propionic acid

692 3-{[5-Cyclopropylmethoxy-1 -(2-fluoro-phenyl)-1 H-pyrazole-3-carbonyl]- amino}-3-(4-methoxy-2-methyl-phenyl)-propionic acid

693 (S)-3-{[5-Cyclopropylmethoxy-1 -(2-fluoro-phenyl)-1 H-pyrazole-3-carbonyl]- amino}-3-(2,4-dichloro-phenyl)-propionic acid

694 (S)-3-{[5-Cyclopropylmethoxy-1 -(2-fluoro-phenyl)-1 H-pyrazole-3-carbonyl]- amino}-3-(4-trifluoromethyl-phenyl)-propionic acid

695 (S)-3-{[5-Cyclopropylmethoxy-1 -(2-fluoro-phenyl)-1 H-pyrazole-3-carbonyl]- amino}-3-p-tolyl-propionic acid

696 (S)-3-(2-Chloro-phenyl)-3-{[5-cyclopropylmethoxy-1 -(2-fluoro-phenyl)-1 H- pyrazole-3-carbonyl]-amino}-propionic acid

697 3-{[5-Cyclopropylmethoxy-1 -(2-fluoro-phenyl)-1 H-pyrazole-3-carbonyl]- amino}-3-(4-fluoro-2-methyl-phenyl)-propionic acid

698 3-{[5-Cyclopropylmethoxy-1 -(2-fluoro-phenyl)-1 H-pyrazole-3-carbonyl]- amino}-3-(4-fluoro-phenyl)-propionic acid

699 (S)-3-{[5-Cyclopropylmethoxy-1 -(2-fluoro-phenyl)-1 H-pyrazole-3-carbonyl]- amino}-3-(2-fluoro-phenyl)-propionic acid

700 (S)-3-{[5-(3,3-Dimethyl-2-oxo-butoxy)-1 -(2-fluoro-phenyl)-1 H-pyrazole-3- carbonyl]-amino}-3-o-tolyl-propionic acid

701 (S)-3-{[5-Cyclopropylmethoxy-1 -(2-fluoro-phenyl)-1 H-pyrazole-3-carbonyl]- amino}-3-(2-trifluoromethyl-phenyl)-propionic acid ExCompound Name

ample

702 (S)-3-{[5-Cyclopropylmethoxy-1 -(2-fluoro-phenyl)-1 H-pyrazole-3-carbonyl]- amino}-3-(2,3-dichloro-phenyl)-propionic acid

703 3-{[5-Cyclopropylmethoxy-1 -(2-fluoro-phenyl)-1 H-pyrazole-3-carbonyl]- amino}-3-(2,3-dimethyl-phenyl)-propionic acid

704 3-{[5-Cyclopropylmethoxy-1 -(2-fluoro-phenyl)-1 H-pyrazole-3-carbonyl]- amino}-3-(2,5-dichloro-phenyl)-propionic acid

705 3-(2-Chloro-4-methoxy-phenyl)-3-{[5-cyclopropylmethoxy-1 -(2-fluoro-phenyl)- 1 H-pyrazole-3-carbonyl]-amino}-propionic acid

706 3-{[5-Ethoxy-1 -(2-fluoro-phenyl)-1 H-pyrazole-3-carbonyl]-amino}-3-(3-fluoro- 2-methyl-phenyl)-propionic acid

707 (S)-3-{[5-Ethoxy-1 -(2-fluoro-phenyl)-1 H-pyrazole-3-carbonyl]-amino}-3- phenyl-propionic acid

708 3-(2,4-Dimethyl-phenyl)-3-{[5-ethoxy-1 -(2-fluoro-phenyl)-1 H-pyrazole-3- carbonyl]-amino}-propionic acid

709 (S)-3-{[5-Ethoxy-1 -(2-fluoro-phenyl)-1 H-pyrazole-3-carbonyl]-amino}-3-(2- methoxy-phenyl)-propionic acid

710 (S)-3-(4-Cyano-phenyl)-3-{[5-ethoxy-1 -(2-fluoro-phenyl)-1 H-pyrazole-3- carbonyl]-amino}-propionic acid

71 1 (S)-3-{[5-Ethoxy-1 -(2-fluoro-phenyl)-1 H-pyrazole-3-carbonyl]-amino}-3-(3- methoxy-phenyl)-propionic acid

712 (S)-3-{[5-Ethoxy-1 -(2-fluoro-phenyl)-1 H-pyrazole-3-carbonyl]-amino}-3-m- tolyl-propionic acid

713 (S)-3-(4-Chloro-phenyl)-3-{[5-ethoxy-1 -(2-fluoro-phenyl)-1 H-pyrazole-3- carbonyl]-amino}-propionic acid

714 3-{[5-Ethoxy-1 -(2-fluoro-phenyl)-1 H-pyrazole-3-carbonyl]-amino}-3-(4- methoxy-2-methyl-phenyl)-propionic acid ExCompound Name

ample

715 (S)-3-{[5-Ethoxy-1 -(2-fluoro-phenyl)-1 H-pyrazole-3-carbonyl]-amino}-3-(4- trifluoromethyl-phenyl)-propionic acid

716 (S)-3-{[5-Ethoxy-1 -(2-fluoro-phenyl)-1 H-pyrazole-3-carbonyl]-amino}-3-p-tolyl- propionic acid

717 (S)-3-(2-Chloro-phenyl)-3-{[5-ethoxy-1 -(2-fluoro-phenyl)-1 H-pyrazole-3- carbonyl]-amino}-propionic acid

718 3-{[5-Ethoxy-1 -(2-fluoro-phenyl)-1 H-pyrazole-3-carbonyl]-amino}-3-(4-fluoro- 2-methyl-phenyl)-propionic acid

719 3-{[5-Ethoxy-1 -(2-fluoro-phenyl)-1 H-pyrazole-3-carbonyl]-amino}-3-(4-fluoro- phenyl)-propionic acid

720 (S)-3-{[5-Ethoxy-1 -(2-fluoro-phenyl)-1 H-pyrazole-3-carbonyl]-amino}-3-(2- fluoro-phenyl)-propionic acid

721 (S)-3-{[5-Ethoxy-1 -(2-fluoro-phenyl)-1 H-pyrazole-3-carbonyl]-amino}-3-(2- trifluoromethyl-phenyl)-propionic acid

722 (S)-3-(2,3-Dichloro-phenyl)-3-{[5-ethoxy-1 -(2-fluoro-phenyl)-1 H-pyrazole-3- carbonyl]-amino}-propionic acid

723 3-(2,3-Dimethyl-phenyl)-3-{[5-ethoxy-1 -(2-fluoro-phenyl)-1 H-pyrazole-3- carbonyl]-amino}-propionic acid

724 3-(2-Chloro-4-methoxy-phenyl)-3-{[5-ethoxy-1 -(2-fluoro-phenyl)-1 H-pyrazole- 3-carbonyl]-amino}-propionic acid

725 3-{[1 -(2-Chloro-phenyl)-5-ethoxy-1 H-pyrazole-3-carbonyl]-amino}-3-(3-fluoro- 2-methyl-phenyl)-propionic acid

726 (S)-3-{[1 -(2-Chloro-phenyl)-5-ethoxy-1 H-pyrazole-3-carbonyl]-amino}-3- phenyl-propionic acid

727 (S)-3-{[1 -(2-Chloro-phenyl)-5-ethoxy-1 H-pyrazole-3-carbonyl]-amino}-3-o- tolyl-propionic acid ExCompound Name

ample

728 3-{[1 -(2-Chloro-phenyl)-5-ethoxy-1 H-pyrazole-3-carbonyl]-amino}-3-(2,4- dimethyl-phenyl)-propionic acid

729 (S)-3-{[1 -(2-Chloro-phenyl)-5-ethoxy-1 H-pyrazole-3-carbonyl]-amino}-3-(2- methoxy-phenyl)-propionic acid

730 (S)-3-{[1 -(2-Chloro-phenyl)-5-ethoxy-1 H-pyrazole-3-carbonyl]-amino}-3-(4- cyano-phenyl)-propionic acid

731 (S)-3-{[1 -(2-Chloro-phenyl)-5-ethoxy-1 H-pyrazole-3-carbonyl]-amino}-3-(3- methoxy-phenyl)-propionic acid

732 (S)-3-{[1 -(2-Chloro-phenyl)-5-ethoxy-1 H-pyrazole-3-carbonyl]-amino}-3-m- tolyl-propionic acid

733 (S)-3-(4-Chloro-phenyl)-3-{[1 -(2-chloro-phenyl)-5-ethoxy-1 H-pyrazole-3- carbonyl]-amino}-propionic acid

734 3-{[1 -(2-Chloro-phenyl)-5-ethoxy-1 H-pyrazole-3-carbonyl]-amino}-3-(4- methoxy-2-methyl-phenyl)-propionic acid

735 (S)-3-{[1 -(2-Chloro-phenyl)-5-ethoxy-1 H-pyrazole-3-carbonyl]-amino}-3-(4- trifluoromethyl-phenyl)-propionic acid

736 (S)-3-{[1 -(2-Chloro-phenyl)-5-ethoxy-1 H-pyrazole-3-carbonyl]-amino}-3-p- tolyl-propionic acid

737 (S)-3-(2-Chloro-phenyl)-3-{[1 -(2-chloro-phenyl)-5-ethoxy-1 H-pyrazole-3- carbonyl]-amino}-propionic acid

738 3-{[1 -(2-Chloro-phenyl)-5-ethoxy-1 H-pyrazole-3-carbonyl]-amino}-3-(4-fluoro- 2-methyl-phenyl)-propionic acid

739 3-{[1 -(2-Chloro-phenyl)-5-ethoxy-1 H-pyrazole-3-carbonyl]-amino}-3-(4-fluoro- phenyl)-propionic acid

740 (S)-3-{[1 -(2-Chloro-phenyl)-5-ethoxy-1 H-pyrazole-3-carbonyl]-amino}-3-(2- fluoro-phenyl)-propionic acid ExCompound Name

ample

741 (S)-3-{[1 -(2-Chloro-phenyl)-5-ethoxy-1 H-pyrazole-3-carbonyl]-amino}-3-(2- trifluoromethyl-phenyl)-propionic acid

742 (S)-3-{[1 -(2-Chloro-phenyl)-5-ethoxy-1 H-pyrazole-3-carbonyl]-amino}-3-(2,3- dichloro-phenyl)-propionic acid

743 3-{[1 -(2-Chloro-phenyl)-5-ethoxy-1 H-pyrazole-3-carbonyl]-amino}-3-(2,3- dimethyl-phenyl)-propionic acid

744 (S)-3-{[1 -(2-Fluoro-phenyl)-5-(2-hydroxy-3,3-dimethyl-butoxy)-1 H-pyrazole-3- carbonyl]-amino}-3-o-tolyl-propionic acid

745 (S)-3-{[1 -(2-Fluoro-phenyl)-5-((R)-2-hydroxy-3,3-dimethyl-butoxy)-1 H- pyrazole-3-carbonyl]-amino}-3-o-tolyl-propionic acid

(3)

746 (S)-3-{[1 -(2-Fluoro-phenyl)-5-((S)-2-hydroxy-3,3-dimethyl-butoxy)-1 H- pyrazole-3-carbonyl]-amino}-3-o-tolyl-propionic acid

(3)

747 (S)-3-{[1 -(2-Fluoro-phenyl)-5-((R)-2-hydroxy-2,3,3-trimethyl-butoxy)-1 H- pyrazole-3-carbonyl]-amino}-3-o-tolyl-propionic acid

(3)

748 (S)-3-{[1 -(2-Fluoro-phenyl)-5-((S)-2-hydroxy-2,3,3-trimethyl-butoxy)-1 H- pyrazole-3-carbonyl]-amino}-3-o-tolyl-propionic acid

(3)

749 (S)-3-{[1 -(2-Fluoro-phenyl)-5-(2-hydroxy-propoxy)-1 H-pyrazole-3-carbonyl]- amino}-3-o-tolyl-propionic acid

750 (S)-3-{[1 -(2-Fluoro-phenyl)-5-(2-hydroxy-2-methyl-butoxy)-1 H-pyrazole-3- carbonyl]-amino}-3-o-tolyl-propionic acid

751 (S)-3-(2,4-Dichloro-phenyl)-3-{[1 -(2-fluoro-phenyl)-5-(2-hydroxy-2-methyl- propoxy)-1 H-pyrazole-3-carbonyl]-amino}-propionic acid ExCompound Name

ample

752 (S)-3-{[1 -(2-Fluoro-phenyl)-5-(2-hydroxy-2-methyl-propoxy)-1 H-pyrazole-3- carbonyl]-amino}-3-o-tolyl-propionic acid

753 (S)-3-(2,4-Dichloro-phenyl)-3-{[1 -(2-fluoro-phenyl)-5-((R)-2-hydroxy-3,3- di methyl -butoxy)-1 H-pyrazole-3-carbonyl]-amino}-propionic acid

(3)

754 (S)-3-(2,4-Dichloro-phenyl)-3-{[1 -(2-fluoro-phenyl)-5-((S)-2-hydroxy-3,3- di methyl -butoxy)-1 H-pyrazole-3-carbonyl]-amino}-propionic acid

(3)

755 (S)-3-{[1 -(2-Fluoro-phenyl)-5-(2-hydroxy-butoxy)-1 H-pyrazole-3-carbonyl]- amino}-3-o-tolyl-propionic acid

756 (S)-3-{[5-(2-Ethyl-2-hydroxy-butoxy)-1 -(2-fluoro-phenyl)-1 H-pyrazole-3- carbonyl]-amino}-3-o-tolyl-propionic acid

757 (S)-3-{[5-(2-Cyclopropyl-2-hydroxy-propoxy)-1 -(2-fluoro-phenyl)-1 H-pyrazole- 3-carbonyl]-amino}-3-o-tolyl-propionic acid

758 (S)-3-(2-Chloro-phenyl)-3-{[1 -(2-fluoro-phenyl)-5-((R)-2-hydroxy-2,3,3- trimethyl-butoxy)-1 H-pyrazole-3-carbonyl]-amino}-propionic acid

(3)

759 (S)-3-(2-Chloro-phenyl)-3-{[1 -(2-fluoro-phenyl)-5-((S)-2-hydroxy-2,3,3- trimethyl-butoxy)-1 H-pyrazole-3-carbonyl]-amino}-propionic acid

(3)

760 (S)-3-{[5-((R)-2-Cyclopropyl-2-hydroxy-ethoxy)-1 -(2-fluoro-phenyl)-1 H- pyrazole-3-carbonyl]-amino}-3-o-tolyl-propionic acid

(3)

761 (S)-3-{[5-((S)-2-Cyclopropyl-2-hydroxy-ethoxy)-1 -(2-fluoro-phenyl)-1 H- pyrazole-3-carbonyl]-amino}-3-o-tolyl-propionic acid

(3) ExCompound Name

ample

762 (S)-3-(2,4-Dichloro-phenyl)-3-{[5-(2-ethyl-2-hydroxy-butoxy)-1 -(2-fluoro- phenyl)-1 H-pyrazole-3-carbonyl]-amino}-propionic acid

763 (S)-3-{[5-((R)-2-Cyclopropyl-2-hydroxy-propoxy)-1 -(2-fluoro-phenyl)-1 H- pyrazole-3-carbonyl]-amino}-3-o-tolyl-propionic acid

(3)

764 (S)-3-{[5-((S)-2-Cyclopropyl-2-hydroxy-propoxy)-1 -(2-fluoro-phenyl)-1 H- pyrazole-3-carbonyl]-amino}-3-o-tolyl-propionic acid

(3)

(S)-3-{[1 -(2-Fluoro-phenyl)-5-((R)-2-hydroxy-2,3-dimethyl-butoxy)-1 H-

765

pyrazole-3-carbonyl]-amino}-3-o-tolyl-propionic acid

(S)-3-{[1 -(2-Fluoro-phenyl)-5-((S)-2-hydroxy-2,3-dimethyl-butoxy)-1 H-

766

pyrazole-3-carbonyl]-amino}-3-p-tolyl-propionic acid

(S)-3-(3-Chloro-phenyl)-3-{[1 -(2-fluoro-phenyl)-5-((R)-2-hydroxy-2,3-dimethyl-

767

butoxy)-1 H-pyrazole-3-carbonyl]-amino}-propionic acid

(S)-3-(4-Fluoro-phenyl)-3-{[1 -(2-fluoro-phenyl)-5-((R)-2-hydroxy-2,3-dimethyl-

768

butoxy)-1 H-pyrazole-3-carbonyl]-amino}-propionic acid

(S)-3-(2,3-Dimethoxy-phenyl)-3-{[1 -(2-fluoro-phenyl)-5-((S)-2-hydroxy-2,3-

769

dimethyl-butoxy)-1 H-pyrazole-3-carbonyl]-amino}-propionic acid

(S)-3-{[1 -(2-Fluoro-phenyl)-5-(2-hydroxy-2,3-dimethyl-butoxy)-1 H-pyrazole-3-

770

carbonyl]-amino}-3-o-tolyl-propionic acid ExCompound Name

ample

(S)-3-(4-Fluoro-phenyl)-3-{[1 -(2-fluoro-phenyl)-5-((R)-2-hydroxy-2,3,3-

771

tri methyl -butoxy)-1 H-pyrazole-3-carbonyl]-amino}-propionic acid

(S)-3-(2,4-Dimethyl-phenyl)-3-{[1 -(2-fluoro-phenyl)-5-((S)-2-hydroxy-2,3-

772

di methyl -butoxy)-1 H-pyrazole-3-carbonyl]-amino}-propionic acid

3-Cyclohexyl-3-{[1 -(2-fluoro-phenyl)-5-((S)-2-hydroxy-2,3,3-trimethyl-butoxy)-

773

1 H-pyrazole-3-carbonyl]-amino}-propionic acid

(S)-3-(3-Chloro-phenyl)-3-{[1 -(2-fluoro-phenyl)-5-((R)-2-hydroxy-2,3,3-

774

tri methyl -butoxy)-1 H-pyrazole-3-carbonyl]-amino}-propionic acid

(S)-3-(2-Chloro-phenyl)-3-{[1 -(2-fluoro-phenyl)-5-(2-hydroxy-2,3-dimethyl-

775

butoxy)-1 H-pyrazole-3-carbonyl]-amino}-propionic acid

(S)-3-(2,3-Dichloro-phenyl)-3-{[1 -(2-fluoro-phenyl)-5-((R)-2-hydroxy-3,3-

776

dimethyl-butoxy)-1 H-pyrazole-3-carbonyl]-amino}-propionic acid

(S)-3-(2-Chloro-phenyl)-3-{[5-(3,3-dimethyl-2-oxo-butoxy)-1 -(2-fluoro-phenyl)-

777

1 H-pyrazole-3-carbonyl]-amino}-propionic acid

(S)-3-(3-Cyano-phenyl)-3-{[1 -(2-fluoro-phenyl)-5-((R)-2-hydroxy-2,3,3-

778

trimethyl-butoxy)-1 H-pyrazole-3-carbonyl]-amino}-propionic acid

(S)-3-(3-Fluoro-phenyl)-3-{[1 -(2-fluoro-phenyl)-5-((R)-2-hydroxy-2,3,3-

779

tri methyl -butoxy)-1 H-pyrazole-3-carbonyl]-amino}-propionic acid ExCompound Name

ample

(S)-3-{[1 -(2-Fluoro-phenyl)-5-((R)-2-hydroxy-2,3,3-trimethyl-butoxy)-1 H-

780

pyrazole-3-carbonyl]-amino}-3-p-tolyl-propionic acid

(S)-3-{[1 -(2-Fluoro-phenyl)-5-((S)-2-hydroxy-2,3,3-trimethyl-butoxy)-1 H-

781

pyrazole-3-carbonyl]-amino}-3-p-tolyl-propionic acid

(S)-3-(3-Fluoro-phenyl)-3-{[1 -(2-fluoro-phenyl)-5-(2-hydroxy-2,3-dimethyl-

782

butoxy)-1 H-pyrazole-3-carbonyl]-amino}-propionic acid

(S)-3-{[1 -(2-Fluoro-phenyl)-5-((S)-2-hydroxy-2,3-dimethyl-butoxy)-1 H-

783

pyrazole-3-carbonyl]-amino}-3-(2-methoxy-phenyl)-propionic acid

(S)-3-{[1 -(2-Fluoro-phenyl)-5-((S)-2-hydroxy-2,3-dimethyl-butoxy)-1 H-

784

pyrazole-3-carbonyl]-amino}-3-(2-trifluoromethyl-phenyl)-propionic acid

(S)-3-(3-Chloro-phenyl)-3-{[1 -(2-fluoro-phenyl)-5-(2-hydroxy-2,3-dimethyl-

785

butoxy)-1 H-pyrazole-3-carbonyl]-amino}-propionic acid

3-Cyclohexyl-3-{[1 -(2-fluoro-phenyl)-5-((R)-2-hydroxy-2,3-dimethyl-butoxy)-

786

1 H-pyrazole-3-carbonyl]-amino}-propionic acid

(S)-3-{[1 -(2-Fluoro-phenyl)-5-(2-hydroxy-2,3-dimethyl-butoxy)-1 H-pyrazole-3-

787

carbonyl]-amino}-3-p-tolyl-propionic acid

(S)-3-{[1 -(2-Fluoro-phenyl)-5-((R)-2-hydroxy-3,3-dimethyl-butoxy)-1 H-

788

pyrazole-3-carbonyl]-amino}-3-p-tolyl-propionic acid ExCompound Name

ample

(S)-3-(2-Chloro-phenyl)-3-{[1 -(2-fluoro-phenyl)-5-((S)-2-hydroxy-2,3,3-

789

tri methyl -butoxy)-1 H-pyrazole-3-carbonyl]-amino}-propionic acid

(S)-3-(2-Chloro-phenyl)-3-{[1 -(2-fluoro-phenyl)-5-((R)-2-hydroxy-2,3,3-

790

tri methyl -butoxy)-1 H-pyrazole-3-carbonyl]-amino}-propionic acid

(S)-3-{[5-(3,3-Dimethyl-2-oxo-butoxy)-1 -(2-fluoro-phenyl)-1 H-pyrazole-3-

791

carbonyl]-amino}-3-p-tolyl-propionic acid

(S)-3-{[1 -(2-Fluoro-phenyl)-5-((S)-2-hydroxy-3,3-dimethyl-butoxy)-1 H-

792

pyrazole-3-carbonyl]-amino}-3-m-tolyl-propionic acid

(S)-3-(2-Chloro-phenyl)-3-{[1 -(2-fluoro-phenyl)-5-((R)-2-hydroxy-3,3-dimethyl-

793

butoxy)-1 H-pyrazole-3-carbonyl]-amino}-propionic acid

(S)-3-(4-Chloro-phenyl)-3-{[1 -(2-fluoro-phenyl)-5-((S)-2-hydroxy-3,3-dimethyl-

794

butoxy)-1 H-pyrazole-3-carbonyl]-amino}-propionic acid

(S)-3-(3-Chloro-phenyl)-3-{[1 -(2-fluoro-phenyl)-5-((R)-2-hydroxy-3,3-dimethyl-

795

butoxy)-1 H-pyrazole-3-carbonyl]-amino}-propionic acid

(S)-3-(3-Chloro-phenyl)-3-{[5-(3,3-dimethyl-2-oxo-butoxy)-1 -(2-fluoro-phenyl)-

796

1 H-pyrazole-3-carbonyl]-amino}-propionic acid

(S)-3-(2-Chloro-phenyl)-3-{[1 -(2-fluoro-phenyl)-5-((S)-2-hydroxy-3,3-dimethyl-

797

butoxy)-1 H-pyrazole-3-carbonyl]-amino}-propionic acid ExCompound Name

ample

(S)-3-(3-Chloro-phenyl)-3-{[1 -(2-fluoro-phenyl)-5-((S)-2-hydroxy-2,3,3-

798

tri methyl -butoxy)-1 H-pyrazole-3-carbonyl]-amino}-propionic acid

(S)-3-{[1 -(2-Fluoro-phenyl)-5-((S)-2-hydroxy-2,3,3-trimethyl-butoxy)-1 H-

799

pyrazole-3-carbonyl]-amino}-3-(2-trifluoromethyl-phenyl)-propionic acid

(S)-3-(2,3-Dichloro-phenyl)-3-{[1 -(2-fluoro-phenyl)-5-((S)-2-hydroxy-3,3-

800

di methyl -butoxy)-1 H-pyrazole-3-carbonyl]-amino}-propionic acid

(S)-3-{[1 -(2-Fluoro-phenyl)-5-((S)-2-hydroxy-3,3-dimethyl-butoxy)-1 H-

801

pyrazole-3-carbonyl]-amino}-3-p-tolyl-propionic acid

(S)-3-{[1 -(2-Fluoro-phenyl)-5-(2-hydroxy-2,3-dimethyl-butoxy)-1 H-pyrazole-3-

802

carbonyl]-amino}-3-(3-methoxy-phenyl)-propionic acid

3-Cyclohexyl-3-{[1 -(2-fluoro-phenyl)-5-((S)-2-hydroxy-2,3-dimethyl-butoxy)-

803

1 H-pyrazole-3-carbonyl]-amino}-propionic acid

(S)-3-{[1 -(2-Fluoro-phenyl)-5-((R)-2-hydroxy-3,3-dimethyl-butoxy)-1 H-

804

pyrazole-3-carbonyl]-amino}-3-m-tolyl-propionic acid

(S)-3-{[5-(3,3-Dimethyl-2-oxo-butoxy)-1 -(2-fluoro-phenyl)-1 H-pyrazole-3-

805

carbonyl]-amino}-3-m-tolyl-propionic acid

(S)-3-{[1 -(2-Fluoro-phenyl)-5-((R)-2-hydroxy-2,3-dimethyl-butoxy)-1 H-

806

pyrazole-3-carbonyl]-amino}-3-(3-methoxy-phenyl)-propionic acid ExCompound Name

ample

(S)-3-(3-Cyano-phenyl)-3-{[1 -(2-fluoro-phenyl)-5-(2-hydroxy-2,3-dimethyl-

807

butoxy)-1 H-pyrazole-3-carbonyl]-amino}-propionic acid

(S)-3-(2,6-Difluoro-phenyl)-3-{[1 -(2-fluoro-phenyl)-5-(2-hydroxy-2,3-dimethyl-

808

butoxy)-1 H-pyrazole-3-carbonyl]-amino}-propionic acid

(S)-3-(3-Chloro-phenyl)-3-{[1 -(2-fluoro-phenyl)-5-((S)-2-hydroxy-3,3-dimethyl-

809

butoxy)-1 H-pyrazole-3-carbonyl]-amino}-propionic acid

(S)-3-{[1 -(2-Fluoro-phenyl)-5-((S)-2-hydroxy-2,3,3-trimethyl-butoxy)-1 H-

810

pyrazole-3-carbonyl]-amino}-3-(2-methoxy-phenyl)-propionic acid

(S)-3-{[1 -(2-Fluoro-phenyl)-5-(2-hydroxy-2,3-dimethyl-butoxy)-1 H-pyrazole-3-

81 1

carbonyl]-amino}-3-(2-methoxy-phenyl)-propionic acid

(S)-3-{[1 -(2-Fluoro-phenyl)-5-(2-hydroxy-2,3-dimethyl-butoxy)-1 H-pyrazole-3-

812

carbonyl]-amino}-3-(2-trifluoromethyl-phenyl)-propionic acid

3-Cyclohexyl-3-{[1 -(2-fluoro-phenyl)-5-(2-hydroxy-2,3-dimethyl-butoxy)-1 H-

813

pyrazole-3-carbonyl]-amino}-propionic acid

3-{[1 -(2-Fluoro-phenyl)-5-(2-hydroxy-2,3-dimethyl-butoxy)-1 H-pyrazole-3-

814

carbonyl]-amino}-5-methyl-hexanoic acid

(R)-3-(4-Chloro-phenyl)-3-{[1 -(2-fluoro-phenyl)-5-(2-hydroxy-3,3-dimethyl-

815

butoxy)-1 H-pyrazole-3-carbonyl]-amino}-propionic acid ExCompound Name

ample

(S)-3-(2,4-Dichloro-phenyl)-3-{[1 -(2-fluoro-phenyl)-5-((R)-2-hydroxy-2,3-

816

di methyl -butoxy)-1 H-pyrazole-3-carbonyl]-amino}-propionic acid

(S)-3-(2,6-Difluoro-phenyl)-3-{[1 -(2-fluoro-phenyl)-5-((S)-2-hydroxy-2,3-

817

di methyl -butoxy)-1 H-pyrazole-3-carbonyl]-amino}-propionic acid

3-{[1 -(2-Fluoro-phenyl)-5-((S)-2-hydroxy-2,3,3-trimethyl-butoxy)-1 H-pyrazole-

818

3-carbonyl]-amino}-4-phenyl-butyric acid

(S)-3-(3-Fluoro-phenyl)-3-{[1 -(2-fluoro-phenyl)-5-((S)-2-hydroxy-2,3,3-

819

trimethyl-butoxy)-1 H-pyrazole-3-carbonyl]-amino}-propionic acid

3-Cyclohexyl-3-{[1 -(2-fluoro-phenyl)-5-((R)-2-hydroxy-2,3,3-trimethyl-butoxy)-

820

1 H-pyrazole-3-carbonyl]-amino}-propionic acid

3-{[1 -(2-Fluoro-phenyl)-5-((R)-2-hydroxy-2,3-dimethyl-butoxy)-1 H-pyrazole-3-

821

carbonyl]-amino}-4-phenyl-butyric acid

(S)-3-{[1 -(2-Fluoro-phenyl)-5-((R)-2-hydroxy-2,3-dimethyl-butoxy)-1 H-

822

pyrazole-3-carbonyl]-amino}-3-(2-methoxy-phenyl)-propionic acid

3-{[1 -(2-Fluoro-phenyl)-5-((R)-2-hydroxy-2,3-dimethyl-butoxy)-1 H-pyrazole-3-

823

carbonyl]-amino}-5-methyl-hexanoic acid

(1 -{[1 -(2-Fluoro-phenyl)-5-((R)-2-hydroxy-2,3-dimethyl-butoxy)-1 H-pyrazole-3-

824

carbonyl]-amino}-cyclopentyl)-acetic acid ExCompound Name

ample

(1 -{[1 -(2-Fluoro-phenyl)-5-((S)-2-hydroxy-2,3-dimethyl-butoxy)-1 H-pyrazole-3-

825

carbonyl]-amino}-cyclopentyl)-acetic acid

3-{[1 -(2-Fluoro-phenyl)-5-((S)-2-hydroxy-2,3-dimethyl-butoxy)-1 H-pyrazole-3-

826

carbonyl]-amino}-4-phenyl-butyric acid

3-{[1 -(2-Fluoro-phenyl)-5-((R)-2-hydroxy-2,3-dimethyl-butoxy)-1 H-pyrazole-3-

827

carbonyl]-amino}-2-phenyl-propionic acid

(S)-3-(4-Chloro-phenyl)-3-{[1 -(2-fluoro-phenyl)-5-((R)-2-hydroxy-3,3-dimethyl-

828

butoxy)-1 H-pyrazole-3-carbonyl]-amino}-propionic acid

3-{[1 -(2-Fluoro-phenyl)-5-(2-hydroxy-2,3-dimethyl-butoxy)-1 H-pyrazole-3-

829

carbonyl]-amino}-4-phenyl-butyric acid

3-{[1 -(2-Fluoro-phenyl)-5-((S)-2-hydroxy-2,3-dimethyl-butoxy)-1 H-pyrazole-3-

830

carbonyl]-amino}-2-phenyl-propionic acid

(S)-4-(4-Cyano-phenyl)-3-{[1 -(2-fluoro-phenyl)-5-((S)-2-hydroxy-2,3,3-

832

tri methyl -butoxy)-1 H-pyrazole-3-carbonyl]-amino}-butyric acid

(S)-3-{[1 -(2-Fluoro-phenyl)-5-((S)-2-hydroxy-2,3-dimethyl-butoxy)-1 H-

833

pyrazole-3-carbonyl]-amino}-3-o-tolyl-propionic acid

(S)-4-(4-Cyano-phenyl)-3-{[1 -(2-fluoro-phenyl)-5-((S)-2-hydroxy-2,3-dimethyl-

834

butoxy)-1 H-pyrazole-3-carbonyl]-amino}-butyric acid ExCompound Name

ample

(S)-3-(2-Fluoro-phenyl)-3-{[1 -(2-fluoro-phenyl)-5-((S)-2-hydroxy-2,3-dimethyl-

835

butoxy)-1 H-pyrazole-3-carbonyl]-amino}-propionic acid

(S)-4-(4-Cyano-phenyl)-3-{[1 -(2-fluoro-phenyl)-5-(2-hydroxy-2,3-dimethyl-

836

butoxy)-1 H-pyrazole-3-carbonyl]-amino}-butyric acid

(S)-3-{[1 -(2-Fluoro-phenyl)-5-((S)-2-hydroxy-2,3-dimethyl-butoxy)-1 H-

837

pyrazole-3-carbonyl]-amino}-4-phenyl-butyric acid

(S)-3-{[1 -(2-Fluoro-phenyl)-5-(2-hydroxy-2,3-dimethyl-butoxy)-1 H-pyrazole-3-

838

carbonyl]-amino}-4-phenyl-butyric acid

(S)-3-(2,3-Dichloro-phenyl)-3-{[5-(3,3-dimethyl-2-oxo-butoxy)-1 -(2-fluoro-

839

phenyl)-1 H-pyrazole-3-carbonyl]-amino}-propionic acid

(S)-3-{[1 -(2-Fluoro-phenyl)-5-((S)-2-hydroxy-2,3-dimethyl-butoxy)-1 H-

840

pyrazole-3-carbonyl]-amino}-3-(4-methoxy-phenyl)-propionic acid

(S)-3-{[1 -(2-Fluoro-phenyl)-5-((S)-2-hydroxy-2,3-dimethyl-butoxy)-1 H-

841

pyrazole-3-carbonyl]-amino}-5-methyl-hexanoic acid

(S)-3-{[1 -(2-Fluoro-phenyl)-5-(2-hydroxy-2,3-dimethyl-butoxy)-1 H-pyrazole-3-

842

carbonyl]-amino}-5-methyl-hexanoic acid

(1 -{[1 -(2-Fluoro-phenyl)-5-(2-hydroxy-2,3-dimethyl-butoxy)-1 H-pyrazole-3-

843

carbonyl]-amino}-cyclopentyl)-acetic acid ExCompound Name

ample

(S)-3-(4-Fluoro-phenyl)-3-{[1 -(2-fluoro-phenyl)-5-(2-hydroxy-2,3-dimethyl-

844

butoxy)-1 H-pyrazole-3-carbonyl]-amino}-propionic acid

(S)-3-(2,4-Dimethyl-phenyl)-3-{[1 -(2-fluoro-phenyl)-5-(2-hydroxy-2,3-dimethyl-

845

butoxy)-1 H-pyrazole-3-carbonyl]-amino}-propionic acid

(S)-3-(2-Fluoro-phenyl)-3-{[1 -(2-fluoro-phenyl)-5-(2-hydroxy-2,3-dimethyl-

846

butoxy)-1 H-pyrazole-3-carbonyl]-amino}-propionic acid

(S)-3-(2,3-Dimethoxy-phenyl)-3-{[1 -(2-fluoro-phenyl)-5-(2-hydroxy-2,3-

847

di methyl -butoxy)-1 H-pyrazole-3-carbonyl]-amino}-propionic acid

(S)-3-{[1 -(2-Fluoro-phenyl)-5-(2-hydroxy-2,3-dimethyl-butoxy)-1 H-pyrazole-3-

848

carbonyl]-amino}-3-(4-methoxy-phenyl)-propionic acid

(S)-3-(2,4-Dichloro-phenyl)-3-{[1 -(2-fluoro-phenyl)-5-((S)-2-hydroxy-2,3-

849

dimethyl-butoxy)-1 H-pyrazole-3-carbonyl]-amino}-propionic acid

(S)-3-{[1 -(2-Fluoro-phenyl)-5-((R)-2-hydroxy-2,3-dimethyl-butoxy)-1 H-

850

pyrazole-3-carbonyl]-amino}-3-(4-methoxy-phenyl)-propionic acid

3-{[1 -(2-Fluoro-phenyl)-5-((S)-2-hydroxy-2,3,3-trimethyl-butoxy)-1 H-pyrazole-

851

3-carbonyl]-amino}-5-methyl-hexanoic acid

(S)-3-{[1 -(2-Fluoro-phenyl)-5-((S)-2-hydroxy-2,3,3-trimethyl-butoxy)-1 H-

852

pyrazole-3-carbonyl]-amino}-4-phenyl-butyric acid ExCompound Name

ample

(1 -{[1 -(2-Fluoro-phenyl)-5-((R)-2-hydroxy-2,3,3-trimethyl-butoxy)-1 H-pyrazole-

853

3-carbonyl]-amino}-cyclopentyl)-acetic acid

(S)-3-(2-Fluoro-phenyl)-3-{[1 -(2-fluoro-phenyl)-5-((R)-2-hydroxy-2,3,3-

854

tri methyl -butoxy)-1 H-pyrazole-3-carbonyl]-amino}-propionic acid

(S)-3-(2,3-Dimethoxy-phenyl)-3-{[1 -(2-fluoro-phenyl)-5-((R)-2-hydroxy-2,3,3-

855

trimethyl-butoxy)-1 H-pyrazole-3-carbonyl]-amino}-propionic acid

(S)-3-{[1 -(2-Fluoro-phenyl)-5-((R)-2-hydroxy-2,3,3-trimethyl-butoxy)-1 H-

856

pyrazole-3-carbonyl]-amino}-3-(3-methoxy-phenyl)-propionic acid

(S)-3-{[1 -(2-Fluoro-phenyl)-5-((R)-2-hydroxy-2,3-dimethyl-butoxy)-1 H-

857

pyrazole-3-carbonyl]-amino}-3-o-tolyl-propionic acid

(S)-3-{[1 -(2-Fluoro-phenyl)-5-((R)-2-hydroxy-2,3-dimethyl-butoxy)-1 H-

858

pyrazole-3-carbonyl]-amino}-5-methyl-hexanoic acid

(S)-3-(2,4-Dimethyl-phenyl)-3-{[1 -(2-fluoro-phenyl)-5-((R)-2-hydroxy-2,3-

859

dimethyl-butoxy)-1 H-pyrazole-3-carbonyl]-amino}-propionic acid

(S)-3-{[1 -(2-Fluoro-phenyl)-5-((R)-2-hydroxy-2,3-dimethyl-butoxy)-1 H-

860

pyrazole-3-carbonyl]-amino}-3-p-tolyl-propionic acid

(S)-3-(2-Chloro-phenyl)-3-{[1 -(2-fluoro-phenyl)-5-((R)-2-hydroxy-2,3-dimethyl-

861

butoxy)-1 H-pyrazole-3-carbonyl]-amino}-propionic acid ExCompound Name

ample

(S)-3-(2-Fluoro-phenyl)-3-{[1 -(2-fluoro-phenyl)-5-((R)-2-hydroxy-2,3-dimethyl-

862

butoxy)-1 H-pyrazole-3-carbonyl]-amino}-propionic acid

(S)-3-{[1 -(2-Fluoro-phenyl)-5-((R)-2-hydroxy-2,3-dimethyl-butoxy)-1 H-

863

pyrazole-3-carbonyl]-amino}-3-(2-trifluoromethyl-phenyl)-propionic acid

(S)-3-{[1 -(2-Fluoro-phenyl)-5-((R)-2-hydroxy-2,3-dimethyl-butoxy)-1 H-

864

pyrazole-3-carbonyl]-amino}-4-phenyl-butyric acid

(S)-3-(3-Cyano-phenyl)-3-{[1 -(2-fluoro-phenyl)-5-((R)-2-hydroxy-2,3-dimethyl-

865

butoxy)-1 H-pyrazole-3-carbonyl]-amino}-propionic acid

(S)-3-(2,3-Dimethoxy-phenyl)-3-{[1 -(2-fluoro-phenyl)-5-((R)-2-hydroxy-2,3-

866

dimethyl-butoxy)-1 H-pyrazole-3-carbonyl]-amino}-propionic acid

(S)-4-(4-Cyano-phenyl)-3-{[1 -(2-fluoro-phenyl)-5-((R)-2-hydroxy-2,3-dimethyl-

867

butoxy)-1 H-pyrazole-3-carbonyl]-amino}-butyric acid

(S)-3-(2,6-Difluoro-phenyl)-3-{[1 -(2-fluoro-phenyl)-5-((R)-2-hydroxy-2,3-

868

di methyl -butoxy)-1 H-pyrazole-3-carbonyl]-amino}-propionic acid

(S)-3-(3-Fluoro-phenyl)-3-{[1 -(2-fluoro-phenyl)-5-((R)-2-hydroxy-2,3-dimethyl-

869

butoxy)-1 H-pyrazole-3-carbonyl]-amino}-propionic acid

(S)-3-{[1 -(2-Fluoro-phenyl)-5-((S)-2-hydroxy-2,3-dimethyl-butoxy)-1 H-

870

pyrazole-3-carbonyl]-amino}-3-o-tolyl-propionic acid ExCompound Name

ample

3-{[1 -(2-Fluoro-phenyl)-5-((S)-2-hydroxy-2,3-dimethyl-butoxy)-1 H-pyrazole-3-

871

carbonyl]-amino}-5-methyl-hexanoic acid

(S)-3-(4-Fluoro-phenyl)-3-{[1 -(2-fluoro-phenyl)-5-((S)-2-hydroxy-2,3-dimethyl-

872

butoxy)-1 H-pyrazole-3-carbonyl]-amino}-propionic acid

(S)-3-(2-Chloro-phenyl)-3-{[1 -(2-fluoro-phenyl)-5-((S)-2-hydroxy-2,3-dimethyl-

873

butoxy)-1 H-pyrazole-3-carbonyl]-amino}-propionic acid

(S)-3-(3-Cyano-phenyl)-3-{[1 -(2-fluoro-phenyl)-5-((S)-2-hydroxy-2,3-dimethyl-

874

butoxy)-1 H-pyrazole-3-carbonyl]-amino}-propionic acid

(S)-3-{[1 -(2-Fluoro-phenyl)-5-((S)-2-hydroxy-2,3-dimethyl-butoxy)-1 H-

875

pyrazole-3-carbonyl]-amino}-3-(3-methoxy-phenyl)-propionic acid

(S)-3-(3-Fluoro-phenyl)-3-{[1 -(2-fluoro-phenyl)-5-((S)-2-hydroxy-2,3-dimethyl-

876

butoxy)-1 H-pyrazole-3-carbonyl]-amino}-propionic acid

(S)-3-(3-Chloro-phenyl)-3-{[1 -(2-fluoro-phenyl)-5-((S)-2-hydroxy-2,3-dimethyl-

877

butoxy)-1 H-pyrazole-3-carbonyl]-amino}-propionic acid

(S)-3-{[1 -(2-Fluoro-phenyl)-5-((S)-2-hydroxy-2,3,3-trimethyl-butoxy)-1 H-

878

pyrazole-3-carbonyl]-amino}-5-methyl-hexanoic acid

(1 -{[1 -(2-Fluoro-phenyl)-5-((S)-2-hydroxy-2,3,3-trimethyl-butoxy)-1 H-pyrazole-

879

3-carbonyl]-amino}-cyclopentyl)-acetic acid ExCompound Name

ample

(S)-3-(4-Fluoro-phenyl)-3-{[1 -(2-fluoro-phenyl)-5-((S)-2-hydroxy-2,3,3-

880

tri methyl -butoxy)-1 H-pyrazole-3-carbonyl]-amino}-propionic acid

(S)-3-(2,4-Dimethyl-phenyl)-3-{[1 -(2-fluoro-phenyl)-5-((S)-2-hydroxy-2,3,3-

881

tri methyl -butoxy)-1 H-pyrazole-3-carbonyl]-amino}-propionic acid

(S)-3-(2-Fluoro-phenyl)-3-{[1 -(2-fluoro-phenyl)-5-((S)-2-hydroxy-2,3,3-

883

trimethyl-butoxy)-1 H-pyrazole-3-carbonyl]-amino}-propionic acid

(S)-3-(2,3-Dimethoxy-phenyl)-3-{[1 -(2-fluoro-phenyl)-5-((S)-2-hydroxy-2,3,3-

884

tri methyl -butoxy)-1 H-pyrazole-3-carbonyl]-amino}-propionic acid

(S)-3-{[1 -(2-Fluoro-phenyl)-5-((S)-2-hydroxy-2,3,3-trimethyl-butoxy)-1 H-

885

pyrazole-3-carbonyl]-amino}-3-(3-methoxy-phenyl)-propionic acid

(S)-3-{[1 -(2-Fluoro-phenyl)-5-((R)-2-hydroxy-2,3,3-trimethyl-butoxy)-1 H-

886

pyrazole-3-carbonyl]-amino}-5-methyl-hexanoic acid

(S)-3-{[1 -(2-Fluoro-phenyl)-5-((R)-2-hydroxy-2,3,3-trimethyl-butoxy)-1 H-

888

pyrazole-3-carbonyl]-amino}-3-(2-trifluoromethyl-phenyl)-propionic acid

(S)-4-(4-Cyano-phenyl)-3-{[1 -(2-fluoro-phenyl)-5-((R)-2-hydroxy-2,3,3-

889

trimethyl-butoxy)-1 H-pyrazole-3-carbonyl]-amino}-butyric acid

(S)-3-{[1 -(2-Fluoro-phenyl)-5-((R)-2-hydroxy-2,3,3-trimethyl-butoxy)-1 H-

890

pyrazole-3-carbonyl]-amino}-3-(4-methoxy-phenyl)-propionic acid ExCompound Name

ample

(S)-3-{[1 -(2-Fluoro-phenyl)-5-(2-hydroxy-2-phenyl-propoxy)-1 H-pyrazole-3-

891

carbonyl]-amino}-3-o-tolyl-propionic acid

1 -(2-Fluoro-phenyl)-5-methoxy-1 H-pyrazole-3-carboxylic acid {(S)-2-

892 [(pyridin-2-ylmethyl)-carbamoyl]-1 -o-tolyl-ethyl}-amide; compound with

trifluoro-acetic acid

1 -(2-Fluoro-phenyl)-5-methoxy-1 H-pyrazole-3-carboxylic acid [(S)-2-

893

(cyclopropylmethyl-carbamoyl)-1 -o-tolyl-ethyl]-amide

1 - (2-Fluoro-phenyl)-5-methoxy-1 H-pyrazole-3-carboxylic acid {(S)-2-[(furan-

894

2- ylmethyl)-carbamoyl]-1 -o-tolyl-ethyl}-amide

1 -(2-Fluoro-phenyl)-5-methoxy-1 H-pyrazole-3-carboxylic acid [(S)-2-(3-

895 dimethylamino-propylcarbamoyl)-1 -o-tolyl-ethyl]-amide; compound with

trifluoro-acetic acid

1 -(2-Fluoro-phenyl)-5-methoxy-1 H-pyrazole-3-carboxylic acid [(S)-2-(1 -ethyl-

896

propylcarbamoyl)-1 -o-tolyl-ethyl]-amide

1 -(2-Fluoro-phenyl)-5-methoxy-1 H-pyrazole-3-carboxylic acid ((S)-2-

897

cyclohexylcarbamoyl-1 -o-tolyl-ethyl)-amide

1 -(2-Fluoro-phenyl)-5-methoxy-1 H-pyrazole-3-carboxylic acid [(S)-3-((S)-3-

898

hydroxy-pyrrolidin-1 -yl)-3-oxo-1 -o-tolyl-propyl]-amide

1 - (2-Fluoro-phenyl)-5-methoxy-1 H-pyrazole-3-carboxylic acid [(S)-1 -o-tolyl-

899

2- ((R)-1 ,2,2-trimethyl-propylcarbamoyl)-ethyl]-amide ExCompound Name

ample

1 -(2-Fluoro-phenyl)-5-methoxy-1 H-pyrazole-3-carboxylic acid [(S)-3-((R)-3-

900

hydroxy-pyrrolidin-1 -yl)-3-oxo-1 -o-tolyl-propyl]-amide

1 -(2-Fluoro-phenyl)-5-methoxy-1 H-pyrazole-3-carboxylic acid [(S)-2-((S)-

901

sec-butylcarbamoyl)-1 -o-tolyl-ethyl]-amide

1 -(2-Fluoro-phenyl)-5-methoxy-1 H-pyrazole-3-carboxylic acid [(S)-3-((S)-3-

902

hydroxy-piperidin-1 -yl)-3-oxo-1 -o-tolyl-propyl]-amide

1 -(2-Fluoro-phenyl)-5-methoxy-1 H-pyrazole-3-carboxylic acid [(S)-2-

903

(carbamoylmethyl-methyl-carbamoyl)-1 -o-tolyl-ethyl]-amide

1 -(2-Fluoro-phenyl)-5-methoxy-1 H-pyrazole-3-carboxylic acid [(S)-2-((R)-1 -

904

cyclopropyl-ethylcarbamoyl)-1 -o-tolyl-ethyl]-amide

1 -(2-Fluoro-phenyl)-5-methoxy-1 H-pyrazole-3-carboxylic acid [(S)-2-((S)-1 -

905

cyclopropyl-ethylcarbamoyl)-1 -o-tolyl-ethyl]-amide

1 -(2-Fluoro-phenyl)-5-methoxy-1 H-pyrazole-3-carboxylic acid ((S)-2-

906

cyclobutylcarbamoyl-1 -o-tolyl-ethyl)-amide

1 -(2-Fluoro-phenyl)-5-methoxy-1 H-pyrazole-3-carboxylic acid {(S)-2-

907 [(pyridin-3-ylmethyl)-carbamoyl]-1 -o-tolyl-ethyl}-amide; compound with trifluoro-acetic acid

1 -(2-Fluoro-phenyl)-5-methoxy-1 H-pyrazole-3-carboxylic acid ((S)-2-

908

cyclopentylcarbamoyl-1 -o-tolyl-ethyl)-amide ExCompound Name

ample

1 -(2-Fluoro-phenyl)-5-methoxy-1 H-pyrazole-3-carboxylic acid [(S)-2-(2-

909

methoxy-1 -methyl-ethylcarbamoyl)-1 -o-tolyl-ethyl]-amide

1 -(2-Fluoro-phenyl)-5-methoxy-1 H-pyrazole-3-carboxylic acid [(S)-2-(2,2-

910

difluoro-ethylcarbamoyl)-1 -o-tolyl-ethyl]-amide

1 - (2-Fluoro-phenyl)-5-methoxy-1 H-pyrazole-3-carboxylic acid [(S)-1 -o-tolyl-

91 1

2- (2,2,2-trifluoro-ethylcarbamoyl)-ethyl]-amide

1 -(2-Fluoro-phenyl)-5-methoxy-1 H-pyrazole-3-carboxylic acid [(S)-2-(2-

912

cyclopropyl-ethylcarbamoyl)-1 -o-tolyl-ethyl]-amide

1 -(2-Fluoro-phenyl)-5-methoxy-1 H-pyrazole-3-carboxylic acid {(S)-2-

913

[(pyrimidin-5-ylmethyl)-carbamoyl]-1 -o-tolyl-ethyl}-amide

1 -(2-Fluoro-phenyl)-5-methoxy-1 H-pyrazole-3-carboxylic acid ((S)-2-

914

butylcarbamoyl-1 -o-tolyl-ethyl)-amide

1 -(2-Fluoro-phenyl)-5-methoxy-1 H-pyrazole-3-carboxylic acid {(S)-2-[(furan-

915

3-ylmethyl)-carbamoyl]-1 -o-tolyl-ethyl}-amide

1 -(2-Fluoro-phenyl)-5-methoxy-1 H-pyrazole-3-carboxylic acid {(S)-2-

916 [(pyridin-4-ylmethyl)-carbamoyl]-1 -o-tolyl-ethyl}-amide; compound with

trifluoro-acetic acid

1 -(2-Fluoro-phenyl)-5-methoxy-1 H-pyrazole-3-carboxylic acid [(S)-2-(1 ,1 -

917

dimethyl-propylcarbamoyl)-1 -o-tolyl-ethyl]-amide ExCompound Name

ample

1 -(2-Fluoro-phenyl)-5-methoxy-1 H-pyrazole-3-carboxylic acid [(S)-2-((R)-

918

sec-butylcarbamoyl)-1 -o-tolyl-ethyl]-amide

1 -(2-Fluoro-phenyl)-5-methoxy-1 H-pyrazole-3-carboxylic acid ((S)-2-

919

isobutylcarbamoyl-1 -o-tolyl-ethyl)-amide

1 - (2-Fluoro-phenyl)-5-methoxy-1 H-pyrazole-3-carboxylic acid [(S)-1 -o-tolyl-

920

2- ((S)-1 ,2,2-trimethyl-propylcarbamoyl)-ethyl]-amide

1 -(2-Fluoro-phenyl)-5-methoxy-1 H-pyrazole-3-carboxylic acid [(S)-2-(1 -

921

methoxymethyl-propylcarbamoyl)-1 -o-tolyl-ethyl]-amide

1 -(2-Fluoro-phenyl)-5-methoxy-1 H-pyrazole-3-carboxylic acid ((S)-2-tert-

922

butylcarbamoyl-1 -o-tolyl-ethyl)-amide

1 -(2-Fluoro-phenyl)-5-methoxy-1 H-pyrazole-3-carboxylic acid [(S)-2-(5-

923

methyl-1 H-pyrazol-3-ylcarbamoyl)-1 -o-tolyl-ethyl]-amide

1 -(2-Fluoro-phenyl)-5-methoxy-1 H-pyrazole-3-carboxylic acid [(S)-2-(2,2-

924

dimethyl-propylcarbamoyl)-1 -o-tolyl-ethyl]-amide

1 -(2-Fluoro-phenyl)-5-methoxy-1 H-pyrazole-3-carboxylic acid [(S)-2-(3-

925

hydroxy-2,2-dimethyl-propylcarbamoyl)-1 -o-tolyl-ethyl]-amide

1 -(2-Fluoro-phenyl)-5-methoxy-1 H-pyrazole-3-carboxylic acid [(S)-2-

926

(cyanomethyl-carbamoyl)-1 -o-tolyl-ethyl]-amide ExCompound Name

ample

1 -(2-Fluoro-phenyl)-5-methoxy-1 H-pyrazole-3-carboxylic acid [(S)-2-((R)-1 -

927

hydroxymethyl-2-methyl-propylcarbamoyl)-1 -o-tolyl-ethyl]-amide

1 -(2-Fluoro-phenyl)-5-methoxy-1 H-pyrazole-3-carboxylic acid {(S)-2-[(1 H-

928

tetrazol-5-ylmethyl)-carbamoyl]-1 -o-tolyl-ethyl}-amide

1 -(2-Fluoro-phenyl)-5-methoxy-1 H-pyrazole-3-carboxylic acid ((S)-2-

929

isopropylcarbamoyl-1 -o-tolyl-ethyl)-amide

1 -(2-Fluoro-phenyl)-5-methoxy-1 H-pyrazole-3-carboxylic acid [(S)-2-(1 -

930

methyl-1 H-pyrazol-3-ylcarbamoyl)-1 -o-tolyl-ethyl]-amide

1 -(2-Fluoro-phenyl)-5-methoxy-1 H-pyrazole-3-carboxylic acid [(S)-2-(2-oxo-

931

pyrrolidin-3-ylcarbamoyl)-1 -o-tolyl-ethyl]-amide

1 -(2-Fluoro-phenyl)-5-methoxy-1 H-pyrazole-3-carboxylic acid [(S)-2-(5-

932

methyl-isoxazol-3-ylcarbamoyl)-1 -o-tolyl-ethyl]-amide

1 -(2-Fluoro-phenyl)-5-methoxy-1 H-pyrazole-3-carboxylic acid ((S)-2-

933

cyclopropylcarbamoyl-1 -o-tolyl-ethyl)-amide

1 -(2-Fluoro-phenyl)-5-methoxy-1 H-pyrazole-3-carboxylic acid {(S)-2-

934

[(isoxazol-5-ylmethyl)-carbamoyl]-1 -o-tolyl-ethyl}-amide

1 -(2-Fluoro-phenyl)-5-methoxy-1 H-pyrazole-3-carboxylic acid [(S)-2-(2-

935

methoxy-ethylcarbamoyl)-1 -o-tolyl-ethyl]-amide ExCompound Name

ample

1 -(2-Fluoro-phenyl)-5-methoxy-1 H-pyrazole-3-carboxylic acid [(S)-2-((S)-1 -

936

hydroxymethyl-2-methyl-propylcarbamoyl)-1 -o-tolyl-ethyl]-amide

1 -(2-Fluoro-phenyl)-5-methoxy-1 H-pyrazole-3-carboxylic acid [(S)-2-((S)-2-

937

methoxy-1 -methyl-ethylcarbamoyl)-1 -o-tolyl-ethyl]-amide

1 -(2-Fluoro-phenyl)-5-methoxy-1 H-pyrazole-3-carboxylic acid ((S)-2-{[(S)-1 -

938

(tetrahydro-furan-2-yl)methyl]-carbamoyl}-1 -o-tolyl-ethyl)-amide

1 -(2-Fluoro-phenyl)-5-methoxy-1 H-pyrazole-3-carboxylic acid [(S)-2-((R)-1 ,2-

939

dimethyl-propylcarbamoyl)-1 -o-tolyl-ethyl]-amide

(3) The two compounds of examples 745 and 746; the two compounds of examples 747 and 748; the two compounds of examples 753 and 754; the two compounds of examples 758 and 759; the two compounds of examples 760 and 761 ; and the two compounds of examples 763 and 764 each are two diastereomeric compounds, one of them being the diastereomer with R configuration in the alcohol moiety and the other of them being the diastereomer with S configuration in the alcohol moiety (the

stereochemistry in the alcohol moiety was not determined; it was arbitrarily assigned R configuration in the first diastereomer eluted from the chromatography column and S configuration in the second diastereomer eluted from the chromatography column). Compound Table 2. Example compounds of the formula II

Ex.

Compound name

No.

(S)-3-[(5-Methoxy-6-phenyl-pyhdine-2-carbonyl)-amino]-3-o-tolyl-propionic

1

acid

(S)-3-(2,4-Dichloro-phenyl)-3-[(5-methoxy-6-phenyl-pyhdine-2-carbonyl)-

2

amino]-propionic acid

(S)-3-[(6-Chloro-5-methoxy-pyridine-2-carbonyl)-amino]-3-o-tolyl-propionic

3

acid

(S)-3-{[3-(4,6-Dimethoxy-pyrimidin-2-yloxy)-pyhdine-2-carbonyl]-amino}-3-o-

4

tolyl-propionic acid

5 (S)-3-[(Pyhdine-2-carbonyl)-amino]-3-o-tolyl-propionic acid

6 (S)-3-[(Pyhdine-4-carbonyl)-amino]-3-o-tolyl-propionic acid

7 (S)-3-[(5-Bromo-pyridine-3-carbonyl)-amino]-3-o-tolyl-propionic acid

8 (S)-3-[(Pyhdine-3-carbonyl)-amino]-3-o-tolyl-propionic acid

9 (S)-3-[(3-Methoxy-pyhdine-2-carbonyl)-amino]-3-o-tolyl-propionic acid

10 (S)-3-[(6-Methyl-pyridine-2-carbonyl)-amino]-3-o-tolyl-propionic acid

1 1 (S)-3-[(4,6-Dimethyl-pyridine-3-carbonyl)-amino]-3-o-tolyl-propionic acid

12 (S)-3-[(6-Methylamino-pyrazine-2-carbonyl)-amino]-3-o-tolyl-propionic acid

(S)-3-[(2,6-Bis-dimethylamino-pyhmidine-4-carbonyl)-amino]-3-o-tolyl-

13

propionic acid (S)-3-[(4-Methyl-pyridine-2-carbonyl)-amino]-3-o-tolyl-propionic acid

(S)-3-[(5-Phenyl-pyridine-3-carbonyl)-annino]-3-o-tolyl-propionic acid

(S)-3-[(2,6-Dimethoxy-pyrimidine-4-carbonyl)-amino]-3-o-tolyl-propionic acid

(S)-3-[([1 ,6]Naphthyridine-2-carbonyl)-annino]-3-o-tolyl-propionic acid

(S)-3-[(4-Ethyl-pyridine-2-carbonyl)-amino]-3-o-tolyl-propionic acid

(S)-3-[(2-Acetylamino-pyridine-4-carbonyl)-annino]-3-o-tolyl-propionic acid

(S)-3-[(3,4,5,6-Tetrahydro-2H-[1 ,2']bipyridinyl-4'-carbonyl)-amino]-3-o-tolyl- propionic acid

(S)-3-[(2-Methoxy-pyridine-4-carbonyl)-annino]-3-o-tolyl-propionic acid

(S)-3-{[2-(2,2-Dimethyl-propionylamino)-pyridine-4-carbonyl]-amino}-3-o- tolyl-propionic acid

(S)-3-[(6-Bromo-5-nnethoxy-pyridine-2-carbonyl)-annino]-3-o-tolyl-propionic acid

(S)-3-[(6-Methoxy-pyridine-3-carbonyl)-annino]-3-o-tolyl-propionic acid

(S)-3-[(6-Morpholin-4-yl-pyridine-2-carbonyl)-amino]-3-o-tolyl-propionic acid

(S)-3-[(2-Pyrrolidin-1 -yl-pyridine-4-carbonyl)-amino]-3-o-tolyl-propionic acid

(S)-3-[(1 -Ethyl-3,6-dimethyl-1 H-pyrazolo[3,4-b]pyridine-4-carbonyl)-amino]- 3-o-tolyl-propionic acid

(S)-3-[(6-Cyclopropyl-1 ,3-dimethyl-1 H-pyrazolo[3,4-b]pyridine-4-carbonyl)- amino]-3-o-tolyl-propionic acid (S)-3-[(2-Morpholin-4-yl-pyridine-4-carbonyl)-amino]-3-o-tolyl-propionic acid

(S)-3-[(4,6-Dimethoxy-pyrimidine-2-carbonyl)-amino]-3-o-tolyl-propionic acid

(S)-3-[(6-Methoxy-pyridine-2-carbonyl)-annino]-3-o-tolyl-propionic acid

(S)-3-{[6-(Tetrahydro-pyran-4-yloxy)-pyridine-3-carbonyl]-annino}-3-o-tolyl- propionic acid

(S)-3-[(3-Fluoro-pyridine-2-carbonyl)-annino]-3-o-tolyl-propionic acid

(S)-3-[(3H-lmidazo[4,5-b]pyridine-5-carbonyl)-amino]-3-o-tolyl-propionic acid; compound with trifluoro-acetic acid

(S)-3-{[4-(Pyrimidin-2-ylsulfanyl)-pyndine-2-carbonyl]-amino}-3-o-tolyl- propionic acid

(S)-3-[(2-Methyl-pyridine-4-carbonyl)-amino]-3-o-tolyl-propionic acid

(S)-3-[(6-Phenyl-pyridine-2-carbonyl)-annino]-3-o-tolyl-propionic acid

(S)-3-[(3-Phenyl-pyridine-2-carbonyl)-annino]-3-o-tolyl-propionic acid

(S)-3-[(4-Phenyl-pyridine-2-carbonyl)-annino]-3-o-tolyl-propionic acid

(S)-3-[(5-Phenyl-pyridine-2-carbonyl)-annino]-3-o-tolyl-propionic acid

(S)-3-[(5-Pyrrolidin-1 -yl-pyridine-3-carbonyl)-amino]-3-o-tolyl-propionic acid; compound with trifluoro-acetic acid

(S)-3-[(5-Methyl-pyrazine-2-carbonyl)-amino]-3-o-tolyl-propionic acid

(S)-3-{[6-(3-Methoxy-phenyl)-pyridine-2-carbonyl]-amino}-3-o-tolyl-propionic acid (S)-3-{[6-(2-Methoxy-phenyl)-pyridine-2-carbonyl]-amino}-3-o-tolyl-propionic acid

(S)-3-{[6-(4-Methoxy-phenyl)-pyridine-2-carbonyl]-amino}-3-o-tolyl-propionic acid

(S)-3-[(6-Phenoxy-pyridine-3-carbonyl)-amino]-3-o-tolyl-propionic acid

(S)-3-[(4-Hydroxy-pyridine-2-carbonyl)-amino]-3-o-tolyl-propionic acid

(S)-3-[(6-Fluoro-pyridine-2-carbonyl)-annino]-3-o-tolyl-propionic acid

(S)-3-[(6-Pyrrolidin-1 -yl-pyridine-3-carbonyl)-amino]-3-o-tolyl-propionic acid

(S)-3-[(4-Morpholin-4-yl-pyridine-2-carbonyl)-amino]-3-o-tolyl-propionic acid

(S)-3-[(4,6-Dimethyl-pyridine-2-carbonyl)-amino]-3-o-tolyl-propionic acid

(S)-3-[(2-Amino-6-isobutyl-pyrimidine-4-carbonyl)-amino]-3-o-tolyl-propionic acid; compound with trifluoro-acetic acid

(S)-3-[(3,6-Difluoro-pyridine-2-carbonyl)-annino]-3-o-tolyl-propionic acid

(S)-3-[(3,4,5,6-Tetrahydro-2H-[1 ,2']bipyridinyl-6'-carbonyl)-amino]-3-o-tolyl- propionic acid

(S)-3-[(2,6-Dimethyl-pyrimidine-4-carbonyl)-amino]-3-o-tolyl-propionic acid

(S)-3-[(6-lmidazol-1 -yl-pyridine-2-carbonyl)-amino]-3-o-tolyl-propionic acid

(S)-3-{[5-(4-Methoxy-phenyl)-pyridine-3-carbonyl]-annino}-3-o-tolyl-propionic acid

(S)-3-[(6-Methoxy-[2,4']bipyridinyl-4-carbonyl)-annino]-3-o-tolyl-propionic acid; compound with trifluoro-acetic acid (S)-3-[(6-Methoxy-[2,3']bipyridinyl-4-carbonyl)-amino]-3-o-tolyl-propionic acid; compound with trifluoro-acetic acid

(S)-3-o-Tolyl-3-{[5-(3-tnfluoromethyl-phenyl)-pyridine-3-carbonyl]-amino}- propionic acid

(S)-3-{[5-(2,4-Dichloro-phenyl)-pyridine-3-carbonyl]-annino}-3-o-tolyl- propionic acid

(S)-3-{[5-(4-Fluoro-phenyl)-pyridine-3-carbonyl]-annino}-3-o-tolyl-propionic acid

(S)-3-o-Tolyl-3-[(5-p-tolyl-pyridine-3-carbonyl)-annino]-propionic acid

(S)-3-o-Tolyl-3-{[5-(4-tnfluoromethyl-phenyl)-pyridine-3-carbonyl]-amino}- propionic acid

(S)-3-{[5-(3-Methoxy-phenyl)-pyridine-3-carbonyl]-annino}-3-o-tolyl-propionic acid

(S)-3-o-Tolyl-3-{[5-(2-tnfluoromethyl-phenyl)-pyridine-3-carbonyl]-amino}- propionic acid

(S)-3-{[5-(2-Methoxy-phenyl)-pyridine-3-carbonyl]-annino}-3-o-tolyl-propionic acid

(S)-3-o-Tolyl-3-[(5-m-tolyl-pyridine-3-carbonyl)-annino]-propionic acid

(S)-3-{[5-(2-Fluoro-phenyl)-pyridine-3-carbonyl]-annino}-3-o-tolyl-propionic acid

(S)-3-{[5-(3-Cyano-phenyl)-pyridine-3-carbonyl]-amino}-3-o-tolyl-propionic acid

(S)-3-{[5-(4-Cyano-phenyl)-pyridine-3-carbonyl]-amino}-3-o-tolyl-propionic acid

(S)-3-{[5-(3,4-Dimethoxy-phenyl)-pyndine-3-carbonyl]-annino}-3-o-tolyl- propionic acid

(S)-3-{[5-(2,4-Difluoro-phenyl)-pyridine-3-carbonyl]-annino}-3-o-tolyl- propionic acid (S)-3-{[5-(3,4-Difluoro-phenyl)-pyridine-3-carbonyl]-annino}-3-o-tolyl-

74

propionic acid

(S)-3-{[5-(2,6-Difluoro-phenyl)-pyridine-3-carbonyl]-annino}-3-o-tolyl-

75

propionic acid

(S)-3-[(5-Benzo[1 ,3]dioxol-5-yl-pyridine-3-carbonyl)-annino]-3-o-tolyl-

76

propionic acid

(S)-3-{[5-(3,4-Dimethyl-phenyl)-pyndine-3-carbonyl]-annino}-3-o-tolyl-

77

propionic acid

(S)-3-o-Tolyl-3-{[5-(3,4,5-trinnethoxy-phenyl)-pyndine-3-carbonyl]-annino}-

78

propionic acid

(S)-3-{[5-(2,3-Difluoro-phenyl)-pyridine-3-carbonyl]-annino}-3-o-tolyl-

79

propionic acid

(S)-3-{[5-(2-Cyano-phenyl)-pyridine-3-carbonyl]-amino}-3-o-tolyl-propionic

80

acid

(S)-3-{[5-(3,5-Dimethyl-isoxazol-4-yl)-pyndine-3-carbonyl]-annino}-3-o-tolyl-

81

propionic acid

(S)-3-{[5-(4-Fluoro-2-methyl-phenyl)-pyridine-3-carbonyl]-annino}-3-o-tolyl-

82

propionic acid

(S)-3-[(5-Pyrimidin-5-yl-pyridine-3-carbonyl)-amino]-3-o-tolyl-propionic acid;

83

compound with trifluoro-acetic acid

(S)-3-{[5-(2-Dimethylcarbamoyl-phenyl)-pyridine-3-carbonyl]-amino}-3-o-

84

tolyl-propionic acid

(S)-3-{[5-(4-Fluoro-2-methoxy-phenyl)-pyridine-3-carbonyl]-annino}-3-o-tolyl-

85

propionic acid

(S)-3-{[5-(2-Methoxy-4-trifluoromethyl-phenyl)-pyridine-3-carbonyl]-amino}-3-

86

o-tolyl-propionic acid

(S)-3-{[5-(1 -Benzyl-1 H-pyrazol-4-yl)-pyridine-3-carbonyl]-annino}-3-o-tolyl-

87

propionic acid

(S)-3-{[5-(2-Fluoro-5-methoxy-phenyl)-pyridine-3-carbonyl]-annino}-3-o-tolyl-

88

propionic acid (S)-3-{[5-(2-Dimethylamino-pyrimidin-5-yl)-pyridine-3-carbonyl]-ami^

89

tolyl-propionic acid; compound with trifluoro-acetic acid

(S)-3-[(2'-Morpholin-4-yl-[3,4']bipyridinyl-5-carbonyl)-amino]-3-o-tolyl-

90

propionic acid

91 (S)-3-[(5'-Fluoro-[3,3]bipyridinyl-5-carbonyl)-amino]-3-o-tolyl-propionic acid

(S)-3-{[2-(4-Methoxy-phenyl)-pyridine-4-carbonyl]-amino}-3-o-tolyl-propionic

92

acid

(S)-3-o-Tolyl-3-{[2-(4-tnfluoromethyl-phenyl)-pyridine-4-carbonyl]-amino}-

93

propionic acid

(S)-3-{[2-(3-Methoxy-phenyl)-pyridine-4-carbonyl]-amino}-3-o-tolyl-propionic

94

acid

(S)-3-{[2-(2-Methoxy-phenyl)-pyridine-4-carbonyl]-amino}-3-o-tolyl-propionic

95

acid

96 (S)-3-o-Tolyl-3-[(2-m-tolyl-pyridine-4-carbonyl)-annino]-propionic acid

(S)-3-{[2-(2-Fluoro-phenyl)-pyridine-4-carbonyl]-annino}-3-o-tolyl-propionic

97

acid

(S)-3-{[2-(3,4-Dimethoxy-phenyl)-pyndine-4-carbonyl]-annino}-3-o-tolyl-

98

propionic acid

(S)-3-{[2-(3,5-Difluoro-phenyl)-pyridine-4-carbonyl]-annino}-3-o-tolyl-

99

propionic acid

(S)-3-{[2-(3,4-Difluoro-phenyl)-pyridine-4-carbonyl]-annino}-3-o-tolyl-

100

propionic acid

(S)-3-[(2-Benzo[1 ,3]dioxol-5-yl-pyridine-4-carbonyl)-annino]-3-o-tolyl-

101

propionic acid

(S)-3-o-Tolyl-3-{[2-(3,4,5-trinnethoxy-phenyl)-pyndine-4-carbonyl]-annino}-

102

propionic acid

103 (S)-3-[([2,3']Bipyridinyl-4-carbonyl)-annino]-3-o-tolyl-propionic acid (S)-3-{[2-(2,5-Dichloro-phenyl)-pyridine-4-carbonyl]-annino}-3-o-tolyl-

104

propionic acid

(S)-3-{[2-(3,5-Dimethyl-isoxazol-4-yl)-pyndine-4-carbonyl]-annino}-3-o-tolyl-

105

propionic acid

106 (S)-3-[(2'-Methyl-[2,4 bipyridinyl-4-carbonyl)-amino]-3-o-tolyl-propionic acid

(S)-3-{[2-(4-Fluoro-2-methoxy-phenyl)-pyridine-4-carbonyl]-annino}-3-o-tolyl-

107

propionic acid

(S)-3-{[2-(1 -Benzyl-1 H-pyrazol-4-yl)-pyridine-4-carbonyl]-annino}-3-o-tolyl-

108

propionic acid; compound with trifluoro-acetic acid

(S)-3-{[2-(2-Fluoro-5-methoxy-phenyl)-pyridine-4-carbonyl]-annino}-3-o-tolyl-

109

propionic acid

(S)-3-{[2-(3-Cyclopropylmethoxy-phenyl)-pyridine-4-carbonyl]-annino}-3-o-

1 10

tolyl-propionic acid

(S)-3-{[5-(3-Chloro-4-fluoro-phenyl)-pyridine-3-carbonyl]-amino}-3-o-tolyl-

1 1 1

propionic acid

(S)-3-{[5-(2-Chloro-phenyl)-pyridine-3-carbonyl]-annino}-3-o-tolyl-propionic

1 12

acid

(S)-3-{[5-(4-tert-Butyl-phenyl)-pyridine-3-carbonyl]-annino}-3-o-tolyl-propionic

1 13

acid

(S)-3-{[5-(2,3-Dichloro-phenyl)-pyridine-3-carbonyl]-annino}-3-o-tolyl-

1 14

propionic acid

1 15 (S)-3-[([3,4']Bipyridinyl-5-carbonyl)-annino]-3-o-tolyl-propionic acid

(S)-3-{[5-(2,3-Dimethyl-phenyl)-pyridine-3-carbonyl]-amino}-3-o-tolyl-

1 16

propionic acid

(S)-3-{[5-(2,4-Dimethyl-phenyl)-pyridine-3-carbonyl]-amino}-3-o-tolyl-

1 17

propionic acid

1 18 (S)-3-[(2'-Methyl-[3,4 bipyridinyl-5-carbonyl)-amino]-3-o-tolyl-propionic acid (S)-3-{[5-(4-Chloro-2-methoxy-phenyl)-pyridine-3-carbonyl]-amino}-3-o-tolyl- propionic acid

(S)-3-({5-[3-(5-Methyl-[1 ,3,4]oxadiazol-2-yl)-phenyl]-pyridine-3-carbonyl}- amino)-3-o-tolyl-propionic acid

(S)-3-{[5-(3-Chloro-4-dimethylcarbannoyl-phenyl)-pyndine-3-carbonyl]- amino}-3-o-tolyl-propionic acid

(S)-3-[(2-Biphenyl-3-yl-pyridine-4-carbonyl)-amino]-3-o-tolyl-propionic acid

(S)-3-{[2-(2,3-Dichloro-phenyl)-pyridine-4-carbonyl]-annino}-3-o-tolyl- propionic acid

(S)-3-{[2-(3,4-Dimethyl-phenyl)-pyridine-4-carbonyl]-amino}-3-o-tolyl- propionic acid

(S)-3-{[2-(2,3-Difluoro-phenyl)-pyridine-4-carbonyl]-annino}-3-o-tolyl- propionic acid

(S)-3-{[2-(2-Cyano-phenyl)-pyridine-4-carbonyl]-amino}-3-o-tolyl-propionic acid

(S)-3-{[2-(4-Fluoro-2-methyl-phenyl)-pyridine-4-carbonyl]-annino}-3-o-tolyl- propionic acid

(S)-3-{[2-(2-Methoxy-4-trifluoromethyl-phenyl)-pyridine-4-carbonyl]-amino}-3- o-tolyl-propionic acid

(S)-3-{[2-(4-Chloro-2-methoxy-phenyl)-pyridine-4-carbonyl]-annino}-3-o-tolyl- propionic acid

(S)-3-[(2'-Morpholin-4-yl-[2,4']bipyridinyl-4-carbonyl)-amino]-3-o-tolyl- propionic acid

(S)-3-[(5'-Fluoro-[2,3']bipyridinyl-4-carbonyl)-amino]-3-o-tolyl-propionic acid

(S)-3-({2-[3-(1 -Hydroxy-1 -methyl-ethyl)-phenyl]-pyridine-4-carbonyl}-amino)- 3-o-tolyl-propionic acid

(S)-3-o-Tolyl-3-{[6-(3-tnfluoromethyl-phenyl)-pyridine-2-carbonyl]-amino}- propionic acid (S)-3-{[6-(3-Chloro-4-fluoro-phenyl)-pyridine-2-carbonyl]-amino}-3-o-tolyl-

134

propionic acid

(S)-3-{[6-(4-Fluoro-phenyl)-pyridine-2-carbonyl]-annino}-3-o-tolyl-propionic

135

acid

(S)-3-{[6-(4-Chloro-phenyl)-pyridine-2-carbonyl]-annino}-3-o-tolyl-propionic

136

acid

137 (S)-3-o-Tolyl-3-[(6-p-tolyl-pyridine-2-carbonyl)-annino]-propionic acid

(S)-3-o-Tolyl-3-{[6-(4-trifluoronnethyl-phenyl)-pyndine-2-carbonyl]-annino}-

138

propionic acid

(S)-3-o-Tolyl-3-{[6-(2-trifluoronnethyl-phenyl)-pyndine-2-carbonyl]-annino}-

139

propionic acid

(S)-3-{[6-(3-Chloro-phenyl)-pyridine-2-carbonyl]-annino}-3-o-tolyl-propionic

140

acid

141 (S)-3-o-Tolyl-3-[(6-m-tolyl-pyridine-2-carbonyl)-annino]-propionic acid

(S)-3-{[6-(2-Chloro-phenyl)-pyridine-2-carbonyl]-annino}-3-o-tolyl-propionic

142

acid

(S)-3-{[6-(2-Fluoro-phenyl)-pyridine-2-carbonyl]-annino}-3-o-tolyl-propionic

143

acid

(S)-3-{[6-(4-tert-Butyl-phenyl)-pyridine-2-carbonyl]-annino}-3-o-tolyl-propionic

144

acid

(S)-3-{[6-(3-Cyano-phenyl)-pyridine-2-carbonyl]-amino}-3-o-tolyl-propionic

145

acid

(S)-3-{[6-(4-Cyano-phenyl)-pyridine-2-carbonyl]-amino}-3-o-tolyl-propionic

146

acid

147 (S)-3-[(6-Biphenyl-3-yl-pyridine-2-carbonyl)-amino]-3-o-tolyl-propionic acid

(S)-3-{[6-(3,4-Dimethoxy-phenyl)-pyndine-2-carbonyl]-annino}-3-o-tolyl-

148

propionic acid (S)-3-{[6-(2,4-Difluoro-phenyl)-pyridine-2-carbonyl]-annino}-3-o-tolyl-

149

propionic acid

(S)-3-{[6-(3,5-Difluoro-phenyl)-pyridine-2-carbonyl]-annino}-3-o-tolyl-

150

propionic acid

(S)-3-{[6-(3,4-Difluoro-phenyl)-pyridine-2-carbonyl]-annino}-3-o-tolyl-

151

propionic acid

(S)-3-[(6-Benzo[1 ,3]dioxol-5-yl-pyridine-2-carbonyl)-annino]-3-o-tolyl-

152

propionic acid

(S)-3-{[6-(3,4-Dimethyl-phenyl)-pyridine-2-carbonyl]-amino}-3-o-tolyl-

153

propionic acid

(S)-3-o-Tolyl-3-{[6-(3,4,5-trinnethoxy-phenyl)-pyndine-2-carbonyl]-annino}-

154

propionic acid

155 (S)-3-[([2,3']Bipyridinyl-6-carbonyl)-annino]-3-o-tolyl-propionic acid

(S)-3-{[6-(2,3-Difluoro-phenyl)-pyridine-2-carbonyl]-annino}-3-o-tolyl-

156

propionic acid

(S)-3-{[6-(2-Cyano-phenyl)-pyridine-2-carbonyl]-amino}-3-o-tolyl-propionic

157

acid

(S)-3-{[6-(2,5-Difluoro-phenyl)-pyridine-2-carbonyl]-annino}-3-o-tolyl-

158

propionic acid

(S)-3-{[6-(3,5-Dimethyl-isoxazol-4-yl)-pyndine-2-carbonyl]-annino}-3-o-tolyl-

159

propionic acid

(S)-3-{[6-(4-Fluoro-2-methyl-phenyl)-pyridine-2-carbonyl]-annino}-3-o-tolyl-

160

propionic acid

(S)-3-{[6-(2,3-Dimethyl-phenyl)-pyridine-2-carbonyl]-amino}-3-o-tolyl-

161

propionic acid

(S)-3-{[6-(2,4-Dimethyl-phenyl)-pyridine-2-carbonyl]-amino}-3-o-tolyl-

162

propionic acid

163 (S)-3-[(2'-Methyl-[2,4 bipyridinyl-6-carbonyl)-amino]-3-o-tolyl-propionic acid (S)-3-[(6-Pyrimidin-5-yl-pyridine-2-carbonyl)-amino]-3-o-tolyl-propionic acid;

164

compound with trifluoro-acetic acid

(S)-3-{[6-(5-Fluoro-2-methyl-phenyl)-pyridine-2-carbonyl]-annino}-3-o-tolyl-

165

propionic acid

(S)-3-{[6-(4-Fluoro-2-methoxy-phenyl)-pyridine-2-carbonyl]-annino}-3-o-tolyl-

166

propionic acid

(S)-3-{[6-(2-Methoxy-4-trifluoromethyl-phenyl)-pyridine-2-carbonyl]-amino}-3-

167

o-tolyl-propionic acid

(S)-3-{[6-(4-Chloro-2-methoxy-phenyl)-pyridine-2-carbonyl]-annino}-3-o-tolyl-

168

propionic acid

(S)-3-{[6-(1 -Benzyl-1 H-pyrazol-4-yl)-pyridine-2-carbonyl]-annino}-3-o-tolyl-

169

propionic acid; compound with trifluoro-acetic acid

(S)-3-{[6-(2-Fluoro-5-methoxy-phenyl)-pyridine-2-carbonyl]-amino}-3-o-tolyl-

170

propionic acid

(S)-3-{[6-(3-Cyclopropylmethoxy-phenyl)-pyridine-2-carbonyl]-amino}-3-o-

171

tolyl-propionic acid

(S)-3-{[6-(3-Fluoro-2-methyl-phenyl)-pyridine-2-carbonyl]-amino}-3-o-tolyl-

172

propionic acid

(S)-3-{[6-(2-Dimethylamino-pyrimidin-5-yl)-pyridine-2-carbonyl]-amino}-3-o-

173

tolyl-propionic acid; compound with trifluoro-acetic acid

(S)-3-{[6-(3-Chloro-4-dimethylcarbamoyl-phenyl)-pyridine-2-carbonyl]-

174

amino}-3-o-tolyl-propionic acid

(S)-3-{[6-(5-Chloro-2-fluoro-4-methyl-phenyl)-pyridine-2-carbonyl]-amino}-3-

175

o-tolyl-propionic acid

(S)-3-({6-[3-(1 -Hydroxy-1 -methyl-ethyl)-phenyl]-pyridine-2-carbonyl}-amino)-

176

3-o-tolyl-propionic acid

(S)-3-{[2-(2-Dimethylamino-pyrimidin-5-yl)-pyridine-4-carbonyl]-amino}-3-o-

177

tolyl-propionic acid; compound with trifluoro-acetic acid

(S)-3-{[6-(2-Fluoro-phenyl)-5-methoxy-pyridine-2-carbonyl]-amino}-3-o-tolyl-

178

propionic acid (S)-3-{[2-(3-Chloro-phenyl)-pyridine-4-carbonyl]-amino}-3-o-tolyl-propionic

179

acid

(S)-3-{[6-(2-Fluoro-5-methyl-phenyl)-pyridine-2-carbonyl]-annino}-3-o-tolyl-

180

propionic acid

(S)-3-{[5-Methoxy-6-(3-trifluoromethyl-phenyl)-pyridine-2-carbonyl]-amino}-3-

181

p-tolyl-propionic acid

(S)-3-[(5-Methoxy-6-phenyl-pyridine-2-carbonyl)-annino]-3-p-tolyl-propionic

182

acid

(S)-3-{[6-(2,4-Dichloro-phenyl)-5-methoxy-pyridine-2-carbonyl]-annino}-3-p-

183

tolyl-propionic acid

(S)-3-{[6-(3-Chloro-4-fluoro-phenyl)-5-methoxy-pyridine-2-carbonyl]-annino}-

184

3-p-tolyl-propionic acid

(S)-3-{[6-(4-Fluoro-phenyl)-5-methoxy-pyridine-2-carbonyl]-annino}-3-p-tolyl-

185

propionic acid

(S)-3-{[6-(4-Chloro-phenyl)-5-methoxy-pyridine-2-carbonyl]-annino}-3-p-tolyl-

186

propionic acid

(S)-3-{[5-Methoxy-6-(4-methoxy-phenyl)-pyridine-2-carbonyl]-annino}-3-p-

187

tolyl-propionic acid

(S)-3-[(5-Methoxy-6-p-tolyl-pyridine-2-carbonyl)-annino]-3-p-tolyl-propionic

188

acid

(S)-3-{[5-Methoxy-6-(4-trifluoromethyl-phenyl)-pyridine-2-carbonyl]-amino}-3-

189

p-tolyl-propionic acid

(S)-3-[(5-Methoxy-6-o-tolyl-pyridine-2-carbonyl)-annino]-3-p-tolyl-propionic

190

acid

(S)-3-{[5-Methoxy-6-(3-methoxy-phenyl)-pyridine-2-carbonyl]-annino}-3-p-

191

tolyl-propionic acid

(S)-3-{[5-Methoxy-6-(2-trifluoromethyl-phenyl)-pyridine-2-carbonyl]-amino}-3-

192

p-tolyl-propionic acid

(S)-3-{[6-(3-Chloro-phenyl)-5-methoxy-pyridine-2-carbonyl]-annino}-3-p-tolyl-

193

propionic acid (S)-3-{[6-(3-Fluoro-phenyl)-5-methoxy-pyridine-2-carbonyl]-annino}-3-p-tolyl-

194

propionic acid

(S)-3-[(5-Methoxy-6-naphthalen-2-yl-pyridine-2-carbonyl)-annino]-3-p-tolyl-

195

propionic acid

(S)-3-{[5-Methoxy-6-(2-methoxy-phenyl)-pyridine-2-carbonyl]-annino}-3-p-

196

tolyl-propionic acid

(S)-3-[(5-Methoxy-6-m-tolyl-pyridine-2-carbonyl)-amino]-3-p-tolyl-propionic

197

acid

(S)-3-{[6-(2-Chloro-phenyl)-5-methoxy-pyridine-2-carbonyl]-annino}-3-p-tolyl-

198

propionic acid

(S)-3-{[6-(2-Fluoro-phenyl)-5-methoxy-pyridine-2-carbonyl]-annino}-3-p-tolyl-

199

propionic acid

(S)-3-{[6-(4-tert-Butyl-phenyl)-5-methoxy-pyridine-2-carbonyl]-annino}-3-p-

200

tolyl-propionic acid

(S)-3-{[6-(3-Cyano-phenyl)-5-methoxy-pyridine-2-carbonyl]-annino}-3-p-tolyl-

201

propionic acid

(S)-3-{[6-(4-Cyano-phenyl)-5-methoxy-pyridine-2-carbonyl]-annino}-3-p-tolyl-

202

propionic acid

(S)-3-{[6-(3-Acetyl-phenyl)-5-methoxy-pyridine-2-carbonyl]-annino}-3-p-tolyl-

203

propionic acid

(S)-3-[(6-Biphenyl-3-yl-5-methoxy-pyridine-2-carbonyl)-annino]-3-p-tolyl-

204

propionic acid

(S)-3-{[6-(4-Acetyl-phenyl)-5-methoxy-pyridine-2-carbonyl]-annino}-3-p-tolyl-

205

propionic acid

(S)-3-{[6-(2,4-Difluoro-phenyl)-5-methoxy-pyridine-2-carbonyl]-annino}-3-p-

206

tolyl-propionic acid

(S)-3-{[6-(3,5-Difluoro-phenyl)-5-methoxy-pyridine-2-carbonyl]-annino}-3-p-

207

tolyl-propionic acid

(S)-3-{[6-(3,4-Difluoro-phenyl)-5-methoxy-pyridine-2-carbonyl]-annino}-3-p-

208

tolyl-propionic acid (S)-3-{[6-(2,3-Dichloro-phenyl)-5-methoxy-pyridine-2-carbonyl]-annino}-3-p-

209

tolyl-propionic acid

(S)-3-{[6-(5-Acetyl-thiophen-2-yl)-5-methoxy-pyridine-2-carbonyl]-annino}-3-

210

p-tolyl-propionic acid

(S)-3-{[6-(2-Chloro-5-trifluoronnethyl-phenyl)-5-nnethoxy-pyridine-2-carbonyl]-

21 1

amino}-3-p-tolyl-propionic acid

(S)-3-{[6-(3-Fluoro-2-methyl-phenyl)-5-nnethoxy-pyridine-2-carbonyl]-annino}-

212

3-(2-fluoro-phenyl)-propionic acid

(S)-3-{[6-(2-Chloro-5-trifluoronnethyl-phenyl)-5-nnethoxy-pyridine-2-carbonyl]-

213

amino}-3-(2-fluoro-phenyl)-propionic acid

(S)-3-(2-Chloro-phenyl)-3-{[6-(2-fluoro-4-trifluoromethyl-phenyl)-5-methoxy-

214

pyridine-2-carbonyl]-amino}-propionic acid

215 (S)-3-[(3-Methoxy-[2,4 bipyridinyl-6-carbonyl)-amino]-3-p-tolyl-propionic acid

216 (S)-3-[(3-Methoxy-[2,3 bipyridinyl-6-carbonyl)-amino]-3-p-tolyl-propionic acid

(S)-3-{[6-(2,3-Difluoro-phenyl)-5-methoxy-pyridine-2-carbonyl]-annino}-3-p-

217

tolyl-propionic acid

(S)-3-{[6-(2,5-Difluoro-phenyl)-5-methoxy-pyridine-2-carbonyl]-annino}-3-p-

218

tolyl-propionic acid

(S)-3-{[6-(2,5-Dichloro-phenyl)-5-methoxy-pyridine-2-carbonyl]-annino}-3-p-

219

tolyl-propionic acid

(S)-3-{[6-(3,5-Dimethyl-isoxazol-4-yl)-5-nnethoxy-pyridine-2-carbonyl]-

220

amino}-3-p-tolyl-propionic acid

(S)-3-{[6-(4-Fluoro-2-methyl-phenyl)-5-nnethoxy-pyridine-2-carbonyl]-annino}-

221

3-p-tolyl-propionic acid

(S)-3-{[6-(2,3-Dimethyl-phenyl)-5-methoxy-pyridine-2-carbonyl]-annino}-3-p-

222

tolyl-propionic acid

(S)-3-{[6-(3-Fluoro-4-methyl-phenyl)-5-nnethoxy-pyridine-2-carbonyl]-annino}-

223

3-p-tolyl-propionic acid (S)-3-{[6-(2,4-Dimethyl-phenyl)-5-methoxy-pyridine-2-carbonyl]-amino}-3-p-

224

tolyl-propionic acid

(S)-3-{[6-(4-Fluoro-3-methyl-phenyl)-5-methoxy-pyridine-2-carbonyl]-amino}-

225

3-p-tolyl-propionic acid

(S)-3-[(5-Methoxy-6-pyrimidin-5-yl-pyridine-2-carbonyl)-amino]-3-p-tolyl-

226

propionic acid

(S)-3-[(6'-Fluoro-3-methoxy-[2,3']bipyridinyl-6-carbonyl)-annino]-3-p-tolyl-

227

propionic acid

(S)-3-{[6-(2-Dimethylcarbannoyl-phenyl)-5-nnethoxy-pyridine-2-carbonyl]-

228

amino}-3-p-tolyl-propionic acid

(S)-3-[(3,2'-Dimethoxy-[2,3]bipyridinyl-6-carbonyl)-amino]-3-p-tolyl-propionic

229

acid

(S)-3-{[6-(5-Fluoro-2-methyl-phenyl)-5-nnethoxy-pyridine-2-carbonyl]-annino}-

230

3-p-tolyl-propionic acid

(S)-3-{[6-(4-Fluoro-2-methoxy-phenyl)-5-nnethoxy-pyridine-2-carbonyl]-

231

amino}-3-p-tolyl-propionic acid

(S)-3-{[6-(4-Chloro-2-methoxy-phenyl)-5-methoxy-pyridine-2-carbonyl]-

232

amino}-3-p-tolyl-propionic acid

(S)-3-{[6-(5-Chloro-2-methoxy-phenyl)-5-nnethoxy-pyridine-2-carbonyl]-

233

amino}-3-p-tolyl-propionic acid

(S)-3-{[6-(5-Fluoro-2-methoxy-phenyl)-5-nnethoxy-pyridine-2-carbonyl]-

234

amino}-3-p-tolyl-propionic acid

(S)-3-{[6-(2,5-Dimethoxy-phenyl)-5-methoxy-pyridine-2-carbonyl]-amino}-3-

235

p-tolyl-propionic acid

(S)-3-{[6-(2-Fluoro-5-trifluoromethyl-phenyl)-5-methoxy-pyridine-2-carbonyl]-

236

amino}-3-p-tolyl-propionic acid

(S)-3-{[5-Methoxy-6-(5-methyl-furan-2-yl)-pyridine-2-carbonyl]-amino}-3-p-

237

tolyl-propionic acid

(S)-3-{[5-Methoxy-6-(1 -methyl-1 H-pyrazol-4-yl)-pyridine-2-carbonyl]-annino}-

238

3-p-tolyl-propionic acid (S)-3-{[6-(2-Fluoro-5-nnethoxy-phenyl)-5-nnethoxy-pyridine-2-carbonyl]-

239

amino}-3-p-tolyl-propionic acid

(S)-3-{[6-(5-tert-Butyl-2-methoxy-phenyl)-5-nnethoxy-pyridine-2-carbonyl]-

240

amino}-3-p-tolyl-propionic acid

(S)-3-{[6-(2-Fluoro-4-trifluoronnethyl-phenyl)-5-nnethoxy-pyridine-2-carbonyl]-

241

amino}-3-p-tolyl-propionic acid

(S)-3-{[6-(2-Fluoro-5-methyl-phenyl)-5-nnethoxy-pyridine-2-carbonyl]-annino}-

242

3-p-tolyl-propionic acid

(S)-3-{[6-(3-Chloro-2-methyl-phenyl)-5-methoxy-pyridine-2-carbonyl]-amino}-

243

3-p-tolyl-propionic acid

(S)-3-{[6-(3-Fluoro-2-methyl-phenyl)-5-methoxy-pyridine-2-carbonyl]-amino}-

244

3-p-tolyl-propionic acid

(S)-3-{[6-(5-Chloro-2-fluoro-phenyl)-5-methoxy-pyridine-2-carbonyl]-amino}-

245

3-p-tolyl-propionic acid

(S)-3-{[6-(4-Chloro-3-fluoro-phenyl)-5-methoxy-pyridine-2-carbonyl]-amino}-

246

3-p-tolyl-propionic acid

(S)-3-[(2'-Chloro-3-methoxy-5'-methyl-[2,3']bipyridinyl-6-carbonyl)-amino]-3-

247

p-tolyl-propionic acid

(S)-3-{[6-(3-Chloro-5-methyl-phenyl)-5-methoxy-pyridine-2-carbonyl]-amino}-

248

3-p-tolyl-propionic acid

(S)-3-({5-Methoxy-6-[3-(5-methyl-[1 ,3,4]oxadiazol-2-yl)-phenyl]-pyridine-2-

249

carbonyl}-amino)-3-p-tolyl-propionic acid

(S)-3-{[5-Methoxy-6-(1 ,3,5-trimethyl-1 H-pyrazol-4-yl)-pyndine-2-carbonyl]-

250

amino}-3-p-tolyl-propionic acid

(S)-3-{[5-Methoxy-6-(1 -methyl-1 H-i^

251

p-tolyl-propionic acid

(S)-3-{[6-(4-Chloro-3-methoxy-phenyl)-5-methoxy-pyridine-2-carbonyl]-

252

amino}-3-p-tolyl-propionic acid

(S)-3-(2-Fluoro-phenyl)-3-{[5-methoxy-6-(3-trifluoromethyl-phenyl)-pyridine-

253

2-carbonyl]-amino}-propionic acid (S)-3-(2-Fluoro-phenyl)-3-[(5-methoxy-6-phenyl-pyridine-2-carbonyl)-amino]-

254

propionic acid

(S)-3-{[6-(2,4-Dichloro-phenyl)-5-methoxy-pyridine-2-carbonyl]-annino}-3-(2-

255

fluoro-phenyl)-propionic acid

(S)-3-{[6-(3-Chloro-4-fluoro-phenyl)-5-methoxy-pyridine-2-carbonyl]-annino}-

256

3-(2-fluoro-phenyl)-propionic acid

(S)-3-(2-Fluoro-phenyl)-3-{[6-(4-fluoro-phenyl)-5-methoxy-pyridine-2-

257

carbonyl]-amino}-propionic acid

(S)-3-{[6-(4-Chloro-phenyl)-5-methoxy-pyridine-2-carbonyl]-annino}-3-(2-

258

fluoro-phenyl)-propionic acid

(S)-3-(2-Fluoro-phenyl)-3-{[5-methoxy-6-(4-nnethoxy-phenyl)-pyridine-2-

259

carbonyl]-amino}-propionic acid

(S)-3-(2-Fluoro-phenyl)-3-[(5-methoxy-6-p-tolyl-pyridine-2-carbonyl)-annino]-

260

propionic acid

(S)-3-(2-Fluoro-phenyl)-3-{[5-methoxy-6-(4-trifluoronnethyl-phenyl)-pyridine-

261

2-carbonyl]-amino}-propionic acid

(S)-3-(2-Fluoro-phenyl)-3-[(5-methoxy-6-o-tolyl-pyridine-2-carbonyl)-annino]-

262

propionic acid

(S)-3-(2-Fluoro-phenyl)-3-{[5-methoxy-6-(3-nnethoxy-phenyl)-pyridine-2-

263

carbonyl]-amino}-propionic acid

(S)-3-(2-Fluoro-phenyl)-3-{[5-methoxy-6-(2-trifluoronnethyl-phenyl)-pyridine-

264

2-carbonyl]-amino}-propionic acid

(S)-3-{[6-(3-Chloro-phenyl)-5-methoxy-pyridine-2-carbonyl]-annino}-3-(2-

265

fluoro-phenyl)-propionic acid

(S)-3-(2-Fluoro-phenyl)-3-{[6-(3-fluoro-phenyl)-5-methoxy-pyridine-2-

266

carbonyl]-amino}-propionic acid

(S)-3-(2-Fluoro-phenyl)-3-[(5-methoxy-6-naphthalen-2-yl-pyridine-2-

267

carbonyl)-amino]-propionic acid

(S)-3-(2-Fluoro-phenyl)-3-{[5-methoxy-6-(2-nnethoxy-phenyl)-pyridine-2-

268

carbonyl]-amino}-propionic acid (S)-3-(2-Fluoro-phenyl)-3-[(5-methoxy-6-m-tolyl-pyridine-2-carbonyl)-amino]-

269

propionic acid

(S)-3-{[6-(2-Chloro-phenyl)-5-methoxy-pyridine-2-carbonyl]-annino}-3-(2-

270

fluoro-phenyl)-propionic acid

(S)-3-(2-Fluoro-phenyl)-3-{[6-(2-fluoro-phenyl)-5-methoxy-pyridine-2-

271

carbonyl]-amino}-propionic acid

(S)-3-{[6-(4-tert-Butyl-phenyl)-5-methoxy-pyridine-2-carbonyl]-annino}-3-(2-

272

fluoro-phenyl)-propionic acid

(S)-3-{[6-(3-Cyano-phenyl)-5-methoxy-pyridine-2-carbonyl]-annino}-3-(2-

273

fluoro-phenyl)-propionic acid

(S)-3-{[6-(4-Cyano-phenyl)-5-methoxy-pyridine-2-carbonyl]-annino}-3-(2-

274

fluoro-phenyl)-propionic acid

(S)-3-{[6-(3-Acetyl-phenyl)-5-methoxy-pyridine-2-carbonyl]-annino}-3-(2-

275

fluoro-phenyl)-propionic acid

(S)-3-[(6-Biphenyl-3-yl-5-methoxy-pyridine-2-carbonyl)-annino]-3-(2-fluoro-

276

phenylj-propionic acid

(S)-3-{[6-(4-Acetyl-phenyl)-5-methoxy-pyridine-2-carbonyl]-annino}-3-(2-

277

fluoro-phenyl)-propionic acid

(S)-3-{[6-(2,4-Difluoro-phenyl)-5-methoxy-pyridine-2-carbonyl]-annino}-3-(2-

278

fluoro-phenyl)-propionic acid

(S)-3-{[6-(3,5-Difluoro-phenyl)-5-methoxy-pyridine-2-carbonyl]-annino}-3-(2-

279

fluoro-phenyl)-propionic acid

(S)-3-{[6-(3,4-Difluoro-phenyl)-5-methoxy-pyridine-2-carbonyl]-annino}-3-(2-

280

fluoro-phenyl)-propionic acid

(S)-3-{[6-(2,3-Dichloro-phenyl)-5-methoxy-pyridine-2-carbonyl]-annino}-3-(2-

281

fluoro-phenyl)-propionic acid

(S)-3-(2-Fluoro-phenyl)-3-[(3-methoxy-[2,4']bipyridinyl-6-carbonyl)-amino]-

282

propionic acid

(S)-3-{[6-(5-Cyano-thiophen-2-yl)-5-methoxy-pyridine-2-carbonyl]-annino}-3-

283

(2-fluoro-phenyl)-propionic acid (S)-3-(2-Fluoro-phenyl)-3-[(3-methoxy-[2,3 bipyridinyl-6-carbonyl)-amino]-

284

propionic acid

(S)-3-{[6-(2,3-Difluoro-phenyl)-5-methoxy-pyridine-2-carbonyl]-annino}-3-(2-

285

fluoro-phenyl)-propionic acid

(S)-3-{[6-(2,5-Difluoro-phenyl)-5-methoxy-pyridine-2-carbonyl]-annino}-3-(2-

286

fluoro-phenyl)-propionic acid

(S)-3-{[6-(3,5-Dimethyl-isoxazol-4-yl)-5-nnethoxy-pyridine-2-carbonyl]-

287

amino}-3-(2-fluoro-phenyl)-propionic acid

(S)-3-{[6-(4-Fluoro-2-methyl-phenyl)-5-nnethoxy-pyridine-2-carbonyl]-annino}-

288

3-(2-fluoro-phenyl)-propionic acid

(S)-3-{[6-(2,3-Dimethyl-phenyl)-5-methoxy-pyridine-2-carbonyl]-amino}-3-(2-

289

fluoro-phenyl)-propionic acid

(S)-3-{[6-(3-Fluoro-4-methyl-phenyl)-5-nnethoxy-pyridine-2-carbonyl]-annino}-

290

3-(2-fluoro-phenyl)-propionic acid

(S)-3-{[6-(2,4-Dimethyl-phenyl)-5-methoxy-pyridine-2-carbonyl]-annino}-3-(2-

291

fluoro-phenyl)-propionic acid

(S)-3-{[6-(4-Fluoro-3-methyl-phenyl)-5-nnethoxy-pyridine-2-carbonyl]-annino}-

292

3-(2-fluoro-phenyl)-propionic acid

(S)-3-(2-Fluoro-phenyl)-3-[(5-methoxy-6-pyrinnidin-5-yl-pyridine-2-carbonyl)-

293

amino]-propionic acid

(S)-3-[(6'-Fluoro-3-methoxy-[2,3']bipyridinyl-6-carbonyl)-amino]-3-(2-fluoro-

294

phenylj-propionic acid

(S)-3-{[6-(2-Dimethylcarbannoyl-phenyl)-5-nnethoxy-pyridine-2-carbonyl]-

295

amino}-3-(2-fluoro-phenyl)-propionic acid

(S)-3-[(3,2'-Dimethoxy-[2,3']bipyridinyl-6-carbonyl)-amino]-3-(2-fluoro-

296

phenylj-propionic acid

(S)-3-{[6-(5-Fluoro-2-methyl-phenyl)-5-nnethoxy-pyridine-2-carbonyl]-annino}-

297

3-(2-fluoro-phenyl)-propionic acid

(S)-3-{[6-(4-Fluoro-2-methoxy-phenyl)-5-nnethoxy-pyridine-2-carbonyl]-

298

amino}-3-(2-fluoro-phenyl)-propionic acid (S)-3-{[6-(4-Chloro-2-nnethoxy-phenyl)-5-nnethoxy-pyridine-2-carbonyl]-

299

amino}-3-(2-fluoro-phenyl)-propionic acid

(S)-3-{[6-(5-Chloro-2-methoxy-phenyl)-5-nnethoxy-pyridine-2-carbonyl]-

300

amino}-3-(2-fluoro-phenyl)-propionic acid

(S)-3-{[6-(5-Fluoro-2-methoxy-phenyl)-5-nnethoxy-pyridine-2-carbonyl]-

301

amino}-3-(2-fluoro-phenyl)-propionic acid

(S)-3-(2-Fluoro-phenyl)-3-{[5-methoxy-6-(1 -methyl-1 H-indol-5-yl)-pyridine-2-

302

carbonyl]-amino}-propionic acid

(S)-3-{[6-(2,5-Dimethoxy-phenyl)-5-methoxy-pyridine-2-carbonyl]-annino}-3-

303

(2-fluoro-phenyl)-propionic acid

(S)-3-(2-Fluoro-phenyl)-3-{[6-(2-fluoro-5-trifluoronnethyl-phenyl)-5-nnethoxy-

304

pyridine-2-carbonyl]-amino}-propionic acid

(S)-3-(2-Fluoro-phenyl)-3-{[5-methoxy-6-(5-nnethyl-furan-2-yl)-pyridine-2-

305

carbonyl]-amino}-propionic acid

(S)-3-(2-Fluoro-phenyl)-3-{[5-methoxy-6-(1 -nnethyl-1 H-pyrazol-4-yl)-pyridine-

306

2-carbonyl]-amino}-propionic acid

(S)-3-{[6-(2-Fluoro-5-methoxy-phenyl)-5-nnethoxy-pyridine-2-carbonyl]-

307

amino}-3-(2-fluoro-phenyl)-propionic acid

(S)-3-{[6-(5-tert-Butyl-2-methoxy-phenyl)-5-nnethoxy-pyridine-2-carbonyl]-

308

amino}-3-(2-fluoro-phenyl)-propionic acid

(S)-3-(2-Fluoro-phenyl)-3-{[6-(2-fluoro-4-trifluoronnethyl-phenyl)-5-nnethoxy-

309

pyridine-2-carbonyl]-amino}-propionic acid

(S)-3-{[6-(2-Fluoro-5-methyl-phenyl)-5-nnethoxy-pyridine-2-carbonyl]-annino}-

310

3-(2-fluoro-phenyl)-propionic acid

(S)-3-{[6-(3-Chloro-2-methyl-phenyl)-5-methoxy-pyridine-2-carbonyl]-amino}-

31 1

3-(2-fluoro-phenyl)-propionic acid

(S)-3-{[6-(5-Chloro-2-fluoro-phenyl)-5-methoxy-pyridine-2-carbonyl]-annino}-

312

3-(2-fluoro-phenyl)-propionic acid

(S)-3-{[6-(4-Chloro-3-fluoro-phenyl)-5-methoxy-pyridine-2-carbonyl]-annino}-

313

3-(2-fluoro-phenyl)-propionic acid (S)-3-[(2'-Chloro-3-methoxy-5'-methyl-[2,3']bipyridinyl-6-carbonyl)-amino]-3-

314

(2-fluoro-phenyl)-propionic acid

(S)-3-{[6-(3-Chloro-5-methyl-phenyl)-5-methoxy-pyridine-2-carbonyl]-amino}-

315

3-(2-fluoro-phenyl)-propionic acid

(S)-3-(2-Fluoro-phenyl)-3-({5-methoxy-6-[3-(5-methyl-[1 ,3,4]oxadiazol-2-yl)-

316

phenyl]-pyridine-2-carbonyl}-annino)-propionic acid

(S)-3-(2-Fluoro-phenyl)-3-{[5-methoxy-6-(1 ,3,5-trimethyl-1 H-pyrazol-4-yl)-

317

pyridine-2-carbonyl]-amino}-propionic acid

(S)-3-(2-Fluoro-phenyl)-3-{[5-methoxy-6-(1 -methyl-1 H-indol-6-yl)-pyridine-2-

318

carbonyl]-amino}-propionic acid

(S)-3-{[6-(4-Chloro-3-methoxy-phenyl)-5-nnethoxy-pyridine-2-carbonyl]-

319

amino}-3-(2-fluoro-phenyl)-propionic acid

(S)-3-{[6-(3-Chloro-2-fluoro-phenyl)-5-methoxy-pyridine-2-carbonyl]-annino}-

320

3-(2-fluoro-phenyl)-propionic acid

(S)-3-(2-Fluoro-phenyl)-3-[(3-methoxy-2'-morpholin-4-yl-[2,4']bipyridinyl-6-

321

carbonyl)-amino]-propionic acid

(S)-3-(2-Fluoro-phenyl)-3-{[5-methoxy-6-(2-methyl-furan-3-yl)-pyridine-2-

322

carbonyl]-amino}-propionic acid

(S)-3-{[6-(2-Chloro-5-methyl-phenyl)-5-methoxy-pyridine-2-carbonyl]-amino}-

323

3-(2-fluoro-phenyl)-propionic acid

(S)-3-{[6-(2-Chloro-3-fluoro-phenyl)-5-methoxy-pyridine-2-carbonyl]-annino}-

324

3-(2-fluoro-phenyl)-propionic acid

(S)-3-{[6-(4-Cyano-2-fluoro-phenyl)-5-methoxy-pyridine-2-carbonyl]-annino}-

325

3-(2-fluoro-phenyl)-propionic acid

(S)-3-(2-Fluoro-phenyl)-3-({6-[3-(3-hydroxy-oxetan-3-yl)-phenyl]-5-methoxy-

326

pyridine-2-carbonyl}-annino)-propionic acid

(S)-3-(2-Fluoro-phenyl)-3-({6-[3-(1 -hydroxy-1 -methyl-ethyl)-phenyl]-5-

327

methoxy-pyridine-2-carbonyl}-annino)-propionic acid

(S)-3-{[6-(2-Chloro-3-methyl-phenyl)-5-methoxy-pyridine-2-carbonyl]-amino}-

328

3-(2-fluoro-phenyl)-propionic acid (S)-3-(2-Chloro-phenyl)-3-{[5-methoxy-6-(3-trifluoromethyl-phenyl)-pyridine-

329

2-carbonyl]-amino}-propionic acid

(S)-3-(2-Chloro-phenyl)-3-[(5-methoxy-6-phenyl-pyridine-2-carbonyl)-annino]-

330

propionic acid

(S)-3-(2-Chloro-phenyl)-3-{[6-(2,4-dichloro-phenyl)-5-methoxy-pyridine-2-

331

carbonyl]-amino}-propionic acid

(S)-3-{[6-(3-Chloro-4-fluoro-phenyl)-5-methoxy-pyridine-2-carbonyl]-annino}-

332

3-(2-chloro-phenyl)-propionic acid

(S)-3-(2-Chloro-phenyl)-3-{[6-(4-fluoro-phenyl)-5-methoxy-pyridine-2-

333

carbonyl]-amino}-propionic acid

(S)-3-(2-Chloro-phenyl)-3-{[6-(4-chloro-phenyl)-5-methoxy-pyridine-2-

334

carbonyl]-amino}-propionic acid

(S)-3-(2-Chloro-phenyl)-3-{[5-methoxy-6-(4-nnethoxy-phenyl)-pyridine-2-

335

carbonyl]-amino}-propionic acid

(S)-3-(2-Chloro-phenyl)-3-[(5-methoxy-6-p-tolyl-pyridine-2-carbonyl)-annino]-

336

propionic acid

(S)-3-(2-Chloro-phenyl)-3-{[5-methoxy-6-(4-trifluoronnethyl-phenyl)-pyridine-

337

2-carbonyl]-amino}-propionic acid

(S)-3-(2-Chloro-phenyl)-3-[(5-methoxy-6-o-tolyl-pyridine-2-carbonyl)-annino]-

338

propionic acid

(S)-3-(2-Chloro-phenyl)-3-{[5-methoxy-6-(3-nnethoxy-phenyl)-pyridine-2-

339

carbonyl]-amino}-propionic acid

(S)-3-(2-Chloro-phenyl)-3-{[6-(3-chloro-phenyl)-5-methoxy-pyridine-2-

340

carbonyl]-amino}-propionic acid

(S)-3-(2-Chloro-phenyl)-3-{[5-(3-fluoro-phenyl)-6-methoxy-pyridine-3-

341

carbonyl]-amino}-propionic acid

(S)-3-{[6-Methoxy-5-(4-trifluoromethyl-phenyl)-pyridine-3-carbonyl]-amino}-3-

342

o-tolyl-propionic acid

(S)-3-(2-Chloro-phenyl)-3-{[6-methoxy-5-(3-trifluoronnethyl-phenyl)-pyridine-

343

3-carbonyl]-amino}-propionic acid (S)-3-(2-Chloro-phenyl)-3-[(6-methoxy-5-phenyl-pyridine-3-carbonyl)-amino]-

344

propionic acid

(S)-3-{[5-(3-Chloro-4-fluoro-phenyl)-6-methoxy-pyridine-3-carbonyl]-annino}-

345

3-(2-chloro-phenyl)-propionic acid

(S)-3-(2-Chloro-phenyl)-3-{[5-(4-fluoro-phenyl)-6-methoxy-pyridine-3-

346

carbonyl]-amino}-propionic acid

(S)-3-{[5-Methoxy-6-(3-trifluoromethyl-phenyl)-pyridine-2-carbonyl]-amino}-3-

347

o-tolyl-propionic acid

(S)-3-{[6-(2,4-Dichloro-phenyl)-5-methoxy-pyridine-2-carbonyl]-annino}-3-o-

348

tolyl-propionic acid

(S)-3-{[6-(3-Chloro-4-fluoro-phenyl)-5-methoxy-pyridine-2-carbonyl]-annino}-

349

3-o-tolyl-propionic acid

(S)-3-{[6-(4-Fluoro-phenyl)-5-methoxy-pyridine-2-carbonyl]-annino}-3-o-tolyl-

350

propionic acid

(S)-3-{[6-(4-Chloro-phenyl)-5-methoxy-pyridine-2-carbonyl]-annino}-3-o-tolyl-

351

propionic acid

(S)-3-[(5-Methoxy-6-p-tolyl-pyridine-2-carbonyl)-annino]-3-o-tolyl-propionic

352

acid

(S)-3-{[5-Methoxy-6-(4-trifluoromethyl-phenyl)-pyridine-2-carbonyl]-amino}-3-

353

o-tolyl-propionic acid

(S)-3-{[6-(3-Chloro-phenyl)-5-methoxy-pyridine-2-carbonyl]-annino}-3-o-tolyl-

354

propionic acid

(S)-3-{[5-Methoxy-6-(2-methoxy-phenyl)-pyridine-2-carbonyl]-annino}-3-o-

355

tolyl-propionic acid

(S)-3-[(5-Methoxy-6-m-tolyl-pyridine-2-carbonyl)-amino]-3-o-tolyl-propionic

356

acid

(S)-3-{[6-(2-Chloro-phenyl)-5-methoxy-pyridine-2-carbonyl]-annino}-3-o-tolyl-

357

propionic acid

(S)-3-{[6-(4-tert-Butyl-phenyl)-5-methoxy-pyridine-2-carbonyl]-annino}-3-o-

358

tolyl-propionic acid (S)-3-{[6-(3-Cyano-phenyl)-5-methoxy-pyridine-2-carbonyl]-annino}-3-o-tolyl-

359

propionic acid

(S)-3-{[6-(3-Acetyl-phenyl)-5-methoxy-pyridine-2-carbonyl]-annino}-3-o-tolyl-

360

propionic acid

(S)-3-{[6-(4-Acetyl-phenyl)-5-methoxy-pyridine-2-carbonyl]-annino}-3-o-tolyl-

361

propionic acid

(S)-3-{[6-(3,5-Difluoro-phenyl)-5-methoxy-pyridine-2-carbonyl]-annino}-3-o-

362

tolyl-propionic acid

(S)-3-{[6-(3,4-Difluoro-phenyl)-5-methoxy-pyridine-2-carbonyl]-annino}-3-o-

363

tolyl-propionic acid

(S)-3-{[6-(5-Acetyl-thiophen-2-yl)-5-methoxy-pyridine-2-carbonyl]-annino}-3-

364

o-tolyl-propionic acid

365 (S)-3-[(3-Methoxy-[2,4']bipyridinyl-6-carbonyl)-annino]-3-o-tolyl-propionic acid

(S)-3-{[6-(2,5-Difluoro-phenyl)-5-methoxy-pyridine-2-carbonyl]-annino}-3-o-

366

tolyl-propionic acid

(S)-3-{[6-(2,5-Dichloro-phenyl)-5-methoxy-pyridine-2-carbonyl]-annino}-3-o-

367

tolyl-propionic acid

(S)-3-{[6-(3,5-Dimethyl-isoxazol-4-yl)-5-nnethoxy-pyridine-2-carbonyl]-

368

amino}-3-o-tolyl-propionic acid

(S)-3-{[6-(2,3-Dimethyl-phenyl)-5-methoxy-pyridine-2-carbonyl]-annino}-3-o-

369

tolyl-propionic acid

(S)-3-{[6-(3-Fluoro-4-methyl-phenyl)-5-nnethoxy-pyridine-2-carbonyl]-annino}-

370

3-o-tolyl-propionic acid

(S)-3-{[6-(2,4-Dimethyl-phenyl)-5-methoxy-pyridine-2-carbonyl]-annino}-3-o-

371

tolyl-propionic acid

(S)-3-[(5-Methoxy-6-pyrimidin-5-yl-pyridine-2-carbonyl)-amino]-3-o-tolyl-

372

propionic acid

(S)-3-[(6'-Fluoro-3-methoxy-[2,3']bipyridinyl-6-carbonyl)-annino]-3-o-tolyl-

373

propionic acid (S)-3-{[6-(2-Dimethylcarbamoyl-phenyl)-5-methoxy-pyridine-2-carbonyl]-

374

amino}-3-o-tolyl-propionic acid

(S)-3-{[6-(4-Fluoro-2-methoxy-phenyl)-5-nnethoxy-pyridine-2-carbonyl]-

375

amino}-3-o-tolyl-propionic acid

(S)-3-{[5-Methoxy-6-(5-methyl-furan-2-yl)-pyridine-2-carbonyl]-annino}-3-o-

376

tolyl-propionic acid

(S)-3-{[5-Methoxy-6-(1 -methyl-1 H-pyrazol-4-yl)-pyridine-2-carbonyl]-amino}-

377

3-o-tolyl-propionic acid

(S)-3-{[6-(3-Chloro-5-methyl-phenyl)-5-methoxy-pyridine-2-carbonyl]-amino}-

378

3-o-tolyl-propionic acid

(S)-3-{[5-Methoxy-6-(1 ,3,5-trinnethyl-1 H-pyrazol-4-yl)-pyndine-2-carbonyl]-

379

amino}-3-o-tolyl-propionic acid

(S)-3-{[5-Methoxy-6-(1 -methyl-1 H-indol-6-yl)-pyridine-2-carbonyl]-amino}-3-

380

o-tolyl-propionic acid

(S)-3-[(3-Methoxy-2'-morpholin-4-yl-[2,4 bipyridinyl-6-carbonyl)-amino]-3-o-

381

tolyl-propionic acid

(S)-3-{[6-(2-Chloro-5-methyl-phenyl)-5-methoxy-pyridine-2-carbonyl]-amino}-

382

3-o-tolyl-propionic acid

(S)-3-{[6-(2-Chloro-3-fluoro-phenyl)-5-methoxy-pyridine-2-carbonyl]-amino}-

383

3-o-tolyl-propionic acid

(S)-3-({6-[3-(3-Hydroxy-oxetan-3-yl)-phenyl]-5-methoxy-pyridine-2-carbonyl}-

384

amino)-3-o-tolyl-propionic acid

(S)-3-({6-[3-(1 -Hydroxy-1 -methyl -ethyl )-phenyl]-5-methoxy-pyridine-2-

385

carbonyl}-amino)-3-o-tolyl-propionic acid

(S)-3-(2-Chloro-phenyl)-3-{[5-(4-chloro-phenyl)-6-methoxy-pyridine-3-

386

carbonyl]-amino}-propionic acid

(S)-3-(2-Chloro-phenyl)-3-{[6-methoxy-5-(4-nnethoxy-phenyl)-pyridine-3-

387

carbonyl]-amino}-propionic acid

(S)-3-(2-Chloro-phenyl)-3-[(6-methoxy-5-p-tolyl-pyridine-3-carbonyl)-annino]-

388

propionic acid (S)-3-(2-Chloro-phenyl)-3-{[6-methoxy-5-(4-trifluoromethyl-phenyl)-pyridine-

389

3-carbonyl]-amino}-propionic acid

(S)-3-(2-Chloro-phenyl)-3-[(6-methoxy-5-o-tolyl-pyridine-3-carbonyl)-annino]-

390

propionic acid

(S)-3-(2-Chloro-phenyl)-3-{[6-methoxy-5-(3-nnethoxy-phenyl)-pyridine-3-

391

carbonyl]-amino}-propionic acid

(S)-3-(2-Chloro-phenyl)-3-{[5-(3-chloro-phenyl)-6-methoxy-pyridine-3-

392

carbonyl]-amino}-propionic acid

(S)-3-(2-Chloro-phenyl)-3-[(6-methoxy-5-naphthalen-2-yl-pyridine-3-

393

carbonyl)-amino]-propionic acid

(S)-3-(2-Chloro-phenyl)-3-{[6-methoxy-5-(2-nnethoxy-phenyl)-pyridine-3-

394

carbonyl]-amino}-propionic acid

(S)-3-(2-Chloro-phenyl)-3-[(6-methoxy-5-m-tolyl-pyndine-3-carbonyl)-amino]-

395

propionic acid

(S)-3-{[5-(4-tert-Butyl-phenyl)-6-methoxy-pyridine-3-carbonyl]-annino}-3-(2-

396

chloro-phenyl)-propionic acid

(S)-3-(2-Chloro-phenyl)-3-{[5-(3-cyano-phenyl)-6-methoxy-pyridine-3-

397

carbonyl]-amino}-propionic acid

(S)-3-(2-Chloro-phenyl)-3-{[5-(4-cyano-phenyl)-6-methoxy-pyridine-3-

398

carbonyl]-amino}-propionic acid

(S)-3-{[5-(3-Acetyl-phenyl)-6-methoxy-pyridine-3-carbonyl]-annino}-3-(2-

399

chloro-phenyl)-propionic acid

(S)-3-[(5-Biphenyl-3-yl-6-methoxy-pyridine-3-carbonyl)-annino]-3-(2-chloro-

400

phenyl)-propionic acid

(S)-3-{[5-(4-Acetyl-phenyl)-6-methoxy-pyridine-3-carbonyl]-annino}-3-(2-

401

chloro-phenyl)-propionic acid

(S)-3-(2-Chloro-phenyl)-3-{[5-(3,5-difluoro-phenyl)-6-methoxy-pyridine-3-

402

carbonyl]-amino}-propionic acid

(S)-3-(2-Chloro-phenyl)-3-{[5-(3,4-difluoro-phenyl)-6-methoxy-pyridine-3-

403

carbonyl]-amino}-propionic acid (S)-3-(2-Chloro-phenyl)-3-{[5-(4-fluoro-2-methyl-phenyl)-6-methoxy-pyridine-

404

3-carbonyl]-amino}-propionic acid

(S)-3-[(6-Methoxy-5-phenyl-pyridine-3-carbonyl)-annino]-3-o-tolyl-propionic

405

acid

(S)-3-{[5-(3-Chloro-4-fluoro-phenyl)-6-methoxy-pyridine-3-carbonyl]-annino}-

406

3-o-tolyl-propionic acid

(S)-3-{[5-(4-Fluoro-phenyl)-6-methoxy-pyridine-3-carbonyl]-annino}-3-o-tolyl-

407

propionic acid

(S)-3-{[5-(4-Chloro-phenyl)-6-methoxy-pyridine-3-carbonyl]-annino}-3-o-tolyl-

408

propionic acid

(S)-3-{[6-Methoxy-5-(4-methoxy-phenyl)-pyridine-3-carbonyl]-annino}-3-o-

409

tolyl-propionic acid

(S)-3-[(6-Methoxy-5-p-tolyl-pyridine-3-carbonyl)-annino]-3-o-tolyl-propionic

410

acid

(S)-3-[(6-Methoxy-5-o-tolyl-pyridine-3-carbonyl)-annino]-3-o-tolyl-propionic

41 1

acid

(S)-3-{[6-Methoxy-5-(3-methoxy-phenyl)-pyridine-3-carbonyl]-annino}-3-o-

412

tolyl-propionic acid

(S)-3-{[5-(3-Chloro-phenyl)-6-methoxy-pyridine-3-carbonyl]-annino}-3-o-tolyl-

413

propionic acid

(S)-3-{[5-(3-Fluoro-phenyl)-6-methoxy-pyridine-3-carbonyl]-annino}-3-o-tolyl-

414

propionic acid

(S)-3-[(6-Methoxy-5-naphthalen-2-yl-pyridine-3-carbonyl)-annino]-3-o-tolyl-

415

propionic acid

(S)-3-{[6-Methoxy-5-(2-methoxy-phenyl)-pyridine-3-carbonyl]-annino}-3-o-

416

tolyl-propionic acid

(S)-3-[(6-Methoxy-5-m-tolyl-pyridine-3-carbonyl)-amino]-3-o-tolyl-propionic

417

acid

(S)-3-{[5-(2-Fluoro-phenyl)-6-methoxy-pyridine-3-carbonyl]-annino}-3-o-tolyl-

418

propionic acid (S)-3-{[5-(4-tert-Butyl-phenyl)-6-methoxy-pyridine-3-carbonyl]-annino}-3-o-

419

tolyl-propionic acid

(S)-3-{[5-(3-Cyano-phenyl)-6-methoxy-pyridine-3-carbonyl]-annino}-3-o-tolyl-

420

propionic acid

(S)-3-{[5-(4-Cyano-phenyl)-6-methoxy-pyridine-3-carbonyl]-annino}-3-o-tolyl-

421

propionic acid

(S)-3-{[5-(3-Acetyl-phenyl)-6-methoxy-pyridine-3-carbonyl]-annino}-3-o-tolyl-

422

propionic acid

(S)-3-[(5-Biphenyl-3-yl-6-methoxy-pyridine-3-carbonyl)-annino]-3-o-tolyl-

423

propionic acid

(S)-3-{[5-(4-Acetyl-phenyl)-6-methoxy-pyridine-3-carbonyl]-annino}-3-o-tolyl-

424

propionic acid

(S)-3-{[5-(3,4-Difluoro-phenyl)-6-methoxy-pyridine-3-carbonyl]-annino}-3-o-

425

tolyl-propionic acid

(S)-3-(2-Chloro-phenyl)-3-{[6-(3-fluoro-phenyl)-5-methoxy-pyridine-2-

426

carbonyl]-amino}-propionic acid

(S)-3-(2-Chloro-phenyl)-3-[(5-methoxy-6-naphthalen-2-yl-pyridine-2-

427

carbonyl)-amino]-propionic acid

(S)-3-(2-Chloro-phenyl)-3-{[5-methoxy-6-(2-nnethoxy-phenyl)-pyridine-2-

428

carbonyl]-amino}-propionic acid

(S)-3-(2-Chloro-phenyl)-3-[(5-methoxy-6-m-tolyl-pyndine-2-carbonyl)-amino]-

429

propionic acid

(S)-3-(2-Chloro-phenyl)-3-{[6-(2-chloro-phenyl)-5-methoxy-pyridine-2-

430

carbonyl]-amino}-propionic acid

(S)-3-(2-Chloro-phenyl)-3-{[6-(2-fluoro-phenyl)-5-methoxy-pyridine-2-

431

carbonyl]-amino}-propionic acid

(S)-3-{[6-(4-tert-Butyl-phenyl)-5-methoxy-pyridine-2-carbonyl]-annino}-3-(2-

432

chloro-phenyl)-propionic acid

(S)-3-(2-Chloro-phenyl)-3-{[6-(3-cyano-phenyl)-5-methoxy-pyridine-2-

433

carbonyl]-amino}-propionic acid (S)-3-(2-Chloro-phenyl)-3-{[6-(4-cyano-phenyl)-5-methoxy-pyridine-2-

434

carbonyl]-amino}-propionic acid

(S)-3-{[6-(3-Acetyl-phenyl)-5-methoxy-pyridine-2-carbonyl]-annino}-3-(2-

435

chloro-phenyl)-propionic acid

(S)-3-[(6-Biphenyl-3-yl-5-methoxy-pyridine-2-carbonyl)-annino]-3-(2-chloro-

436

phenylj-propionic acid

(S)-3-{[6-(4-Acetyl-phenyl)-5-methoxy-pyridine-2-carbonyl]-annino}-3-(2-

437

chloro-phenyl)-propionic acid

(S)-3-(2-Chloro-phenyl)-3-{[6-(2,4-difluoro-phenyl)-5-methoxy-pyridine-2-

438

carbonyl]-amino}-propionic acid

(S)-3-(2-Chloro-phenyl)-3-{[6-(3,5-difluoro-phenyl)-5-methoxy-pyridine-2-

439

carbonyl]-amino}-propionic acid

(S)-3-(2-Chloro-phenyl)-3-{[6-(3,4-difluoro-phenyl)-5-methoxy-pyridine-2-

440

carbonyl]-amino}-propionic acid

(S)-3-(2-Chloro-phenyl)-3-{[6-(2,3-dichloro-phenyl)-5-methoxy-pyridine-2-

441

carbonyl]-amino}-propionic acid

(S)-3-{[6-(5-Acetyl-thiophen-2-yl)-5-methoxy-pyridine-2-carbonyl]-annino}-3-

442

(2-chloro-phenyl)-propionic acid

(S)-3-(2-Chloro-phenyl)-3-[(3-methoxy-[2,4 bipyridinyl-6-carbonyl)-amino]-

443

propionic acid

(S)-3-(2-Chloro-phenyl)-3-[(3-methoxy-[2,3']bipyridinyl-6-carbonyl)-amino]-

444

propionic acid

(S)-3-(2-Chloro-phenyl)-3-{[6-(2,3-difluoro-phenyl)-5-methoxy-pyridine-2-

445

carbonyl]-amino}-propionic acid

(S)-3-(2-Chloro-phenyl)-3-{[6-(2,5-difluoro-phenyl)-5-methoxy-pyridine-2-

446

carbonyl]-amino}-propionic acid

(S)-3-(2-Chloro-phenyl)-3-{[6-(4-fluoro-2-methyl-phenyl)-5-nnethoxy-pyridine-

447

2-carbonyl]-amino}-propionic acid

(S)-3-(2-Chloro-phenyl)-3-{[6-(2,3-dimethyl-phenyl)-5-methoxy-pyridine-2-

448

carbonyl]-amino}-propionic acid (S)-3-(2-Chloro-phenyl)-3-{[6-(3-fluoro-4-methyl-phenyl)-5-methoxy-pyridine-

449

2-carbonyl]-amino}-propionic acid

(S)-3-(2-Chloro-phenyl)-3-{[6-(2,4-dimethyl-phenyl)-5-methoxy-pyridine-2-

450

carbonyl]-amino}-propionic acid

(S)-3-(2-Chloro-phenyl)-3-{[6-(4-fluoro-3-methyl-phenyl)-5-nnethoxy-pyridine-

451

2-carbonyl]-amino}-propionic acid

(S)-3-(2-Chloro-phenyl)-3-[(5-methoxy-6-pyrimidin-5-yl-pyndine-2-carbonyl)-

452

amino]-propionic acid

(S)-3-(2-Chloro-phenyl)-3-[(6'-fluoro-3-methoxy-[2,3']bipyridinyl-6-carbonyl)-

453

amino]-propionic acid

(S)-3-(2-Chloro-phenyl)-3-{[6-(2-dimethylcarbannoyl-phenyl)-5-nnethoxy-

454

pyridine-2-carbonyl]-amino}-propionic acid

(S)-3-(2-Chloro-phenyl)-3-[(3,2'-dimethoxy-[2,3']bipyridinyl-6-carbonyl)-

455

amino]-propionic acid

(S)-3-(2-Chloro-phenyl)-3-{[6-(5-fluoro-2-methyl-phenyl)-5-nnethoxy-pyridine-

456

2-carbonyl]-amino}-propionic acid

(S)-3-(2-Chloro-phenyl)-3-{[6-(4-fluoro-2-methoxy-phenyl)-5-nnethoxy-

457

pyridine-2-carbonyl]-amino}-propionic acid

(S)-3-{[6-(4-Chloro-2-methoxy-phenyl)-5-nnethoxy-pyridine-2-carbonyl]-

458

amino}-3-(2-chloro-phenyl)-propionic acid

(S)-3-{[6-(5-Chloro-2-methoxy-phenyl)-5-nnethoxy-pyridine-2-carbonyl]-

459

amino}-3-(2-chloro-phenyl)-propionic acid

(S)-3-(2-Chloro-phenyl)-3-{[6-(5-fluoro-2-methoxy-phenyl)-5-nnethoxy-

460

pyridine-2-carbonyl]-annino}-propionic acid

(S)-3-(2-Chloro-phenyl)-3-{[6-(2,5-dimethoxy-phenyl)-5-nnethoxy-pyridine-2-

461

carbonyl]-amino}-propionic acid

(S)-3-(2-Chloro-phenyl)-3-{[6-(2-fluoro-5-trifluoronnethyl-phenyl)-5-nnethoxy-

462

pyridine-2-carbonyl]-annino}-propionic acid

(S)-3-(2-Chloro-phenyl)-3-{[5-methoxy-6-(5-methyl-furan-2-yl)-pyridine-2-

463

carbonyl]-amino}-propionic acid (S)-3-{[5-Methoxy-6-(2-trifluoromethyl-phenyl)-pyridine-2-carbonyl]-amino}-3-

464

o-tolyl-propionic acid

(S)-3-{[6-(4-Cyano-phenyl)-5-methoxy-pyridine-2-carbonyl]-annino}-3-o-tolyl-

465

propionic acid

(S)-3-{[6-(2,4-Difluoro-phenyl)-5-methoxy-pyridine-2-carbonyl]-annino}-3-o-

466

tolyl-propionic acid

(S)-3-{[6-(4-Fluoro-2-methyl-phenyl)-5-nnethoxy-pyridine-2-carbonyl]-annino}-

467

3-o-tolyl-propionic acid

(S)-3-[(3,2'-Dimethoxy-[2,3]bipyridinyl-6-carbonyl)-amino]-3-o-tolyl-propionic

468

acid

(S)-3-[(2'-Chloro-3-methoxy-5'-methyl-[2,3']bipyridinyl-6-carbonyl)-amino]-3-

469

o-tolyl-propionic acid

(S)-3-[(3'-Fluoro-3-methoxy-[2,4']bipyridinyl-6-carbonyl)-annino]-3-o-tolyl-

470

propionic acid

(S)-3-({5-Methoxy-6-[3-(5-methyl-[1 ,3,4]oxadiazol-2-yl)-phenyl]-pyridine-2-

471

carbonyl}-amino)-3-o-tolyl-propionic acid

(S)-3-{[5-Methoxy-6-(2-methyl-furan-3-yl)-pyridine-2-carbonyl]-annino}-3-o-

472

tolyl-propionic acid

(S)-3-{[6-(4-Cyano-2-fluoro-phenyl)-5-methoxy-pyridine-2-carbonyl]-annino}-

473

3-o-tolyl-propionic acid

(S)-3-(2-Chloro-phenyl)-3-{[6-(2-fluoro-5-methoxy-phenyl)-5-nnethoxy-

474

pyridine-2-carbonyl]-amino}-propionic acid

(S)-3-{[6-(5-tert-Butyl-2-methoxy-phenyl)-5-nnethoxy-pyridine-2-carbonyl]-

475

amino}-3-(2-chloro-phenyl)-propionic acid

(S)-3-(2-Chloro-phenyl)-3-{[6-(2-fluoro-5-methyl-phenyl)-5-nnethoxy-pyridine-

476

2-carbonyl]-amino}-propionic acid

(S)-3-{[6-(3-Chloro-2-methyl-phenyl)-5-methoxy-pyridine-2-carbonyl]-amino}-

477

3-(2-chloro-phenyl)-propionic acid

(S)-3-(2-Chloro-phenyl)-3-{[6-(3-fluoro-2-methyl-phenyl)-5-nnethoxy-pyridine-

478

2-carbonyl]-amino}-propionic acid (S)-3-{[6-(5-Chloro-2-fluoro-phenyl)-5-methoxy-pyridine-2-carbonyl]-annino}-

479

3-(2-chloro-phenyl)-propionic acid

(S)-3-{[6-(4-Chloro-3-fluoro-phenyl)-5-methoxy-pyridine-2-carbonyl]-annino}-

480

3-(2-chloro-phenyl)-propionic acid

(S)-3-[(2'-Chloro-3-methoxy-5'-methyl-[2,3']bipyridinyl-6-carbonyl)-amino]-3-

481

(2-chloro-phenyl)-propionic acid

(S)-3-(2-Chloro-phenyl)-3-[(3'-fluoro-3-methoxy-[2,4']bipyridinyl-6-carbonyl)-

482

amino]-propionic acid

(S)-3-{[6-(3-Chloro-5-methyl-phenyl)-5-methoxy-pyridine-2-carbonyl]-amino}-

483

3-(2-chloro-phenyl)-propionic acid

(S)-3-(2-Chloro-phenyl)-3-({5-methoxy-6-[3-(5-methyl-[1 ,3,4]oxadiazol-2-yl)-

484

phenyl]-pyridine-2-carbonyl}-annino)-propionic acid

(S)-3-(2-Chloro-phenyl)-3-[(5-methoxy-6-pyrazin-2-yl-pyridine-2-carbonyl)-

485

amino]-propionic acid

(S)-3-(2-Chloro-phenyl)-3-{[5-methoxy-6-(1 ,3,5-trimethyl-1 H-pyrazol-4-yl)-

486

pyridine-2-carbonyl]-amino}-propionic acid

(S)-3-(2-Chloro-phenyl)-3-{[5-methoxy-6-(1 -methyl-1 H-indol-6-yl)-pyridine-2-

487

carbonyl]-amino}-propionic acid

(S)-3-{[6-(4-Chloro-3-methoxy-phenyl)-5-nnethoxy-pyridine-2-carbonyl]-

488

amino}-3-(2-chloro-phenyl)-propionic acid

(S)-3-{[6-(3-Chloro-2-fluoro-phenyl)-5-methoxy-pyridine-2-carbonyl]-annino}-

489

3-(2-chloro-phenyl)-propionic acid

(S)-3-(2-Chloro-phenyl)-3-[(3-methoxy-2'-morpholin-4-yl-[2,4']bipyridinyl-6-

490

carbonyl)-amino]-propionic acid

(S)-3-(2-Chloro-phenyl)-3-{[5-methoxy-6-(2-methyl-furan-3-yl)-pyridine-2-

491

carbonyl]-amino}-propionic acid

(S)-3-{[6-(2-Chloro-5-methyl-phenyl)-5-methoxy-pyridine-2-carbonyl]-amino}-

492

3-(2-chloro-phenyl)-propionic acid

(S)-3-{[6-(2-Chloro-3-fluoro-phenyl)-5-methoxy-pyridine-2-carbonyl]-annino}-

493

3-(2-chloro-phenyl)-propionic acid (S)-3-(2-Chloro-phenyl)-3-{[6-(4-cyano-2-fluoro-phenyl)-5-methoxy-pyridine-

494

2-carbonyl]-amino}-propionic acid

(S)-3-(2-Chloro-phenyl)-3-({6-[3-(3-hydroxy-oxetan-3-yl)-phenyl]-5-methoxy-

495

pyridine-2-carbonyl}-amino)-propionic acid

(S)-3-(2-Chloro-phenyl)-3-({6-[3-(1 -hydroxy-1 -methyl-ethyl)-phenyl]-5-

496

methoxy-pyridine-2-carbonyl}-annino)-propionic acid

(S)-3-{[6-(2-Chloro-3-methyl-phenyl)-5-methoxy-pyridine-2-carbonyl]-amino}-

497

3-(2-chloro-phenyl)-propionic acid

498 3-Biphenyl-4-yl-3-[(3,6-dichloro-pyridine-2-carbonyl)-amino]-propionic acid

3-Biphenyl-4-yl-3-[(4-chloro-3-methoxy-pyridine-2-carbonyl)-annino]-

499

propionic acid

3-Biphenyl-4-yl-3-[(2-chloro-6-methyl-pyridine-4-carbonyl)-amino]-propionic

500

acid

501 3-Biphenyl-4-yl-3-[(6-chloro-pyridine-2-carbonyl)-annino]-propionic acid

3-Biphenyl-4-yl-3-[(5-chloro-6-hydroxy-pyridine-3-carbonyl)-annino]-propionic

502

acid

503 3-Biphenyl-4-yl-3-[(2-chloro-pyridine-4-carbonyl)-annino]-propionic acid

504 3-Biphenyl-4-yl-3-[(5-chloro-pyridine-3-carbonyl)-annino]-propionic acid

3-Biphenyl-4-yl-3-[(5-chloro-6-methoxy-pyridine-3-carbonyl)-annino]-

505

propionic acid

506 (S)-3-[(3,6-Dichloro-pyridine-2-carbonyl)-annino]-3-o-tolyl-propionic acid

(S)-3-[(2-Chloro-6-methyl-pyridine-4-carbonyl)-annino]-3-o-tolyl-propionic

507

acid

(S)-3-[(2-Chloro-6-methoxy-pyridine-4-carbonyl)-annino]-3-o-tolyl-propionic

508

acid 509 (S)-3-[(2,6-Dichloro-pyridine-4-carbonyl)-amino]-3-o-tolyl-propionic acid

510 (S)-3-[(6-Chloro-pyridine-2-carbonyl)-amino]-3-o-tolyl-propionic acid

(S)-3-[(5-Chloro-6-hydroxy-pyridine-3-carbonyl)-amino]-3-o-tolyl-propionic

51 1

acid

512 (S)-3-[(2-Chloro-pyridine-4-carbonyl)-amino]-3-o-tolyl-propionic acid

513 (S)-3-[(5-Chloro-pyridine-3-carbonyl)-amino]-3-o-tolyl-propionic acid

514 (S)-3-[(6-Chloro-pyrazine-2-carbonyl)-amino]-3-o-tolyl-propionic acid

(S)-3-[(3,5-Diamino-6-chloro-pyrazine-2-carbonyl)-amino]-3-o-tolyl-propionic

515

acid

3-Biphenyl-4-yl-3-{[5-chloro-6-(2-hydroxy-ethylamino)-pyridine-3-carbonyl]-

516

amino}-propionic acid

(S)-3-[(5-Chloro-6-methoxy-pyridine-3-carbonyl)-annino]-3-o-tolyl-propionic

517

acid

518 (S)-3-[(2,5-Dichloro-pyridine-3-carbonyl)-annino]-3-o-tolyl-propionic acid

3-Biphenyl-4-yl-3-[(3,5-diamino-6-chloro-pyrazine-2-carbonyl)-annino]-

519

propionic acid

(S)-3-[(4-Chloro-3-methoxy-pyridine-2-carbonyl)-annino]-3-o-tolyl-propionic

520

acid

521 3-(2-Chloro-phenyl)-3-[(pyrazine-2-carbonyl)-amino]-propionic acid

522 3-(2-Chloro-phenyl)-3-[(pyridine-3-carbonyl)-annino]-propionic acid 523 3-(2-Chloro-phenyl)-3-[(pyridine-2-carbonyl)-annino]-propionic acid

524 3-(2-Chloro-phenyl)-3-[(pyridine-4-carbonyl)-annino]-propionic acid

525 3-(2-Chloro-phenyl)-3-[(5-methyl-pyrazine-2-carbonyl)-amino]-propionic acid

526 3-(2-Chloro-phenyl)-3-[(2-methyl-pyridine-4-carbonyl)-amino]-propionic acid

527 3-(2-Chloro-phenyl)-3-[(6-methyl-pyridine-2-carbonyl)-amino]-propionic acid

528 3-(2-Chloro-phenyl)-3-[(4-methyl-pyridine-2-carbonyl)-amino]-propionic acid

529 3-(2-Chloro-phenyl)-3-[(4-hydroxy-pyridine-2-carbonyl)-annino]-propionic acid

530 3-(2-Chloro-phenyl)-3-[(3-fluoro-pyridine-2-carbonyl)-annino]-propionic acid

531 3-(2-Chloro-phenyl)-3-[(6-fluoro-pyridine-2-carbonyl)-annino]-propionic acid

532 3-(2-Chloro-phenyl)-3-[(4-ethyl-pyridine-2-carbonyl)-amino]-propionic acid 3-(2-Chloro-phenyl)-3-[(4,6-dimethyl-pyridine-2-carbonyl)-amino]-propionic

533

acid

3-(2-Chloro-phenyl)-3-[(4,6-dimethyl-pyridine-3-carbonyl)-amino]-propionic

534

acid

3-(2-Chloro-phenyl)-3-[(6-methylamino-pyrazine-2-carbonyl)-amino]-

535

propionic acid

3-(2-Chloro-phenyl)-3-[(2-methoxy-pyridine-4-carbonyl)-annino]-propionic

536

acid

3-(2-Chloro-phenyl)-3-[(6-methoxy-pyridine-3-carbonyl)-annino]-propionic

537

acid

3-(2-Chloro-phenyl)-3-[(6-methoxy-pyridine-2-carbonyl)-amino]-propionic

538

acid

3-(2-Chloro-phenyl)-3-[(3-methoxy-pyridine-2-carbonyl)-annino]-propionic

539

acid

540 3-(2-Chloro-phenyl)-3-[(6-chloro-pyridine-2-carbonyl)-amino]-propionic acid

3-(2-Chloro-phenyl)-3-[(3,6-difluoro-pyridine-2-carbonyl)-amino]-propionic

541

acid

3-(2-Chloro-phenyl)-3-[(3H-imidazo[4,5-b]pyridine-5-carbonyl)-amino]-

542

propionic acid; compound with trifluoro-acetic acid 543 3-(2-Chloro-phenyl)-3-[([1 ,8]naphthyridine-2-carbonyl)-amino]-propionic acid

544 3-(2-Chloro-phenyl)-3-[([1 ,6]naphthyridine-2-carbonyl)-amino]-propionic acid

3-[(2-Acetylamino-pyridine-4-carbonyl)-amino]-3-(2-chloro-phenyl)-propionic

545

acid

3-[(2-Amino-6-isopropyl-pyrimidine-4-carbonyl)-amino]-3-(2-chloro-phenyl)-

546

propionic acid; compound with trifluoro-acetic acid

(S)-3-{[6-(2-Fluoro-phenyl)-pyridine-2-carbonyl]-amino}-3-phenyl-propionic

547

acid

3-(2-Chloro-phenyl)-3-[(4,6-dimethoxy-pyrimidine-2-carbonyl)-amino]-

548

propionic acid

3-(2-Chloro-phenyl)-3-[(2,6-dimethoxy-pyrimidine-4-carbonyl)-amino]-

549

propionic acid

3-[(6-Chloro-5-methoxy-pyridine-2-carbonyl)-annino]-3-(2-chloro-phenyl)-

550

propionic acid

3-(2-Chloro-phenyl)-3-[(6-imidazol-1 -yl-pyridine-2-carbonyl)-amino]-propionic

551

acid

3-(2-Chloro-phenyl)-3-[(3,6-dichloro-pyridine-2-carbonyl)-amino]-propionic

552

acid 3-(2-Chloro-phenyl)-3-[(2-pyrrolidin-1 -yl-pyridine-4-carbonyl)-amino]-

553

propionic acid; compound with trifluoro-acetic acid

3-(2-Chloro-phenyl)-3-[(6-pyrrolidin-1 -yl-pyridine-3-carbonyl)-annino]-

554

propionic acid; compound with trifluoro-acetic acid

3-(2-Chloro-phenyl)-3-[(5-pyrrolidin-1 -yl-pyridine-3-carbonyl)-amino]-

555

propionic acid; compound with trifluoro-acetic acid

(S)-3-{[5-Chloro-6-(2-hydroxy-ethylamino)-pyridine-3-carbonyl]-amino}-3-o-

556

tolyl-propionic acid

3-[(2-Amino-6-isobutyl-pyrimidine-4-carbonyl)-amino]-3-(2-chloro-phenyl)-

557

propionic acid

558 (S)-3-{[6-(2-Fluoro-phenyl)-pyridine-2-carbonyl]-amino}-3-phenyl-butyric acid

(S)-3-{[6-(2-Fluoro-phenyl)-pyridine-2-carbonyl]-amino}-3-p-tolyl-propionic

559

acid

(S)-3-{[6-(2-Fluoro-phenyl)-pyridine-2-carbonyl]-amino}-3-m-tolyl-propionic

560

acid

561 (R)-3-{[6-(2-Fluoro-phenyl)-pyridine-2-carbonyl]-amino}-4-phenyl-butyric acid

562 3-[(6-Bromo-pyridine-2-carbonyl)-amino]-3-(2-chloro-phenyl)-propionic acid 563 3-(2-Chloro-phenyl)-3-[(6-phenyl-pyridine-2-carbonyl)-amino]-propionic acid

564 3-(2-Chloro-phenyl)-3-[(3-phenyl-pyridine-2-carbonyl)-amino]-propionic acid

565 3-(2-Chloro-phenyl)-3-[(4-phenyl-pyridine-2-carbonyl)-amino]-propionic acid

566 3-(2-Chloro-phenyl)-3-[(5-phenyl-pyridine-3-carbonyl)-amino]-propionic acid

(S)-3-{[6-(2-Chloro-phenyl)-pyridine-2-carbonyl]-amino}-3-phenyl-propionic

567

acid

568 3-[(5-Bromo-pyridine-3-carbonyl)-amino]-3-(2-chloro-phenyl)-propionic acid

(S)-3-(3-Fluoro-phenyl)-3-{[6-(2-fluoro-phenyl)-pyridine-2-carbonyl]-amino}-

569

propionic acid

(S)-3-(2-Fluoro-phenyl)-3-{[6-(2-fluoro-phenyl)-pyridine-2-carbonyl]-amino}-

570

propionic acid

(S)-3-(4-Fluoro-phenyl)-3-{[6-(2-fluoro-phenyl)-pyridine-2-carbonyl]-amino}-

571

propionic acid

3-(2-Chloro-phenyl)-3-[(3,4,5,6-tetrahydro-2H-[1 ,2']bipyridinyl-4'-carbonyl)-

572

amino]-propionic acid; compound with trifluoro-acetic acid 3-(2-Chloro-phenyl)-3-[(3,4,5,6-tetrahydro-2H-[1 ,2']bipyridinyl-6'-carbonyl)-

573

amino]-propionic acid; compound with trifluoro-acetic acid

3-(2-Chloro-phenyl)-3-[(6-morpholin-4-yl-pyridine-2-carbonyl)-amino]-

574

propionic acid; compound with trifluoro-acetic acid

3-(2-Chloro-phenyl)-3-[(4-morpholin-4-yl-pyridine-2-carbonyl)-amino]-

575

propionic acid; compound with trifluoro-acetic acid

3-(2-Chloro-phenyl)-3-[(2-morpholin-4-yl-pyridine-4-carbonyl)-amino]-

576

propionic acid; compound with trifluoro-acetic acid

577 (S)-3-[(6-Methoxy-biphenyl-3-carbonyl)-amino]-3-o-tolyl-propionic acid

578 (S)-3-[(3-Methoxy-[2,3']bipyridinyl-6-carbonyl)-amino]-3-o-tolyl-propionic acid

3-[(2,6-Bis-dimethylamino-pyrimidine-4-carbonyl)-amino]-3-(2-chloro-

579

phenyl)-propionic acid; compound with trifluoro-acetic acid

(S)-3-{[6-(2-Chloro-phenyl)-pyridine-2-carbonyl]-amino}-3-p-tolyl-propionic

580

acid

581 (S)-3-{[6-(2-Chloro-phenyl)-pyridine-2-carbonyl]-amino}-3-phenyl-butyric acid

(S)-3-{[6-(2-Chloro-phenyl)-pyridine-2-carbonyl]-amino}-3-m-tolyl-propionic

582

acid (R)-3-{[6-(2-Chloro-phenyl)-pyridine-2-carbonyl]-amino}-4-phenyl-butyric

583

acid

(S)-3-{[6-(2-Fluoro-phenyl)-pyridine-2-carbonyl]-annino}-3-(4-nnethoxy-

584

phenyl)-propionic acid

3-(2-Chloro-phenyl)-3-[(6-phenoxy-pyridine-3-carbonyl)-amino]-propionic

585

acid

(S)-3-{[6-(2-Chloro-phenyl)-pyridine-2-carbonyl]-annino}-3-(2-fluoro-phenyl)-

586

propionic acid

(S)-3-{[6-(2-Chloro-phenyl)-pyridine-2-carbonyl]-annino}-3-(3-fluoro-phenyl)-

587

propionic acid

(S)-3-{[6-(2-Chloro-phenyl)-pyridine-2-carbonyl]-annino}-3-(4-fluoro-phenyl)-

588

propionic acid

3-(2-Chloro-phenyl)-3-{[6-(2-fluoro-phenyl)-pyridine-2-carbonyl]-annino}-

589

propionic acid

(S)-3-(3-Chloro-phenyl)-3-{[6-(2-fluoro-phenyl)-pyridine-2-carbonyl]-amino}-

590

propionic acid

(S)-3-(4-Chloro-phenyl)-3-{[6-(2-fluoro-phenyl)-pyridine-2-carbonyl]-amino}-

591

propionic acid

3-(2-Chloro-phenyl)-3-[(1 -ethyl-3,6-dimethyl-1 H-pyrazolo[3,4-b]pyridine-4-

592

carbonyl)-amino]-propionic acid 3-(2-Chloro-phenyl)-3-{[2-(2,2-dimethyl-propionylamino)-pyridine-4-

593

carbonyl]-amino}-propionic acid

3-(2-Chloro-phenyl)-3-{[6-(tetrahydro-pyran-4-yloxy)-pyridine-3-carbonyl]-

594

amino}-propionic acid

3-(2-Chloro-phenyl)-3-{[6-(4-methoxy-phenyl)-pyridine-2-carbonyl]-annino}-

595

propionic acid

3-(2-Chloro-phenyl)-3-{[6-(3-methoxy-phenyl)-pyridine-2-carbonyl]-annino}-

596

propionic acid

3-(2-Chloro-phenyl)-3-{[6-(2-methoxy-phenyl)-pyridine-2-carbonyl]-annino}-

597

propionic acid

3-[(6-Bromo-5-nnethoxy-pyridine-2-carbonyl)-annino]-3-(2-chloro-phenyl)-

598

propionic acid

(S)-3-{[6-(2-Chloro-phenyl)-pyridine-2-carbonyl]-annino}-3-(4-nnethoxy-

599

phenyl)-propionic acid

3-(2-Chloro-phenyl)-3-[(6-cyclopropyl-1 ,3-dimethyl-1 H-pyrazolo[3,4-

600

b]pyridine-4-carbonyl)-annino]-propionic acid

3-(2-Chloro-phenyl)-3-{[4-(pyrinnidin-2-ylsulfanyl)-pyndine-2-carbonyl]-

601

amino}-propionic acid

(S)-3-(4-Chloro-phenyl)-3-{[6-(2-chloro-phenyl)-pyridine-2-carbonyl]-annino}-

602

propionic acid (S)-3-(3-Chloro-phenyl)-3-{[6-(2-chloro-phenyl)-pyridine-2-carbonyl]-annino}-

603

propionic acid

3-(2-Chloro-phenyl)-3-{[6-(2-chloro-phenyl)-pyridine-2-carbonyl]-amino}-

604

propionic acid

(S)-3-(2,4-Dichloro-phenyl)-3-{[6-(2-fluoro-phenyl)-pyridine-2-carbonyl]-

605

amino}-propionic acid

(S)-3-(2,3-Dichloro-phenyl)-3-{[6-(2-fluoro-phenyl)-pyridine-2-carbonyl]-

606

amino}-propionic acid

(S)-3-{[6-(2-Fluoro-phenyl)-pyridine-2-carbonyl]-annino}-3-(2-tnfluoronnethyl-

607

phenyl)-propionic acid

(S)-3-{[6-(2-Fluoro-phenyl)-pyridine-2-carbonyl]-annino}-3-(4-tnfluoronnethyl-

608

phenyl)-propionic acid

(S)-3-{[6-(2-Fluoro-phenyl)-pyridine-2-carbonyl]-annino}-3-(3-tnfluoronnethyl-

609

phenyl)-propionic acid

(S)-3-{[6-(2-Chloro-phenyl)-pyridine-2-carbonyl]-annino}-3-(2,3-dichloro-

610

phenyl)-propionic acid

(S)-3-{[6-(2-Chloro-phenyl)-pyridine-2-carbonyl]-annino}-3-(2,4-dichloro-

61 1

phenyl)-propionic acid

(S)-3-{[6-(2-Chloro-phenyl)-pyndine-2-carbonyl]-amino}-3-(2-trifluoromethyl-

612

phenyl)-propionic acid (S)-3-{[6-(2-Chloro-phenyl)-pyndine-2-carbonyl]-amino}-3-(4-trifluoromethyl-

613

phenyl)-propionic acid

(S)-3-{[6-(2-Chloro-phenyl)-pyndine-2-carbonyl]-amino}-3-(3-trifluoromethyl-

614

phenyl)-propionic acid

3-(2-Chloro-phenyl)-3-{[3-(4,6-dimethoxy-pyrinnidin-2-yloxy)-pyridine-2-

615

carbonyl]-amino}-propionic acid

3-(2-Chloro-phenyl)-3-[(6-phenyl-2-piperidin-1 -yl-pynmidine-4-carbonyl)-

616

amino]-propionic acid; compound with trifluoro-acetic acid

(S)-3-{[6-Bromo-5-(3,3-dinnethyl-2-oxo-butoxy)-pyridine-2-carbonyl]-annino}-

617

3-o-tolyl-propionic acid

(S)-3-{[5-(3,3-Dimethyl-2-oxo-butoxy)-6-phenyl-pyndine-2-carbonyl]-annino}-

618

3-o-tolyl-propionic acid

(S)-3-{[5-((S)-2-Hydroxy-3,3-dimethyl-butoxy)-6-phenyl-pyndine-2-carbonyl]-

619

amino}-3-o-tolyl-propionic acid

(S)-3-{[5-((R)-2-Hydroxy-3,3-dimethyl-butoxy)-6-phenyl-pyndine-2-carbonyl]-

620

amino}-3-o-tolyl-propionic acid

Compound Table 3. Example compounds of the formula III

Ex.

Compound name

No.

(S)-3-[(5-Amino-1 -phenyl-1 H-pyrazole-3-carbonyl)-amino]-3-o-tolyl-propionic

1

acid

3-[(5-Amino-1 -phenyl-1 H-pyrazole-3-carbonyl)-amino]-3-(4'-fluoro-biphenyl-4-

2

yl)-propionic acid (S)-3-{[5-Amino-1 -(2-fluoro-phenyl)-1 H-pyrazole-3-carbonyl]-amino}-3-o-tolyl- propionic acid

3-{[5-Amino-1 -(2-fluoro-phenyl)-1 H-pyrazole-3-carbonyl]-amino}-3-(4'-fluoro- biphenyl-4-yl)-propionic acid

(S)-3-{[5-Amino-4-cyano-1 -(2-fluoro-phenyl)-1 H-pyrazole-3-carbonyl]-annino}-

3-o-tolyl-propionic acid

(S)-3-[(1 -Phenyl-5-pyrrolidin-1 -yl-1 H-pyrazole-3-carbonyl)-amino]-3-o-tolyl- propionic acid

3-{[5-Amino-1 -(2-fluoro-phenyl)-1 H-pyrazole-3-carbonyl]-amino}-3-(4-pyridin-

2-yl-phenyl)-propionic acid

(S)-3-{[5-Amino-1 -(2-fluoro-phenyl)-1 H-pyrazole-3-carbonyl]-annino}-3-(2,3- dichloro-phenyl)-propionic acid

3-{[5-Amino-1 -(2-fluoro-phenyl)-1 H-pyrazole-3-carbonyl]-amino}-3-(2,5- dichloro-phenyl)-propionic acid

(S)-3-{[1 -Phenyl-5-(3-phenyl-ureido)-1 H-pyrazole-3-carbonyl]-amino}-3-o-tolyl- propionic acid

(S)-3-[(5-Methanesulfonylamino-1 -phenyl-1 H-pyrazole-3-carbonyl)-amino]-3- o-tolyl-propionic acid

(S)-3-{[5-(1 ,1 -Dioxo-1 lambda6-isothiazolidin-2-yl)-1 -(2-fluoro-phenyl)-1 H- pyrazole-3-carbonyl]-amino}-3-o-tolyl-propionic acid

(S)-3-{[1 -(2-Fluoro-phenyl)-5-pyrrolidin-1 -yl-1 H-pyrazole-3-carbonyl]-amino}-3- o-tolyl-propionic acid

(S)-3-{[1 -(2-Fluoro-phenyl)-5-(2-oxo-pyrrolidin-1 -yl)-1 H-pyrazole-3-carbonyl]- amino}-3-o-tolyl-propionic acid

(S)-3-{[5-(2-Oxo-pyrrolidin-1 -yl)-1 -phenyl-1 H-pyrazole-3-carbonyl]-amino}-3-o- tolyl-propionic acid

(S)-3-{[5-(1 ,1 -Dioxo-1 lambda6-isothiazolidin-2-yl)-1 -phenyl-1 H-pyrazole-3- carbonyl]-amino}-3-o-tolyl-propionic acid

(S)-3-{[5-(2-Oxo-piperidin-1 -yl)-1 -phenyl-1 H-pyrazole-3-carbonyl]-amino}-3-o- tolyl-propionic acid

(S)-3-{[1 -(2-Fluoro-phenyl)-5-(2-oxo-piperidin-1 -yl)-1 H-pyrazole-3-carbonyl]- amino}-3-o-tolyl-propionic acid (S)-3-{[1 -Phenyl-5-(pyridin-2-ylamino)-1 H-pyrazole-3-carbonyl]-amino}-3-o- tolyl-propionic acid -[(4H-Benzo[4,5]imidazo[1 ,2-b]pyrazole-2-carbonyl)-annino]-3-(3,4-difluoro- phenyl)-propionic acid

3-[(4H-Benzo[4,5]imidazo[1 ,2-b]pyrazole-2-carbonyl)-annino]-3-(4-cyano- phenylj-propionic acid

-Benzo[1 ,3]dioxol-4-yl-3-[(4H-benzo[4,5]innidazo[1 ,2-b]pyrazole-2-carbonyl)- amino]-propionic acid

3-[(4H-Benzo[4,5]imidazo[1 ,2-b]pyrazole-2-carbonyl)-annino]-3-(3-fluoro- phenyl)-propionic acid

3-[(4H-Benzo[4,5]imidazo[1 ,2-b]pyrazole-2-carbonyl)-annino]-3-(2-fluoro- phenyl)-propionic acid

3-[(4H-Benzo[4,5]imidazo[1 ,2-b]pyrazole-2-carbonyl)-amino]-4,4-dimethyl- pentanoic acid

3-[(4H-Benzo[4,5]imidazo[1 ,2-b]pyrazole-2-carbonyl)-annino]-3-(3-phenoxy- phenyl)-propionic acid

2-[(4H-Benzo[4,5]imidazo[1 ,2-b]pyrazole-2-carbonyl)-annino]-3-nnethoxy-3- methyl-butyric acid

(1 R,2R)-2-[(4H-Benzo[4,5]imidazo[1 ,2-b]pyrazole-2-carbonyl)-amino]- cyclohexanecarboxylic acid

(1 S,2R)-2-[(4H-Benzo[4,5]imidazo[1 ,2-b]pyrazole-2-carbonyl)-amino]- cyclopentanecarboxylic acid

3-[(4H-Benzo[4,5]imidazo[1 ,2-b]pyrazole-2-carbonyl)-annino]-3-(2-phenoxy- phenyl)-propionic acid

-[(4H-Benzo[4,5]imidazo[1 ,2-b]pyrazole-2-carbonyl)-amino]-3-(2-nnethoxy-5- trifluoromethyl-phenyl)-propionic acid

3-[(4H-Benzo[4,5]imidazo[1 ,2-b]pyrazole-2-carbonyl)-amino]-3-(2-chloro-5- fluoro-phenyl)-propionic acid

-[(4H-Benzo[4,5]imidazo[1 ,2-b]pyrazole-2-carbonyl)-annino]-3-(2,5-difluoro- phenyl)-propionic acid

3-[(4H-Benzo[4,5]imidazo[1 ,2-b]pyrazole-2-carbonyl)-amino]-3-(4-fluoro- phenyl)-propionic acid 3-[(4H-Benzo[4,5]imidazo[1 ,2-b]pyrazole-2-carbonyl)-amino]-3-o-tolyl- propionic acid

(R)-1 -(4H-Benzo[4,5]imidazo[1 ,2-b]pyrazole-2-carbonyl)-pipendine-3- carboxylic acid

(S)-3-[(4H-Benzo[4,5]imidazo[1 ,2-b]pyrazole-2-carbonyl)-annino]-3-(3-cyano- phenyl)-propionic acid

(S)-3-[(4H-Benzo[4,5]imidazo[1 ,2-b]pyrazole-2-carbonyl)-annino]-3-o-tolyl- propionic acid

(S)-3-[(4H-Benzo[4,5]imidazo[1 ,2-b]pyrazole-2-carbonyl)-amino]-3-m-tolyl- propionic acid

(S)-3-[(4H-Benzo[4,5]imidazo[1 ,2-b]pyrazole-2-carbonyl)-annino]-3-(2-fluoro- phenyl)-propionic acid

(S)-3-[(4H-Benzo[4,5]imidazo[1 ,2-b]pyrazole-2-carbonyl)-annino]-3-phenyl- propionic acid

(R)-3-[(4H-Benzo[4,5]imidazo[1 ,2-b]pyrazole-2-carbonyl)-annino]-3-p-tolyl- propionic acid

-[(4H-Benzo[4,5]imidazo[1 ,2-b]pyrazole-2-carbonyl)-amino]-3-methyl-butyric acid

(R)-3-[(4H-Benzo[4,5]imidazo[1 ,2-b]pyrazole-2-carbonyl)-amino]-4-methyl- pentanoic acid

(S)-1 -(4H-Benzo[4,5]imidazo[1 ,2-b]pyrazole-2-carbonyl)-pipendine-3- carboxylic acid

(S)-3-[(4H-Benzo[4,5]imidazo[1 ,2-b]pyrazole-2-carbonyl)-annino]-4-phenyl- butyric acid

(R)-3-[(4H-Benzo[4,5]imidazo[1 ,2-b]pyrazole-2-carbonyl)-annino]-3-o-tolyl- propionic acid

(S)-3-[(4H-Benzo[4,5]imidazo[1 ,2-b]pyrazole-2-carbonyl)-amino]-5-nnethyl- hexanoic acid

(S)-3-[(4H-Benzo[4,5]imidazo[1 ,2-b]pyrazole-2-carbonyl)-annino]-3-(2-chloro- phenyl)-propionic acid

(S)-3-{[5-(Cyclopropylmethyl-annino)-1 -phenyl-1 H-pyrazole-3-carbonyl]- amino}-3-o-tolyl-propionic acid

(S)-3-{[5-(Bis-cyclopropylmethyl-annino)-1 -phenyl-1 H-pyrazole-3-carbonyl]- amino}-3-o-tolyl-propionic acid (S)-3-{[5-(2,2-Dimethyl-propionylannino)-1 -phenyl-1 H-pyrazole-3-carbonyl]- amino}-3-o-tolyl-propionic acid

(S)-3-(2,4-Dichloro-phenyl)-3-{[5-(2,2-dimethyl-propionylamino)-1 -phenyl-1 H- pyrazole-3-carbonyl]-amino}-propionic acid

(S)-3-(2-Chloro-phenyl)-3-{[5-(2,2-dimethyl-propionylamino)-1 -phenyl-1 H- pyrazole-3-carbonyl]-amino}-propionic acid

(S)-3-({5-[(2,2-Dimethyl-propionyl)-methyl-amino]-1 -phenyl-1 H-pyrazole-3- carbonyl}-amino)-3-o-tolyl-propionic acid

(S)-3-{[5-(3,3-Dimethyl-2-oxo-butylannino)-1 -phenyl-1 H-pyrazole-3-carbonyl]- amino}-3-o-tolyl-propionic acid

(S)-3-{[5-(2-Hydroxy-3,3-dimethyl-butylamino)-1 -phenyl-1 H-pyrazole-3- carbonyl]-amino}-3-o-tolyl-propionic acid

(S)-3-{[5-(2-Hydroxy-2,3,3-trimethyl-butylamino)-1 -phenyl-1 H-pyrazole-3- carbonyl]-amino}-3-o-tolyl-propionic acid

(S)-3-{[5-((R)-2-Hydroxy-3,3-dimethyl-butylamino)-1 -phenyl-1 H-pyrazole-3- carbonyl]-amino}-3-o-tolyl-propionic acid

(S)-3-{[5-((S)-2-Hydroxy-3,3-dimethyl-butylamino)-1 -phenyl-1 H-pyrazole-3- carbonyl]-amino}-3-o-tolyl-propionic acid

(S)-3-({5-[(5-Methyl-furan-2-carbonyl)-amino]-1 -phenyl-1 H-pyrazole-3- carbonyl}-amino)-3-o-tolyl-propionic acid

(S)-3-(2,4-Dichloro-phenyl)-3-({5-[(5-methyl-furan-2-carbonyl)-amino]-1 - phenyl-1 H-pyrazole-3-carbonyl}-amino)-propionic acid

(S)-3-{[5-(Benzoyl-methyl-annino)-1 -phenyl-1 H-pyrazole-3-carbonyl]-amino}-3- o-tolyl-propionic acid

(S)-3-{[5-(Benzoyl-methyl-annino)-1 -phenyl-1 H-pyrazole-3-carbonyl]-amino}-3-

(2,4-dichloro-phenyl)-propionic acid

(S)-3-({5-[(2-Hydroxy-3,3-dimethyl-butyl)-methyl-amino]-1 -phenyl-1 H- pyrazole-3-carbonyl}-amino)-3-o-tolyl-propionic acid

(S)-3-[(5-Benzoylamino-1 -phenyl-1 H-pyrazole-3-carbonyl)-amino]-3-o-tolyl- propionic acid

(S)-3-[(5-Benzoylamino-1 -phenyl-1 H-pyrazole-3-carbonyl)-amino]-3-(2,4- dichloro-phenyl)-propionic acid (S)-3-({5-[2-((1 R,2S,5R)-2-lsopropyl-5-methyl-cyclohexyloxy)-acetylamino]-1 -

68

phenyl-1 H-pyrazole-3-carbonyl}-amino)-3-o-tolyl-propionic acid

(S)-3-[(5-Diphenylacetylamino-1 -phenyl-1 H-pyrazole-3-carbonyl)-amino]-3-o-

69

tolyl-propionic acid

(S)-3-{[5-(Benzoyl-methyl-annino)-1 -phenyl-1 H-pyrazole-3-carbonyl]-amino}-3-

70

(2-chloro-phenyl)-propionic acid

(S)-3-{[5-(Benzoyl-methyl-annino)-1 -phenyl-1 H-pyrazole-3-carbonyl]-amino}-3-

71

(3-chloro-phenyl)-propionic acid

(S)-3-{[5-(Benzoyl-methyl-annino)-1 -phenyl-1 H-pyrazole-3-carbonyl]-amino}-3-

72

p-tolyl-propionic acid

3-[(5-Benzoylamino-1 -phenyl-1 H-pyrazole-3-carbonyl)-amino]-5-methyl-

73

hexanoic acid

3-[(5-Benzoylamino-1 -phenyl-1 H-pyrazole-3-carbonyl)-amino]-3-cyclohexyl-

74

propionic acid

3-[(5-Benzoylamino-1 -phenyl-1 H-pyrazole-3-carbonyl)-amino]-4-phenyl-

75

butyric acid

(S)-3-[(5-Benzoylamino-1 -phenyl-1 H-pyrazole-3-carbonyl)-amino]-5-methyl-

76

hexanoic acid

{1 -[(5-Benzoylamino-1 -phenyl-1 H-pyrazole-3-carbonyl)-amino]-cyclopentyl}-

77

acetic acid

(S)-3-[(5-Benzoylamino-1 -phenyl-1 H-pyrazole-3-carbonyl)-amino]-3-(4-fluoro-

78

phenyl)-propionic acid

(S)-3-[(5-Benzoylamino-1 -phenyl-1 H-pyrazole-3-carbonyl)-amino]-3-(2,4-

79

dimethyl-phenyl)-propionic acid

(S)-3-[(5-Benzoylamino-1 -phenyl-1 H-pyrazole-3-carbonyl)-amino]-3-p-tolyl-

80

propionic acid

(S)-3-[(5-Benzoylamino-1 -phenyl-1 H-pyrazole-3-carbonyl)-amino]-3-(2-chloro-

81

phenyl)-propionic acid

3-[(5-Benzoylamino-1 -phenyl-1 H-pyrazole-3-carbonyl)-amino]-2-phenyl-

82

propionic acid

(S)-3-[(5-Benzoylamino-1 -phenyl-1 H-pyrazole-3-carbonyl)-amino]-3-(2-fluoro-

83

phenyl)-propionic acid (S)-3-[(5-Benzoylamino-1 -phenyl-1 H-pyrazole-3-carbonyl)-amino]-3-(2-

84

trifluoromethyl-phenyl)-propionic acid

(S)-3-[(5-Ethylamino-1 -phenyl-1 H-pyrazole-3-carbonyl)-amino]-3-o-tolyl-

85

propionic acid

(3R,4S)-1 -(5-Benzoylamino-1 -phenyl-1 H-pyrazole-3-carbonyl)-4-phenyl-

86

pyrrolidine-3-carboxylic acid

(3R,4S)-4-Phenyl-1 -(1 -phenyl-5-phenylacetylamino-1 H-pyrazole-3-carbonyl)-

87

pyrrolidine-3-carboxylic acid

(3S,4R)-4-Phenyl-1 -(1 -phenyl-5-phenylacetylamino-1 H-pyrazole-3-carbonyl)-

88

pyrrolidine-3-carboxylic acid

Example Table 4. Example compounds of the formula IV

Ex¬

Compound name

ample

1 (S)-3-[(2-Phenyl-1 H-imidazole-4-carbonyl)-amino]-3-o-tolyl-propionic acid

2 (S)-3-[(5-Phenyl-isoxazole-3-carbonyl)-amino]-3-o-tolyl-propionic acid

3 3-Cyclohexyl-3-[(5-methyl-2-phenyl-oxazole-4-carbonyl)-amino]-propionic acid

4 3-[(5-Methyl-2-phenyl-oxazole-4-carbonyl)-amino]-4-phenyl-butyric acid

5 (S)-3-[(5-Methyl-2-phenyl-oxazole-4-carbonyl)-amino]-3-o-tolyl-propionic

acid

6 (S)-3-[(1 -lsopropyl-1 H-indazole-3-carbonyl)-amino]-3-o-tolyl-propionic acid

7 (S)-3-(2-Fluoro-phenyl)-3-[(5-methyl-2-phenyl-oxazole-4-carbonyl)-amino]- propionic acid

8 (S)-3-(3-Fluoro-phenyl)-3-[(5-methyl-2-phenyl-oxazole-4-carbonyl)-amino]- propionic acid

9 (S)-3-(4-Fluoro-phenyl)-3-[(5-methyl-2-phenyl-oxazole-4-carbonyl)-amino]- propionic acid

10 (S)-3-{[2-(2-Fluoro-phenyl)-5-methyl-oxazole-4-carbonyl]-amino}-3-phenyl- propionic acid (R)-3-{[3-(2-Fluoro-phenyl)-[1 ,2,4]oxadiazole-5-carbonyl]-annino}-4-phenyl- butyric acid

(S)-3-{[5-(2-Fluoro-phenyl)-[1 ,2,4]oxadiazole-3-carbonyl]-annino}-3-p-tolyl- propionic acid

(R)-3-{[5-(2-Fluoro-phenyl)-[1 ,2,4]oxadiazole-3-carbonyl]-annino}-4-phenyl- butyric acid

(S)-3-{[5-(2-Fluoro-phenyl)-[1 ,2,4]oxadiazole-3-carbonyl]-annino}-3-phenyl- butyric acid

(S)-3-{[5-(2-Fluoro-phenyl)-[1 ,2,4]oxadiazole-3-carbonyl]-annino}-3-o-tolyl- propionic acid

(S)-3-{[5-(2-Fluoro-phenyl)-[1 ,2,4]oxadiazole-3-carbonyl]-annino}-3-nn-tolyl- propionic acid

(S)-3-(2-Fluoro-phenyl)-3-{[5-(2-fluoro-phenyl)-[1 ,2,4]oxadiazole-3-carbonyl]- amino}-propionic acid

(S)-3-(3-Fluoro-phenyl)-3-{[5-(2-fluoro-phenyl)-[1 ,2,4]oxadiazole-3-carbonyl]- amino}-propionic acid

(S)-3-(4-Fluoro-phenyl)-3-{[5-(2-fluoro-phenyl)-[1 ,2,4]oxadiazole-3-carbonyl]- amino}-propionic acid

(S)-3-{[5-(2,3-Difluoro-phenyl)-[1 ,2,4]oxadiazole-3-carbonyl]-amino}-3- phenyl-propionic acid

(S)-3-[(1 -Ethyl-5-phenyl-1 H-pyrazole-3-carbonyl)-amino]-3-o-tolyl-propionic acid

(S)-3-[(5-lsopropyl-2-phenyl-oxazole-4-carbonyl)-amino]-3-phenyl-propionic acid

(S)-3-(4-Methoxy-phenyl)-3-[(5-methyl-2-phenyl-oxazole-4-carbonyl)-annino]- propionic acid

(S)-3-(3-Methoxy-phenyl)-3-[(5-methyl-2-phenyl-oxazole-4-carbonyl)-amino]- propionic acid

(S)-3-{[2-(2-Fluoro-phenyl)-5-methyl-oxazole-4-carbonyl]-annino}-3-o-tolyl- propionic acid

(S)-3-{[5-(4-Chloro-phenyl)-isoxazole-3-carbonyl]-amino}-3-o-tolyl-propionic acid

(S)-3-{[2-(2-Fluoro-phenyl)-5-methyl-oxazole-4-carbonyl]-amino}-3-m-tolyl- propionic acid

(S)-3-(3-Chloro-phenyl)-3-[(5-methyl-2-phenyl-oxazole-4-carbonyl)-amino]- propionic acid (R)-3-{[2-(2-Fluoro-phenyl)-5-methyl-oxazole-4-carbonyl]-annino}-4-phenyl- butyric acid

(S)-3-{[2-(2-Fluoro-phenyl)-5-methyl-oxazole-4-carbonyl]-annino}-3-phenyl- butyric acid

(S)-3-{3-[3-(2-Fluoro-phenyl)-[1 ,2,4]oxadiazol-5-yl]-propionylannino}-3- phenyl-propionic acid

(S)-3-(2-Chloro-phenyl)-3-[(5-methyl-2-phenyl-oxazole-4-carbonyl)-annino]- propionic acid

(S)-3-{[1 -(2-Chloro-phenyl)-5-methyl-1 H-[1 ,2,4]triazole-3-carbonyl]-amino}- 3-phenyl-propionic acid

3-Cyclohexyl-3-[(5-isopropyl-2-phenyl-oxazole-4-carbonyl)-amino]-propionic acid

(S)-3-(2-Fluoro-phenyl)-3-{[2-(2-fluoro-phenyl)-5-methyl-oxazole-4- carbonyl]-amino}-propionic acid

(S)-3-(3-Fluoro-phenyl)-3-{[2-(2-fluoro-phenyl)-5-methyl-oxazole-4- carbonyl]-amino}-propionic acid

(S)-3-(4-Fluoro-phenyl)-3-{[2-(2-fluoro-phenyl)-5-methyl-oxazole-4- carbonyl]-amino}-propionic acid

(S)-3-{[5-(2,3-Difluoro-phenyl)-[1 ,2,4]oxadiazole-3-carbonyl]-annino}-3-p- tolyl-propionic acid

(S)-3-{[5-(2,3-Difluoro-phenyl)-[1 ,2,4]oxadiazole-3-carbonyl]-annino}-3-nn- tolyl-propionic acid

(S)-3-{[5-(2,3-Difluoro-phenyl)-[1 ,2,4]oxadiazole-3-carbonyl]-amino}-3- phenyl-butyric acid

(R)-3-{[5-(2,3-Difluoro-phenyl)-[1 ,2,4]oxadiazole-3-carbonyl]-annino}-4- phenyl-butyric acid

(S)-3-{[5-(2,3-Difluoro-phenyl)-[1 ,2,4]oxadiazole-3-carbonyl]-annino}-3-o- tolyl-propionic acid

(S)-3-{[5-(2,3-Difluoro-phenyl)-[1 ,2,4]oxadiazole-3-carbonyl]-amino}-3-(2- fluoro-phenyl)-propionic acid

(S)-3-{[5-(2,3-Difluoro-phenyl)-[1 ,2,4]oxadiazole-3-carbonyl]-amino}-3-(4- fluoro-phenyl)-propionic acid

3-[(5-lsopropyl-2-phenyl-oxazole-4-carbonyl)-amino]-4-phenyl-butyric acid

(S)-3-[(5-Dimethylsulfamoyl-2-methyl-furan-3-carbonyl)-amino]-3-o-tolyl- propionic acid (S)-3-(2-Fluoro-phenyl)-3-[(5-isopropyl-2-phenyl-oxazole-4-carbonyl)- amino]-propionic acid

(S)-3-(4-Fluoro-phenyl)-3-[(5-isopropyl-2-phenyl-oxazole-4-carbonyl)- amino]-propionic acid

(R)-3-{3-[3-(2-Fluoro-phenyl)-[1 ,2,4]oxadiazol-5-yl]-propionylannino}-4- phenyl-butyric acid

(S)-3-{3-[3-(2-Fluoro-phenyl)-[1 ,2,4]oxadiazol-5-yl]-propionylannino}-3-nn- tolyl-propionic acid

(S)-3-{3-[3-(2-Fluoro-phenyl)-[1 ,2,4]oxadiazol-5-yl]-propionylannino}-3- phenyl-butyric acid

(S)-3-{3-[3-(2-Fluoro-phenyl)-[1 ,2,4]oxadiazol-5-yl]-propionylannino}-3-p- tolyl-propionic acid

(S)-3-{3-[3-(2-Fluoro-phenyl)-[1 ,2,4]oxadiazol-5-yl]-propionylannino}-3-o- tolyl-propionic acid

(S)-Cyclohexyl-{[5-(4-trifluoronnethyl-pyridin-3-yl)-[1 ,2,4]oxadiazole-3- carbonyl]-amino}-acetic acid

(S)-3-{[1 -(2-Chloro-phenyl)-5-methyl-1 H-[1 ,2,4]triazole-3-carbonyl]-amino}- 3-p-tolyl-propionic acid

(S)-3-{[1 -(2-Chloro-phenyl)-5-ethyl-1 H-[1 ,2,4]triazole-3-carbonyl]-amino}-3- phenyl-propionic acid

(S)-3-{[1 -(2-Chloro-phenyl)-5-methyl-1 H-[1 ,2,4]triazole-3-carbonyl]-amino}- 3-o-tolyl-propionic acid

(S)-3-(3-Chloro-phenyl)-3-{[2-(2-fluoro-phenyl)-5-methyl-oxazole-4- carbonyl]-amino}-propionic acid

3-(2-Chloro-phenyl)-3-{[2-(2-fluoro-phenyl)-5-methyl-oxazole-4-carbonyl]- amino}-propionic acid

(S)-3-(4-Chloro-phenyl)-3-{[2-(2-fluoro-phenyl)-5-methyl-oxazole-4- carbonyl]-amino}-propionic acid

(S)-3-{[1 -Methyl-4-(propane-1 -sulfonylamino)-1 H-pyrazole-3-carbonyl]- amino}-3-o-tolyl-propionic acid (S)-3-[(5-lsopropyl-2-phenyl-oxazole-4-carbonyl)-amino]-3-(3-nnethoxy- phenyl)-propionic acid

(S)-3-(2,3-Dimethoxy-phenyl)-3-[(5-nnethyl-2-phenyl-oxazole-4-carbonyl)- amino]-propionic acid

(S)-3-(2-Chloro-phenyl)-3-[(5-isopropyl-2-phenyl-oxazole-4-carbonyl)- amino]-propionic acid

3-Cyclohexyl-3-[(2-phenyl-5-trifluoronnethyl-oxazole-4-carbonyl)-annino]- propionic acid

(S)-3-[(1 ,5-Diphenyl-1 H-[1 ,2,4]triazole-3-carbonyl)-amino]-3-phenyl- propionic acid

(S)-3-{[1 -(2-Chloro-phenyl)-5-ethyl-1 H-[1 ,2,4]triazole-3-carbonyl]-amino}-3- o-tolyl-propionic acid

(S)-3-{[1 -(2-Chloro-phenyl)-5-ethyl-1 H-[1 ,2,4]triazole-3-carbonyl]-amino}-3- p-tolyl-propionic acid

(S)-3-[(1 -Benzyl-1 H-indazole-3-carbonyl)-amino]-3-o-tolyl-propionic acid

(S)-3-{3-[3-(2-Fluoro-phenyl)-[1 ,2,4]oxadiazol-5-yl]-propionylamino}-3-(4- methoxy-phenyl)-propionic acid

(S)-3-(2,4-Dichloro-phenyl)-3-[(5-methyl-2-phenyl-oxazole-4-carbonyl)- amino]-propionic acid

(S)-3-(2,3-Dichloro-phenyl)-3-[(5-methyl-2-phenyl-oxazole-4-carbonyl)- amino]-propionic acid

(S)-3-[(2-Phenyl-5-trifluoronnethyl-oxazole-4-carbonyl)-annino]-3-o-tolyl- propionic acid

(S)-3-[(5-Methyl-2-phenyl-oxazole-4-carbonyl)-amino]-3-(2-trifluoromethyl- phenylj-propionic acid

(S)-3-(3-Fluoro-phenyl)-3-[(2-phenyl-5-trifluoronnethyl-oxazole-4-carbonyl)- amino]-propionic acid

(S)-3-{[5-(2-Fluoro-phenyl)-[1 ,2,4]oxadiazole-3-carbonyl]-amino}-3-(2- trifluoronnethyl-phenyl)-propionic acid

(S)-3-{[5-(2-Fluoro-phenyl)-[1 ,2,4]oxadiazole-3-carbonyl]-amino}-3-(3- trifluoronnethyl-phenyl)-propionic acid

(S)-3-{[1 -(2-Chloro-phenyl)-5-cyclopropyl-1 H-[1 ,2,4]triazole-3-carbonyl]- amino}-3-o-tolyl-propionic acid 83 (S)-3-{[1 -(2-Chloro-phenyl)-5-cyclopropyl-1 H-[1 ,2,4]triazole-3-carbonyl]- amino}-3-p-tolyl-propionic acid

84 (S)-3-[(1 ,5-Diphenyl-1 H-[1 ,2,4]triazole-3-carbonyl)-annino]-3-o-tolyl-propionic acid

85 (S)-3-{[1 -(2-Chloro-phenyl)-5-isopropyl-1 H-[1 ,2,4]triazole-3-carbonyl]- amino}-3-p-tolyl-propionic acid

86 3-[(1 ,5-Diphenyl-1 H-[1 ,2,4]triazole-3-carbonyl)-annino]-4-phenyl-butync acid

87 (S)-3-{[1 -(2-Chloro-phenyl)-5-isopropyl-1 H-[1 ,2,4]triazole-3-carbonyl]- amino}-3-o-tolyl-propionic acid

88 (S)-3-{[1 -(2-Chloro-phenyl)-5-propyl-1 H-[1 ,2,4]triazole-3-carbonyl]-amino}-3- p-tolyl-propionic acid

89 (S)-3-{[1 -(2-Chloro-phenyl)-5-propyl-1 H-[1 ,2,4]triazole-3-carbonyl]-amino}-3- o-tolyl-propionic acid

90 (S)-3-[(1 ,5-Diphenyl-1 H-[1 ,2,4]triazole-3-carbonyl)-amino]-3-(2-fluoro- phenyl)-propionic acid

91 (S)-3-[(1 ,5-Diphenyl-1 H-[1 ,2,4]triazole-3-carbonyl)-amino]-3-(4-fluoro- phenyl)-propionic acid

92 (S)-3-{[2-(2-Fluoro-phenyl)-5-methyl-oxazole-4-carbonyl]-annino}-3-(3- trifluoromethyl-phenyl)-propionic acid

93 (S)-3-{[2-(2-Fluoro-phenyl)-5-methyl-oxazole-4-carbonyl]-annino}-3-(4- trifluoronnethyl-phenyl)-propionic acid

94 (S)-3-(2,3-Dichloro-phenyl)-3-{[2-(2-fluoro-phenyl)-5-methyl-oxazole-4- carbonyl]-amino}-propionic acid

95 (S)-3-{[4-(2,2-Dimethyl-propane-1 -sulfonylamino)-1 -methyl-1 H-pyrazole-3- carbonyl]-amino}-3-o-tolyl-propionic acid

96 (S)-3-(3-Chloro-phenyl)-3-[(2-phenyl-5-trifluoronnethyl-oxazole-4-carbonyl)- amino]-propionic acid

97 (S)-3-(2-Chloro-phenyl)-3-[(2-phenyl-5-trifluoronnethyl-oxazole-4-carbonyl)- amino]-propionic acid

98 (S)-3-[(1 -Benzyl-5-phenyl-1 H-pyrazole-3-carbonyl)-amino]-3-o-tolyl- propionic acid

99 (S)-3-(4-Chloro-phenyl)-2-{[5-(4-trifluoromethyl-pyridin-3-yl)- [1 ,2,4]oxadiazole-3-carbonyl]-annino}-propionic acid

100 (S)-3-{[1 -Ethyl-5-(2-propyl-piperidine-1 -carbonyl)-1 H-pyrazole-3-carbonyl]- amino}-3-phenyl-propionic acid 101 (S)-3-{[5-(2,3-Difluoro-phenyl)-[1 ,2,4]oxadiazole-3-carbonyl]-amino}-3-(2- trifluoromethyl-phenyl)-propionic acid

102 (S)-3-[(1 ,5-Diphenyl-1 H-[1 ,2,4]triazole-3-carbonyl)-amino]-3-(3-methoxy- phenyl)-propionic acid

103 (S)-3-(2,3-Dichloro-phenyl)-3-[(5-isopropyl-2-phenyl-oxazole-4-carbonyl)- amino]-propionic acid

104 (S)-3-(3-Chloro-phenyl)-3-[(1 ,5-diphenyl-1 H-[1 ,2,4]triazole-3-carbonyl)- amino]-propionic acid

105 (S)-3-(2,4-Dichloro-phenyl)-3-[(5-isopropyl-2-phenyl-oxazole-4-carbonyl)- amino]-propionic acid

106 (S)-3-(2-Chloro-phenyl)-3-[(1 ,5-diphenyl-1 H-[1 ,2,4]triazole-3-carbonyl)- amino]-propionic acid

107 (S)-3-{[1 -(2,6-Dichloro-phenyl)-5-ethyl-1 H-[1 ,2,4]triazole-3-carbonyl]-amino}- 3-p-tolyl-propionic acid

108 (S)-3-{[1 -(2,6-Dichloro-phenyl)-5-ethyl-1 H-[1 ,2,4]triazole-3-carbonyl]-amino}- 3-o-tolyl-propionic acid

109 (S)-3-[(4-Cyclohexylmethanesulfonylannino-1 -nnethyl-1 H-pyrazole-3- carbonyl)-amino]-3-phenyl-propionic acid

1 10 (S)-3-{3-[3-(2-Fluoro-phenyl)-[1 ,2,4]oxadiazol-5-yl]-propionylamino}-3-(2- trifluoromethyl-phenyl)-propionic acid

1 1 1 (S)-3-{3-[3-(2-Fluoro-phenyl)-[1 ,2,4]oxadiazol-5-yl]-propionylamino}-3-(4- trifluoromethyl-phenyl)-propionic acid

1 12 (S)-3-(2,3-Dichloro-phenyl)-3-{3-[3-(2-fluoro-phenyl)-[1 ,2,4]oxadiazol-5-yl]- propionylamino}-propionic acid

1 13 (S)-3-{3-[3-(2-Fluoro-phenyl)-[1 ,2,4]oxadiazol-5-yl]-propionylamino}-3-(3- trifluoromethyl-phenyl)-propionic acid

1 14 (S)-3-{[1 -Ethyl-5-(2-propyl-piperidine-1 -carbonyl)-1 H-pyrazole-3-carbonyl]- amino}-3-o-tolyl-propionic acid

1 15 (S)-3-{[1 -Ethyl-5-(2-propyl-piperidine-1 -carbonyl)-1 H-pyrazole-3-carbonyl]- amino}-3-p-tolyl-propionic acid

1 16 (S)-3-{[1 -Ethyl-5-(2-propyl-piperidine-1 -carbonyl)-1 H-pyrazole-3-carbonyl]- amino}-3-nn-tolyl-propionic acid

1 17 (S)-3-[(1 -Methyl-4-phenylmethanesulfonylannino-1 H-pyrazole-3-carbonyl)- amino]-3-o-tolyl-propionic acid

1 18 (S)-3-{[1 -(4-Fluoro-benzyl)-5-phenyl-1 H-pyrazole-3-carbonyl]-amino}-3-o- tolyl-propionic acid 1 19 (S)-3-[(4-Cyclohexylmethanesulfonylannino-1 -nnethyl-1 H-pyrazole-3- carbonyl)-amino]-3-o-tolyl-propionic acid

120 (S)-3-(2,3-Dimethoxy-phenyl)-3-[(2-phenyl-5-tnfluoronnethyl-oxazole-4- carbonyl)-amino]-propionic acid

121 (S)-3-{[1 -Methyl-4-(2-phenyl-ethanesulfonylamino)-1 H-pyrazole-3-carbonyl]- amino}-3-o-tolyl-propionic acid

122 (S)-3-(2,3-Dichloro-phenyl)-3-[(2-phenyl-5-trifluoronnethyl-oxazole-4- carbonyl)-amino]-propionic acid

123 (S)-3-(2,4-Dichloro-phenyl)-3-[(2-phenyl-5-trifluoronnethyl-oxazole-4- carbonyl)-amino]-propionic acid

124 (S)-3-(2,3-Dichloro-phenyl)-3-[(1 ,5-diphenyl-1 H-[1 ,2,4]triazole-3-carbonyl)- amino]-propionic acid

125 (S)-3-(2,4-Dichloro-phenyl)-3-[(1 ,5-diphenyl-1 H-[1 ,2,4]triazole-3-carbonyl)- amino]-propionic acid

126 (S)-3-(2,4-Dichloro-phenyl)-3-[(1 ,5-diphenyl-1 H-[1 ,2,4]triazole-3-carbonyl)- amino]-propionic acid

Compound Table 5. Example compounds of the formulae Va and Vb

Ex¬

Compound Name

ample

1 (R)-4-Phenyl-3-[(4-phenyl-thiazole-2-carbonyl)-amino]-butyric acid

2 3-(4'-Fluoro-biphenyl-4-yl)-3-[(2-phenyl-thiazole-4-carbonyl)-amino]-propionic acid

3 (S)-3-[(4-Phenyl-thiazole-2-carbonyl)-amino]-3-m-tolyl-propionic acid

4 (S)-3-Phenyl-3-[(4-phenyl-thiazole-2-carbonyl)-amino]-butyric acid

5 (S)-3-{[2-(4-Methoxy-phenyl)-thiazole-4-carbonyl]-amino}-3-o-tolyl-propionic acid

(S)-3-{[2-(3,5-Dimethyl-pyrazol-1 -yl)-thiazole-4-carbonyl]-amino}-3-o-tolyl-propionic

6

acid

7 (S)-3-[(2-Pyridin-4-yl-thiazole-4-carbonyl)-amino]-3-o-tolyl-propionic acid

8 (S)-3-[(2-Pyrazin-2-yl-thiazole-4-carbonyl)-amino]-3-o-tolyl-propionic acid Ex¬

Compound Name

ample

(S)-3-{[2-(3-Methyl-5-trifluoromethyl-pyrazol-1 -yl)-thiazole-4-carbonyl]-amino}-3-o-

9

tolyl-propionic acid

10 (S)-3-o-Tolyl-3-[(2-p-tolyl-thiazole-4-carbonyl)-amino]-propionic acid

1 1 (S)-3-[(4-Phenyl-thiazole-2-carbonyl)-amino]-3-p-tolyl-propionic acid

12 (S)-3-(2,3-Dichloro-phenyl)-3-[(2-o-tolyl-thiazole-4-carbonyl)-amino]-propionic acid

13 (S)-3-(2,3-Dichloro-phenyl)-3-[(2-phenyl-thiazole-4-carbonyl)-amino]-propionic acid

(S)-3-(2,3-Dichloro-phenyl)-3-{[2-(2,3-dichloro-phenyl)-thiazole-4-carbonyl]-amino}-

14

propionic acid

(S)-3-(2,3-Dichloro-phenyl)-3-{[2-(2-fluoro-phenyl)-thiazole-4-carbonyl]-amino}-

15

propionic acid

(S)-3-(2,3-Dichloro-phenyl)-3-{[2-(4-trifluoromethyl-phenyl)-thiazole-4-carbonyl]-

16

amino}-propionic acid

(S)-3-(2,3-Dimethoxy-phenyl)-3-[(2-o-tolyl-thiazole-4-carbonyl)-amino]-propionic

17

acid

(S)-3-(2,3-Dimethoxy-phenyl)-3-[(2-phenyl-thiazole-4-carbonyl)-amino]-propionic

18

acid

(S)-3-(2,3-Dimethoxy-phenyl)-3-{[2-(2-fluoro-phenyl)-thiazole-4-carbonyl]-amino}-

19

propionic acid

(S)-3-(2,3-Dimethoxy-phenyl)-3-{[2-(4-trifluoromethyl-phenyl)-thiazole-4-carbonyl]-

20

amino}-propionic acid

21 (S)-3-(2,4-Dichloro-phenyl)-3-[(2-o-tolyl-thiazole-4-carbonyl)-amino]-propionic acid

22 (S)-3-(2,4-Dichloro-phenyl)-3-[(2-phenyl-thiazole-4-carbonyl)-amino]-propionic acid

(S)-3-(2,4-Dichloro-phenyl)-3-{[2-(2,3-dichloro-phenyl)-thiazole-4-carbonyl]-amino}-

23

propionic acid Ex¬

Compound Name

ample

(S)-3-(2,4-Dichloro-phenyl)-3-{[2-(2-fluoro-phenyl)-thiazole-4-carbonyl]-amino}-

24

propionic acid

(S)-3-(2,4-Dichloro-phenyl)-3-{[2-(4-trifluoromethyl-phenyl)-thiazole-4-carbonyl]-

25

amino}-propionic acid

26 (S)-3-(2-Chloro-phenyl)-3-[(2-o-tolyl-thiazole-4-carbonyl)-amino]-propionic acid

27 (S)-3-(2-Chloro-phenyl)-3-[(2-phenyl-thiazole-4-carbonyl)-amino]-propionic acid

(S)-3-(2-Chloro-phenyl)-3-{[2-(2,3-dichloro-phenyl)-thiazole-4-carbonyl]-amino}-

28

propionic acid

(S)-3-(2-Chloro-phenyl)-3-{[2-(2-chloro-phenyl)-thiazole-4-carbonyl]-amino}-

29

propionic acid

(S)-3-(2-Chloro-phenyl)-3-{[2-(2-fluoro-phenyl)-thiazole-4-carbonyl]-amino}-

30

propionic acid

(S)-3-(2-Chloro-phenyl)-3-{[2-(3-chloro-phenyl)-thiazole-4-carbonyl]-amino}-

31

propionic acid

(S)-3-(2-Chloro-phenyl)-3-{[2-(4-chloro-phenyl)-thiazole-4-carbonyl]-amino}-

32

propionic acid

(S)-3-(2-Chloro-phenyl)-3-{[2-(4-trifluoromethyl-phenyl)-thiazole-4-carbonyl]-

33

amino}-propionic acid

34 (S)-3-(2-Fluoro-phenyl)-3-[(2-o-tolyl-thiazole-4-carbonyl)-amino]-propionic acid

35 (S)-3-(2-Fluoro-phenyl)-3-[(2-phenyl-thiazole-4-carbonyl)-amino]-propionic acid

(S)-3-(2-Fluoro-phenyl)-3-{[2-(2-fluoro-phenyl)-thiazole-4-carbonyl]-amino}-

36

propionic acid

(S)-3-(2-Fluoro-phenyl)-3-{[2-(4-trifluoromethyl-phenyl)-thiazole-4-carbonyl]-

37

amino}-propionic acid Ex¬

Compound Name

ample

(S)-3-(2-Trifluoromethyl-phenyl)-3-{[2-(4-trifluoromethyl-phenyl)-thiazole-4-

38

carbonyl]-amino}-propionic acid

39 (S)-3-(3-Chloro-phenyl)-3-[(2-o-tolyl-thiazole-4-carbonyl)-amino]-propionic acid

40 (S)-3-(3-Chloro-phenyl)-3-[(2-phenyl-thiazole-4-carbonyl)-amino]-propionic acid

(S)-3-(3-Chloro-phenyl)-3-{[2-(2,3-dichloro-phenyl)-thiazole-4-carbonyl]-amino}-

41

propionic acid

(S)-3-(3-Chloro-phenyl)-3-{[2-(2-chloro-phenyl)-thiazole-4-carbonyl]-amino}-

42

propionic acid

(S)-3-(3-Chloro-phenyl)-3-{[2-(2-fluoro-phenyl)-thiazole-4-carbonyl]-amino}-

43

propionic acid

(S)-3-(3-Chloro-phenyl)-3-{[2-(3-chloro-phenyl)-thiazole-4-carbonyl]-amino}-

44

propionic acid

(S)-3-(3-Chloro-phenyl)-3-{[2-(4-chloro-phenyl)-thiazole-4-carbonyl]-amino}-

45

propionic acid

(S)-3-(3-Chloro-phenyl)-3-{[2-(4-trifluoromethyl-phenyl)-thiazole-4-carbonyl]-

46

amino}-propionic acid

47 (S)-3-(3-Fluoro-phenyl)-3-[(2-o-tolyl-thiazole-4-carbonyl)-amino]-propionic acid

48 (S)-3-(3-Fluoro-phenyl)-3-[(2-phenyl-thiazole-4-carbonyl)-amino]-propionic acid

(S)-3-(3-Fluoro-phenyl)-3-{[2-(2-fluoro-phenyl)-thiazole-4-carbonyl]-amino}-

49

propionic acid

(S)-3-(3-Fluoro-phenyl)-3-{[2-(4-trifluoromethyl-phenyl)-thiazole-4-carbonyl]-

50

amino}-propionic acid

51 (S)-3-(4-Fluoro-phenyl)-3-[(4-phenyl-thiazole-2-carbonyl)-amino]-propionic acid

52 (S)-3-(3-Methoxy-phenyl)-3-[(2-phenyl-thiazole-4-carbonyl)-amino]-propionic acid

53 (S)-3-(2-Fluoro-phenyl)-3-[(4-phenyl-thiazole-2-carbonyl)-amino]-propionic acid Ex¬

Compound Name

ample

54 (S)-3-(4-Fluoro-phenyl)-3-[(2-o-tolyl-thiazole-4-carbonyl)-amino]-propionic acid

55 (S)-3-(3-Fluoro-phenyl)-3-[(4-phenyl-thiazole-2-carbonyl)-amino]-propionic acid

(S)-3-(4-Fluoro-phenyl)-3-{[2-(2-fluoro-phenyl)-thiazole-4-carbonyl]-amino}-

56

propionic acid

57 (S)-{[2-(3-Chloro-phenyl)-thiazole-4-carbonyl]-amino}-cyclohexyl-acetic acid

58 (S)-3-(4-Chloro-phenyl)-2-[(2-phenyl-thiazole-4-carbonyl)-amino]-propionic acid

59 (S)-3-(4-Methoxy-phenyl)-3-[(2-phenyl-thiazole-4-carbonyl)-amino]-propionic acid

(S)-3-(4-Methoxy-phenyl)-3-{[2-(4-trifluoromethyl-phenyl)-thiazole-4-carbonyl]-

60

amino}-propionic acid

(S)-3-[(2-o-Tolyl-thiazole-4-carbonyl)-amino]-3-(2-trifluoromethyl-phenyl)-propionic

61

acid

(S)-3-[(2-Phenyl-thiazole-4-carbonyl)-amino]-3-(2-trifluoromethyl-phenyl)-propionic

62

acid

63 (S)-3-[(2-Phenyl-thiazole-4-carbonyl)-amino]-3-o-tolyl-propionic acid

(S)-3-{[2-(2,3-Dichloro-phenyl)-thiazole-4-carbonyl]-amino}-3-(2,3-dimethoxy-

64

phenyl)-propionic acid

65 (S)-3-(3-Chloro-phenyl)-3-[(4-phenyl-thiazole-2-carbonyl)-amino]-propionic acid

(S)-3-{[2-(2,3-Dichloro-phenyl)-thiazole-4-carbonyl]-amino}-3-(2-trifluoromethyl-

66

phenyl)-propionic acid

(S)-3-{[2-(2,3-Dichloro-phenyl)-thiazole-4-carbonyl]-amino}-3-(3-fluoro-phenyl)-

67

propionic acid

68 3-(2-Chloro-phenyl)-3-[(4-phenyl-thiazole-2-carbonyl)-amino]-propionic acid

69 (S)-3-(4-Chloro-phenyl)-3-[(4-phenyl-thiazole-2-carbonyl)-amino]-propionic acid

70 (S)-3-[(4-Methyl-2-p-tolyl-thiazole-5-carbonyl)-amino]-3-o-tolyl-propionic acid Ex¬

Compound Name

ample

71 (S)-3-{[2-(2,3-Dichloro-phenyl)-thiazole-4-carbonyl]-amino}-3-o-tolyl-propionic acid

72 (S)-3-(4-Chloro-phenyl)-2-[(2-o-tolyl-thiazole-4-carbonyl)-amino]-propionic acid

(S)-3-{[2-(2-Chloro-phenyl)-thiazole-4-carbonyl]-amino}-3-(2,3-dichloro-phenyl)-

73

propionic acid

(S)-3-{[2-(2-Chloro-phenyl)-thiazole-4-carbonyl]-amino}-3-(2,3-dimethoxy-phenyl)-

74

propionic acid

(S)-3-{[2-(2-Chloro-phenyl)-thiazole-4-carbonyl]-amino}-3-(2,4-dichloro-phenyl)-

75

propionic acid

(S)-3-{[2-(2-Chloro-phenyl)-thiazole-4-carbonyl]-amino}-3-(2-fluoro-phenyl)-

76

propionic acid

(S)-3-{[2-(2-Chloro-phenyl)-thiazole-4-carbonyl]-amino}-3-(2-trifluoromethyl-

77

phenyl)-propionic acid

(S)-3-{[2-(2-Chloro-phenyl)-thiazole-4-carbonyl]-amino}-3-(3-fluoro-phenyl)-

78

propionic acid

(S)-3-{[2-(2-Chloro-phenyl)-thiazole-4-carbonyl]-amino}-3-(3-methoxy-phenyl)-

79

propionic acid

(S)-3-{[2-(2-Chloro-phenyl)-thiazole-4-carbonyl]-amino}-3-(4-fluoro-phenyl)-

80

propionic acid

(S)-3-(4-Chloro-phenyl)-2-{[2-(2-chloro-phenyl)-thiazole-4-carbonyl]-amino}-

81

propionic acid

82 (S)-3-{[2-(2-Chloro-phenyl)-thiazole-4-carbonyl]-amino}-3-o-tolyl-propionic acid

83 (S)-3-{[2-(2-Chloro-phenyl)-thiazole-4-carbonyl]-amino}-3-phenyl-propionic acid

(S)-3-{[2-(2-Fluoro-phenyl)-thiazole-4-carbonyl]-amino}-3-(2-trifluoromethyl-

84

phenyl)-propionic acid Ex¬

Compound Name

ample

(S)-3-{[2-(2-Fluoro-phenyl)-thiazole-4-carbonyl]-amino}-3-(3-methoxy-phenyl)-

85

propionic acid

(S)-3-{[2-(2-Fluoro-phenyl)-thiazole-4-carbonyl]-amino}-3-(4-methoxy-phenyl)-

86

propionic acid

87 (S)-3-{[2-(2-Fluoro-phenyl)-thiazole-4-carbonyl]-amino}-3-o-tolyl-propionic acid

88 (S)-3-{[2-(2-Fluoro-phenyl)-thiazole-4-carbonyl]-amino}-3-phenyl-propionic acid

(S)-3-{[2-(3-Chloro-phenyl)-thiazole-4-carbonyl]-amino}-3-(2,3-dichloro-phenyl)-

89

propionic acid

(S)-3-{[2-(3-Chloro-phenyl)-thiazole-4-carbonyl]-amino}-3-(2,3-dimethoxy-phenyl)-

90

propionic acid

(S)-3-{[2-(3-Chloro-phenyl)-thiazole-4-carbonyl]-amino}-3-(2,4-dichloro-phenyl)-

91

propionic acid

(S)-3-{[2-(3-Chloro-phenyl)-thiazole-4-carbonyl]-amino}-3-(2-fluoro-phenyl)-

92

propionic acid

(S)-3-{[2-(3-Chloro-phenyl)-thiazole-4-carbonyl]-amino}-3-(2-trifluoromethyl-

93

phenyl)-propionic acid

(S)-3-{[2-(3-Chloro-phenyl)-thiazole-4-carbonyl]-amino}-3-(3-fluoro-phenyl)-

94

propionic acid

95 (S)-3-(2,3-Dichloro-phenyl)-3-[(4-phenyl-thiazole-2-carbonyl)-amino]-propionic acid

96 (S)-3-(2,4-Dichloro-phenyl)-3-[(4-phenyl-thiazole-2-carbonyl)-amino]-propionic acid

(S)-3-[(4-Phenyl-thiazole-2-carbonyl)-amino]-3-(4-trifluoromethyl-phenyl)-propionic

97

acid

98 (S)-3-{[2-(3-Chloro-phenyl)-thiazole-4-carbonyl]-amino}-3-o-tolyl-propionic acid

(S)-3-[(4-Phenyl-thiazole-2-carbonyl)-amino]-3-(3-trifluoromethyl-phenyl)-propionic

99

acid Ex¬

Compound Name

ample

(S)-3-{[2-(4-Chloro-phenyl)-thiazole-4-carbonyl]-amino}-3-(2,3-dichloro-phenyl)-

100

propionic acid

(S)-3-{[2-(4-Chloro-phenyl)-thiazole-4-carbonyl]-amino}-3-(2,3-dimethoxy-phenyl)-

101

propionic acid

(S)-3-{[2-(4-Chloro-phenyl)-thiazole-4-carbonyl]-amino}-3-(2,4-dichloro-phenyl)-

102

propionic acid

(3S,4R)-4-Phenyl-1 -[4-(4-trifluoromethyl-phenyl)-thiazole-2-carbonyl]-pyrrolidine-3-

103

carboxylic acid

(S)-3-{[2-(4-Chloro-phenyl)-thiazole-4-carbonyl]-amino}-3-(2-trifluoromethyl-

104

phenyl)-propionic acid

(S)-3-{[2-(4-Chloro-phenyl)-thiazole-4-carbonyl]-amino}-3-(3-fluoro-phenyl)-

105

propionic acid

(S)-3-{[2-(4-Chloro-phenyl)-thiazole-4-carbonyl]-amino}-3-(3-methoxy-phenyl)-

106

propionic acid

(S)-3-(4-Chloro-phenyl)-2-{[2-(4-trifluoromethyl-phenyl)-thiazole-4-carbonyl]-

107

amino}-propionic acid

(S)-3-{[2-(4-Chloro-phenyl)-thiazole-4-carbonyl]-amino}-3-(4-methoxy-phenyl)-

108

propionic acid

109 (S)-3-{[2-(4-Chloro-phenyl)-thiazole-4-carbonyl]-amino}-3-o-tolyl-propionic acid

1 10 (S)-3-{[2-(4-Chloro-phenyl)-thiazole-4-carbonyl]-amino}-3-phenyl-propionic acid

1 1 1 (S)-3-o-Tolyl-3-[(2-o-tolyl-thiazole-4-carbonyl)-amino]-propionic acid

(S)-3-o-Tolyl-3-{[2-(4-trifluoromethyl-phenyl)-thiazole-4-carbonyl]-amino}-propionic

1 12

acid

1 13 (S)-3-Phenyl-3-[(2-o-tolyl-thiazole-4-carbonyl)-amino]-propionic acid

1 14 2-Phenyl-3-[(2-o-tolyl-thiazole-4-carbonyl)-amino]-propionic acid Ex¬

Compound Name

ample

1 15 2-Phenyl-3-[(2-phenyl-thiazole-4-carbonyl)-amino]-propionic acid

1 16 3-{[2-(2,3-Dichloro-phenyl)-thiazole-4-carbonyl]-amino}-2-phenyl-propionic acid

1 17 3-{[2-(2,3-Dichloro-phenyl)-thiazole-4-carbonyl]-amino}-4-phenyl-butyric acid

1 18 3-{[2-(2-Chloro-phenyl)-thiazole-4-carbonyl]-amino}-2-phenyl-propionic acid

1 19 3-{[2-(2-Chloro-phenyl)-thiazole-4-carbonyl]-amino}-3-cyclohexyl-propionic acid

120 3-{[2-(2-Chloro-phenyl)-thiazole-4-carbonyl]-amino}-4-phenyl-butyric acid

121 3-{[2-(2-Fluoro-phenyl)-thiazole-4-carbonyl]-amino}-2-phenyl-propionic acid

122 3-{[2-(2-Fluoro-phenyl)-thiazole-4-carbonyl]-amino}-4-phenyl-butyric acid

123 3-{[2-(3-Chloro-phenyl)-thiazole-4-carbonyl]-amino}-2-phenyl-propionic acid

124 3-{[2-(3-Chloro-phenyl)-thiazole-4-carbonyl]-amino}-3-cyclohexyl-propionic acid

125 3-{[2-(3-Chloro-phenyl)-thiazole-4-carbonyl]-amino}-4-phenyl-butyric acid

126 3-{[2-(4-Chloro-phenyl)-thiazole-4-carbonyl]-amino}-3-cyclohexyl-propionic acid

127 3-{[2-(4-Chloro-phenyl)-thiazole-4-carbonyl]-amino}-4-phenyl-butyric acid

128 3-Cyclohexyl-3-[(2-o-tolyl-thiazole-4-carbonyl)-amino]-propionic acid

129 3-Cyclohexyl-3-[(2-phenyl-thiazole-4-carbonyl)-amino]-propionic acid

130 3-Cyclohexyl-3-{[2-(2,3-dichloro-phenyl)-thiazole-4-carbonyl]-amino}-propionic acid

131 3-Cyclohexyl-3-{[2-(2-fluoro-phenyl)-thiazole-4-carbonyl]-amino}-propionic acid

3-Cyclohexyl-3-{[2-(4-trifluoromethyl-phenyl)-thiazole-4-carbonyl]-amino}-propionic

132

acid

133 4-Phenyl-3-[(2-o-tolyl-thiazole-4-carbonyl)-amino]-butyric acid

134 4-Phenyl-3-[(2-phenyl-thiazole-4-carbonyl)-amino]-butyric acid

135 4-Phenyl-3-{[2-(4-trifluoromethyl-phenyl)-thiazole-4-carbonyl]-amino}-butyric acid

136 (S)-3-[(4-Phenyl-thiazole-2-carbonyl)-amino]-3-o-tolyl-propionic acid Ĳ76

References

Kannel WB, Wolf PA, Benjamin EJ, Levy D. Prevalence, incidence, prognosis, and predisposing conditions for atrial fibrillation: population-based estimates. Am J Cardiol. 1998;82:2N-9N.

Brand FN, Abbott RD, Kannel WB, Wolf PA. Characteristics and prognosis of lone atrial fibrillation. 30-year follow-up in the Framingham Study. JAMA. 1985;254:3449-3453.

Movahed MR, Hashemzadeh M, Jamal MM. Diabetes mellitus is a strong, independent risk for atrial fibrillation and flutter in addition to other cardiovascular disease. Int J Cardiol. 2005;105:315-318.

Ostgren CJ, Merlo J, Rastam L, Lindblad U. Atrial fibrillation and its association with type 2 diabetes and hypertension in a Swedish community. Diabetes Obes Metab. 2004;6:367-374.

Kato T, Yamashita T, Sekiguchi A, Sagara K, Takamura M, Takata S, Kaneko S, Aizawa T, Fu LT. What are arrhythmogenic substrates in diabetic rat atria? J Cardiovasc Electrophysiol. 2006;17:890-894.

Schotten U, Verheule S, Kirchhof P, Goette A. Pathophysiological mechanisms of atrial fibrillation: a translational appraisal. Physiol Rev. 201 1 ;91 :265-325.

Regensteiner JG, Sippel J, McFarling ET, Wolfel EE, Hiatt WR. Effects of non- insulin-dependent diabetes on oxygen consumption during treadmill exercise. Med Sci Sports Exerc. 1995;27:875-881 .

Regensteiner JG, Bauer TA, Reusch JE, Brandenburg SL, Sippel JM, Vogelsong AM, Smith S, Wolfel EE, Eckel RH, Hiatt WR. Abnormal oxygen uptake kinetic responses in women with type II diabetes mellitus. J Appl Physiol. 1998;85:310-317.

9. Wei M, Gibbons LW, Mitchell TL, Kampert JB, Lee CD, Blair SN. The association between cardiorespiratory fitness and impaired fasting glucose and type 2 diabetes mellitus in men. Ann Intern Med. 1999;130:89-96.

10 Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. Stroke. 1991 ;22:983-988.

1 1 Hiraiwa M. Cathepsin A/protective protein: an unusual lysosomal multifunctional protein. Cell Mol Life Sci. 1999;56:894-907.

12 Jackman HL, Massad MG, Sekosan M, Tan F, Brovkovych V, Marcic BM, Erdos EG. Angiotensin 1 -9 and 1 -7 release in human heart: role of cathepsin A. Hypertension. 2002;39:976-981 . 13 Urata H, Hoffmann S, Ganten D. Tissue angiotensin II system in the human heart. Eur Heart J. 1994;15 Suppl D:68-78. 14 Urata H, Ganten D. Cardiac angiotensin II formation: the angiotensin-l converting enzyme and human chymase. Eur Heart J. 1993;14 Suppl 1:177-182. 15 Steckelings UM, Rompe F, Kaschina E, Unger T. The evolving story of the RAAS in hypertension, diabetes and CV disease: moving from macrovascular to microvascular targets. Fundam Clin Pharmacol. 2009;23:693-703.

16 Ito H, Majima M, Nakajima S, Hayashi I, Katori M, Izumi T. Effect of prolonged administration of a urinary kinase inhibitor, ebelactone B on the development of deoxycorticosterone acetate-salt hypertension in rats. Br J Pharmacol. 1999;126:613-620.

17 Hayashi I, Majima M, Fujita T, Okumura T, Kumagai Y, Tomita N, Morishita R, Higaki J, Ogiwara T. In vivo transfer of antisense oligonucleotide against urinary kininase blunts deoxycorticosterone acetate-salt hypertension in rats. Br J Pharmacol. 2000;131 :820-826. 18 19 Neuberger HR, Schotten U, Verheule S, Eijsbouts S, Blaauw Y, van Hunnik A, Allessie M. Development of a substrate of atrial fibrillation during chronic atrioventricular block in the goat. Circulation. 2005;1 1 1 :30-37. 20. Jarvinen V, Kupari M, Hekali P, Poutanen VP. Assessment of left atrial volumes and phasic function using cine magnetic resonance imaging in normal subjects. Am J Cardiol. 1994;73:1 135-1 138.

21 . Nori D, Raff G, Gupta V, Gentry R, Boura J, Haines DE. Cardiac magnetic resonance imaging assessment of regional and global left atrial function before and after catheter ablation for atrial fibrillation. J Interv Card Electrophysiol. 2009;26:109-1 17.

22. Polontchouk L, Haefliger JA, Ebelt B, Schaefer T, Stuhlmann D, Mehlhorn U, Kuhn-Regnier F, De Vivie ER, Dhein S. Effects of chronic atrial fibrillation on gap junction distribution in human and rat atria. J Am Coll Cardiol. 2001 ;38:883-

891 .

23. Li D, Fareh S, Leung TK, Nattel S. Promotion of atrial fibrillation by heart failure in dogs: atrial remodeling of a different sort. Circulation. 1999;100:87-95.

24. Satoh T, Zipes DP. Cesium-induced atrial tachycardia degenerating into atrial fibrillation in dogs: atrial torsades de pointes? J Cardiovasc Electrophysiol.

1998;9:970-975.

25. Rocken C, Peters B, Juenemann G, Saeger W, Klein HU, Huth C, Roessner A, Goette A. Atrial amyloidosis: an arrhythmogenic substrate for persistent atrial fibrillation. Circulation. 2002;106:2091 -2097. 26. Takahashi M, Hoshii Y, Kawano H, Gondo T, Yokota T, Okabayashi H, Shimada I, Ishihara T. Ultrastructural evidence for the formation of amyloid fibrils within cardiomyocytes in isolated atrial amyloid. Amyloid. 1998;5:35-42.

27. Rucker-Martin C, Milliez P, Tan S, Decrouy X, Recouvreur M, Vranckx R, Delcayre C, Renaud JF, Dunia I, Segretain D, Hatem SN. Chronic hemodynamic overload of the atria is an important factor for gap junction remodeling in human and rat hearts. Cardiovasc Res. 2006;72:69-79.

28. Burstein B, Comtois P, Michael G, Nishida K, Villeneuve L, Yeh YH, Nattel S.

Changes in connexin expression and the atrial fibrillation substrate in congestive heart failure. Circ Res. 2009 4;105:1213-1222. 29. Cosson S, Kevorkian JP. Left ventricular diastolic dysfunction: an early sign of diabetic cardiomyopathy? Diabetes Metab. 2003;29:455-466.

30. Schafer S, Huber J, Wihler C, Rutten H, Busch AE, Linz W. Impaired left ventricular relaxation in type 2 diabetic rats is related to myocardial accumulation of N(epsilon)-(carboxymethyl) lysine. Eur J Heart Fail. 2006;8:2-6.

31 . Daniels A, Linz D, van Bilsen M, Rutten H, Sadowski T, Ruf S, Juretschke HP, Neumann-Haefelin C, Munts C, van der Vusse GJ, van Nieuwenhoven FA. Long-term severe diabetes only leads to mild cardiac diastolic dysfunction in Zucker diabetic fatty rats. Eur J Heart Fail. 2012;14:193-201 .

32. Acar G, Akcay A, Sokmen A, Ozkaya M, Guler E, Sokmen G, Kaya H, Nacar AB, Tuncer C. Assessment of atrial electromechanical delay, diastolic functions, and left atrial mechanical functions in patients with type 1 diabetes mellitus. J Am Soc Echocardiogr. 2009;22:732-738.

33. Wakili R, Yeh YH, Yan Qi X, Greiser M, Chartier D, Nishida K, Maguy A, Villeneuve LR, Boknik P, Voigt N, Krysiak J, Kaab S, Ravens U, Linke WA,

Stienen GJ, Shi Y, Tardif JC, Schotten U, Dobrev D, Nattel S. Multiple potential molecular contributors to atrial hypocontractility caused by atrial tachycardia remodeling in dogs. Circ Arrhythm Electrophysiol. 2010;3(5):530-41 .

34. Greiser M, Neuberger HR, Harks E, El-Armouche A, Boknik P, de Haan S, Verheyen F, Verheule S, Schmitz W, Ravens U, Nattel S, Allessie MA, Dobrev

D, Schotten U. Distinct contractile and molecular differences between two goat models of atrial dysfunction: AV block-induced atrial dilatation and atrial fibrillation. J Mol Cell Cardiol. 2009;46:385-394.

35. Mihm MJ, Yu F, Carnes CA, Reiser PJ, McCarthy PM, Van Wagoner DR, Bauer JA. Impaired myofibrillar energetics and oxidative injury during human atrial fibrillation. Circulation. 2001 ;104:174-180.

36. Okamoto H. Osteopontin and cardiovascular system. Mol Cell Biochem.

2007;300:1 -7. 37. Xie Z, Singh M, Singh K. Osteopontin modulates myocardial hypertrophy in response to chronic pressure overload in mice. Hypertension. 2004;44:826-831 .

38. Ashizawa N, Graf K, Do YS, Nunohiro T, Giachelli CM, Meehan WP, Tuan TL, Hsueh WA. Osteopontin is produced by rat cardiac fibroblasts and mediates A(ll)-induced DNA synthesis and collagen gel contraction. J Clin Invest.

1996;98:2218-2227.

39. Trueblood NA, Xie Z, Communal C, Sam F, Ngoy S, Liaw L, Jenkins AW, Wang J, Sawyer DB, Bing OH, Apstein CS, Colucci WS, Singh K. Exaggerated left ventricular dilation and reduced collagen deposition after myocardial infarction in mice lacking osteopontin. Circ Res. 2001 ;88:1080-1087.

40. Subramanian V, Krishnamurthy P, Singh K, Singh M. Lack of osteopontin improves cardiac function in streptozotocin-induced diabetic mice. Am J Physiol Heart Circ Physiol. 2007;292:H673-83.

41 . Hanna N, Cardin S, Leung TK, Nattel S. Differences in atrial versus ventricular remodeling in dogs with ventricular tachypacing-induced congestive heart failure. Cardiovasc Res. 2004;63:236-244.

42. Erdos EG, Jackman HL, Brovkovych V, Tan F, Deddish PA. Products of angiotensin I hydrolysis by human cardiac enzymes potentiate bradykinin. J Mol Cell Cardiol. 2002;34:1569-1576.

43. Linz W, Wiemer G, Gohlke P, Unger T, Scholkens BA. Contribution of kinins to the cardiovascular actions of angiotensin-converting enzyme inhibitors. Pharmacol Rev. 1995;47:25-49.

44. Ruskoaho H. Atrial natriuretic peptide: synthesis, release, and metabolism.

Pharmacol Rev. 1992;44:479-602.

Claims

1 . A compound of the formula I, in any of its stereoisomeric forms or a mixture of stereoisomeric forms in any ratio, or a physiologically acceptable salt thereof, or a physiologically acceptable solvate of any of them,

wherein

E is chosen from the series consisting of C(R³) and N;

R³ is chosen from the series consisting of hydrogen, halogen, (Ci-C6)-alkyl, (Ci-Ce)- alkyl-O-, (Ci-C₆)-alkyl-S(O)_m- and NC-; R¹⁰ is chosen from the series consisting of R^{1 1}-O-, R¹²-N(R¹³)-C(O)-O- and Het²-C(O)- O-;

R⁷³ is chosen from the series consisting of hydrogen, (Ci-C6)-alkyl;

or

Het⁴, independently of each other group Het⁴, is a saturated or unsaturated 4- membered to 8-membered monocyclic heterocycle which comprises one to four ring heteroatoms chosen from the series consisting of nitrogen, oxygen and sulfur which is optionally substituted by one or more identical or different substituents chosen from the series consisting of halogen, (Ci-C₄)-alkyl, HO-, (Ci-C₄)-alkyl-O-, oxo and NC-; m, independently of each other number m, is an integer chosen from the series consisting of 0, 1 and 2; wherein all cycloalkyl groups, independently of each other, are optionally substituted by one or more identical or different substituents chosen from the series consisting of fluorine and (Ci-C₄)-alkyl; wherein all alkyl, C_sH_2s, C_uH_2u, (CH₂)_X and (CH₂)_y groups, independently of each other, and independently of any other substituents, are optionally substituted by one or more fluorine substituents; or a compound of the formula II, in any of its stereoisomeric forms or a mixture of stereoisomeric forms in any ratio, or a physiologically acceptable salt thereof, or physiologically acceptable solvate of any of them,

wherein

A is chosen from the series consisting of C(R¹) and N; D is chosen from the series consisting of C(R²) and N; E is chosen from the series consisting of C(R³) and N;

L is chosen from the series consisting of C(R⁴) and N;

where at least one and at most two of A, D, E or L is N;

G is chosen from the series consisting of R⁷¹-O-C(O)-, R⁷²-N(R⁷³)-C(O)- and tetrazol-5- yl;

R¹ is chosen from the series consisting of hydrogen, halogen, (Ci-C6)-alkyl, HO-, (Ci- C₆)-alkyl-O-, (Ci-C₆)-alkyl-S(0)_m- and NC-; R² is chosen from the series consisting of hydrogen, halogen, (Ci-C₇)-alkyl, (C1-C-6)- alkyl-O-, (Ci-C₆)-alkyl-CO-, (Ci-C₆)-alkyl-CO-HN-, -NR¹²R¹³, Het^2, (C₃-C₇)-cycloalkyl- C_sH_2s- and Ar-C₃H_2s-, wherein s is an integer chosen from the series consisting of 0, 1 , 2 and 3; R³ is chosen from the series consisting of hydrogen, halogen, (Ci-C6)-alkyl, (C1-C-6)- alkyl-S(O)_m-, Het⁴-(O)_r, -NR¹²R¹³, Het², R¹¹-O-, R¹²-N(R¹³)-C(O)-O- and Het²-C(O)-O- and NC-, wherein s is an integer chosen from the series consisting of 0, 1 , 2 and 3 and wherein t is an integer chosen from the series consisting of 0 and 1 ;

R¹⁰ is chosen from the series consisting hydrogen, halogen, (Ci-C6)-alkyl, (C1-C-6)- alkyl-O-, (Ci-C₆)-alkyl-S(O)_m-, HO-, -NR¹²R¹³, Het², phenyl-C₃H_2s-(O)t-, wherein s is an integer chosen from the series consisting of 0, 1 , 2 and 3 and wherein t is an integer chosen from the series consisting of 0 and 1 ; or R¹ and R² or R² and R³ or form pyridyl;

or R¹ and R² are -C((Ci-C₃)-alkyl)=N-N((Ci-C₃)-alkyl)-;

or R² and R³ are -NH-CH=N-; with the proviso that one of R¹, R², R³, R⁴ or R¹⁰ is a cyclic substituent; R¹¹ is chosen from the series consisting of hydrogen, R¹⁴, (C3-C₇)-cycloalkyl, Ar and Het³;

R¹⁴ is (Ci-Cio)-alkyl which is optionally substituted by one or more identical or different substituents chosen from the series consisting of halogen, HO-, R¹⁶-O-, oxo, (C3-C7)- cycloalkyl, Ar, Het¹, Het³, NC-, H₂N-C(O)-, (Ci-C₄)-alkyl-NH-C(O)-, di((Ci-C₄)-alkyl)N- C(O)-, Het¹-C(O)-, (Ci-C₄)-alkyl-C(O)-NH- and (Ci-C₄)-alkyl-S(0)_m-;

R¹⁵ is (Ci-C6)-alkyl which is optionally substituted by one or more identical or different substituents chosen from the series consisting halogen, HO- and (Ci-C6)-alkyl-O-; R¹⁶ is (Ci-C6)-alkyl which is optionally substituted by one or more identical or different substituents chosen from the series consisting of HO-, (Ci-C₄)-alkyl-O- and NC-; R³⁰ is chosen from the series consisting of R³¹ , (C3-C₇)-cycloalkyl, R³²-C_uH_2u- and

R is (Ci-Cio)-alkyl which is optionally substituted by one or more identical or different substituents chosen from the series consisting of halogen, (C3-C₇)-cycloalkyl, HO-, (Ci- C₆)-alkyl-O-, (Ci-C₆)-alkyl-S(0)_m- and NC-;

R is chosen from the series consisting of phenyl and an aromatic 5-membered or 6- membered monocyclic heterocycle which comprises one, two or three identical or different ring heteroatoms chosen from the series consisting of nitrogen, oxygen and sulfur and is bonded via a ring carbon atom, wherein the phenyl and the heterocycle all are optionally substituted by one or more identical or different substituents chosen from the series consisting of halogen, (Ci-C6)-alkyl, (C3-C₇)-cycloalkyl, R³³, HO-, (C1-C-6)- alkyl-O-, R³³-O-, R³³-(Ci-C₄)-alkyl-O-, -O-CH2-O-, -O-CF2-O-, (Ci-C₆)-alkyl-S(O)_m-, H₂N-S(O)₂-, (Ci-C₄)-alkyl-NH-S(O)₂-, di((Ci-C₄)-alkyl)N-S(O)₂-, H₂N-, (Ci-C₆)-alkyl-NH- , di((Ci-C₆)-alkyl)N-, Het¹, (Ci-C₄)-alkyl-C(O)-NH-, Ar-C(O)-NH-, (Ci-C₄)-alkyl-S(O)₂- NH- and NC-;

R⁴⁰ is chosen from the series consisting of hydrogen and (Ci-C₄)-alkyl; or R and R together are (CH₂)_X which is optionally substituted by one or more identical or different (Ci-C₄)-alkyl substituents, wherein x is an integer chosen from the series consisting of 2, 3, 4 and 5;

R⁷³ is chosen from the series consisting of hydrogen, (Ci-C6)-alkyl;

or

R⁷² and R⁷³ together with the nitrogen atom to which they are bonded form a saturated 4-membered to 7-membered monocyclic heterocycle, which contain optionally one further ring heteroatom chosen from the series consisting of nitrogen, oxygen and sulfur, which is optionally substituted by one or more identical or different substituents chosen from the series consisting of halogen, (Ci-C₄)-alkyl, HO- and (Ci-C₄)-alkyl-O-; Ar, independently of each other group Ar, is chosen from the series consisting of phenyl and an aromatic 5-membered or 6-membered monocyclic heterocycle which comprises one, two or three identical or different ring heteroatoms chosen from the series consisting of nitrogen, oxygen and sulfur and is bonded via a ring carbon atom, wherein the phenyl and the heterocycle all are optionally substituted by one or more identical or different substituents chosen from the series consisting of halogen, (C1-C-6)- alkyl, HO-(Ci-C₆)-alkyl, Het⁴, -(CH₂)_X-Phenyl, (Ci-C₆)-alkyl-O-, (C₃-C₇)-cycloalkyl- (CH₂)x-O-, -CF₃, -CO-(Ci-C₆)-alkyl, -NR¹²R¹³, Het², -CO-NR¹²R¹³, CO-Het², (Ci-C₆)- alkyl-S(O)_m-, H₂N-S(O)₂- and NC-;

Het³, independently of each other group Het³, is a saturated 4-membered to 7- membered monocyclic heterocycle which comprises one or two identical or different ring heteroatoms chosen from the series consisting of nitrogen, oxygen and sulfur and is bonded via a ring carbon atom, which is optionally substituted by one or more identical or different substituents chosen from the series consisting of fluorine, (Ci-C₄)- alkyl and oxo; Het⁴, independently of each other group Het⁴, is a saturated or unsaturated 4- membered to 8-mennbered monocyclic heterocycle which comprises one to four ring heteroatoms chosen from the series consisting of nitrogen, oxygen and sulfur which is optionally substituted by one or more identical or different substituents chosen from the series consisting of halogen, (Ci-C₄)-alkyl, HO-, (Ci-C₄)-alkyl-O-, oxo and NC-; m, independently of each other number m, is an integer chosen from the series consisting of 0, 1 and 2; wherein all cycloalkyl groups, independently of each other, are optionally substituted by one or more identical or different substituents chosen from the series consisting of fluorine and (Ci-C₄)-alkyl; wherein all alkyl, C_sH_2s, C_uH_2u, (CH₂)_X and (CH₂)_y groups, independently of each other, and independently of any other substituents, are optionally substituted by one or more fluorine substituents; or

a compound of the formula III, in any of its stereoisomeric forms or a mixture of stereoisomeric forms in any ratio, or a physiologically acceptable salt thereof, or physiologically acceptable solvate of any of them,

wherein

A is chosen from the series consisting of C(R ) and N;

D is chosen from the series consisting of N(R²), O and S;

E is chosen from the series consisting of C(R³) and N G is chosen from the series consisting of R -O-C(O)-, R -N(R )-C(O)-, NC- and tetrazol-5-yl; R¹ is chosen from the series consisting of hydrogen, halogen, (Ci-C6)-alkyl, Ar, HO-, (Ci-C₆)-alkyl-O-, (Ci-C₆)-alkyl-S(O)_m- and NC-;

or R¹⁰ and R¹¹ form Het²;

R⁷³ is chosen from the series consisting of hydrogen, (Ci-C6)-alkyl;

or

Het⁴, independently of each other group Het⁴, is a saturated or unsaturated 4- membered to 8-membered monocyclic heterocycle which comprises one to four ring heteroatoms chosen from the series consisting of nitrogen, oxygen and sulfur which is optionally substituted by one or more identical or different substituents chosen from the series consisting of halogen, (Ci-C₄)-alkyl, HO-, (Ci-C₄)-alkyl-O-, oxo and NC-; m, independently of each other number m, is an integer chosen from the series consisting of 0, 1 and 2; wherein all cycloalkyl groups, independently of each other, are optionally substituted by one or more identical or different substituents chosen from the series consisting of fluorine and (Ci-C₄)-alkyl; wherein all alkyl, C_sH_2s, C_uH_2u, (CH₂)_X and (CH₂)_y groups, independently of each other, and independently of any other substituents, are optionally substituted by one or more fluorine substituents; or

a compound of the formula IV, in any of its stereoisomeric forms or a mixture of stereoisomeric forms in any ratio, or a physiologically acceptable salt thereof, or physiologically acceptable solvate of any of them,

wherein Ht is chosen from the series consisting of

G is chosen from the series consisting of R -O-C(O)-, R -N(R )-C(O)-, NC- and tetrazol-5-yl; R¹ is chosen from the series consisting of hydrogen, halogen, (Ci-C6)-alkyl, CF₃, (C3- C₇)-cycloalkyl-C₃H₂s-, Ar-C₃H_2s-, Ar-O, (d-C₆)-alkyl-O-, (Ci-C₆)-alkyl-S(0)_m- and NC-; wherein s is an integer chosen from the series consisting of 0, 1 , 2 and 3; R² is chosen from the series consisting of hydrogen, halogen, (Ci-C6)-alkyl, CF₃, (Cr C₆)-alkyl-O-, (Ci-C₆)-alkyl-S(0)_m- and NC-;

R³ is chosen from the series consisting of hydrogen, (Ci-C6)-alkyl; R⁴ is chosen from the series consisting of (Ci-C₇)-alkyl, (C3-C₇)-cycloalkyl-C₃H_2s- and Ar-C₃H_2s-, wherein s is an integer chosen from the series consisting of 0, 1 , 2 and 3;

R¹⁰ is chosen from the series consisting of R^{1 1} , Het²-C(O)-, R¹⁴-C(O)- and (C1-C4)- alkyl-S(O)_m-;

R¹⁴ is (Ci-Cio)-alkyl which is optionally substituted by one or more identical or different substituents chosen from the series consisting of halogen, HO-, R¹⁶-O-, oxo, (C3-C7)- cycloalkyl, Ar, Het¹ , Het³, NC-, H₂N-C(O)-, (Ci-C₄)-alkyl-NH-C(O)-, di((Ci-C₄)-alkyl)N- C(O)-, Het¹-C(O)-, (Ci-C₄)-alkyl-C(0)-NH- and (Ci-C₄)-alkyl-S(0)_m-;

Het³-C_uH_2u-, wherein u is an integer chosen from the series consisting of 0, 1 , 2 and 3; R is (Ci-Cio)-alkyl which is substituted by one or more identical or different

substituents chosen from the series consisting of halogen, (C3-C₇)-cycloalkyl, HO-, (Ci- C₆)-alkyl-O-, (Ci-C₆)-alkyl-S(0)_m- and NC-; R³² is chosen from the series consisting of phenyl and an aromatic 5-membered or 6- membered monocyclic heterocycle which comprises one, two or three identical or different ring heteroatoms chosen from the series consisting of nitrogen, oxygen and sulfur and is bonded via a ring carbon atom, wherein the phenyl and the heterocycle all are optionally substituted by one or more identical or different substituents chosen from the series consisting of halogen, (Ci-C6)-alkyl, (C3-C₇)-cycloalkyl, HO-, (Ci-C-6)-alkyl-0- , R³³-O-, R³³-(Ci-C₄)-alkyl-O-, -O-CH₂-O-, -O-CF₂-O-, (Ci-C₆)-alkyl-S(O)_m-, H₂N-S(O)₂-, (Ci-C₄)-alkyl-NH-S(O)₂-, di((Ci-C₄)-alkyl)N-S(O)₂-, H₂N-, (Ci-C₆)-alkyl-NH-, di((Ci-C₆)- alkyl)N-, Het¹, (Ci-C₄)-alkyl-C(O)-NH-, Ar-C(O)-NH-, (Ci-C₄)-alkyl-S(O)₂-NH- and NC-; R³³ is chosen from the series consisting of phenyl and an aromatic 5-membered or 6- membered monocyclic heterocycle which comprises one, two or three identical or different ring heteroatoms chosen from the series consisting of nitrogen, oxygen and sulfur and is bonded via a ring carbon atom, wherein the phenyl and the heterocycle all are optionally substituted by one or more identical or different substituents chosen from the series consisting of halogen, (Ci-C6)-alkyl, (C3-C₇)-cycloalkyl, HO-, (Ci-C-6)-alkyl-0- , (Ci-C₆)-alkyl-S(O)_m-, H₂N-S(O)₂-, (Ci-C₄)-alkyl-NH-S(O)₂-, di((Ci-C₄)-alkyl)N-S(O)₂- and NC-;

R⁴⁰ is chosen from the series consisting of hydrogen and (Ci-C₄)-alkyl; or R³⁰ and R⁴⁰ together are (CH₂)_X which is optionally substituted by one or more identical or different (Ci-C₄)-alkyl substituents, wherein x is an integer chosen from the series consisting of 2, 3, 4 and 5; R⁵⁰ is chosen from the series consisting of hydrogen, (Ci-C6)-alkyl, HO- and (d-Ce)- alkyl-O-; R is chosen from the series consisting of hydrogen and (Ci-C6)-alkyl; or R⁵⁰ and R⁶⁰ together are (CH₂)_y which is optionally substituted by one or more identical or different (Ci-C₄)-alkyl substituents, wherein y is an integer chosen from the series consisting of 2, 3, 4 and 5; or R³⁰ and R⁵⁰ together are (CH₂)_Z which is optionally substituted by one or more identical or different (Ci-C₄)-alkyl substituents, wherein z is an integer chosen from the series consisting of 2, 3, 4 and 5;

R⁷¹ is chosen from the series consisting of hydrogen and (Ci-Cs)-alkyl which is optionally substituted by one or more identical or different substituents chosen from the series consisting (Ci-C6)-alkyl-O- and (Ci-C6)-alkyl-C(O)-O-; R⁷² is chosen from the series consisting of hydrogen, (Ci-C6)-alkyl, (C3-C6)-cycloalkyl, -CH2-(CH₂)_b-(C3-C₆)-cycloalkyl, Het⁴ and -(CH₂)_b-Het⁴, where alkyl or cycloalkyl is optionally substituted by one or more identical or different substituents chosen from the series consisting of halogen, HO-, HOOC-, (Ci-C₆)-alkyl-O- and (Ci-C₆)-alkyl-C(O)-O-, NC-, N((Ci-C₄)-alkyl)₂ and b is 0, 1 or 2;

R⁷³ is chosen from the series consisting of hydrogen, (Ci-C6)-alkyl;

or

Ar, independently of each other group Ar, is chosen from the series consisting of phenyl and an aromatic 5-membered or 6-membered monocyclic heterocycle which comprises one, two or three identical or different ring heteroatoms chosen from the series consisting of nitrogen, oxygen and sulfur and is bonded via a ring carbon atom, wherein the phenyl and the heterocycle all are optionally substituted by one or more identical or different substituents chosen from the series consisting of halogen, (C1-C-6)- alkyl, (Ci-C₆)-alkyl-0-, -O-CH₂-O-, O-CH₂-CH₂-O-, -O-CF₂-O-, (Ci-C₆)-alkyl-S(O)_m-, H₂N-S(O)₂-, CF₃ and NC-; Het¹, independently of each other group Het¹, is a saturated or unsaturated 4- membered to 8-membered monocyclic heterocycle which comprises a ring nitrogen atom via which Het¹ is bonded and optionally one or two identical or different further ring heteroatoms chosen from the series consisting of nitrogen, oxygen and sulfur, which is optionally substituted by one or more identical or different substituents chosen from the series consisting of halogen, (Ci-C₄)-alkyl, HO-, (Ci-C₄)-alkyl-O-, oxo and NC-;

Het⁴, independently of each other group Het⁴, is a saturated or unsaturated 4- membered to 8-membered monocyclic heterocycle which comprises one to four ring heteroatoms chosen from the series consisting of nitrogen, oxygen and sulfur which is optionally substituted by one or more identical or different substituents chosen from the series consisting of halogen, (Ci-C₄)-alkyl, HO-, (Ci-C₄)-alkyl-O-, oxo and NC-; m, independently of each other number m, is an integer chosen from the series consisting of 0, 1 and 2; wherein all cycloalkyl groups, independently of each other, are optionally substituted by one or more identical or different substituents chosen from the series consisting of fluorine and (Ci-C₄)-alkyl; wherein all alkyl, C_sH_2s, C_uH_2u, (CH₂)_x and (CH₂)_y groups, independently of each other, and independently of any other substituents, are optionally substituted by one or more fluorine substituents; or a compound of the formula Va or Vb,

in any of its stereoisomeric forms or a mixture of stereoisomeric forms in any ratio, or a physiologically acceptable salt thereof, or a physiologically acceptable solvate of any of them,

wherein

G is chosen from the series consisting of R⁷¹-O-C(O)-, R⁷²-N(R⁷³)-C(O)-, NC- and tetrazol-5-yl; R¹ is chosen from the series consisting of hydrogen, halogen, (Ci-C6)-alkyl, CF₃, (C3- C₇)-cycloalkyl-C₃H₂s-, Ar-C₃H_2s-, Ar-O, (d-C₆)-alkyl-O-, (Ci-C₆)-alkyl-S(0)_m- and NC-; wherein s is an integer chosen from the series consisting of 0, 1 , 2 and 3; R² is chosen from the series consisting of hydrogen, halogen, (Ci-C6)-alkyl, CF₃, HO-, (Ci-C₆)-alkyl-O-, and NC-;

R¹⁰ is chosen from the series consisting of R¹¹ , Het²-C(O)-, R¹⁴-C(O)- and (C1-C4)- alkyl-S(O)_m-;

R³⁰ is chosen from the series consisting of R³¹ , (C3-C₇)-cycloalkyl, R³²-C_uH_2u- and Het³-C_uH_2u-, wherein u is an integer chosen from the series consisting of 0, 1 , 2 and 3; R³¹ is (Ci-Cio)-alkyl which is optionally substituted by one or more identical or different substituents chosen from the series consisting of halogen, (C3-C₇)-cycloalkyl, HO-, (Ci- C₆)-alkyl-O-, (Ci-C₆)-alkyl-S(0)_m- and NC-;

R³² is chosen from the series consisting of phenyl and an aromatic 5-membered or 6- membered monocyclic heterocycle which comprises one, two or three identical or different ring heteroatoms chosen from the series consisting of nitrogen, oxygen and sulfur and is bonded via a ring carbon atom, wherein the phenyl and the heterocycle all are optionally substituted by one or more identical or different substituents chosen from the series consisting of halogen, (CrC6)-alkyl, (C3-C₇)-cycloalkyl, R³³, HO-, (C1-C-6)- alkyl-O-, R³³-O-, R³³-(Ci-C₄)-alkyl-O-, -O-CH2-O-, -O-CF2-O-, (Ci-C₆)-alkyl-S(O)_m-, H₂N-S(O)₂-, (Ci-C₄)-alkyl-NH-S(O)₂-, di((Ci-C₄)-alkyl)N-S(O)₂-, H₂N-, (Ci-C₆)-alkyl-NH- , di((Ci-C₆)-alkyl)N-, Het¹, (Ci-C₄)-alkyl-C(O)-NH-, (Ci-C₄)-alkyl-S(O)₂-NH- and NC-;

R⁵⁰ is chosen from the series consisting of hydrogen, (Ci-C6)-alkyl, HO- and (C1-C6)- alkyl-O-; R⁶⁰ is chosen from the series consisting of hydrogen and (Ci-C6)-alkyl; or R⁵⁰ and R⁶⁰ together are (CH₂)_y which is optionally substituted by one or more identical or different (Ci-C₄)-alkyl substituents, wherein y is an integer chosen from the series consisting of 2, 3, 4 and 5; R is chosen from the series consisting of hydrogen and (Ci-CsJ-alkyl which is optionally substituted by one or more identical or different substituents chosen from the series consisting (Ci-C6)-alkyl-O- and (Ci-C6)-alkyl-C(O)-O-; R⁷² is chosen from the series consisting of hydrogen, (Ci-C6)-alkyl, (C3-C6)-cycloalkyl, -CH2-(CH₂)_b-(C3-C₆)-cycloalkyl, Het⁴ and -(CH₂)_b-Het⁴, where alkyl or cycloalkyl is optionally substituted by one or more identical or different substituents chosen from the series consisting of halogen, HO-, HOOC-, (Ci-C₆)-alkyl-O- and (Ci-C₆)-alkyl-C(O)-O-, NC-, N((Ci-C₄)-alkyl)₂ and b is 0, 1 or 2;

R⁷³ is chosen from the series consisting of hydrogen, (Ci-C6)-alkyl;

or

Ar, independently of each other group Ar, is chosen from the series consisting of phenyl and an aromatic 5-membered or 6-membered monocyclic heterocycle which comprises one, two or three identical or different ring heteroatoms chosen from the series consisting of nitrogen, oxygen and sulfur and is bonded via a ring carbon atom, wherein the phenyl and the heterocycle all are optionally substituted by one or more identical or different substituents chosen from the series consisting of halogen, (Ci-Ce)- alkyl, (Ci-C₆)-alkyl-O-, -O-CH₂-O-, -O-CH₂-CH₂-, O-O-CF₂-O-, CF₃, (d-C₆)-alkyl- S(O)_m-, H₂N-S(O)₂- and NC-;

Het¹, independently of each other group Het¹, is a saturated or unsaturated 4- membered to 8-membered monocyclic heterocycle which comprises a ring nitrogen atom via which Het¹ is bonded and optionally one or two identical or different further ring heteroatoms chosen from the series consisting of nitrogen, oxygen and sulfur, which is optionally substituted by one or more identical or different substituents chosen from the series consisting of halogen, (Ci-C₄)-alkyl, HO-, (Ci-C₄)-alkyl-O-, oxo and NC-; Het² is a saturated 4-membered to 7-membered monocyclic heterocycle which comprises a ring nitrogen atom via which Het² is bonded and optionally one further ring heteroatom chosen from the series consisting of nitrogen, oxygen and sulfur, which is optionally substituted by one or more identical or different substituents chosen from the series consisting of halogen, (Ci-C₄)-alkyl, HO- and (Ci-C₄)-alkyl-O-;

or

Telaprevir; or

Boceprevir;

for use in a method of prevention and/or treatment of atrial fibrillation.

2. (S)-3-{[1 -(2-Fluoro-phenyl)-5-methoxy-1 H-pyrazole-3-carbonyl]-amino}-3-o-tolyl- propionic acid or a physiologically acceptable salt thereof, or a physiologically acceptable solvate of any of thereof for use in a method of prevention and/or treatment of atrial fibrillation.

3. A compound of the formula II, in any of its stereoisomeric forms or a mixture of stereoisomeric forms in any ratio, or a physiologically acceptable salt thereof, or a physiologically acceptable solvate of any of them,

wherein

A is chosen from the series consisting of C(R ) and N;

D is chosen from the series consisting of C(R²) and N;

E is chosen from the series consisting of C(R³) and N;

L is chosen from the series consisting of C(R⁴) and N;

where at least one and at most two of A, D, E or L is N; G is chosen from the series consisting of R -O-C(O)-, R -N(R )-C(O)- and tetrazol-5- yi;

R¹ is chosen from the series consisting of hydrogen, halogen, (Ci-C6)-alkyl, HO-, (Ci- C₆)-alkyl-O-, (Ci-C₆)-alkyl-S(O)_m- and NC-;

R² is chosen from the series consisting of hydrogen, halogen, (Ci-C₇)-alkyl, (d-Ce)- alkyl-O-, (Ci-C₆)-alkyl-CO-, (Ci-C₆)-alkyl-CO-HN-, -NR¹²R¹³, Het^2, (C₃-C₇)-cycloalkyl- C_sH_2s- and Ar-C₃H_2s-, wherein s is an integer chosen from the series consisting of 0, 1 , 2 and 3;

R³ is chosen from the series consisting of hydrogen, halogen, (Ci-C6)-alkyl, (d-Ce)- alkyl-S(O)_m-, Het⁴-(O)_r, -NR¹²R¹³, Het², R¹¹-O-, R¹²-N(R¹³)-C(O)-O- and Het²-C(O)-O- and NC-, wherein s is an integer chosen from the series consisting of 0, 1 , 2 and 3 and wherein t is an integer chosen from the series consisting of 0 and 1 ;

R⁴ is chosen from the series consisting of hydrogen, halogen, (Ci-C6)-alkyl, (d-Ce)- alkyl-O-, HO-, NR¹²R¹³, Het²; R¹⁰ is chosen from the series consisting hydrogen, halogen, (Ci-C6)-alkyl, (d-Ce)- alkyl-O-, (d-C₆)-alkyl-S(O)_m-, HO-, -NR¹²R¹³, Het², phenyl-C₃H₂s-(O)t-, wherein s is an integer chosen from the series consisting of 0, 1 , 2 and 3 and wherein t is an integer chosen from the series consisting of 0 and 1 ; or R¹ and R² or R² and R³ or form pyridyl;

or R¹ and R² are -C((Ci-C₃)-alkyl)=N-N((Ci-C₃)-alkyl)-;

R¹¹ is chosen from the series consisting of hydrogen, R¹⁴, (C3-C₇)-cycloalkyl, Ar and Het³; R¹² and R¹³ are independently of each other chosen from the series consisting of hydrogen and R¹⁵; R¹⁴ is (Ci-Cio)-alkyl which is optionally substituted by one or more identical or different substituents chosen from the series consisting of halogen, HO-, R¹⁶-O-, oxo, (C3-C7)- cycloalkyl, Ar, Het¹, Het³, NC-, H₂N-C(O)-, (Ci-C₄)-alkyl-NH-C(O)-, di((Ci-C₄)-alkyl)N- C(O)-, Het¹-C(O)-, (Ci-C₄)-alkyl-C(O)-NH- and (Ci-C₄)-alkyl-S(0)_m-; R¹⁵ is (Ci-C6)-alkyl which is optionally substituted by one or more identical or different substituents chosen from the series consisting halogen, HO- and (Ci-C6)-alkyl-O-;

R³² is chosen from the series consisting of phenyl and an aromatic 5-membered or 6- membered monocyclic heterocycle which comprises one, two or three identical or different ring heteroatoms chosen from the series consisting of nitrogen, oxygen and sulfur and is bonded via a ring carbon atom, wherein the phenyl and the heterocycle all are optionally substituted by one or more identical or different substituents chosen from the series consisting of halogen, (Ci-C6)-alkyl, (C3-C₇)-cycloalkyl, R³³, HO-, (C1-C-6)- alkyl-O-, R³³-O-, R³³-(Ci-C₄)-alkyl-O-, -O-CH2-O-, -O-CF2-O-, (Ci-C₆)-alkyl-S(O)_m-, H₂N-S(O)₂-, (Ci-C₄)-alkyl-NH-S(O)₂-, di((Ci-C₄)-alkyl)N-S(O)₂-, H₂N-, (Ci-C₆)-alkyl-NH- , di((Ci-C₆)-alkyl)N-, Het¹, (Ci-C₄)-alkyl-C(O)-NH-, Ar-C(O)-NH-, (Ci-C₄)-alkyl-S(O)₂- NH- and NC-; R is chosen from the series consisting of phenyl and an aromatic 5-membered or 6- membered monocyclic heterocycle which comprises one, two or three identical or different ring heteroatoms chosen from the series consisting of nitrogen, oxygen and sulfur and is bonded via a ring carbon atom, wherein the phenyl and the heterocycle all are optionally substituted by one or more identical or different substituents chosen from the series consisting of halogen, (Ci-C6)-alkyl, (C3-C₇)-cycloalkyl, HO-, (Ci-C-6)-alkyl-0- , (Ci-C₆)-alkyl-S(O)_m-, H₂N-S(O)₂-, (Ci-C₄)-alkyl-NH-S(O)₂-, di((Ci-C₄)-alkyl)N-S(O)₂- and NC-;

R⁵⁰ is chosen from the series consisting of hydrogen, (Ci-C6)-alkyl, HO- and (d-Ce)- alkyl-O-; R⁶⁰ is chosen from the series consisting of hydrogen and (Ci-C6)-alkyl; or R⁵⁰ and R⁶⁰ together are (CH₂)_y which is optionally substituted by one or more identical or different (Ci-C₄)-alkyl substituents, wherein y is an integer chosen from the series consisting of 2, 3, 4 and 5;

R⁷¹ is chosen from the series consisting of hydrogen and (Ci-Cs)-alkyl which is optionally substituted by one or more identical or different substituents chosen from the series consisting (Ci-C6)-alkyl-O- and (Ci-C6)-alkyl-C(O)-O-; R⁷² is chosen from the series consisting of hydrogen, (Ci-C6)-alkyl, (C3-C6)-cycloalkyl, -CH₂-(CH₂)_b-(C₃-C₆)-cycloalkyl, Het⁴ and -(CH₂)_b-Het⁴, where alkyl or cycloalkyl is optionally substituted by one or more identical or different substituents chosen from the series consisting of halogen, HO-, HOOC-, (Ci-C₆)-alkyl-0- and (Ci-C₆)-alkyl-C(O)-O-, NC-, N((Ci-C₄)-alkyl)₂ and b is 0, 1 or 2;

R⁷³ is chosen from the series consisting of hydrogen, (Ci-C6)-alkyl;

or

Het² is a saturated 4-membered to 7-membered monocyclic heterocycle which comprises a ring nitrogen atom via which Het² is bonded and optionally one further ring heteroatom chosen from the series consisting of nitrogen, oxygen and sulfur, which is optionally substituted by one or more identical or different substituents chosen from the series consisting of halogen, (Ci-C₄)-alkyl, HO- and (Ci-C₄)-alkyl-O-; Het³, independently of each other group Het³, is a saturated 4-membered to 7- membered monocyclic heterocycle which comprises one or two identical or different ring heteroatoms chosen from the series consisting of nitrogen, oxygen and sulfur and is bonded via a ring carbon atom, which is optionally substituted by one or more identical or different substituents chosen from the series consisting of fluorine, (Ci-C₄)- alkyl and oxo;

Het⁴, independently of each other group Het⁴, is a saturated or unsaturated 4- membered to 8-membered monocyclic heterocycle which comprises one to four ring heteroatoms chosen from the series consisting of nitrogen, oxygen and sulfur which is optionally substituted by one or more identical or different substituents chosen from the series consisting of halogen, (Ci-C₄)-alkyl, HO-, (Ci-C₄)-alkyl-O-, oxo and NC-; m, independently of each other number m, is an integer chosen from the series consisting of 0, 1 and 2; wherein all cycloalkyl groups, independently of each other, are optionally substituted by one or more identical or different substituents chosen from the series consisting of fluorine and (Ci-C₄)-alkyl; wherein all alkyl, C_sH_2s, C_uH_2u, (CH₂)_X and (CH₂)_y groups, independently of each other, and independently of any other substituents, are optionally substituted by one or more fluorine substituents; or a compound of the formula III, in any of its stereoisomeric forms or a mixture of stereoisomeric forms in any ratio, or a physiologically acceptable salt thereof, or a physiologically acceptable solvate of any of them,

wherein

E is chosen from the series consisting of C(R³) and N;

R³ is chosen from the series consisting of hydrogen, halogen, (Ci-C6)-alkyl, (d-Ce)- alkyl-O-, (Ci-C₆)-alkyl-S(O)_m- and NC-;

R¹⁰ is chosen from the series consisting of R¹¹ , R¹²-N(R¹³)-C(O)- and Het²-C(O)-, R¹⁴- C(O)- and (Ci-C₄)-alkyl-S(O)_m-;

R¹¹ is chosen from the series consisting of hydrogen, R¹⁴, (C3-C₇)-cycloalkyl, Ar and Het³; or R¹⁰ and R¹¹ form Het²;

R¹² and R¹³ are independently of each other chosen from the series consisting of hydrogen, R¹⁵ and Ar;

R¹⁴ is (Ci-Cio)-alkyl which is optionally substituted by one or more identical or different substituents chosen from the series consisting of halogen, HO-, R¹⁶-O-, R¹⁷-O-, oxo, (C₃-C₇)-cycloalkyl, Ar, Het¹, Het³, NC-, H₂N-C(O)-, (Ci-C₄)-alkyl-NH-C(O)-, di((d-C₄)- alkyl)N-C(O)-, Het¹-C(O)-, (Ci-C₄)-alkyl-C(O)-NH- and (Ci-C₄)-alkyl-S(O)_m-;

R¹⁵ is (Ci-C6)-alkyl which is optionally substituted by one or more identical or different substituents chosen from the series consisting halogen, HO- and (Ci-C6)-alkyl-O-;

R¹⁷ is (C3-C₇)-cycloalkyl-C_uH_2u- which is optionally substituted by one or more identical or different substituents chosen from the series consisting halogen, (Ci-C6)-alkyl, HO- and (Ci-C6)-alkyl-O-, wherein u is an integer chosen from the series consisting of 0, 1 , 2 and 3;

R¹⁸ is chosen from the series of hydrogen, halogen, (Ci-C6)-alkyl, HO- and (Ci-Ce)- alkyl-O-;

R¹⁹ is chosen from the series of hydrogen, halogen, (Ci-C6)-alkyl, HO- and (Ci-Ce)- alkyl-O-;

R³⁰ is chosen from the series consisting of R³¹ , (C3-C₇)-cycloalkyl, R³²-C_uH_2u- and Het³-C_uH_2u-, wherein u is an integer chosen from the series consisting of 0, 1 , 2 and 3; R is (Ci-Cio)-alkyl which is optionally substituted by one or more identical or different substituents chosen from the series consisting of halogen, (C3-C₇)-cycloalkyl, HO-, (Ci- C₆)-alkyl-O-, (Ci-C₆)-alkyl-S(0)_m- and NC-; R³² is chosen from the series consisting of phenyl and an aromatic 5-membered or 6- membered monocyclic heterocycle which comprises one, two or three identical or different ring heteroatoms chosen from the series consisting of nitrogen, oxygen and sulfur and is bonded via a ring carbon atom, wherein the phenyl and the heterocycle all are optionally substituted by one or more identical or different substituents chosen from the series consisting of halogen, (Ci-C₆)-alkyl, (C₃-C₇)-cycloalkyl, R³³, HO-, (Ci-C₆)- alkyl-O-, R³³-O-, R³³-(Ci-C₄)-alkyl-O-, -O-CH₂-O-, -O-CF₂-O-, (Ci-C₆)-alkyl-S(O)_m-, H₂N-S(O)₂-, (Ci-C₄)-alkyl-NH-S(O)₂-, di((Ci-C₄)-alkyl)N-S(O)₂-, H₂N-, (Ci-C₆)-alkyl-NH- , di((Ci-C₆)-alkyl)N-, Het¹, (Ci-C₄)-alkyl-C(O)-NH-, Ar-C(O)-NH-, (Ci-C₄)-alkyl-S(O)₂- NH- and NC-;

R⁵⁰ is chosen from the series consisting of hydrogen, (Ci-C6)-alkyl, HO- and (d-Ce)- alkyl-O-; R is chosen from the series consisting of hydrogen and (Ci-C6)-alkyl; or R⁵⁰ and R⁶⁰ together are (CH₂)_y which is optionally substituted by one or more identical or different (Ci-C₄)-alkyl substituents, wherein y is an integer chosen from the series consisting of 2, 3, 4 and 5; or R³⁰ and R⁵⁰ together are (CH₂)_Z which is optionally substituted by one or more identical or different (Ci-C₄)-alkyl substituents, wherein z is an integer chosen from the series consisting of 2, 3, 4 and 5;

R⁷³ is chosen from the series consisting of hydrogen, (Ci-C6)-alkyl;

or

Ar, independently of each other group Ar, is chosen from the series consisting of phenyl and an aromatic 5-membered or 6-membered monocyclic heterocycle which comprises one, two or three identical or different ring heteroatoms chosen from the series consisting of nitrogen, oxygen and sulfur and is bonded via a ring carbon atom, wherein the phenyl and the heterocycle all are optionally substituted by one or more identical or different substituents chosen from the series consisting of halogen, (C1-C-6)- alkyl, (Ci-C₆)-alkyl-0-, -O-CH₂-O-, -O-CF₂-O-, (Ci-C₆)-alkyl-S(O)_m-, H₂N-S(O)₂- and NC-;

Het⁴, independently of each other group Het⁴, is a saturated or unsaturated 4- membered to 8-membered monocyclic heterocycle which comprises one to four ring heteroatoms chosen from the series consisting of nitrogen, oxygen and sulfur which is optionally substituted by one or more identical or different substituents chosen from the series consisting of halogen, (Ci-C₄)-alkyl, HO-, (Ci-C₄)-alkyl-O-, oxo and NC-; m, independently of each other number m, is an integer chosen from the series consisting of 0, 1 and 2; wherein all cycloalkyi groups, independently of each other, are optionally substituted by one or more identical or different substituents chosen from the series consisting of fluorine and (Ci-C₄)-alkyl; wherein all alkyl, C_sH_2s, C_uH_2u, (CH₂)_x and (CH₂)_y groups, independently of each other, and independently of any other substituents, are optionally substituted by one or more fluorine substituents; or a compound of the formula IV, in any of its stereoisomeric forms or a mixture of stereoisomeric forms in any ratio, or a physiologically acceptable salt thereof, or a physiologically acceptable solvate of any of them,

wherein Ht is chosen from the series consisting of

R¹ is chosen from the series consisting of hydrogen, halogen, (Ci-C6)-alkyl, CF₃, (C3- C₇)-cycloalkyl-C₃H₂s-, Ar-C₃H_2s-, Ar-O, (Ci-C₆)-alkyl-O-, (Ci-C₆)-alkyl-S(O)_m- and NC-; wherein s is an integer chosen from the series consisting of 0, 1 , 2 and 3; R² is chosen from the series consisting of hydrogen, halogen, (Ci-C6)-alkyl, CF₃, (Cr C₆)-alkyl-O-, (Ci-C₆)-alkyl-S(O)_m- and NC-;

R³ is chosen from the series consisting of hydrogen, (Ci-C6)-alkyl; R⁴ is chosen from the series consisting of (Ci-C₇)-alkyl, (C3-C₇)-cycloalkyl-C₃H_2s- and Ar-C₃H_2s-, wherein s is an integer chosen from the series consisting of 0, 1 , 2 and 3; R⁵ is chosen from the series consisting of hydrogen, halogen, (Ci-C6)-alkyl, (C1-C-6)- alkyl-O-, (Ci-C₆)-alkyl-S(0)_m- and NC-;

R¹¹ is chosen from the series consisting of hydrogen, R¹⁴, (C3-C₇)-cycloalkyl, Ar and Het³; R¹⁴ is (Ci-Cio)-alkyl which is optionally substituted by one or more identical or different substituents chosen from the series consisting of halogen, HO-, R¹⁶-O-, oxo, (C3-C7)- cycloalkyl, Ar, Het¹, Het³, NC-, H₂N-C(O)-, (Ci-C₄)-alkyl-NH-C(O)-, di((Ci-C₄)-alkyl)N- C(O)-, Het¹-C(O)-, (Ci-C₄)-alkyl-C(O)-NH- and (Ci-C₄)-alkyl-S(0)_m-; R¹⁶ is (Ci-C6)-alkyl which is optionally substituted by one or more identical or different substituents chosen from the series consisting of HO-, (Ci-C₄)-alkyl-O- and NC-;

R³¹ is (Ci-Cio)-alkyl which is substituted by one or more identical or different

substituents chosen from the series consisting of halogen, (C3-C₇)-cycloalkyl, HO-, (Ci- C₆)-alkyl-O-, (Ci-C₆)-alkyl-S(0)_m- and NC-; R³² is chosen from the series consisting of phenyl and an aromatic 5-membered or 6- membered monocyclic heterocycle which comprises one, two or three identical or different ring heteroatoms chosen from the series consisting of nitrogen, oxygen and sulfur and is bonded via a ring carbon atom, wherein the phenyl and the heterocycle all are optionally substituted by one or more identical or different substituents chosen from the series consisting of halogen, (Ci-C6)-alkyl, (C3-C₇)-cycloalkyl, HO-, (Ci-C-6)-alkyl-0- , R³³-O-, R³³-(Ci-C₄)-alkyl-O-, -O-CH2-O-, -O-CF2-O-, (Ci-C₆)-alkyl-S(O)_m-, H₂N-S(O)₂-, (Ci-C₄)-alkyl-NH-S(O)₂-, di((Ci-C₄)-alkyl)N-S(O)₂-, H₂N-, (Ci-C₆)-alkyl-NH-, di((Ci-C₆)- alkyl)N-, Het¹ , (Ci-C₄)-alkyl-C(O)-NH-, Ar-C(O)-NH-, (Ci-C₄)-alkyl-S(O)₂-NH- and NC-;

R⁷³ is chosen from the series consisting of hydrogen, (Ci-C6)-alkyl;

or

Ar, independently of each other group Ar, is chosen from the series consisting of phenyl and an aromatic 5-membered or 6-membered monocyclic heterocycle which comprises one, two or three identical or different ring heteroatoms chosen from the series consisting of nitrogen, oxygen and sulfur and is bonded via a ring carbon atom, wherein the phenyl and the heterocycle all are optionally substituted by one or more identical or different substituents chosen from the series consisting of halogen, (Ci-Ce)- alkyl, (Ci-C₆)-alkyl-O-, -O-CH₂-O-, O-CH₂-CH₂-O-, -O-CF₂-O-, (Ci-C₆)-alkyl-S(O)_m-, H₂N-S(O)₂-, CF₃ and NC-;

Het² is a saturated 4-mennbered to 7-mennbered monocyclic heterocycle which comprises a ring nitrogen atom via which Het² is bonded and optionally one further ring heteroatom chosen from the series consisting of nitrogen, oxygen and sulfur, which is optionally substituted by one or more identical or different substituents chosen from the series consisting of halogen, (Ci-C₄)-alkyl, HO-, oxo and (Ci-C₄)-alkyl-O-;

wherein

R¹ is chosen from the series consisting of hydrogen, halogen, (Ci-C6)-alkyl, CF₃, (C3- C₇)-cycloalkyl-C₃H₂s-, Ar-C₃H_2s-, Ar-O, (d-C₆)-alkyl-O-, (Ci-C₆)-alkyl-S(0)_m- and NC-; wherein s is an integer chosen from the series consisting of 0, 1 , 2 and 3; R² is chosen from the series consisting of hydrogen, halogen, (Ci-C6)-alkyl, CF₃, HO-, (Ci-C₆)-alkyl-O-, and NC-;

R¹⁰ is chosen from the series consisting of R¹¹ , Het²-C(O)-, R¹⁴-C(O)- and (C1-C4)- alkyl-S(O)_m-; R¹¹ is chosen from the series consisting of hydrogen, R¹⁴, (C3-C₇)-cycloalkyl, Ar and Het³;

R³² is chosen from the series consisting of phenyl and an aromatic 5-membered or 6- membered monocyclic heterocycle which comprises one, two or three identical or different ring heteroatoms chosen from the series consisting of nitrogen, oxygen and sulfur and is bonded via a ring carbon atom, wherein the phenyl and the heterocycle all are optionally substituted by one or more identical or different substituents chosen from the series consisting of halogen, (Ci-C6)-alkyl, (C3-C₇)-cycloalkyl, R³³, HO-, (C1-C-6)- alkyl-O-, R³³-O-, R³³-(Ci-C₄)-alkyl-O-, -O-CH2-O-, -O-CF2-O-, (Ci-C₆)-alkyl-S(O)_m-,

H₂N-S(O)₂-, (Ci-C₄)-alkyl-NH-S(O)₂-, di((Ci-C₄)-alkyl)N-S(O)₂-, H₂N-, (Ci-C₆)-alkyl-NH- , di((Ci-C₆)-alkyl)N-, Het¹, (Ci-C₄)-alkyl-C(O)-NH-, (Ci-C₄)-alkyl-S(O)₂-NH- and NC-;

R⁵⁰ is chosen from the series consisting of hydrogen, (Ci-C6)-alkyl, HO- and (C1-C-6)- alkyl-O-; R⁶⁰ is chosen from the series consisting of hydrogen and (Ci-C6)-alkyl; or R⁵⁰ and R⁶⁰ together are (CH₂)_y which is optionally substituted by one or more identical or different (Ci-C₄)-alkyl substituents, wherein y is an integer chosen from the series consisting of 2, 3, 4 and 5;

R⁷³ is chosen from the series consisting of hydrogen, (Ci-C6)-alkyl;

or R and R together with the nitrogen atom to which they are bonded form a saturated 4-membered to 7-membered monocyclic heterocycle, which contain optionally one further ring heteroatom chosen from the series consisting of nitrogen, oxygen and sulfur, which is optionally substituted by one or more identical or different substituents chosen from the series consisting of halogen, (Ci-C₄)-alkyl, HO- and (Ci-C₄)-alkyl-O-;

Het² is a saturated 4-membered to 7-membered monocyclic heterocycle which comprises a ring nitrogen atom via which Het² is bonded and optionally one further ring heteroatom chosen from the series consisting of nitrogen, oxygen and sulfur, which is optionally substituted by one or more identical or different substituents chosen from the series consisting of halogen, (Ci-C₄)-alkyl, HO- and (Ci-C₄)-alkyl-O-; Het³, independently of each other group Het³, is a saturated 4-mennbered to 7- membered monocyclic heterocycle which comprises one or two identical or different ring heteroatoms chosen from the series consisting of nitrogen, oxygen and sulfur and is bonded via a ring carbon atom, which is optionally substituted by one or more identical or different substituents chosen from the series consisting of fluorine, (Ci-C₄)- alkyl and oxo;

or

Telaprevir;

or

Boceprevir;

for use in a method of prevention and/or treatment of atrial fibrillation.

4. A pharmaceutical composition of a compound as claimed in claim 1 , 2 or 3 for use in a method of prevention and/or treatment of atrial fibrillation.

5. A compound as claimed in claims 1 , 2 or 3

for use in a method of prevention and/or treatment of the development of an arrhythmogenic substrate in the atrium.

6. A compound as claimed in claims 1 , 2 or 3

for use in a method of prevention and/or treatment of atrial remodeling in type 2 diabetes.

7. A compound as claimed in claims 1 , 2 or 3

for use in a method of prevention and/or treatment of diabetes-induced atrial

arrythmogenic remodeling.

8. A pharmaceutical composition of a compound as claimed in claim 1 , 2 or 3

9. A pharmaceutical composition of a compound as claimed in claim 1 , 2 or 3

10. A pharmaceutical composition of a compound as claimed in claim 1 , 2 or 3 for use in a method of prevention and/or treatment of diabetes-induced atrial arrythmogenic remodeling.